Dual variable domain immunoglobulins and uses thereof

ABSTRACT

Engineered multivalent and multispecific binding proteins, methods of making, and their uses in the prevention, diagnosis, and/or treatment of disease are provided.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a non-provisional application claiming priority toU.S. Provisional Application Ser. No. 61/370,269, filed Aug. 3, 2010,and U.S. Provisional Application Ser. No. 61/377,134, filed Aug. 26,2010, the entire contents of which are hereby incorporated by reference.

FIELD

Multivalent and multispecific binding proteins that bind IL-1β andIL-17, methods of making, and specifically to their uses in the,diagnosis, prevention and/or treatment of acute and chronic inflammatorydiseases, cancer, and other diseases are provided.

BACKGROUND

Engineered proteins, such as multispecific antibodies that bind to twoor more antigens are known in the art. Such multispecific bindingproteins can be generated using cell fusion, chemical conjugation, orrecombinant DNA techniques.

Bispecific antibodies have been produced using quadroma technology (seeMilstein, C. and Cuello, A. C. (1983) Nature 305(5934):537-40) based onthe somatic fusion of two different hybridoma cell lines expressingmurine monoclonal antibodies (mAbs) with the desired specificities ofthe bispecific antibody. Because of the random pairing of two differentimmunoglobulin (Ig) heavy and light chains within the resultinghybrid-hybridoma (or quadroma) cell line, up to ten different Ig speciesare generated, of which only one is the functional bispecific antibody.The presence of mis-paired by-products, and significantly reducedproduction yields, means sophisticated purification procedures arerequired.

Bispecific antibodies can also be produced by chemical conjugation oftwo different mAbs (see Staerz, U. D., et al. (1985) Nature 314(6012):628-31). This approach does not yield homogeneous preparation. Otherapproaches have used chemical conjugation of two different mAbs orsmaller antibody fragments (see Brennan, M., et al. (1985) Science229(4708): 81-3).

Another method used to produce bispecific antibodies is the coupling oftwo parental antibodies with a hetero-bifunctional crosslinker, but theresulting bispecific antibodies suffer from significant molecularheterogeneity because reaction of the crosslinker with the parentalantibodies is not site-directed. To obtain more homogeneous preparationsof bispecific antibodies two different Fab fragments have beenchemically crosslinked at their hinge cysteine residues in asite-directed manner (see Glennie, M. J., et al. (1987) J. Immunol.139(7): 2367-75). But this method results in Fab′2 fragments, not a fullIgG molecule.

A wide variety of other recombinant bispecific antibody formats havebeen developed (see Kriangkum, J., et al. (2001) Biomol. Engin. 18(2):31-40). Amongst them tandem single-chain Fv molecules and diabodies, andvarious derivatives thereof, are the most widely used. Routinely,construction of these molecules starts from two single-chain Fv (scFv)fragments that recognize different antigens (see Economides, A. N., etal. (2003) Nat. Med. 9(1): 47-52). Tandem scFv molecules (taFv)represent a straightforward format simply connecting the two scFvmolecules with an additional peptide linker. The two scFv fragmentspresent in these tandem scFv molecules form separate folding entities.Various linkers can be used to connect the two scFv fragments andlinkers with a length of up to 63 residues (see Nakanishi, K., et al.(2001) Ann. Rev. Immunol. 19: 423-74). Although the parental scFvfragments can normally be expressed in soluble form in bacteria, it is,however, often observed that tandem scFv molecules form insolubleaggregates in bacteria. Hence, refolding protocols or the use ofmammalian expression systems are routinely applied to produce solubletandem scFv molecules. In a recent study, in vivo expression bytransgenic rabbits and cattle of a tandem scFv directed against CD28 anda melanoma-associated proteoglycan was reported (see Gracie, J. A., etal. (1999) J. Clin. Invest. 104(10): 1393-401). In this construct, thetwo scFv molecules were connected by a CH1 linker and serumconcentrations of up to 100 mg/L of the bispecific antibody were found.Various strategies including variations of the domain order or usingmiddle linkers with varying length or flexibility were employed to allowsoluble expression in bacteria. A few studies have now reportedexpression of soluble tandem scFv molecules in bacteria (see Leung, B.P., et al. (2000) J. Immunol. 164(12): 6495-502; Ito, A., et al. (2003)J. Immunol. 170(9): 4802-9; Karni, A., et al. (2002) J. Neuroimmunol.125(1-2): 134-40) using either a very short Ala3 linker or longglycine/serine-rich linkers. In a recent study, phage display of atandem scFv repertoire containing randomized middle linkers with alength of 3 or 6 residues was employed to enrich for those moleculesthat are produced in soluble and active form in bacteria. This approachresulted in the isolation of a tandem scFv molecule with a 6 amino acidresidue linker (see Arndt, M. and Krauss, J. (2003) Methods Mol. Biol.207: 305-21). It is unclear whether this linker sequence represents ageneral solution to the soluble expression of tandem scFv molecules.Nevertheless, this study demonstrated that phage display of tandem scFvmolecules in combination with directed mutagenesis is a powerful tool toenrich for these molecules, which can be expressed in bacteria in anactive form.

Bispecific diabodies (Db) utilize the diabody format for expression.Diabodies are produced from scFv fragments by reducing the length of thelinker connecting the VH and VL domain to approximately 5 residues (seePeipp, M. and Valerius, T. (2002) Biochem. Soc. Trans. 30(4): 507-11).This reduction of linker size facilitates dimerization of twopolypeptide chains by crossover pairing of the VH and VL domains.Bispecific diabodies are produced by expressing, two polypeptide chainswith, either the structure VHA-VLB and VHB-VLA (VH-VL configuration), orVLA-VHB and VLB-VHA (VL-VH configuration) within the same cell. A largevariety of different bispecific diabodies have been produced in the pastand most of them are expressed in soluble form in bacteria. However, arecent comparative study demonstrates that the orientation of thevariable domains can influence expression and formation of activebinding sites (see Mack, M. et al. (1995) Proc. Natl. Acad. Sci. USA92(15): 7021-5). Nevertheless, soluble expression in bacteria representsan important advantage over tandem scFv molecules. However, since twodifferent polypeptide chains are expressed within a single cell inactivehomodimers can be produced together with active heterodimers. Thisnecessitates the implementation of additional purification steps inorder to obtain homogenous preparations of bispecific diabodies. Oneapproach to force the generation of bispecific diabodies is theproduction of knob-into-hole diabodies (see Holliger, P., et al. (1993)Proc. Natl. Acad. Sci. USA 90(14): 6444-8.18). This was demonstrated fora bispecific diabody directed against HER2 and CD3. A large knob wasintroduced in the VH domain by exchanging Val37 with Phe and Leu45 withTrp and a complementary hole was produced in the VL domain by mutatingPhe98 to Met and Tyr87 to Ala, either in the anti-HER2 or the anti-CD3variable domains. By using this approach the production of bispecificdiabodies could be increased from 72% by the parental diabody to over90% by the knob-into-hole diabody. Importantly, production yields didonly slightly decrease as a result of these mutations. However, areduction in antigen-binding activity was observed for several analyzedconstructs. Thus, this rather elaborate approach requires the analysisof various constructs in order to identify those mutations that produceheterodimeric molecule with unaltered binding activity. In addition,such approach requires mutational modification of the immunoglobulinsequence at the constant region, thus creating non-native andnon-natural form of the antibody sequence, which may result in increasedimmunogenicity, poor in vivo stability, as well as undesirablepharmacokinetics.

Single-chain diabodies (scDb) represent an alternative strategy forimproving the formation of bispecific diabody-like molecules (seeHolliger, P. and Winter, G. (1997) Cancer Immunol. Immunother. 45(3-4):128-30; Wu, A. M., et al. (1996) Immunotechnology 2(1): p. 21-36).Bispecific single-chain diabodies are produced by connecting the twodiabody-forming polypeptide chains with an additional middle linker witha length of approximately 15 amino acid residues. Consequently, allmolecules with a molecular weight corresponding to monomericsingle-chain diabodies (50-60 kDa) are bispecific. Several studies havedemonstrated that bispecific single chain diabodies are expressed inbacteria in soluble and active form with the majority of purifiedmolecules present as monomers (see Holliger, P. and Winter, G. (1997)Cancer Immunol. Immunother. 45(3-4): 128-30; Wu, A. M., et al. (1996)Immunotechnol. 2(1): 21-36; Pluckthun, A. and Pack, P. (1997)Immunotechnol. 3(2): 83-105; Ridgway, J. B., et al. (1996) ProteinEngin. 9(7): 617-21). Thus, single-chain diabodies combine theadvantages of tandem scFvs (all monomers are bispecific) and diabodies(soluble expression in bacteria).

More recently diabodies have been fused to Fc to generate more Ig-likemolecules, named di-diabodies (see Lu, D., et al. (2004) J. Biol. Chem.279(4): 2856-65). In addition, multivalent antibody constructscomprising two Fab repeats in the heavy chain of an IgG and that bindfour antigen molecules have been described (see WO 0177342A1, andMiller, K., et al. (2003) J. Immunol. 170(9): 4854-61).

There is a need in the art for improved multivalent binding proteinsthat bind two or more antigens. U.S. Pat. No. 7,612,181 provides a novelfamily of binding proteins that bind two or more antigens with highaffinity, and which are called dual variable domain immunoglobulins(DVD-Ig™). The present disclosure provides further novel bindingproteins that bind two or more antigens.

SUMMARY

Multivalent binding proteins that bind two or more antigens areprovided. A novel family of binding proteins capable of binding two ormore antigens with high affinity are also provided.

In one embodiment, a binding protein comprising a polypeptide chain,wherein the polypeptide chain comprises VD1-(X1)n-VD2-C—(X2)n, whereinVD1 is a first variable domain, VD2 is a second variable domain, C is aconstant domain, X1 represents an amino acid or polypeptide, X2represents an Fc region and n is 0 or 1 is provided. In an embodimentthe VD1 and VD2 in the binding protein are heavy chain variable domains.In another embodiment, the heavy chain variable domain is a murine heavychain variable domain, a human heavy chain variable domain, a CDRgrafted heavy chain variable domain, or a humanized heavy chain variabledomain. In yet another, embodiment VD1 and VD2 bind the same antigen. Inanother embodiment VD1 and VD2 bind different antigens. In still anotherembodiment, C is a heavy chain constant domain. For example, X1 is alinker with the proviso that X1 is not CH1. For example, X1 isAKTTPKLEEGEFSEAR (SEQ ID NO: 1); AKTTPKLEEGEFSEARV (SEQ ID NO: 2);AKTTPKLGG (SEQ ID NO: 3); SAKTTPKLGG (SEQ ID NO: 4); SAKTTP (SEQ ID NO:5); RADAAP (SEQ ID NO: 6); RADAAPTVS (SEQ ID NO: 7); RADAAAAGGPGS (SEQID NO: 8); RADAAAA(G₄S)₄ (SEQ ID NO: 9), SAKTTPKLEEGEFSEARV (SEQ ID NO:10); ADAAP (SEQ ID NO: 11); ADAAPTVSIFPP (SEQ ID NO: 12); TVAAP (SEQ IDNO: 13); TVAAPSVFIFPP (SEQ ID NO: 14); QPKAAP (SEQ ID NO: 15);QPKAAPSVTLFPP (SEQ ID NO: 16); AKTTPP (SEQ ID NO: 17); AKTTPPSVTPLAP(SEQ ID NO: 18); AKTTAP (SEQ ID NO: 19); AKTTAPSVYPLAP (SEQ ID NO: 20);ASTKGP (SEQ ID NO: 21); ASTKGPSVFPLAP (SEQ ID NO: 22), GGGGSGGGGSGGGGS(SEQ ID NO: 23); GENKVEYAPALMALS (SEQ ID NO: 24); GPAKELTPLKEAKVS (SEQID NO: 25); GHEAAAVMQVQYPAS (SEQ ID NO: 26); TVAAPSVFIFPPTVAAPSVFIFPP(SEQ ID NO: 27); or ASTKGPSVFPLAPASTKGPSVFPLAP (SEQ ID NO: 28). In anembodiment, X2 is an Fc region. In another embodiment, X2 is a variantFc region.

In an embodiment the binding protein disclosed herein comprises apolypeptide chain, wherein the polypeptide chain comprisesVD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first heavy chain variabledomain, VD2 is a second heavy chain variable domain, C is a heavy chainconstant domain, X1 is a linker with the proviso that it is not CH1, andX2 is an Fc region.

In an embodiment, VD1 and VD2 in the binding protein are light chainvariable domains. In an embodiment, the light chain variable domain is amurine light chain variable domain, a human light chain variable domain,a CDR grafted light chain variable domain, or a humanized light chainvariable domain. In one embodiment VD1 and VD2 bind the same antigen. Inanother embodiment VD1 and VD2 bind different antigens. In anembodiment, C is a light chain constant domain. In another embodiment,X1 is a linker with the proviso that X1 is not CL1. In an embodiment, X1is AKTTPKLEEGEFSEAR (SEQ ID NO: 1); AKTTPKLEEGEFSEARV (SEQ ID NO: 2);AKTTPKLGG (SEQ ID NO: 3); SAKTTPKLGG (SEQ ID NO: 4); SAKTTP (SEQ ID NO:5); RADAAP (SEQ ID NO: 6); RADAAPTVS (SEQ ID NO: 7); RADAAAAGGPGS (SEQID NO: 8); RADAAAA(G₄S)₄ (SEQ ID NO: 9); SAKTTPKLEEGEFSEARV (SEQ ID NO:10); ADAAP (SEQ ID NO: 11); ADAAPTVSIFPP (SEQ ID NO: 12); TVAAP (SEQ IDNO: 13); TVAAPSVFIFPP (SEQ ID NO: 14); QPKAAP (SEQ ID NO: 15);QPKAAPSVTLFPP (SEQ ID NO: 16); AKTTPP (SEQ ID NO: 17); AKTTPPSVTPLAP(SEQ ID NO: 18); AKTTAP (SEQ ID NO: 19); AKTTAPSVYPLAP (SEQ ID NO: 20);ASTKGP (SEQ ID NO: 21); ASTKGPSVFPLAP (SEQ ID NO: 22) GGGGSGGGGSGGGGS(SEQ ID NO: 23); GENKVEYAPALMALS (SEQ ID NO: 24); GPAKELTPLKEAKVS (SEQID NO: 25); GHEAAAVMQVQYPAS (SEQ ID NO: 26); TVAAPSVFIFPPTVAAPSVFIFPP(SEQ ID NO: 27); or ASTKGPSVFPLAPASTKGPSVFPLAP (SEQ ID NO: 28. In anembodiment, the binding protein does not comprise X2.

In an embodiment, both the variable heavy and variable light chaincomprise the same linker. In another embodiment, the variable heavy andvariable light chain comprise different linkers. In another embodiment,both the variable heavy and variable light chain comprise a short (about6 amino acids) linker. In another embodiment, both the variable heavyand variable light chain comprise a long (greater than 6 amino acids)linker. In another embodiment, the variable heavy chain comprises ashort linker and the variable light chain comprises a long linker. Inanother embodiment, the variable heavy chain comprises a long linker andthe variable light chain comprises a short linker.

In an embodiment the binding protein disclosed herein comprises apolypeptide chain, wherein said polypeptide chain comprisesVD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first light chain variabledomain, VD2 is a second light chain variable domain, C is a light chainconstant domain, X1 is a linker with the proviso that it is not CH1, andX2 does not comprise an Fc region.

In another embodiment, a binding protein comprising two polypeptidechains, wherein said first polypeptide chain comprisesVD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first heavy chain variabledomain, VD2 is a second heavy chain variable domain, C is a heavy chainconstant domain, X1 is a linker with the proviso that it is not CH1, andX2 is an Fc region; and said second polypeptide chain comprisesVD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first light chain variabledomain, VD2 is a second light chain variable domain, C is a light chainconstant domain, X1 is a linker with the proviso that it is not CH1, andX2 does not comprise an Fc region is provided. In a particularembodiment, the Dual Variable Domain (DVD) binding protein comprisesfour polypeptide chains wherein the first two polypeptide chainscomprises VD1-(X1)n-VD2-C—(X2)n, respectively wherein VD1 is a firstheavy chain variable domain, VD2 is a second heavy chain variabledomain, C is a heavy chain constant domain, X1 is a linker with theproviso that it is not CH1, and X2 is an Fc region; and the second twopolypeptide chain comprises VD1-(X1)n-VD2-C—(X2)n respectively, whereinVD1 is a first light chain variable domain, VD2 is a second light chainvariable domain, C is a light chain constant domain, X1 is a linker withthe proviso that it is not CH1, and X2 does not comprise an Fc region.Such a Dual Variable Domain (DVD) protein has four antigen bindingsites.

In another embodiment the binding proteins disclosed herein are capableof binding one or more targets. Accordingly, in some embodiments, thebinding proteins comprise at least two variable domain sequences (e.g.,VD1 and VD2) capable of binding at least two different targets. In someembodiments, VD1 and VD2 are independently chosen. Therefore, in someembodiments, VD1 and VD2 comprise the same SEQ ID NO and, in otherembodiments, VD1 and VD2 comprise different SEQ ID NOS.

In another embodiment the binding proteins disclosed herein bind one ormore targets. In an embodiment, the target is a cytokine, a cell surfaceprotein, an enzyme, or a receptor. In another embodiment, the bindingprotein modulates a biological function of one or more targets. Inanother embodiment, the binding protein neutralizes one or more targets.In yet another embodiment, the cytokine is a lymphokine, monokine,polypeptide hormone, receptor, or tumor marker. For example, in someembodiments, the binding protein is capable of binding two or more ofthe following: IL-1β (seq. 1), IL-1β (seq. 2), IL-1β (seq. 3), IL-1β(seq. 4), IL-1β (seq. 5), IL-17 (seq. 1), IL-17 (seq. 2), or IL-17 (seq.3).

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 50 or SEQ ID NO. 52; and a DVD light chain aminoacid sequence SEQ ID NO. 51 or SEQ ID NO. 53. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO.50 and aDVD light chain amino acid sequence of SEQ ID NO: 51. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 52 and a DVD light chain amino acidsequence of SEQ ID NO: 53.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 54 or SEQ ID NO. 56; and a DVD light chain aminoacid sequence SEQ ID NO. 55 or SEQ ID NO. 57. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 54 and aDVD light chain amino acid sequence of SEQ ID NO: 55. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 56 and a DVD light chain amino acidsequence of SEQ ID NO: 57.

In another embodiment, the binding protein capable of binding IL-1β(seq. 3) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 58 or SEQ ID NO. 60; and a DVD light chain aminoacid sequence SEQ ID NO. 59 or SEQ ID NO. 61. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 58 and aDVD light chain amino acid sequence of SEQ ID NO: 59. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 60 and a DVD light chain amino acidsequence of SEQ ID NO: 61.

In another embodiment, the binding protein capable of binding IL-1β(seq. 4) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 62 or SEQ ID NO. 64; and a DVD light chain aminoacid sequence SEQ ID NO. 63 or SEQ ID NO. 65. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 62 and aDVD light chain amino acid sequence of SEQ ID NO: 63. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 64 and a DVD light chain amino acidsequence of SEQ ID NO: 65.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 66 or SEQ ID NO. 68; and a DVD light chain aminoacid sequence SEQ ID NO. 67 or SEQ ID NO. 69. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 66 and aDVD light chain amino acid sequence of SEQ ID NO: 67. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 68 and a DVD light chain amino acidsequence of SEQ ID NO: 69.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 70 or SEQ ID NO. 72; and a DVD light chain aminoacid sequence SEQ ID NO. 71 or SEQ ID NO. 73. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 70 and aDVD light chain amino acid sequence of SEQ ID NO: 71. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 72 and a DVD light chain amino acidsequence of SEQ ID NO: 73.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 74 or SEQ ID NO. 76; and a DVD light chain aminoacid sequence SEQ ID NO. 75 or SEQ ID NO. 77. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 74 and aDVD light chain amino acid sequence of SEQ ID NO: 75. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 76 and a DVD light chain amino acidsequence of SEQ ID NO: 77.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 78 or SEQ ID NO. 80; and a DVD light chain aminoacid sequence SEQ ID NO. 79 or SEQ ID NO. 81. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 78 and aDVD light chain amino acid sequence of SEQ ID NO: 79. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 80 and a DVD light chain amino acidsequence of SEQ ID NO: 81.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 4) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 82 or SEQ ID NO. 84; and a DVD light chain aminoacid sequence SEQ ID NO. 83 or SEQ ID NO. 85. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 82 and aDVD light chain amino acid sequence of SEQ ID NO: 83. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 84 and a DVD light chain amino acidsequence of SEQ ID NO: 85.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 86 or SEQ ID NO. 88; and a DVD light chain aminoacid sequence SEQ ID NO. 87 or SEQ ID NO. 89. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 86 and aDVD light chain amino acid sequence of SEQ ID NO: 87. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 88 and a DVD light chain amino acidsequence of SEQ ID NO: 89.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 90 or SEQ ID NO. 92; and a DVD light chain aminoacid sequence SEQ ID NO. 91 or SEQ ID NO. 93. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 90 and aDVD light chain amino acid sequence of SEQ ID NO: 91. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 92 and a DVD light chain amino acidsequence of SEQ ID NO: 93.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 94 or SEQ ID NO. 96; and a DVD light chain aminoacid sequence SEQ ID NO. 95 or SEQ ID NO. 97. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 94 and aDVD light chain amino acid sequence of SEQ ID NO: 95. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 96 and a DVD light chain amino acidsequence of SEQ ID NO: 97.

In another embodiment, the binding protein capable of binding IL-1β(seq. 3) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 98 or SEQ ID NO. 100; and a DVD light chain aminoacid sequence SEQ ID NO. 99 or SEQ ID NO. 101. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 98 and aDVD light chain amino acid sequence of SEQ ID NO: 99. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 100 and a DVD light chain amino acidsequence of SEQ ID NO: 101.

In another embodiment, the binding protein capable of binding IL-1β(seq. 4) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 102 or SEQ ID NO. 104; and a DVD light chain aminoacid sequence SEQ ID NO. 103 or SEQ ID NO. 105. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 102 and aDVD light chain amino acid sequence of SEQ ID NO: 103. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 104 and a DVD light chain amino acidsequence of SEQ ID NO: 105.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 106 or SEQ ID NO. 108; and a DVD light chain aminoacid sequence SEQ ID NO. 107 or SEQ ID NO. 109. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 106 and aDVD light chain amino acid sequence of SEQ ID NO: 107. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 108 and a DVD light chain amino acidsequence of SEQ ID NO: 109.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 110 or SEQ ID NO. 112; and a DVD light chain aminoacid sequence SEQ ID NO. 111 or SEQ ID NO. 113. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO.110 and aDVD light chain amino acid sequence of SEQ ID NO: 111. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 112 and a DVD light chain amino acidsequence of SEQ ID NO: 113.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 114 or SEQ ID NO. 116; and a DVD light chain aminoacid sequence SEQ ID NO. 115 or SEQ ID NO. 117. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 114 and aDVD light chain amino acid sequence of SEQ ID NO: 115. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 116 and a DVD light chain amino acidsequence of SEQ ID NO: 117.

In another embodiment, the binding protein capable of binding IL-1β(seq. 3) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 118 or SEQ ID NO. 120; and a DVD light chain aminoacid sequence SEQ ID NO. 119 or SEQ ID NO. 121. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 118 and aDVD light chain amino acid sequence of SEQ ID NO: 119. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 120 and a DVD light chain amino acidsequence of SEQ ID NO: 121.

In another embodiment, the binding protein capable of binding IL-1β(seq. 4) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 122 or SEQ ID NO. 124; and a DVD light chain aminoacid sequence SEQ ID NO. 123 or SEQ ID NO. 125. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 122 and aDVD light chain amino acid sequence of SEQ ID NO: 123. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 124 and a DVD light chain amino acidsequence of SEQ ID NO: 125.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 126 or SEQ ID NO. 128; and a DVD light chain aminoacid sequence SEQ ID NO. 127 or SEQ ID NO. 129. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 126 and aDVD light chain amino acid sequence of SEQ ID NO: 127. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 128 and a DVD light chain amino acidsequence of SEQ ID NO: 129.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 130 or SEQ ID NO. 132; and a DVD light chain aminoacid sequence SEQ ID NO. 131 or SEQ ID NO. 133. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 130 and aDVD light chain amino acid sequence of SEQ ID NO: 131. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 132 and a DVD light chain amino acidsequence of SEQ ID NO: 133.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 134 or SEQ ID NO. 136; and a DVD light chain aminoacid sequence SEQ ID NO. 135 or SEQ ID NO. 137. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 134 and aDVD light chain amino acid sequence of SEQ ID NO: 135. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 136 and a DVD light chain amino acidsequence of SEQ ID NO: 137.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 138 or SEQ ID NO. 140; and a DVD light chain aminoacid sequence SEQ ID NO. 139 or SEQ ID NO. 141. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 138 and aDVD light chain amino acid sequence of SEQ ID NO: 139. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 140 and a DVD light chain amino acidsequence of SEQ ID NO: 141.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 4) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 142 or SEQ ID NO. 144; and a DVD light chain aminoacid sequence SEQ ID NO. 143 or SEQ ID NO. 145. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 142 and aDVD light chain amino acid sequence of SEQ ID NO: 143. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 144 and a DVD light chain amino acidsequence of SEQ ID NO: 145.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 146 or SEQ ID NO. 148; and a DVD light chain aminoacid sequence SEQ ID NO. 147 or SEQ ID NO. 149. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 146 and aDVD light chain amino acid sequence of SEQ ID NO: 147. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 148 and a DVD light chain amino acidsequence of SEQ ID NO: 149.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 150 or SEQ ID NO. 152; and a DVD light chain aminoacid sequence SEQ ID NO. 151 or SEQ ID NO. 153. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 150 and aDVD light chain amino acid sequence of SEQ ID NO: 151. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 152 and a DVD light chain amino acidsequence of SEQ ID NO: 153.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 154 or SEQ ID NO. 156; and a DVD light chain aminoacid sequence SEQ ID NO. 155 or SEQ ID NO. 157. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 154 and aDVD light chain amino acid sequence of SEQ ID NO: 155. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 156 and a DVD light chain amino acidsequence of SEQ ID NO: 157.

In another embodiment, the binding protein capable of binding IL-1β(seq. 3) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 158 or SEQ ID NO. 160; and a DVD light chain aminoacid sequence SEQ ID NO. 159 or SEQ ID NO. 161. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 158 and aDVD light chain amino acid sequence of SEQ ID NO: 159. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 160 and a DVD light chain amino acidsequence of SEQ ID NO: 161.

In another embodiment, the binding protein capable of binding IL-1β(seq. 4) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 162 or SEQ ID NO. 164; and a DVD light chain aminoacid sequence SEQ ID NO. 163 or SEQ ID NO. 165. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 162 and aDVD light chain amino acid sequence of SEQ ID NO: 163. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 164 and a DVD light chain amino acidsequence of SEQ ID NO: 165.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 166 or SEQ ID NO. 168; and a DVD light chain aminoacid sequence SEQ ID NO. 167 or SEQ ID NO. 169. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 166 and aDVD light chain amino acid sequence of SEQ ID NO: 167. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 168 and a DVD light chain amino acidsequence of SEQ ID NO: 169.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 170 or SEQ ID NO. 172; and a DVD light chain aminoacid sequence SEQ ID NO. 171 or SEQ ID NO. 173. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO:170 and aDVD light chain amino acid sequence of SEQ ID NO: 171. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 172 and a DVD light chain amino acidsequence of SEQ ID NO: 173.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 174 or SEQ ID NO. 176; and a DVD light chain aminoacid sequence SEQ ID NO. 175 or SEQ ID NO. 177. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 174 and aDVD light chain amino acid sequence of SEQ ID NO: 175. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 176 and a DVD light chain amino acidsequence of SEQ ID NO: 177.

In another embodiment, the binding protein capable of binding IL-1β(seq. 3) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 178 or SEQ ID NO. 180; and a DVD light chain aminoacid sequence SEQ ID NO. 179 or SEQ ID NO. 181. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 178 and aDVD light chain amino acid sequence of SEQ ID NO: 179. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 180 and a DVD light chain amino acidsequence of SEQ ID NO: 181.

In another embodiment, the binding protein capable of binding IL-1β(seq. 4) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 182 or SEQ ID NO. 184; and a DVD light chain aminoacid sequence SEQ ID NO. 183 or SEQ ID NO. 185. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 182 and aDVD light chain amino acid sequence of SEQ ID NO: 183. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 184 and a DVD light chain amino acidsequence of SEQ ID NO: 185.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 186 or SEQ ID NO. 188; and a DVD light chain aminoacid sequence SEQ ID NO. 187 or SEQ ID NO. 189. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 186 and aDVD light chain amino acid sequence of SEQ ID NO: 187. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 188 and a DVD light chain amino acidsequence of SEQ ID NO: 189.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 190 or SEQ ID NO. 192; and a DVD light chain aminoacid sequence SEQ ID NO. 191 or SEQ ID NO. 193. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 190 and aDVD light chain amino acid sequence of SEQ ID NO: 191. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 192 and a DVD light chain amino acidsequence of SEQ ID NO: 193.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 194 or SEQ ID NO. 196; and a DVD light chain aminoacid sequence SEQ ID NO. 195 or SEQ ID NO. 197. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 194 and aDVD light chain amino acid sequence of SEQ ID NO: 195. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 196 and a DVD light chain amino acidsequence of SEQ ID NO: 197.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 198 or SEQ ID NO. 200; and a DVD light chain aminoacid sequence SEQ ID NO. 199 or SEQ ID NO. 201. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 198 and aDVD light chain amino acid sequence of SEQ ID NO: 199. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 200 and a DVD light chain amino acidsequence of SEQ ID NO: 201.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 4) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 202 or SEQ ID NO. 204; and a DVD light chain aminoacid sequence SEQ ID NO. 203 or SEQ ID NO. 205. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 202 and aDVD light chain amino acid sequence of SEQ ID NO: 203. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 204 and a DVD light chain amino acidsequence of SEQ ID NO: 205.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 206 or SEQ ID NO. 208; and a DVD light chain aminoacid sequence SEQ ID NO. 207 or SEQ ID NO. 209. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 206 and aDVD light chain amino acid sequence of SEQ ID NO: 207. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 208 and a DVD light chain amino acidsequence of SEQ ID NO: 209.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 210 or SEQ ID NO. 212; and a DVD light chain aminoacid sequence SEQ ID NO. 211 or SEQ ID NO. 213. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 210 and aDVD light chain amino acid sequence of SEQ ID NO: 211. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 212 and a DVD light chain amino acidsequence of SEQ ID NO: 213.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 214 or SEQ ID NO. 216; and a DVD light chain aminoacid sequence SEQ ID NO. 215 or SEQ ID NO. 217. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 214 and aDVD light chain amino acid sequence of SEQ ID NO: 215. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 216 and a DVD light chain amino acidsequence of SEQ ID NO: 217.

In another embodiment, the binding protein capable of binding IL-1β(seq. 3) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 218 or SEQ ID NO. 220; and a DVD light chain aminoacid sequence SEQ ID NO. 219 or SEQ ID NO. 221. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 218 and aDVD light chain amino acid sequence of SEQ ID NO: 219. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 220 and a DVD light chain amino acidsequence of SEQ ID NO: 221.

In another embodiment, the binding protein capable of binding IL-1β(seq. 4) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 222 or SEQ ID NO. 224; and a DVD light chain aminoacid sequence SEQ ID NO. 223 or SEQ ID NO. 225. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 222 and aDVD light chain amino acid sequence of SEQ ID NO: 223. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 224 and a DVD light chain amino acidsequence of SEQ ID NO: 225.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 226 or SEQ ID NO. 228; and a DVD light chain aminoacid sequence SEQ ID NO. 227 or SEQ ID NO. 229. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 226 and aDVD light chain amino acid sequence of SEQ ID NO: 227. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 228 and a DVD light chain amino acidsequence of SEQ ID NO: 229.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 230 or SEQ ID NO. 232; and a DVD light chain aminoacid sequence SEQ ID NO. 231 or SEQ ID NO. 233. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO:230 and aDVD light chain amino acid sequence of SEQ ID NO: 231. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 232 and a DVD light chain amino acidsequence of SEQ ID NO: 233.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 234 or SEQ ID NO. 236; and a DVD light chain aminoacid sequence SEQ ID NO. 235 or SEQ ID NO. 237. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 234 and aDVD light chain amino acid sequence of SEQ ID NO: 235. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 236 and a DVD light chain amino acidsequence of SEQ ID NO: 237.

In another embodiment, the binding protein capable of binding IL-1β(seq. 3) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 238 or SEQ ID NO. 240; and a DVD light chain aminoacid sequence SEQ ID NO. 239 or SEQ ID NO. 241. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 238 and aDVD light chain amino acid sequence of SEQ ID NO: 239. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 240 and a DVD light chain amino acidsequence of SEQ ID NO: 241.

In another embodiment, the binding protein capable of binding IL-1β(seq. 4) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 242 or SEQ ID NO. 244; and a DVD light chain aminoacid sequence SEQ ID NO. 243 or SEQ ID NO. 245. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 242 and aDVD light chain amino acid sequence of SEQ ID NO: 243. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 244 and a DVD light chain amino acidsequence of SEQ ID NO: 245.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 1) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 246 or SEQ ID NO. 248; and a DVD light chain aminoacid sequence SEQ ID NO. 247 or SEQ ID NO. 249. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 1)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 246 and aDVD light chain amino acid sequence of SEQ ID NO: 247. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 1) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 248 and a DVD light chain amino acidsequence of SEQ ID NO: 249.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 250 or SEQ ID NO. 252; and a DVD light chain aminoacid sequence SEQ ID NO. 251 or SEQ ID NO. 253. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 250 and aDVD light chain amino acid sequence of SEQ ID NO: 251. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 252 and a DVD light chain amino acidsequence of SEQ ID NO: 253.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 254 or SEQ ID NO. 256; and a DVD light chain aminoacid sequence SEQ ID NO. 255 or SEQ ID NO. 257. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 254 and aDVD light chain amino acid sequence of SEQ ID NO: 255. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 256 and a DVD light chain amino acidsequence of SEQ ID NO: 257.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 258 or SEQ ID NO. 260; and a DVD light chain aminoacid sequence SEQ ID NO. 259 or SEQ ID NO. 261. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 258 and aDVD light chain amino acid sequence of SEQ ID NO: 259. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 260 and a DVD light chain amino acidsequence of SEQ ID NO: 261.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 4) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 262 or SEQ ID NO. 264; and a DVD light chain aminoacid sequence SEQ ID NO. 263 or SEQ ID NO. 265. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 262 and aDVD light chain amino acid sequence of SEQ ID NO: 263. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 264 and a DVD light chain amino acidsequence of SEQ ID NO: 265.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 2) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 266 or SEQ ID NO. 268; and a DVD light chain aminoacid sequence SEQ ID NO. 267 or SEQ ID NO. 269. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 2)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 266 and aDVD light chain amino acid sequence of SEQ ID NO: 267. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 2) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 268 and a DVD light chain amino acidsequence of SEQ ID NO: 269.

In another embodiment, the binding protein capable of binding IL-1β(seq. 1) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 270 or SEQ ID NO. 272; and a DVD light chain aminoacid sequence SEQ ID NO. 271 or SEQ ID NO. 273. In an embodiment, thebinding protein capable of binding IL-1β (seq. 1) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 270 and aDVD light chain amino acid sequence of SEQ ID NO: 271. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 1) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 272 and a DVD light chain amino acidsequence of SEQ ID NO: 273.

In another embodiment, the binding protein capable of binding IL-1β(seq. 2) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 274 or SEQ ID NO. 276; and a DVD light chain aminoacid sequence SEQ ID NO. 275 or SEQ ID NO. 277. In an embodiment, thebinding protein capable of binding IL-1β (seq. 2) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 274 and aDVD light chain amino acid sequence of SEQ ID NO: 275. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 2) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 276 and a DVD light chain amino acidsequence of SEQ ID NO: 277.

In another embodiment, the binding protein capable of binding IL-1β(seq. 3) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 278 or SEQ ID NO. 280; and a DVD light chain aminoacid sequence SEQ ID NO. 279 or SEQ ID NO. 281. In an embodiment, thebinding protein capable of binding IL-1β (seq. 3) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 278 and aDVD light chain amino acid sequence of SEQ ID NO: 279. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 3) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 280 and a DVD light chain amino acidsequence of SEQ ID NO: 281.

In another embodiment, the binding protein capable of binding IL-1β(seq. 4) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 282 or SEQ ID NO. 284; and a DVD light chain aminoacid sequence SEQ ID NO. 283 or SEQ ID NO. 285. In an embodiment, thebinding protein capable of binding IL-1β (seq. 4) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 282 and aDVD light chain amino acid sequence of SEQ ID NO: 283. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 4) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 284 and a DVD light chain amino acidsequence of SEQ ID NO: 285.

In another embodiment, the binding protein capable of binding IL-1β(seq. 5) and IL-17 (seq. 3) comprises a DVD heavy chain amino acidsequence SEQ ID NO. 286 or SEQ ID NO. 288; and a DVD light chain aminoacid sequence SEQ ID NO. 287 or SEQ ID NO. 289. In an embodiment, thebinding protein capable of binding IL-1β (seq. 5) and IL-17 (seq. 3)comprises a DVD heavy chain amino acid sequence of SEQ ID NO. 286 and aDVD light chain amino acid sequence of SEQ ID NO: 287. In anotherembodiment, the binding protein capable of binding IL-1β (seq. 5) andIL-17 (seq. 3) has a reverse orientation and comprises a DVD heavy chainamino acid sequence of SEQ ID NO. 288 and a DVD light chain amino acidsequence of SEQ ID NO: 289.

In another embodiment, a binding protein comprising a polypeptide chain,wherein said polypeptide chain comprises VD1-(X1)n-VD2-C—(X2)n, wherein;VD1 is a first heavy chain variable domain obtained from a first parentantibody, or antigen binding portion thereof; VD2 is a second heavychain variable domain obtained from a second parent antibody, or antigenbinding portion thereof, which can be the same or different from thefirst parent antibody; C is a heavy chain constant domain; (X1)n is alinker with the proviso that it is not CH1, wherein said (X1)n is eitherpresent or absent; and (X2)n is an Fc region, wherein said (X2)n iseither present or absent is provided. In an embodiment, the Fc region isabsent from the binding protein.

In another embodiment, a binding protein comprising a polypeptide chain,wherein said polypeptide chain comprises VD1-(X1)n-VD2-C—(X2)n, wherein,VD1 is a first light chain variable domain obtained from a first parentantibody or antigen binding portion thereof; VD2 is a second light chainvariable domain obtained from a second parent antibody or antigenbinding portion thereof, which can be the same or different from thefirst parent antibody; C is a light chain constant domain; (X1)n is alinker with the proviso that it is not CH1, wherein said (X1)n is eitherpresent or absent; and (X2)n does not comprise an Fc region, whereinsaid (X2)n is either present or absent is provided. In an embodiment,(X2)n is absent from the binding protein.

In another embodiment, the binding protein comprises first and secondpolypeptide chains, wherein said first polypeptide chain comprises afirst VD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first heavy chain variabledomain obtained from a first parent antibody or antigen binding portionthereof; VD2 is a second heavy chain variable domain obtained from asecond parent antibody or antigen binding portion thereof, which can bethe same or different from the first parent antibody; C is a heavy chainconstant domain; (X1)n is a linker with the proviso that it is not CH1,wherein said (X1)n is either present or absent; and (X2)n is an Fcregion, wherein said (X2)n is either present or absent; and wherein saidsecond polypeptide chain comprises a second VD1-(X1)n-VD2-C—(X2)n,wherein VD1 is a first light chain variable domain obtained from a firstparent antibody or antigen binding portion thereof; VD2 is a secondlight chain variable domain obtained from a second parent antibody orantigen binding portion thereof, which can be the same or different fromthe first parent antibody; C is a light chain constant domain; (X1)n isa linker with the proviso that it is not CH1, wherein said (X1)n iseither present or absent; and (X2)n does not comprise an Fc region,wherein said (X2)n is either present or absent. In another embodiment,the binding protein comprises two first polypeptide chains and twosecond polypeptide chains. In yet another embodiment, (X2)n is absentfrom the second polypeptide. In still another embodiment, the Fc region,if present in the first polypeptide is a native sequence Fc region or avariant sequence Fc region. In still another embodiment, the Fc regionis an Fc region from an IgG1, an Fc region from an IgG2, an Fc regionfrom an IgG3, an Fc region from an IgG4, an Fc region from an IgA, an Fcregion from an IgM, an Fc region from an IgE, or an Fc region from anIgD.

In another embodiment, the binding protein is a DVD-Ig that binds twoantigens comprising four polypeptide chains, wherein, each of the firstand third polypeptide chains comprise VD1-(X1)n-VD2-C—(X2)n, wherein,VD1 is a first heavy chain variable domain obtained from a first parentantibody, or antigen binding portion thereof; VD2 is a second heavychain variable domain obtained from a second parent antibody, or antigenbinding portion thereof, which can be the same as or different from thefirst parent antibody; C is a heavy chain constant domain; (X1)n is alinker with the proviso that it is not CH1, wherein said (X1)n is eitherpresent or absent; and (X2)n is an Fc region, wherein said (X2)n iseither present or absent; and wherein each of the second and fourthpolypeptide chains comprise VD1-(X1)n-VD2-C—(X2)n, wherein VD1 is afirst light chain variable domain obtained from a first parent antibodyor antigen binding portion thereof; VD2 is a second light chain variabledomain obtained from a second parent antibody, or antigen bindingportion thereof, which can be the same as or different from the firstparent antibody; C is a light chain constant domain; (X1)n is a linkerwith the proviso that it is not CH1, wherein said (X1)n is eitherpresent or absent; and (X2)n does not comprise an Fc region, whereinsaid (X2)n is either present or absent.

A method of making a DVD-Ig binding protein by preselecting the parentantibodies is provided. In an embodiment, the method of making a DualVariable Domain Immunoglobulin that binds two antigens comprises thesteps of a) obtaining a first parent antibody, or antigen bindingportion thereof, that binds a first antigen; b) obtaining a secondparent antibody or antigen binding portion thereof, that binds a secondantigen; c) constructing first and third polypeptide chains, each ofwhich comprises VD1-(X1)n-VD2-C—(X2)n, wherein, VD1 is a first heavychain variable domain obtained from said first parent antibody, orantigen binding portion thereof; VD2 is a second heavy chain variabledomain obtained from said second parent antibody or antigen bindingportion thereof, which can be the same as or different from the firstparent antibody; C is a heavy chain constant domain; (X1)n is a linkerwith the proviso that it is not CH1, wherein said (X1)n is eitherpresent or absent; and (X2)n is an Fc region, wherein said (X2)n iseither present or absent; d) constructing second and fourth polypeptidechains each of which comprises VD1-(X1)n-VD2-C—(X2)n, wherein, VD1 is afirst light chain variable domain obtained from said first parentantibody, or antigen binding portion thereof; VD2 is a second lightchain variable domain obtained from said second parent antibody, orantigen binding thereof, which can be the same as or different from thefirst parent antibody; C is a light chain constant domain; (X1)n is alinker with the proviso that it is not CH1, wherein said (X1)n is eitherpresent or absent; and (X2)n does not comprise an Fc region, whereinsaid (X2)n is either present or absent; and e) expressing said first,second, third and fourth polypeptide chains; such that a DVD-Ig bindssaid first antigen and said second antigen is generated.

In still another embodiment, a method of generating a DVD-Ig that bindstwo antigens with desired properties comprising the steps of a)obtaining a first parent antibody, or antigen binding portion thereof,that binds a first antigen and possessing at least one desired propertyexhibited by the DVD-Ig; b) obtaining a second parent antibody, orantigen binding portion thereof, which can be the same as or differentfrom the first parent antibody, can bind to a second antigen andpossesses at least one desired property exhibited by the Dual VariableDomain Immunoglobulin; c) constructing first and third polypeptidechains comprising VD1-(X1)n-VD2-C—(X2)n, wherein; VD1 is a first heavychain variable domain obtained from said first parent antibody, orantigen binding portion thereof; VD2 is a second heavy chain variabledomain obtained from said second parent antibody, or antigen bindingportion thereof; C is a heavy chain constant domain; (X1)n is a linkerwith the proviso that it is not CH1, wherein said (X1)n is eitherpresent or absent; and (X2)n is an Fc region, wherein said (X2)n iseither present or absent; d) constructing second and fourth polypeptidechains comprising VD1-(X1)n-VD2-C—(X2)n, wherein; VD1 is a first lightchain variable domain obtained from said first parent antibody, orantigen binding portion thereof; VD2 is a second light chain variabledomain obtained from said second parent antibody, or antigen bindingportion thereof), which can be the same as or different from the firstparent antibody; C is a light chain constant domain; (X1)n is a linkerwith the proviso that it is not CH1, wherein said (X1)n is eitherpresent or absent; and (X2)n does not comprise an Fc region, whereinsaid (X2)n is either present or absent; e) expressing said first,second, third and fourth polypeptide chains; such that a Dual VariableDomain Immunoglobulin capable of binding said first and said secondantigen with desired properties is generated is provided.

In one embodiment, the VDI of the first and second polypeptide chainsdisclosed herein are obtained from the same parent antibody or antigenbinding portion thereof. In another embodiment, the VDI of the first andsecond polypeptide chains disclosed herein are obtained from differentparent antibodies or antigen binding portions thereof. In anotherembodiment, the VD2 of the first and second polypeptide chains disclosedherein are obtained from the same parent antibody or antigen bindingportion thereof. In another embodiment, the VD2 of the first and secondpolypeptide chains disclosed herein are obtained from different parentantibodies or antigen binding portions thereof.

In one embodiment the first parent antibody or antigen binding portionthereof, and the second parent antibody or antigen binding portionthereof, are the same antibody. In another embodiment the first parentantibody or antigen binding portion thereof, and the second parentantibody or antigen binding portion thereof, are different antibodies.

In one embodiment the first parent antibody or antigen binding portionthereof, binds a first antigen and the second parent antibody or antigenbinding portion thereof, binds a second antigen. In a particularembodiment, the first and second antigens are the same antigen. Inanother embodiment, the parent antibodies bind different epitopes on thesame antigen. In another embodiment the first and second antigens aredifferent antigens. In another embodiment, the first parent antibody orantigen binding portion thereof, binds the first antigen with a potencydifferent from the potency with which the second parent antibody orantigen binding portion thereof, binds the second antigen. In yetanother embodiment, the first parent antibody or antigen binding portionthereof, binds the first antigen with an affinity different from theaffinity with which the second parent antibody or antigen bindingportion thereof, binds the second antigen.

In another embodiment the first parent antibody or antigen bindingportion thereof, and the second parent antibody or antigen bindingportion thereof, are human antibodies, CDR grafted antibodies, orhumanized antibodies. In an embodiment, the antigen binding portions areFab fragments, F(ab′)₂ fragments, bivalent fragments comprising two Fabfragments linked by a disulfide bridge at the hinge region, Fd fragmentsconsisting of the VH and CH1 domains; Fv fragments consisting of the VLand VH domains of a single arm of an antibody, dAb fragments, isolatedcomplementarity determining regions (CDR), single chain antibodies, ordiabodies.

In another embodiment, the binding protein possesses at least onedesired property exhibited by the first parent antibody or antigenbinding portion thereof, or the second parent antibody or antigenbinding portion thereof. Alternatively, the first parent antibody orantigen binding portion thereof and the second parent antibody orantigen binding portion thereof possess at least one desired propertyexhibited by the Dual Variable Domain Immunoglobulin. In an embodiment,the desired property is selected from one or more antibody parameters.In another embodiment, the antibody parameters are antigen specificity,affinity to antigen, potency, biological function, epitope recognition,stability, solubility, production efficiency, immunogenicity,pharmacokinetics, bioavailability, tissue cross reactivity, ororthologous antigen binding. In an embodiment the binding protein ismultivalent. In another embodiment, the binding protein ismultispecific. The multivalent and or multispecific binding proteinsdescribed herein have desirable properties particularly from atherapeutic standpoint. For instance, the multivalent and ormultispecific binding protein may (1) be internalized (and/orcatabolized) faster than a bivalent antibody by a cell expressing anantigen to which the antibodies bind; (2) be an agonist antibody; and/or(3) induce cell death and/or apoptosis of a cell expressing an antigento which the multivalent antibody binds. The “parent antibody,” whichprovides at least one antigen binding specificity of the multivalentand/or multispecific binding proteins, may be one which is internalized(and/or catabolized) by a cell expressing an antigen to which theantibody binds; and/or may be an agonist, cell death-inducing, and/orapoptosis-inducing antibody, and the multivalent and or multispecificbinding protein as described herein may display improvement(s) in one ormore of these properties. Moreover, the parent antibody may lack any oneor more of these properties, but may be endowed with them whenconstructed as a multivalent binding protein as described herein.

In another embodiment, the binding protein has an on rate constant (Kon)to one or more targets of: at least about 10²M⁻¹s⁻¹s⁻¹; at least about10³M⁻¹s⁻¹; at least about at least about 10⁵M⁻¹s⁻¹; or at least about10⁶M⁻¹s⁻¹, as measured by surface plasmon resonance. In an embodiment,the binding protein has an on rate constant (Kon) to one or more targetsbetween about 10²M⁻¹s⁻¹ and about 10³M⁻¹s⁻¹; between about 10³M⁻¹s⁻¹ andabout 10⁴M⁻¹s⁻¹; between about 10⁴M⁻¹s⁻¹ and about 10⁵M⁻¹s⁻¹; or betweenabout 10⁵M⁻¹s⁻¹ and about 10⁶M⁻¹s⁻¹, as measured by surface plasmonresonance.

In another embodiment the binding protein has an off rate constant(Koff) for one or more targets of: at most about 10⁻³ s⁻¹; at most about10⁻⁴ s⁻¹; at most about 10⁻⁵ s⁻¹; or at most about 10⁻⁶ s⁻¹, as measuredby surface plasmon resonance. In an embodiment, the binding protein hasan off rate constant (Koff) to one or more targets of from about 10⁻³s⁻¹ to about 10⁻⁴ s⁻¹; of from about 10⁻⁴ s⁻¹ to about 10⁻⁵ s⁻¹; or offrom about 10⁻⁵ s⁻¹ to about 10⁻⁶ s⁻¹, as measured by surface plasmonresonance.

In another embodiment the binding protein has a dissociation constant(K_(D)) to one or more targets of: at most about 10⁻⁷M; at most about10⁻⁸M; at most about 10⁻⁹M; at most about 10⁻¹⁰M at most about 10⁻¹¹M;at most about 10⁻¹²M; or at most about 10⁻¹³M. In an embodiment, thebinding protein has a dissociation constant (K_(D)) to its targets offrom about 10⁻⁷M to about 10⁻⁸M; of from about 10⁻⁸M to about 10⁻⁹M; offrom about 10⁻⁹M to about 10⁻¹⁰M of from about 10⁻¹⁰M to about 10⁻¹¹M;of from about 10⁻¹¹M to about 10⁻¹²M; or of from about 10⁻¹²M to about10⁻¹³M.

In another embodiment, the binding protein described herein is aconjugate further comprising an agent. In some embodiments, the agent isan immunoadhesion molecule, an imaging agent, a therapeutic agent, or acytotoxic agent. In an embodiment, the imaging agent is a radiolabel, anenzyme, a fluorescent label, a luminescent label, a bioluminescentlabel, a magnetic label, or biotin. In another embodiment, theradiolabel is: ³H, ¹⁴C, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho,or ¹⁵³Sm. In yet another embodiment, the therapeutic or cytotoxic agentis an anti-metabolite, an alkylating agent, an antibiotic, a growthfactor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, ananthracycline, toxin, or an apoptotic agent.

In another embodiment, the binding protein described herein is acrystallized binding protein and exists as a crystal. In an embodiment,the crystal is a carrier-free pharmaceutical controlled release crystal.In yet another embodiment, the crystallized binding protein has agreater half life in vivo than the soluble counterpart of said bindingprotein. In still another embodiment, the crystallized binding proteinretains biological activity.

In another embodiment, the binding protein described herein isglycosylated. For example, the glycosylation is a human glycosylationpattern.

An isolated nucleic acid encoding any one of the binding proteinsdisclosed herein is provided. A further embodiment provides a vectorcomprising the isolated nucleic acid disclosed herein wherein saidvector is pcDNA; pTT (Durocher et al. (2002) Nucl. Acids Res. 30: 2);pTT3 (pTT with additional multiple cloning site; pEFBOS (Mizushima, S,and Nagata, S. (1990) Nucl. Acids Res. 18: 17); pBV; pJV; pcDNA3.1 TOPO;pEF6 TOPO; or pBJ. In an embodiment, the vector is a vector disclosed inU.S. Patent Publication No. 2009/0239259.

In another aspect a host cell is transformed with the vector disclosedherein. In an embodiment, the host cell is a prokaryotic cell. Inanother embodiment, the host cell is E. coli. In a related embodimentthe host cell is a eukaryotic cell. In another embodiment, theeukaryotic cell is a protist cell, an animal cell, a plant cell, or afungal cell. In yet another embodiment, the host cell is a mammaliancell including, but not limited to, CHO, COS; NS0, SP2, PER.C6 or afungal cell, such as Saccharomyces cerevisiae; or an insect cell such asSf9.

In an embodiment, two or more DVD-Igs, e.g., with differentspecificities, are produced in a single recombinant host cell. Forexample, the expression of a mixture of antibodies has been calledOligoclonics™ (Merus B. V., The Netherlands); U.S. Pat. Nos. 7,262,028;7,429,486.

A method of producing a binding protein disclosed herein comprisingculturing any one of the host cells also disclosed herein in a culturemedium under conditions sufficient to produce the binding protein isprovided. In an embodiment, 50%-75% of the binding protein produced bythis method is a dual specific tetravalent binding protein. In aparticular embodiment, 75%-90% of the binding protein produced by thismethod is a dual specific tetravalent binding protein. In a particularembodiment, 90%-95% of the binding protein produced is a dual specifictetravalent binding protein.

One embodiment provides a composition for the release of a bindingprotein wherein the composition comprises a formulation that in turncomprises a crystallized binding protein, as disclosed herein, and aningredient, and at least one polymeric carrier. In another embodiment,the polymeric carrier comprises one or more polymers. In someembodiments, the polymers are poly (acrylic acid), poly(cyanoacrylates), poly (amino acids), poly (anhydrides), poly(depsipeptide), poly (esters), poly (lactic acid), poly(lactic-co-glycolic acid) or PLGA, poly (b-hydroxybutryate), poly(caprolactone), poly (dioxanone); poly (ethylene glycol), poly((hydroxypropyl)methacrylamide, poly [(organo)phosphazene], poly (orthoesters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleicanhydride-alkyl vinyl ether copolymers, pluronic polyols, albumin,alginate, cellulose and cellulose derivatives, collagen, fibrin,gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfatedpolysaccharides, or blends or copolymers thereof. In some embodiments,the ingredient is albumin, sucrose, trehalose, lactitol, gelatin,hydroxypropyl-β-cyclodextrin, methoxypolyethylene glycol or polyethyleneglycol. Another embodiment provides a method for treating a mammalcomprising the step of administering to the mammal an effective amountof the composition disclosed herein.

A pharmaceutical composition comprising a binding protein, as disclosedherein and a pharmaceutically acceptable carrier is provided. In afurther embodiment the pharmaceutical composition comprises at least oneadditional therapeutic agent for treating a disorder. In someembodiments, the additional agent is: a therapeutic agent, an imagingagent, a cytotoxic agent, an angiogenesis inhibitor (including but notlimited to an anti-VEGF antibody or a VEGF-trap), a kinase inhibitor(including but not limited to a KDR and a TIE-2 inhibitor), aco-stimulation molecule blocker (including but not limited to anti-B7.1,anti-B7.2, CTLA4-Ig, anti-CD20), an adhesion molecule blocker (includingbut not limited to an anti-LFA-1 antibody, an anti-E/L selectinantibody, a small molecule inhibitor), an anti-cytokine antibody orfunctional fragment thereof (including but not limited to an anti-IL-18,an anti-TNF, and an anti-IL-6/cytokine receptor antibody), methotrexate,cyclosporin, rapamycin, FK506, a detectable label or reporter, a TNFantagonist, an antirheumatic, a muscle relaxant, a narcotic, anon-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic,a sedative, a local anesthetic, a neuromuscular blocker, anantimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid,an erythropoietin, an immunization, an immunoglobulin, animmunosuppressive, a growth hormone, a hormone replacement drug, aradiopharmaceutical, an antidepressant, an antipsychotic, a stimulant,an asthma medication, a beta agonist, an inhaled steroid, an epinephrineor analog, a cytokine, or a cytokine antagonist.

A method for treating a human subject suffering from a disorder in whichthe target, or targets, that can be bound by the binding proteindisclosed herein is/are detrimental, comprising administering to thehuman subject a binding protein disclosed herein such that the activityof the target, or targets in the human subject is inhibited and one ofmore symptoms is alleviated or treatment is achieved is provided. Forexample, the disorder is arthritis, osteoarthritis, juvenile chronicarthritis, septic arthritis, Lyme arthritis, psoriatic arthritis,reactive arthritis, spondyloarthropathy, systemic lupus erythematosus,Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulindependent diabetes mellitus, thyroiditis, asthma, allergic diseases,psoriasis, dermatitis scleroderma, graft versus host disease, organtransplant rejection, acute or chronic immune disease associated withorgan transplantation, sarcoidosis, atherosclerosis, disseminatedintravascular coagulation, Kawasaki's disease, Grave's disease,nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis,Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys,chronic active hepatitis, uveitis, septic shock, toxic shock syndrome,sepsis syndrome, cachexia, infectious diseases, parasitic diseases,acquired immunodeficiency syndrome, acute transverse myelitis,Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke,primary biliary cirrhosis, hemolytic anemia, malignancies, heartfailure, myocardial infarction, Addison's disease, sporadicpolyglandular deficiency type I and polyglandular deficiency type II,Schmidt's syndrome, adult (acute) respiratory distress syndrome,alopecia, alopecia areata, seronegative arthopathy, arthropathy,Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy,enteropathic synovitis, chlamydia, yersinia and salmonella associatedarthropathy, spondyloarthopathy, atheromatous disease/arteriosclerosis,atopic allergy, autoimmune bullous disease, pemphigus vulgaris,pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmunehaemolytic anaemia, Coombs positive haemolytic anaemia, acquiredpernicious anaemia, juvenile pernicious anaemia, myalgicencephalitis/Royal Free Disease, chronic mucocutaneous candidiasis,giant cell arteritis, primary sclerosing hepatitis, cryptogenicautoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome,Acquired Immunodeficiency Related Diseases, Hepatitis B, Hepatitis C,common varied immunodeficiency (common variable hypogammaglobulinaemia),dilated cardiomyopathy, female infertility, ovarian failure, prematureovarian failure, fibrotic lung disease, cryptogenic fibrosingalveolitis, post-inflammatory interstitial lung disease, interstitialpneumonitis, connective tissue disease associated interstitial lungdisease, mixed connective tissue disease associated lung disease,systemic sclerosis associated interstitial lung disease, rheumatoidarthritis associated interstitial lung disease, systemic lupuserythematosus associated lung disease, dermatomyositis/polymyositisassociated lung disease, Sjögren's disease associated lung disease,ankylosing spondylitis associated lung disease, vasculitic diffuse lungdisease, haemosiderosis associated lung disease, drug-inducedinterstitial lung disease, fibrosis, radiation fibrosis, bronchiolitisobliterans, chronic eosinophilic pneumonia, lymphocytic infiltrativelung disease, postinfectious interstitial lung disease, gouty arthritis,autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmuneor lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibodyhepatitis), autoimmune mediated hypoglycemia, type B insulin resistancewith acanthosis nigricans, hypoparathyroidism, acute immune diseaseassociated with organ transplantation, chronic immune disease associatedwith organ transplantation, osteoarthrosis, primary sclerosingcholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia,autoimmune neutropaenia, renal disease NOS, glomerulonephritides,microscopic vasulitis of the kidneys, lyme disease, discoid lupuserythematosus, male infertility idiopathic or NOS, sperm autoimmunity,multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonaryhypertension secondary to connective tissue disease, Goodpasture'ssyndrome, pulmonary manifestation of polyarteritis nodosa, acuterheumatic fever, rheumatoid spondylitis, Still's disease, systemicsclerosis, Sjörgren's syndrome, Takayasu's disease/arteritis, autoimmunethrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroiddisease, hyperthyroidism, goitrous autoimmune hypothyroidism(Hashimoto's disease), atrophic autoimmune hypothyroidism, primarymyxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liverdisease, chronic liver diseases, alcoholic cirrhosis, alcohol-inducedliver injury, choleosatatis, idiosyncratic liver disease, Drug-Inducedhepatitis, Non-alcoholic Steatohepatitis, allergy and asthma, group Bstreptococci (GBS) infection, mental disorders (e.g., depression andschizophrenia), Th2 Type and Th1 Type mediated diseases, acute andchronic pain (different forms of pain), and cancers such as lung,breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectalcancer and hematopoietic malignancies (leukemia and lymphoma),Abetalipoprotemia, Acrocyanosis, acute and chronic parasitic orinfectious processes, acute leukemia, acute lymphoblastic leukemia(ALL), acute myeloid leukemia (AML), acute or chronic bacterialinfection, acute pancreatitis, acute renal failure, adenocarcinomas,aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis,allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis,allograft rejection, alpha-l-antitrypsin deficiency, amyotrophic lateralsclerosis, anemia, angina pectoris, anterior horn cell degeneration,anti cd3 therapy, antiphospholipid syndrome, anti-receptorhypersensitivity reactions, aortic and peripheral aneuryisms, aorticdissection, arterial hypertension, arteriosclerosis, arteriovenousfistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrialflutter, atrioventricular block, B cell lymphoma, bone graft rejection,bone marrow transplant (BMT) rejection, bundle branch block, Burkitt'slymphoma, Burns, cardiac arrhythmias, cardiac stun syndrome, cardiactumors, cardiomyopathy, cardiopulmonary bypass inflammation response,cartilage transplant rejection, cerebellar cortical degenerations,cerebellar disorders, chaotic or multifocal atrial tachycardia,chemotherapy associated disorders, chronic myelocytic leukemia (CML),chronic alcoholism, chronic inflammatory pathologies, chroniclymphocytic leukemia (CLL), chronic obstructive pulmonary disease(COPD), chronic salicylate intoxication, colorectal carcinoma,congestive heart failure, conjunctivitis, contact dermatitis, carpulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culturenegative sepsis, cystic fibrosis, cytokine therapy associated disorders,Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever,dermatitis, dermatologic conditions, diabetes, diabetes mellitus,diabetic ateriosclerotic disease, Diffuse Lewy body disease, dilatedcongestive cardiomyopathy, disorders of the basal ganglia, Down'sSyndrome in middle age, drug-induced movement disorders induced by drugswhich block CNS dopamine receptors, drug sensitivity, eczema,encephalomyelitis, endocarditis, endocrinopathy, epiglottitis,epstein-barr virus infection, erythromelalgia, extrapyramidal andcerebellar disorders, familial hematophagocytic lymphohistiocytosis,fetal thymus implant rejection, Friedreich's ataxia, functionalperipheral arterial disorders, fungal sepsis, gas gangrene, gastriculcer, glomerular nephritis, graft rejection of any organ or tissue,gram negative sepsis, gram positive sepsis, granulomas due tointracellular organisms, hairy cell leukemia, Hallerrorden-Spatzdisease, hashimoto's thyroiditis, hay fever, heart transplant rejection,hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolyticthrombocytopenic purpura, hemorrhage, hepatitis (A), His bundlearrythmias, HIV infection/HIV neuropathy, Hodgkin's disease,hyperkinetic movement disorders, hypersensitity reactions,hypersensitivity pneumonitis, hypertension, hypokinetic movementdisorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathicAddison's disease, idiopathic pulmonary fibrosis, antibody mediatedcytotoxicity, Asthenia, infantile spinal muscular atrophy, inflammationof the aorta, influenza a, ionizing radiation exposure,iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury,ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal muscularatrophy, Kaposi's sarcoma, kidney transplant rejection, legionella,leishmaniasis, leprosy, lesions of the corticospinal system, lipedema,liver transplant rejection, lymphederma, malaria, malignant Lymphoma,malignant histiocytosis, malignant melanoma, meningitis,meningococcemia, metabolic/idiopathic diseases, migraine headache,mitochondrial multi.system disorder, mixed connective tissue disease,monoclonal gammopathy, multiple myeloma, multiple systems degenerations(Mencel Dejerine-Thomas Shi-Drager and Machado-Joseph), myastheniagravis, mycobacterium avium intracellulare, mycobacterium tuberculosis,myelodyplastic syndrome, myocardial infarction, myocardial ischemicdisorders, nasopharyngeal carcinoma, neonatal chronic lung disease,nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscularatrophies, neutropenic fever, non-hodgkins lymphoma, occlusion of theabdominal aorta and its branches, occlusive arterial disorders, okt3therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures,organomegaly, osteoporosis, pancreas transplant rejection, pancreaticcarcinoma, paraneoplastic syndrome/hypercalcemia of malignancy,parathyroid transplant rejection, pelvic inflammatory disease, perennialrhinitis, pericardial disease, peripheral atherlosclerotic disease,peripheral vascular disorders, peritonitis, pernicious anemia,pneumocystis carinii pneumonia, pneumonia, POEMS syndrome(polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,and skin changes syndrome), post perfusion syndrome, post pump syndrome,post-MI cardiotomy syndrome, preeclampsia, Progressive supranucleoPalsy, primary pulmonary hypertension, radiation therapy, Raynaud'sphenomenon and disease, Raynaud's disease, Refsum's disease, regularnarrow QRS tachycardia, renovascular hypertension, reperfusion injury,restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, SenileDementia of Lewy body type, seronegative arthropathies, shock, sicklecell anemia, skin allograft rejection, skin changes syndrome, smallbowel transplant rejection, solid tumors, specific arrythmias, spinalataxia, spinocerebellar degenerations, streptococcal myositis,structural lesions of the cerebellum, Subacute sclerosingpanencephalitis, Syncope, syphilis of the cardiovascular system,systemic anaphalaxis, systemic inflammatory response syndrome, systemiconset juvenile rheumatoid arthritis, T-cell or FAB ALL, Telangiectasia,thromboangitis obliterans, thrombocytopenia, toxicity, transplants,trauma/hemorrhage, type III hypersensitivity reactions, type IVhypersensitivity, unstable angina, uremia, urosepsis, urticaria,valvular heart diseases, varicose veins, vasculitis, venous diseases,venous thrombosis, ventricular fibrillation, viral and fungalinfections, vital encephalitis/aseptic meningitis, vital-associatedhemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease,xenograft rejection of any organ or tissue, acute coronary syndromes,acute idiopathic polyneuritis, acute inflammatory demyelinatingpolyradiculoneuropathy, acute ischemia, adult Still's disease, alopeciaareata, anaphylaxis, anti-phospholipid antibody syndrome, aplasticanemia, arteriosclerosis, atopic eczema, atopic dermatitis, autoimmunedermatitis, autoimmune disorder associated with streptococcus infection,autoimmune enteropathy, autoimmune hearing loss, autoimmunelymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmunepremature ovarian failure, blepharitis, bronchiectasis, bullouspemphigoid, cardiovascular disease, catastrophic antiphospholipidsyndrome, celiac disease, cervical spondylosis, chronic ischemia,cicatricial pemphigoid, clinically isolated syndrome (cis) with risk formultiple sclerosis, conjunctivitis, childhood onset psychiatricdisorder, chronic obstructive pulmonary disease (COPD), dacryocystitis,dermatomyositis, diabetic retinopathy, diabetes mellitus, diskherniation, disk prolaps, drug induced immune hemolytic anemia,endocarditis, endometriosis, endophthalmitis, episcleritis, erythemamultiforme, erythema multiforme major, gestational pemphigoid,Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathicParkinson's disease, idiopathic interstitial pneumonia, IgE-mediatedallergy, immune hemolytic anemia, inclusion body myositis, infectiousocular inflammatory disease, inflammatory demyelinating disease,inflammatory heart disease, inflammatory kidney disease, IPF/UIP,iritis, keratitis, keratojuntivitis sicca, Kussmaul disease orKussmaul-Meier disease, Landry's paralysis, Langerhan's cellhistiocytosis, livedo reticularis, macular degeneration, microscopicpolyangiitis, morbus bechterev, motor neuron disorders, mucous membranepemphigoid, multiple organ failure, myasthenia gravis, myelodysplasticsyndrome, myocarditis, nerve root disorders, neuropathy, non-A non-Bhepatitis, optic neuritis, osteolysis, ovarian cancer, pauciarticularJRA, peripheral artery occlusive disease (PAOD), peripheral vasculardisease (PVD), peripheral artery, disease (PAD), phlebitis,polyarteritis nodosa (or periarteritis nodosa), polychondritis,polymyalgia rheumatica, poliosis, polyarticular JRA, polyendocrinedeficiency syndrome, polymyositis, polymyalgia rheumatica (PMR),post-pump syndrome, primary Parkinsonism, prostate and rectal cancer andhematopoietic malignancies (leukemia and lymphoma), prostatitis, purered cell aplasia, primary adrenal insufficiency, recurrent neuromyelitisoptica, restenosis, rheumatic heart disease, SAPHO (synovitis, acne,pustulosis, hyperostosis, and osteitis), scleroderma, secondaryamyloidosis, shock lung, scleritis, sciatica, secondary adrenalinsufficiency, silicone associated connective tissue disease,sneddon-wilkinson dermatosis, spondilitis ankylosans, Stevens-Johnsonsyndrome (SJS), systemic inflammatory response syndrome, temporalarteritis, toxoplasmic retinitis, toxic epidermal necrolysis, transversemyelitis, TRAPS (tumor necrosis factor receptor, type 1 allergicreaction, type II diabetes, urticaria, usual interstitial pneumonia(UIP), vasculitis, vernal conjunctivitis, viral retinitis,Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular degeneration,wound healing, yersinia and salmonella associated arthropathy.

In an embodiment, diseases that can be treated or diagnosed with thecompositions and methods provided include, but are not limited to,primary and metastatic cancers, including carcinomas of breast, colon,rectum, lung, oropharynx, hypopharynx, esophagus, stomach, pancreas,liver, gallbladder and bile ducts, small intestine, urinary tract(including kidney, bladder and urothelium), female genital tract(including cervix, uterus, and ovaries as well as choriocarcinoma andgestational trophoblastic disease), male genital tract (includingprostate, seminal vesicles, testes and germ cell tumors), endocrineglands (including the thyroid, adrenal, and pituitary glands), and skin,as well as hemangiomas, melanomas, sarcomas (including those arisingfrom bone and soft tissues as well as Kaposi's sarcoma), tumors of thebrain, nerves, eyes, and meninges (including astrocytomas, gliomas,glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas,and meningiomas), solid tumors arising from hematopoietic malignanciessuch as leukemias, and lymphomas (both Hodgkin's and non-Hodgkin'slymphomas).

In an embodiment, the antibodies provided or antigen-binding portionsthereof, are used to treat cancer or in the prevention or inhibition ofmetastases from the tumors described herein either when used alone or incombination with radiotherapy and/or other chemotherapeutic agents.

A method of treating a patient suffering from a disorder comprising thestep of administering any one of the binding proteins disclosed hereinbefore, concurrently, or after the administration of a second agent, asdiscussed herein is provided. In a particular embodiment the secondagent is budenoside, epidermal growth factor, corticosteroids,cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptopurine,azathioprine, metronidazole, lipoxygenase inhibitors, mesalamine,olsalazine, balsalazide, antioxidants, thromboxane inhibitors, IL-1receptor antagonists, anti-IL-1β mAbs, anti-IL-6 or IL-6 receptor mAbs,growth factors, elastase inhibitors, pyridinyl-imidazole compounds,antibodies or agonists of TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-12,IL-13, IL-15, IL-16, IL-18, IL-23, EMAP-II, GM-CSF, FGF, and PDGF,antibodies of CD2, CD3, CD4, CD8, CD-19, CD25, CD28, CD30, CD40, CD45,CD69, CD90 or their ligands, methotrexate, cyclosporin, FK506,rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, ibuprofen,corticosteroids, prednisolone, phosphodiesterase inhibitors, adenosineagonists, antithrombotic agents, complement inhibitors, adrenergicagents, IRAK, NIK, IKK, p38, MAP kinase inhibitors, IL-1β convertingenzyme inhibitors, TNFα converting enzyme inhibitors, T-cell signallinginhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors, soluble p55 TNF receptor, soluble p75 TNF receptor,sIL-1RI, sIL-1RII, sIL-6R, antiinflammatory cytokines, IL-4, IL-10,IL-11, IL-13, or TGFβ.

In a particular embodiment the pharmaceutical compositions disclosedherein are administered to the patient by at least one mode selectedfrom parenteral, subcutaneous, intramuscular, intravenous,intrarticular, intrabronchial, intraabdominal, intracapsular,intracartilaginous, intracavitary, intracelial, intracerebellar,intracerebroventricular, intracolic, intracervical, intragastric,intrahepatic, intramyocardial, intraosteal, intrapelvic,intrapericardiac, intraperitoneal, intrapleural, intraprostatic,intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,intrasynovial, intrathoracic, intrauterine, intravesical, bolus,vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

At least one anti-idiotypic antibody to at least one binding proteinprovided herein is also provided. The anti-idiotypic antibody includesany protein or peptide containing molecule that comprises at least aportion of an immunoglobulin molecule such as, but not limited to, atleast one complementarily determining region (CDR) of a heavy or lightchain or a ligand binding portion thereof, a heavy chain or light chainvariable region, a heavy chain or light chain constant region, aframework region, or any portion thereof, that can be incorporated intoa binding protein provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is a schematic representation of Dual Variable Domain (DVD)-Igconstructs and shows the strategy for generation of a DVD-Ig from twoparent antibodies;

FIG. 1B, is a schematic representation of constructs DVD1-Ig, DVD2-Ig,and two chimeric mono-specific antibodies from hybridoma clones 2D13.E3(anti-IL-1α) and 13F5.G5 (anti-IL-1β).

DETAILED DESCRIPTION

Multivalent and/or multispecific binding proteins that bind two or moreantigens are provided. Specifically, dual variable domainimmunoglobulins (DVD-Ig), and pharmaceutical compositions thereof, aswell as nucleic acids, recombinant expression vectors and host cells formaking such DVD-Igs are provided. Methods of using the DVD-Igs to detectspecific antigens, either in vitro or in vivo are also provided.

Unless otherwise defined herein, scientific and technical terms usedherein shall have the meanings that are commonly understood by those ofordinary skill in the art. The meaning and scope of the terms should beclear, however, in the event of any latent ambiguity, definitionsprovided herein take precedent over any dictionary or extrinsicdefinition. Further, unless otherwise required by context, singularterms shall include pluralities and plural terms shall include thesingular. In this application, the use of “or” means “and/or” unlessstated otherwise. Furthermore, the use of the term “including,” as wellas other forms, such as “includes” and “included,” is not limiting.Also, terms such as “element” or “component” encompass both elements andcomponents comprising one unit and elements and components that comprisemore than one subunit unless specifically stated otherwise.

Generally, nomenclatures used in connection with, and techniques of,cell and tissue culture, molecular biology, immunology, microbiology,genetics and protein and nucleic acid chemistry and hybridizationdescribed herein are those well known and commonly used in the art. Themethods and techniques discussed herein are generally performedaccording to conventional methods well known in the art and as describedin various general and more specific references that are cited anddiscussed throughout the present specification unless otherwiseindicated. Enzymatic reactions and purification techniques are performedaccording to manufacturers specifications, as commonly accomplished inthe art or as described herein. The nomenclatures used in connectionwith, and the laboratory procedures and techniques of, analyticalchemistry, synthetic organic chemistry, and medicinal and pharmaceuticalchemistry described herein are those well known and commonly used in theart. Standard techniques are used for chemical syntheses, chemicalanalyses, pharmaceutical preparation, formulation, and delivery, andtreatment of patients.

Select terms are defined below:

The term “polypeptide” as used herein, refers to any polymeric chain ofamino acids. The terms “peptide” and “protein” are used interchangeablywith the term polypeptide and also refer to a polymeric chain of aminoacids. The term “polypeptide” encompasses native or artificial proteins,protein fragments and polypeptide analogs of a protein sequence. Apolypeptide may be monomeric or polymeric. Use of “polypeptide” hereinis intended to encompass polypeptide and fragments and variants(including fragments of variants) thereof, unless otherwise stated. Foran antigenic polypeptide, a fragment of polypeptide optionally containsat least one contiguous or nonlinear epitope of polypeptide. The preciseboundaries of the at least one epitope fragment can be confirmed usingordinary skill in the art. The fragment comprises at least about 5contiguous amino acids, such as at least about 10 contiguous aminoacids, at least about 15 contiguous amino acids, or at least about 20contiguous amino acids. A variant of polypeptide is as described herein.

The term “isolated protein” or “isolated polypeptide” is a protein orpolypeptide that by virtue of its origin or source of derivation is notassociated with naturally associated components that accompany it in itsnative state; is substantially free of other proteins from the samespecies; is expressed by a cell from a different species; or does notoccur in nature. Thus, a polypeptide that is chemically synthesized orsynthesized in a cellular system different from the cell from which itnaturally originates will be “isolated” from its naturally associatedcomponents. A protein may also be rendered substantially free ofnaturally associated components by isolation, using protein purificationtechniques well known in the art.

The term “recovering” as used herein, refers to the process of renderinga chemical species such as a polypeptide substantially free of naturallyassociated components by isolation, e.g., using protein purificationtechniques well known in the art.

“Biological activity” as used herein, refers to any one or more inherentbiological properties of a molecule (whether present naturally as foundin vivo, or provided or enabled by recombinant means). Biologicalproperties include but are not limited to binding a receptor; inducingcell proliferation, inhibiting cell growth, inducing other cytokines,inducing apoptosis, and enzymatic activity. Biological activity alsoincludes activity of an Ig molecule.

The terms “specific binding” or “specifically binding,” as used herein,in reference to the interaction of an antibody, a protein, or a peptidewith a second chemical species, mean that the interaction is dependentupon the presence of a particular structure (e.g., an antigenicdeterminant or epitope) on the chemical species; for example, anantibody recognizes and binds to a specific protein structure ratherthan to proteins generally. If an antibody is specific for epitope “A,”the presence of a molecule containing epitope A (or free, unlabeled A),in a reaction containing labeled “A” and the antibody, will reduce theamount of labeled A bound to the antibody.

The term “antibody,” as used herein, broadly refers to anyimmunoglobulin (Ig) molecule comprised of four polypeptide chains, twoheavy (H) chains and two light (L) chains, or any functional fragment,mutant, variant, or derivation thereof, which retains the essentialepitope binding features of an Ig molecule. Such mutant, variant, orderivative antibody formats are known in the art. Nonlimitingembodiments of which are discussed below.

In a full-length antibody, each heavy chain is comprised of a heavychain variable region (abbreviated herein as HCVR or VH) and a heavychain constant region. The heavy chain constant region is comprised ofthree domains, CH1, CH2 and CH3. Each light chain is comprised of alight chain variable region (abbreviated herein as LCVR or VL) and alight chain constant region. The light chain constant region iscomprised of one domain, CL. The VH and VL regions can be furthersubdivided into regions of hypervariability, termed complementaritydetermining regions (CDR), interspersed with regions that are moreconserved, termed framework regions (FR). Each VH and VL is composed ofthree CDRs and four FRs, arranged from amino-terminus tocarboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3,CDR3, and FR4. Immunoglobulin molecules can be of any type (e.g., IgG,IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG2, IgG 3, IgG4, IgA1and IgA2) or subclass.

The term “Fc region” is used to define the C-terminal region of animmunoglobulin heavy chain, which may be generated by papain digestionof an intact antibody. The Fc region may be a native sequence Fc regionor a variant Fc region. The Fc region of an immunoglobulin generallycomprises two constant domains, a CH2 domain and a CH3 domain, andoptionally comprises a CH4 domain. Replacements of amino acid residuesin the Fc portion to alter antibody effector function are known in theart (U.S. Pat. Nos. 5,648,260 and 5,624,821). The Fc portion of anantibody mediates several important effector functions e.g., cytokineinduction, ADCC, phagocytosis, complement dependent cytotoxicity (CDC)and half-life/clearance rate of antibody and antigen-antibody complexes.In some cases these effector functions are desirable for a therapeuticantibody but in other cases might be unnecessary or even deleterious,depending on the therapeutic objectives. Certain human IgG isotypes,particularly IgG1 and IgG3, mediate ADCC and CDC via binding to FcγRsand complement C1q, respectively. Neonatal Fc receptors (FcRn) are thecritical components determining the circulating half-life of antibodies.In still another embodiment at least one amino acid residue is replacedin the constant region of the antibody, for example the Fc region of theantibody, such that effector functions of the antibody are altered. Thedimerization of two identical heavy chains of an immunoglobulin ismediated by the dimerization of CH3 domains and is stabilized by thedisulfide bonds within the hinge region (Huber et al. (1976) Nature 264:415-20; Thies et al. (1999) J. Mol. Biol. 293: 67-79). Mutation ofcysteine residues within the hinge regions to prevent heavy chain-heavychain disulfide bonds will destabilize dimeration of CH3 domains.Residues responsible for CH3 dimerization have been identified(Dall'Acqua (1998) Biochem. 37: 9266-73). Therefore, it is possible togenerate a monovalent half-Ig. Interestingly, these monovalent half Igmolecules have been found in nature for both IgG and IgA subclasses(Seligman (1978) Ann. Immunol. 129: 855-70; Biewenga et al. (1983) Clin.Exp. Immunol. 51: 395-400). The stoichiometry of FcRn: Ig Fc region hasbeen determined to be 2:1 (West et al. (2000) Biochem. 39: 9698-708),and half Fc is sufficient for mediating FcRn binding (Kim et al. (1994)Eur. J. Immunol. 24: 542-548). Mutations to disrupt the dimerization ofCH3 domain may not have greater adverse effect on its FcRn binding asthe residues important for CH3 dimerization are located on the innerinterface of CH3 b sheet structure, whereas the region responsible forFcRn binding is located on the outside interface of CH2-CH3 domains.However, the half-Ig molecule may have certain advantages in tissuepenetration due to its smaller size in comparison to that of a regularantibody. In one embodiment at least one amino acid residue is replacedin the constant region of the binding protein provided herein, forexample the Fc region, such that the dimerization of the heavy chains isdisrupted, resulting in half DVD Ig molecules. The anti-inflammatoryactivity of IgG is completely dependent on sialylation of the N-linkedglycan of the IgG Fc fragment. The precise glycan requirements foranti-inflammatory activity has been determined, such that an appropriateIgG1 Fc fragment can be created, thereby generating a fully recombinant,sialylated IgG1 Fc with greatly enhanced potency (Anthony, R. M., et al.(2008) Science 320: 373-376).

The term “antigen-binding portion” of an antibody (or simply “antibodyportion”), as used herein, refers to one or more fragments of anantibody that retain the ability to bind specifically to an antigen. Ithas been shown that the antigen-binding function of an antibody can beperformed by fragments of a full-length antibody. Such antibodyembodiments may also be bispecific, dual specific, or multi-specificformats; specifically binding to two or more different antigens.Examples of binding fragments encompassed within the term“antigen-binding portion” of an antibody include (i) a Fab fragment, amonovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) aF(ab′)₂ fragment, a bivalent fragment comprising two Fab fragmentslinked by a disulfide bridge at the hinge region; (iii) a Fd fragmentconsisting of the VH and CH1 domains; (iv) a Fv fragment consisting ofthe VL and VH domains of a single arm of an antibody, (v) a dAb fragment(Ward (1989) Nature 341:544-546; PCT Publication No. WO 90/05144 A1),which comprises a single variable domain; and (vi) an isolatedcomplementarity determining region (CDR). Furthermore, although the twodomains of the Fv fragment, VL and VH, are coded for by separate genes,they can be joined, using recombinant methods, by a synthetic linkerthat enables them to be made as a single protein chain in which the VLand VH regions pair to form monovalent molecules (known as single chainFv (scFv); see e.g., Bird et al. (1988) Science 242: 423-426; and Hustonet al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). Such singlechain antibodies are also intended to be encompassed within the term“antigen-binding portion” of an antibody. Other forms of single chainantibodies, such as diabodies are also encompassed. Diabodies arebivalent, bispecific antibodies in which VH and VL domains are expressedon a single polypeptide chain, but using a linker that is too short toallow for pairing between the two domains on the same chain, therebyforcing the domains to pair with complementary domains of another chainand creating two antigen binding sites (see e.g., Holliger, P., et al.(1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al.(1994) Structure 2: 1121-1123). Such antibody binding portions are knownin the art (Kontermann and Dubel eds., Antibody Engineering (2001)Springer-Verlag. New York. p. 790 (ISBN 3-540-41354-5). In additionsingle chain antibodies also include “linear antibodies” comprising apair of tandem Fv segments (VH—CH1-VH—CH1) which, together withcomplementary light chain polypeptides, form a pair of antigen bindingregions (Zapata et al. (1995) Protein Eng. 8(10):1057-1062; and U.S.Pat. No. 5,641,870).

The term “multivalent binding protein” is used throughout thisspecification to denote a binding protein comprising two or more antigenbinding sites. In an embodiment, the multivalent binding protein isengineered to have the three or more antigen binding sites, and isgenerally not a naturally occurring antibody. The term “multispecificbinding protein” refers to a binding protein that binds two or morerelated or unrelated targets. Dual variable domain (DVD) bindingproteins provided herein comprise two or more antigen binding sites andare tetravalent or multivalent binding proteins. DVDs may bemonospecific, i.e., bind one antigen or multispecific, i.e., capable ofbinding two or more antigens. DVD binding proteins comprising two heavychain DVD polypeptides and two light chain DVD polypeptides are referredto as DVD-Ig. Each half of a DVD-Ig comprises a heavy chain DVDpolypeptide, and a light chain DVD polypeptide, and two antigen bindingsites. Each binding site comprises a heavy chain variable domain and alight chain variable domain with a total of 6 CDRs involved in antigenbinding per antigen binding site.

The term “bispecific antibody,” as used herein, refers to full-lengthantibodies that are generated by quadroma technology (see Milstein, C.and Cuello, A. C. (1983) Nature 305(5934): p. 537-540), by chemicalconjugation of two different monoclonal antibodies (see Staerz, U. D. etal. (1985) Nature 314(6012): 628-631), or by knob-into-hole or similarapproaches, which introduce mutations in the Fc region (see Holliger, P.et al. (1993) Proc. Natl. Acad. Sci. USA 90(14): 6444-6448), resultingin multiple different immunoglobulin species of which only one is thefunctional bispecific antibody. By molecular function, a bispecificantibody binds one antigen (or epitope) on one of its two binding arms(one pair of HC/LC), and binds a different antigen (or epitope) on itssecond arm (a different pair of HC/LC). By this definition, a bispecificantibody has two distinct antigen binding arms (in both specificity andCDR sequences), and is monovalent for each antigen it binds to.

The term “dual-specific antibody,” as used herein, refers to full-lengthantibodies that can bind two different antigens (or epitopes) in each ofits two binding arms (a pair of HC/LC) (see PCT Publication No. WO02/02773). Accordingly a dual-specific binding protein has two identicalantigen binding arms, with identical specificity and identical CDRsequences, and is bivalent for each antigen to which it binds.

A “functional antigen binding site” of a binding protein is one thatbinds a target antigen. The antigen binding affinity of the antigenbinding site is not necessarily as strong as the parent antibody fromwhich the antigen binding site is derived, but the ability to bindantigen must be measurable using any one of a variety of methods knownfor evaluating antibody binding to an antigen. Moreover, the antigenbinding affinity of each of the antigen binding sites of a multivalentantibody herein need not be quantitatively the same.

The term “cytokine” is a generic term for proteins released by one cellpopulation, which act on another cell population as intercellularmediators. Examples of such cytokines are lymphokines, monokines, andtraditional polypeptide hormones. Included among the cytokines aregrowth hormone such as human growth hormone, N-methionyl human growthhormone, and bovine growth hormone; parathyroid hormone; thyroxine;insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such asfollicle stimulating hormone (FSH), thyroid stimulating hormone (TSH),and luteinizing hormone (LH); hepatic growth factor; fibroblast growthfactor; prolactin; placental lactogen; tumor necrosis factor-alpha and-beta; mullerian-inhibiting substance; mouse gonadotropin-associatedpeptide; inhibin; activin; vascular endothelial growth factor; integrin;thrombopoietin (TPO); nerve growth factors such as NGF-alpha;platelet-growth factor; placental growth factor, transforming growthfactors (TGFs) such as TGF-alpha and TGF-beta; insulin-like growthfactor-1 and -11; erythropoietin (EPO); osteoinductive factors;interferons such as interferon-alpha, -beta and -gamma colonystimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocytemacrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs)such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10,IL-11, IL-12, IL-13, IL-15, IL-18, IL-21, IL-22, IL-23, and IL-33; atumor necrosis factor such as TNF-alpha or TNF-beta; and otherpolypeptide factors including LIF and kit ligand (KL). As used herein,the term cytokine includes proteins from natural sources or fromrecombinant cell culture and biologically active equivalents of thenative sequence cytokines.

The term “linker” is used to denote polypeptides comprising two or moreamino acid residues joined by peptide bonds and are used to link one ormore antigen binding portions. Such linker polypeptides are well knownin the art (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci.USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123).Exemplary linkers include, but are not limited to, AKTTPKLEEGEFSEAR (SEQID NO: 1); AKTTPKLEEGEFSEARV (SEQ ID NO: 2); AKTTPKLGG (SEQ ID NO: 3);SAKTTPKLGG (SEQ ID NO: 4); SAKTTP (SEQ ID NO: 5); RADAAP (SEQ ID NO: 6);RADAAPTVS (SEQ ID NO: 7); RADAAAAGGPGS (SEQ ID NO: 8); RADAAAA(G₄S)₄(SEQ ID NO: 9); SAKTTPKLEEGEFSEARV (SEQ ID NO: 10); ADAAP (SEQ ID NO:11); ADAAPTVSIFPP (SEQ ID NO: 12); TVAAP (SEQ ID NO: 13); TVAAPSVFIFPP(SEQ ID NO: 14); QPKAAP (SEQ ID NO: 15); QPKAAPSVTLFPP (SEQ ID NO: 16);AKTTPP (SEQ ID NO: 17); AKTTPPSVTPLAP (SEQ ID NO: 18); AKTTAP (SEQ IDNO: 19); AKTTAPSVYPLAP (SEQ ID NO: 20); ASTKGP (SEQ ID NO: 21);ASTKGPSVFPLAP (SEQ ID NO: 22), GGGGSGGGGSGGGGS (SEQ ID NO: 23);GENKVEYAPALMALS (SEQ ID NO: 24); GPAKELTPLKEAKVS (SEQ ID NO: 25);GHEAAAVMQVQYPAS (SEQ ID NO: 26), TVAAPSVFIFPPTVAAPSVFIFPP (SEQ ID NO:27); and ASTKGPSVFPLAPASTKGPSVFPLAP (SEQ ID NO: 28.

An “immunoglobulin constant domain” refers to a heavy or light chainconstant domain. Human IgG heavy chain and light chain constant domainamino acid sequences are known in the art.

The term “monoclonal antibody” or “mAb” as used herein refers to anantibody obtained from a population of substantially homogeneousantibodies, i.e., the individual antibodies comprising the populationare identical except for possible naturally occurring mutations that maybe present in minor amounts. Monoclonal antibodies are highly specific,being directed against a single antigen. Furthermore, in contrast topolyclonal antibody preparations that typically include differentantibodies directed against different determinants (epitopes), each mAbis directed against a single determinant on the antigen. The modifier“monoclonal” is not to be construed as requiring production of theantibody by any particular method.

The term “human antibody,” as used herein, is intended to includeantibodies having variable and constant regions derived from humangermline immunoglobulin sequences. The human antibodies provided hereinmay include amino acid residues not encoded by human germlineimmunoglobulin sequences (e.g., mutations introduced by random orsite-specific mutagenesis in vitro or by somatic mutation in vivo), forexample in the CDRs and in particular CDR3. However, the term “humanantibody,” as used herein, is not intended to include antibodies inwhich CDR sequences derived from the germline of another mammalianspecies, such as a mouse, have been grafted onto human frameworksequences.

The term “recombinant human antibody,” as used herein, is intended toinclude all human antibodies that are prepared, expressed, created orisolated by recombinant means, such as antibodies expressed using arecombinant expression vector transfected into a host cell (describedfurther in Section II C, below), antibodies isolated from a recombinant,combinatorial human antibody library (Hoogenboom H. R. (1997) TIB Tech.15:62-70; Azzazy H., and Highsmith W. E. (2002) Clin. Biochem.35:425-445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques29:128-145; Hoogenboom H., and Chames P. (2000) Immunol. Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that istransgenic for human immunoglobulin genes (see, Taylor, L. D., et al.(1992) Nucl. Acids Res. 20: 6287-6295; Kellermann S-A. and Green L. L.(2002) Current Opinion in Biotechnol. 13: 593-597; Little M. et al.(2000) Immunol. Today 21:364-370) or antibodies prepared, expressed,created or isolated by any other means that involves splicing of humanimmunoglobulin gene sequences to other DNA sequences. Such recombinanthuman antibodies have variable and constant regions derived from humangermline immunoglobulin sequences. In certain embodiments, however, suchrecombinant human antibodies are subjected to in vitro mutagenesis (or,when an animal transgenic for human Ig sequences is used, in vivosomatic mutagenesis) and thus the amino acid sequences of the VH and VLregions of the recombinant antibodies are sequences that, while derivedfrom and related to human germline VH and VL sequences, may notnaturally exist within the human antibody germline repertoire in vivo.

An “affinity matured” antibody is an antibody with one or morealterations in one or more CDRs thereof which result an improvement inthe affinity of the antibody for antigen, compared to a parent antibodywhich does not possess those alteration(s). Exemplary affinity maturedantibodies will have nanomolar or even picomolar affinities for thetarget antigen. Affinity matured antibodies are produced by proceduresknown in the art. Marks et al. (1992) Bio/Technology 10: 779-783describes affinity maturation by VH and VL domain shuffling. Randommutagenesis of CDR and/or framework residues is described by Barbas, etal. (1994) Proc Nat. Acad. Sci. USA 91: 3809-3813; Schier et al. (1995)Gene 169: 147-155; Yelton et al., (1995) J. Immunol. 155: 1994-2004;Jackson et al. (1995) J. Immunol. 154(7): 3310-9; and Hawkins et al.(1992) J. Mol. Biol. 226: 889-896; and selective mutation at selectivemutagenesis positions, contact or hypermutation positions with anactivity enhancing amino acid residue is described in U.S. Pat. No.6,914,128.

The term “chimeric antibody” refers to antibodies which comprise heavyand light chain variable region sequences from one species and constantregion sequences from another species, such as antibodies having murineheavy and light chain variable regions linked to human constant regions.

The term “CDR-grafted antibody” refers to antibodies which compriseheavy and light chain variable region sequences from one species but inwhich the sequences of one or more of the CDR regions of VH and/or VLare replaced with CDR sequences of another species, such as antibodieshaving murine heavy and light chain variable regions in which one ormore of the murine CDRs (e.g., CDR3) has been replaced with human CDRsequences.

The term “humanized antibody” refers to antibodies which comprise heavyand light chain variable region sequences from a non-human species(e.g., a mouse) but in which at least a portion of the VH and/or VLsequence has been altered to be more “human-like,” i.e., more similar tohuman germline variable sequences. One type of humanized antibody is aCDR-grafted antibody, in which non-human CDR sequences are introducedinto human VH and VL sequences to replace the corresponding human CDRsequences. Also “humanized antibody” is an antibody or a variant,derivative, analog or fragment thereof which immunospecifically binds toan antigen of interest and which comprises a framework (FR) regionhaving substantially the amino acid sequence of a human antibody and acomplementary determining region (CDR) having substantially the aminoacid sequence of a non-human antibody. As used herein, the term“substantially” in the context of a CDR refers to a CDR having an aminoacid sequence at least 80%, at least 85%, at least 90%, at least 95%, atleast 98% or at least 99% identical to the amino acid sequence of anon-human antibody CDR. A humanized antibody comprises substantially allof at least one, and typically two, variable domains (Fab, Fab′,F(ab′)2, FabC, Fv) in which all or substantially all of the CDR regionscorrespond to those of a non-human immunoglobulin (i.e., donor antibody)and all or substantially all of the framework regions are those of ahuman immunoglobulin consensus sequence. In an embodiment, a humanizedantibody also comprises at least a portion of an immunoglobulin constantregion (Fc), typically that of a human immunoglobulin. In someembodiments, a humanized antibody contains both the light chain as wellas at least the variable domain of a heavy chain. The antibody also mayinclude the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain. Insome embodiments, a humanized antibody only contains a humanized lightchain. In some embodiments, a humanized antibody only contains ahumanized heavy chain. In specific embodiments, a humanized antibodyonly contains a humanized variable domain of a light chain and/orhumanized heavy chain.

The terms “Kabat numbering,” “Kabat definitions” and “Kabat labeling”are used interchangeably herein. These terms, which are recognized inthe art, refer to a system of numbering amino acid residues which aremore variable (i.e., hypervariable) than other amino acid residues inthe heavy and light chain variable regions of an antibody, or an antigenbinding portion thereof (Kabat et al. (1971) Ann. NY Acad, Sci.190:382-391 and, Kabat, E. A., et al. (1991) Sequences of Proteins ofImmunological Interest, Fifth Edition, U.S. Department of Health andHuman Services, NIH Publication No. 91-3242). For the heavy chainvariable region, the hypervariable region ranges from amino acidpositions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, andamino acid positions 95 to 102 for CDR3. For the light chain variableregion, the hypervariable region ranges from amino acid positions 24 to34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acidpositions 89 to 97 for CDR3.

As used herein, the term “CDR” refers to the complementarity determiningregion within antibody variable sequences. There are three CDRs in eachof the variable regions of the heavy chain and the light chain, whichare designated CDR1, CDR2 and CDR3, for each of the variable regions.The term “CDR set” as used herein refers to a group of three CDRs thatoccur in a single variable region that binds the antigen. The exactboundaries of these CDRs have been defined differently according todifferent systems. The system described by Kabat (Kabat et al.,Sequences of Proteins of Immunological Interest (National Institutes ofHealth, Bethesda, Md. (1987) and (1991)) not only provides anunambiguous residue numbering system applicable to any variable regionof an antibody, but also provides precise residue boundaries definingthe three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia andcoworkers (Chothia &Lesk (1987) J. Mol. Biol. 196:901-917 and Chothia etal. (1989) Nature 342:877-883) found that certain sub-portions withinKabat CDRs adopt nearly identical peptide backbone conformations,despite having great diversity at the level of amino acid sequence.These sub-portions were designated as L1, L2 and L3 or H1, H2 and H3where the “L” and the “H” designate the light chain and the heavy chainregions, respectively. These regions may be referred to as Chothia CDRs,which have boundaries that overlap with Kabat CDRs. Other boundariesdefining CDRs overlapping with the Kabat CDRs have been described byPadlan (1995) FASEB J. 9: 133-139 and MacCallum (1996) J. Mol. Biol.262(5): 732-45. Still other CDR boundary definitions may not strictlyfollow one of the herein systems, but will nonetheless overlap with theKabat CDRs, although they may be shortened or lengthened in light ofprediction or experimental findings that particular residues or groupsof residues or even entire CDRs do not significantly impact antigenbinding. The methods used herein may utilize CDRs defined according toany of these systems, although certain embodiments use Kabat or Chothiadefined CDRs.

As used herein, the term “framework” or “framework sequence” refers tothe remaining sequences of a variable region minus the CDRs. Because theexact definition of a CDR sequence can be determined by differentsystems, the meaning of a framework sequence is subject tocorrespondingly different interpretations. The six CDRs (CDR-L1, -L2,and -L3 of light chain and CDR-H1, -H2, and -H3 of heavy chain) alsodivide the framework regions on the light chain and the heavy chain intofour sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 ispositioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3between FR3 and FR4. Without specifying the particular sub-regions asFR1, FR2, FR3 or FR4, a framework region, as referred by others,represents the combined FR's within the variable region of a single,naturally occurring immunoglobulin chain. As used herein, a FRrepresents one of the four sub-regions, and FRs represents two or moreof the four sub-regions constituting a framework region.

As used herein, the term “germline antibody gene” or “gene fragment”refers to an immunoglobulin sequence encoded by non-lymphoid cells thathave not undergone the maturation process that leads to geneticrearrangement and mutation for expression of a particularimmunoglobulin. (See, e.g., Shapiro et al. (2002) Crit. Rev. Immunol.22(3): 183-200; Marchalonis et al. (2001) Adv. Exp. Med. Biol. 484:13-30). One of the advantages provided by various embodiments providedherein stems from the recognition that germline antibody genes are morelikely than mature antibody genes to conserve essential amino acidsequence structures characteristic of individuals in the species, henceless likely to be recognized as from a foreign source when usedtherapeutically in that species.

As used herein, the term “neutralizing” refers to counteracting thebiological activity of an antigen when a binding protein specificallybinds the antigen. In an embodiment, the neutralizing binding proteinbinds the cytokine and reduces its biologically activity by at leastabout 20%, 40%, 60%, 80%, 85% or more.

The term “activity” includes activities such as the binding specificityand affinity of a DVD-Ig for two or more antigens.

The term “epitope” includes any polypeptide determinant thatspecifically binds to an immunoglobulin or T-cell receptor. In certainembodiments, epitope determinants include chemically active surfacegroupings of molecules such as amino acids, sugar side chains,phosphoryl, or sulfonyl, and, in certain embodiments, may have specificthree dimensional structural characteristics, and/or specific chargecharacteristics. An epitope is a region of an antigen that is bound byan antibody. An epitope thus consists of the amino acid residues of aregion of an antigen (or fragment thereof) known to bind to thecomplementary site on the specific binding partner. An antigenicfragment can contain more than one epitope. In certain embodiments, anantibody is said to specifically bind an antigen when it recognizes itstarget antigen in a complex mixture of proteins and/or macromolecules.Antibodies are said to “bind to the same epitope” if the antibodiescross-compete (one prevents the binding or modulating effect of theother). In addition structural definitions of epitopes (overlapping,similar, identical) are informative, but functional definitions areoften more relevant as they encompass structural (binding) andfunctional (modulation, competition) parameters.

The term “surface plasmon resonance,” as used herein, refers to anoptical phenomenon that allows for the analysis of real-time biospecificinteractions by detection of alterations in protein concentrationswithin a biosensor matrix, for example using the BIAcore® system(BIAcore International AB, a GE Healthcare company, Uppsala, Sweden andPiscataway, N.J.). For further descriptions, see Jönsson, U., et al.(1993) Ann. Biol. Clin. 51:19-26; Jönsson, U., et al. (1991)Biotechniques 11:620-627; Johnsson, B., et al. (1995) J. Mol. Recognit.8:125-131; and Johnnson, B., et al. (1991) Anal. Biochem. 198:268-277.

The term “K_(on),” as used herein, is intended to refer to the on rateconstant for association of a binding protein (e.g., an antibody) to theantigen to form the, e.g., antibody/antigen complex as is known in theart. The “K_(on),” also is known by the terms “association rateconstant,” or “k_(a),” as used interchangeably herein. This valueindicating the binding rate of an antibody to its target antigen or therate of complex formation between an antibody and antigen also is shownby the equation:

Antibody(“Ab”)+Antigen(“Ag”)→Ab−Ag.

The term “K_(off),” as used herein, is intended to refer to the off rateconstant for dissociation of a binding protein (e.g., an antibody) fromthe, e.g., antibody/antigen complex as is known in the art. The “Koff”also is known by the terms “dissociation rate constant” or “kd” as usedinterchangeably herein. This value indicates the dissociation rate of anantibody from its target antigen or separation of Ab−Ag complex overtime into free antibody and antigen as shown by the equation below:

Ab+Ag←Ab−Ag.

The terms “equilibrium dissociation constant” or “K_(D),” as usedinterchangeably herein, refer to the value obtained in a titrationmeasurement at equilibrium, or by dividing the dissociation rateconstant (k_(off)) by the association rate constant (k_(on)). Theassociation rate constant, the dissociation rate constant and theequilibrium dissociation constant are used to represent the bindingaffinity of an antibody to an antigen. Methods for determiningassociation and dissociation rate constants are well known in the art.Using fluorescence-based techniques offers high sensitivity and theability to examine samples in physiological buffers at equilibrium.Other experimental approaches and instruments such as a BIAcore®(biomolecular interaction analysis) assay can be used (e.g., instrumentavailable from BIAcore International AB, a GE Healthcare company,Uppsala, Sweden). Additionally, a KinExA® (Kinetic Exclusion Assay)assay, available from Sapidyne Instruments (Boise, Id.) can also beused.

“Label” and “detectable label” mean a moiety attached to a specificbinding partner, such as an antibody or an analyte, e.g., to render thereaction between members of a specific binding pair, such as an antibodyand an analyte, detectable, and the specific binding partner, e.g.,antibody or analyte, so labeled is referred to as “detectably labeled.”Thus, the term “labeled binding protein” as used herein, refers to aprotein with a label incorporated that provides for the identificationof the binding protein. In an embodiment, the label is a detectablemarker that can produce a signal that is detectable by visual orinstrumental means, e.g., incorporation of a radiolabeled amino acid orattachment to a polypeptide of biotinyl moieties that can be detected bymarked avidin (e.g., streptavidin containing a fluorescent marker orenzymatic activity that can be detected by optical or colorimetricmethods). Examples of labels for polypeptides include, but are notlimited to, the following: radioisotopes or radionuclides (e.g., ³H,¹⁴C, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In, ¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, and ¹⁵³Sm);chromogens, fluorescent labels (e.g., FITC, rhodamine, and lanthanidephosphors), enzymatic labels (e.g., horseradish peroxidase, luciferase,alkaline phosphatase); chemiluminescent markers; biotinyl groups;predetermined polypeptide epitopes recognized by a secondary reporter(e.g., leucine zipper pair sequences, binding sites for secondaryantibodies, metal binding domains, and epitope tags); and magneticagents, such as gadolinium chelates. Representative examples of labelscommonly employed for immunoassays include moieties that produce light,e.g., acridinium compounds, and moieties that produce fluorescence,e.g., fluorescein. Other labels are described herein. In this regard,the moiety itself may not be detectably labeled but may becomedetectable upon reaction with yet another moiety. Use of “detectablylabeled” is intended to encompass the latter type of detectablelabeling.

The term “conjugate” refers to a binding protein, such as an antibody,chemically linked to a second chemical moiety, such as a therapeutic orcytotoxic agent. The term “agent” is used herein to denote a chemicalcompound, a mixture of chemical compounds, a biological macromolecule,or an extract made from biological materials. In an embodiment, thetherapeutic or cytotoxic agents include, but are not limited to,pertussis toxin, taxol, cytochalasin B, gramicidin D, ethidium bromide,emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine,colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione,mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone,glucocorticoids, procaine, tetracaine, lidocaine, propranolol, andpuromycin and analogs or homologs thereof. When employed in the contextof an immunoassay, the conjugate antibody is a detectably labeledantibody used as the detection antibody.

The terms “crystal” and “crystallized” as used herein, refer to abinding protein (e.g., an antibody), or antigen binding portion thereof,that exists in the form of a crystal. Crystals are one form of the solidstate of matter, which is distinct from other forms such as theamorphous solid state or the liquid crystalline state. Crystals arecomposed of regular, repeating, three-dimensional arrays of atoms, ions,molecules (e.g., proteins such as antibodies), or molecular assemblies(e.g., antigen/antibody complexes). These three-dimensional arrays arearranged according to specific mathematical relationships that arewell-understood in the field. The fundamental unit, or building block,that is repeated in a crystal is called the asymmetric unit. Repetitionof the asymmetric unit in an arrangement that conforms to a given,well-defined crystallographic symmetry provides the “unit cell” of thecrystal. Repetition of the unit cell by regular translations in allthree dimensions provides the crystal. See Giege, R. and Ducruix, A.Barrett, Crystallization of Nucleic Acids and Proteins, a PracticalApproach, 2nd ea., pp. 20 1-16, Oxford University Press, New York, N.Y.,(1999).”

The term “polynucleotide” means a polymeric form of two or morenucleotides, either ribonucleotides or deoxynucleotides or a modifiedform of either type of nucleotide. The term includes single and doublestranded forms of DNA.

The term “isolated polynucleotide” shall mean a polynucleotide (e.g., ofgenomic, cDNA, or synthetic origin, or some combination thereof) that,by virtue of its origin, the “isolated polynucleotide” is not associatedwith all or a portion of a polynucleotide with which the “isolatedpolynucleotide” is found in nature; is operably linked to apolynucleotide that it is not linked to in nature; or does not occur innature as part of a larger sequence.

The term “vector,” is intended to refer to a nucleic acid moleculecapable of transporting another nucleic acid to which it has beenlinked. One type of vector is a “plasmid,” which refers to a circulardouble stranded DNA loop into which additional DNA segments may beligated. Another type of vector is a viral vector, wherein additionalDNA segments may be ligated into the viral genome. Certain vectors arecapable of autonomous replication in a host cell into which they areintroduced (e.g., bacterial vectors having a bacterial origin ofreplication and episomal mammalian vectors). Other vectors (e.g.,non-episomal mammalian vectors) can be integrated into the genome of ahost cell upon introduction into the host cell, and thereby arereplicated along with the host genome. Moreover, certain vectors arecapable of directing the expression of genes to which they areoperatively linked. Such vectors are referred to herein as “recombinantexpression vectors” (or simply, “expression vectors”). In general,expression vectors of utility in recombinant DNA techniques are often inthe form of plasmids. In the present specification, “plasmid” and“vector” may be used interchangeably as the plasmid is the most commonlyused form of vector. However, additional embodiments include such otherforms of expression vectors, such as viral vectors (e.g., replicationdefective retroviruses, adenoviruses and adeno-associated viruses),which serve equivalent functions.

The term “operably linked” refers to a juxtaposition wherein thecomponents described are in a relationship permitting them to functionin their intended manner. A control sequence “operably linked” to acoding sequence is ligated in such a way that expression of the codingsequence is achieved under conditions compatible with the controlsequences. “Operably linked” sequences include both expression controlsequences that are contiguous with the gene of interest and expressioncontrol sequences that act in trans or at a distance to control the geneof interest. The term “expression control sequence” as used hereinrefers to polynucleotide sequences which are necessary to effect theexpression and processing of coding sequences to which they are ligated.Expression control sequences include appropriate transcriptioninitiation, termination, promoter and enhancer sequences; efficient RNAprocessing signals such as splicing and polyadenylation signals;sequences that stabilize cytoplasmic mRNA; sequences that enhancetranslation efficiency (i.e., Kozak consensus sequence); sequences thatenhance protein stability; and when desired, sequences that enhanceprotein secretion. The nature of such control sequences differsdepending upon the host organism; in prokaryotes, such control sequencesgenerally include a promoter, a ribosomal binding site, and atranscription termination sequence; in eukaryotes, generally, suchcontrol sequences include a promoter and a transcription terminationsequence. The term “control sequences” is intended to include componentswhose presence is essential for expression and processing, and can alsoinclude additional components whose presence is advantageous, forexample, leader sequences and fusion partner sequences.

“Transformation,” refers to any process by which exogenous DNA enters ahost cell. Transformation may occur under natural or artificialconditions using various methods well known in the art. Transformationmay rely on any known method for the insertion of foreign nucleic acidsequences into a prokaryotic or eukaryotic host cell. The method isselected based on the host cell being transformed and may include, butis not limited to, viral infection, electroporation, lipofection, andparticle bombardment. Such “transformed” cells include stablytransformed cells in which the inserted DNA is capable of replicationeither as an autonomously replicating plasmid or as part of the hostchromosome. They also include cells which transiently express theinserted DNA or RNA for limited periods of time.

The term “recombinant host cell” (or simply “host cell”), is intended torefer to a cell into which exogenous DNA has been introduced. In anembodiment, the host cell comprises two or more (e.g., multiple) nucleicacids encoding antibodies, such as the host cells described in U.S. Pat.No. 7,262,028, for example. Such terms are intended to refer not only tothe particular subject cell, but, also to the progeny of such a cell.Because certain modifications may occur in succeeding generations due toeither mutation or environmental influences, such progeny may not, infact, be identical to the parent cell, but are still included within thescope of the term “host cell” as used herein. In an embodiment, hostcells include prokaryotic and eukaryotic cells selected from any of theKingdoms of life. In another embodiment, eukaryotic cells includeprotist, fungal, plant and animal cells. In another embodiment, hostcells include but are not limited to the prokaryotic cell line E. coli;mammalian cell lines CHO, HEK 293, COS, NS0, SP2 and PER.C6; the insectcell line Sf9; and the fungal cell Saccharomyces cerevisiae.

Standard techniques may be used for recombinant DNA, oligonucleotidesynthesis, and tissue culture and transformation (e.g., electroporation,lipofection). Enzymatic reactions and purification techniques may beperformed according to manufacturers specifications or as commonlyaccomplished in the art or as described herein. The foregoing techniquesand procedures may be generally performed according to conventionalmethods well known in the art and as described in various general andmore specific references that are cited and discussed throughout thepresent specification. See e.g., Sambrook et al. (1989) MolecularCloning: A Laboratory Manual (2d ed., Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y.).

“Transgenic organism,” as known in the art, refers to an organism havingcells that contain a transgene, wherein the transgene introduced intothe organism (or an ancestor of the organism) expresses a polypeptidenot naturally expressed in the organism. A “transgene” is a DNAconstruct, which is stably and operably integrated into the genome of acell from which a transgenic organism develops, directing the expressionof an encoded gene product in one or more cell types or tissues of thetransgenic organism.

The term “regulate” and “modulate” are used interchangeably, and, asused herein, refers to a change or an alteration in the activity of amolecule of interest (e.g., the biological activity of a cytokine).Modulation may be an increase or a decrease in the magnitude of acertain activity or function of the molecule of interest. Exemplaryactivities and functions of a molecule include, but are not limited to,binding characteristics, enzymatic activity, cell receptor activation,and signal transduction.

Correspondingly, the term “modulator” is a compound capable of changingor altering an activity or function of a molecule of interest (e.g., thebiological activity of a cytokine). For example, a modulator may causean increase or decrease in the magnitude of a certain activity orfunction of a molecule compared to the magnitude of the activity orfunction observed in the absence of the modulator. In certainembodiments, a modulator is an inhibitor, which decreases the magnitudeof at least one activity or function of a molecule. Exemplary inhibitorsinclude, but are not limited to, proteins, peptides, antibodies,peptibodies, carbohydrates or small organic molecules. Peptibodies aredescribed, e.g., in WO01/83525.

The term “agonist,” refers to a modulator that, when contacted with amolecule of interest, causes an increase in the magnitude of a certainactivity or function of the molecule compared to the magnitude of theactivity or function observed in the absence of the agonist. Particularagonists of interest may include, but are not limited to, polypeptides,nucleic acids, carbohydrates, and any other molecules that bind to theantigen.

The term “antagonist” or “inhibitor,” refers to a modulator that, whencontacted with a molecule of interest, causes a decrease in themagnitude of a certain activity or function of the molecule compared tothe magnitude of the activity or function observed in the absence of theantagonist. Particular antagonists of interest include those that blockor modulate the biological or immunological activity of the antigen.Antagonists and inhibitors of antigens may include, but are not limitedto, proteins, nucleic acids, carbohydrates, and any other molecules,which bind to the antigen.

As used herein, the term “effective amount” refers to the amount of atherapy which is sufficient to reduce or ameliorate the severity and/orduration of a disorder or one or more symptoms thereof, inhibit orprevent the advancement of a disorder, cause regression of a disorder,inhibit or prevent the recurrence, development, onset or progression ofone or more symptoms associated with a disorder, detect a disorder, orenhance or improve the prophylactic or therapeutic effect(s) of anothertherapy (e.g., prophylactic or therapeutic agent).

“Patient” and “subject” may be used interchangeably herein to refer toan animal, such as a mammal, including a primate (for example, a human,a monkey, and a chimpanzee), a non-primate (for example, a cow, a pig, acamel, a llama, a horse, a goat, a rabbit, a sheep, a hamster, a guineapig, a cat, a dog, a rat, a mouse, and a whale), a bird (e.g., a duck ora goose), and a shark. Preferably, the patient or subject is a human,such as a human being treated or assessed for a disease, disorder orcondition, a human at risk for a disease, disorder or condition, a humanhaving a disease, disorder or condition, and/or human being treated fora disease, disorder or condition.

The term “sample,” as used herein, is used in its broadest sense. A“biological sample,” as used herein, includes, but is not limited to,any quantity of a substance from a living thing or formerly livingthing. Such living things include, but are not limited to, humans, mice,rats, monkeys, dogs, rabbits and other animals. Such substances include,but are not limited to, blood, (e.g., whole blood), plasma, serum,urine, amniotic fluid, synovial fluid, endothelial cells, leukocytes,monocytes, other cells, organs, tissues, bone marrow, lymph nodes andspleen.

“Component,” “components,” and “at least one component,” refer generallyto a capture antibody, a detection or conjugate antibody, a control, acalibrator, a series of calibrators, a sensitivity panel, a container, abuffer, a diluent, a salt, an enzyme, a co-factor for an enzyme, adetection reagent, a pretreatment reagent/solution, a substrate (e.g.,as a solution), a stop solution, and the like that can be included in akit for assay of a test sample, such as a patient urine, serum or plasmasample, in accordance with the methods described herein and othermethods known in the art. Thus, in the context of the presentdisclosure, “at least one component,” “component,” and “components” caninclude a polypeptide or other analyte as above, such as a compositioncomprising an analyte such as polypeptide, which is optionallyimmobilized on a solid support, such as by binding to an anti-analyte(e.g., anti-polypeptide) antibody. Some components can be in solution orlyophilized for reconstitution for use in an assay.

“Control” refers to a composition known to not contain analyte(“negative control”) or to contain analyte (“positive control”). Apositive control can comprise a known concentration of analyte.“Control,” “positive control,” and “calibrator” may be usedinterchangeably herein to refer to a composition comprising a knownconcentration of analyte. A “positive control” can be used to establishassay performance characteristics and is a useful indicator of theintegrity of reagents (e.g., analytes).

“Predetermined cutoff” and “predetermined level” refer generally to anassay cutoff value that is used to assessdiagnostic/prognostic/therapeutic efficacy results by comparing theassay results against the predetermined cutoff/level, where thepredetermined cutoff/level already has been linked or associated withvarious clinical parameters (e.g., severity of disease,progression/nonprogression/improvement, etc.). While the presentdisclosure may provide exemplary predetermined levels, it is well-knownthat cutoff values may vary depending on the nature of the immunoassay(e.g., antibodies employed, etc.). It further is well within theordinary skill of one in the art to adapt the disclosure herein forother immunoassays to obtain immunoassay-specific cutoff values forthose other immunoassays based on this disclosure. Whereas the precisevalue of the predetermined cutoff/level may vary between assays,correlations as described herein (if any) should be generallyapplicable.

“Pretreatment reagent,” e.g., lysis, precipitation and/or solubilizationreagent, as used in a diagnostic assay as described herein is one thatlyses any cells and/or solubilizes any analyte that is/are present in atest sample. Pretreatment is not necessary for all samples, as describedfurther herein. Among other things, solubilizing the analyte (e.g.,polypeptide of interest) may entail release of the analyte from anyendogenous binding proteins present in the sample. A pretreatmentreagent may be homogeneous (not requiring a separation step) orheterogeneous (requiring a separation step). With use of a heterogeneouspretreatment reagent there is removal of any precipitated analytebinding proteins from the test sample prior to proceeding to the nextstep of the assay.

“Quality control reagents” in the context of immunoassays and kitsdescribed herein, include, but are not limited to, calibrators,controls, and sensitivity panels. A “calibrator” or “standard” typicallyis used (e.g., one or more, such as a plurality) in order to establishcalibration (standard) curves for interpolation of the concentration ofan analyte, such as an antibody or an analyte. Alternatively, a singlecalibrator, which is near a predetermined positive/negative cutoff, canbe used. Multiple calibrators (i.e., more than one calibrator or avarying amount of calibrator(s)) can be used in conjunction so as tocomprise a “sensitivity panel.”

“Risk” refers to the possibility or probability of a particular eventoccurring either presently or at some point in the future. “Riskstratification” refers to an array of known clinical risk factors thatallows physicians to classify patients into a low, moderate, high orhighest risk of developing a particular disease, disorder or condition.

“Specific” and “specificity” in the context of an interaction betweenmembers of a specific binding pair (e.g., an antigen (or fragmentthereof) and an antibody (or antigenically reactive fragment thereof))refer to the selective reactivity of the interaction. The phrase“specifically binds to” and analogous phrases refer to the ability ofantibodies (or antigenically reactive fragments thereof) to bindspecifically to analyte (or a fragment thereof) and not bindspecifically to other entities.

“Specific binding partner” is a member of a specific binding pair. Aspecific binding pair comprises two different molecules, whichspecifically bind to each other through chemical or physical means.Therefore, in addition to antigen and antibody specific binding pairs ofcommon immunoassays, other specific binding pairs can include biotin andavidin (or streptavidin), carbohydrates and lectins, complementarynucleotide sequences, effector and receptor molecules, cofactors andenzymes, enzyme inhibitors and enzymes, and the like. Furthermore,specific binding pairs can include members that are analogs of theoriginal specific binding members, for example, an analyte-analog.Immunoreactive specific binding members include antigens, antigenfragments, and antibodies, including monoclonal and polyclonalantibodies as well as complexes, fragments, and variants (includingfragments of variants) thereof, whether isolated or recombinantlyproduced.

“Variant” as used herein means a polypeptide that differs from a givenpolypeptide (e.g., IL-18, BNP, NGAL or HIV polypeptide oranti-polypeptide antibody) in amino acid sequence by the addition (e.g.,insertion), deletion, or conservative substitution of amino acids, butthat retains the biological activity of the given polypeptide (e.g., avariant IL-1β can compete with anti-IL-1β antibody for binding toIL-18). A conservative substitution of an amino acid, i.e., replacing anamino acid with a different amino acid of similar properties (e.g.,hydrophilicity and degree and distribution of charged regions) isrecognized in the art as typically involving a minor change. These minorchanges can be identified, in part, by considering the hydropathic indexof amino acids, as understood in the art (see, e.g., Kyte et al. (1982)J. Mol. Biol. 157: 105-132). The hydropathic index of an amino acid isbased on a consideration of its hydrophobicity and charge. It is knownin the art that amino acids of similar hydropathic indexes can besubstituted and still retain protein function. In one aspect, aminoacids having hydropathic indexes of ±2 are substituted. Thehydrophilicity of amino acids also can be used to reveal substitutionsthat would result in proteins retaining biological function. Aconsideration of the hydrophilicity of amino acids in the context of apeptide permits calculation of the greatest local average hydrophilicityof that peptide, a useful measure that has been reported to correlatewell with antigenicity and immunogenicity (see, e.g., U.S. Pat. No.4,554,101. Substitution of amino acids having similar hydrophilicityvalues can result in peptides retaining biological activity, for exampleimmunogenicity, as is understood in the art. In one aspect,substitutions are performed with amino acids having hydrophilicityvalues within ±2 of each other. Both the hydrophobicity index and thehydrophilicity value of amino acids are influenced by the particularside chain of that amino acid. Consistent with that observation, aminoacid substitutions that are compatible with biological function areunderstood to depend on the relative similarity of the amino acids, andparticularly the side chains of those amino acids, as revealed by thehydrophobicity, hydrophilicity, charge, size, and other properties.“Variant” also can be used to describe a polypeptide or fragment thereofthat has been differentially processed, such as by proteolysis,phosphorylation, or other post-translational modification, yet retainsits biological activity or antigen reactivity, e.g., the ability to bindto IL-18. Use of “variant” herein is intended to encompass fragments ofa variant unless otherwise contradicted by context.

I. Generation of DVD Binding Protein

Dual Variable Domain binding proteins that bind one or more targets andmethods of making the same are provided. In an embodiment, the bindingprotein comprises a polypeptide chain, wherein said polypeptide chaincomprises VD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first variable domain,VD2 is a second variable domain, C is a constant domain, X1 representsan amino acid or polypeptide, X2 represents an Fc region and n is 0or 1. The binding protein can be generated using various techniques.Expression vectors, host cells, and methods of generating the bindingprotein are provided.

A. Generation of Parent Monoclonal Antibodies

The variable domains of the DVD binding protein can be obtained fromparent antibodies, including polyclonal and mAbs that bind antigens ofinterest. These antibodies may be naturally occurring or may begenerated by recombinant technology.

MAbs can be prepared using a wide variety of techniques known in the artincluding the use of hybridoma, recombinant, and phage displaytechnologies, or a combination thereof. For example, mAbs can beproduced using hybridoma techniques including those known in the art andtaught, for example, in Harlow et al. (1988) Antibodies: A LaboratoryManual, (Cold Spring Harbor Laboratory Press, 2nd ed.); Hammerling, etal. (1981) in: Monoclonal Antibodies and T-Cell Hybridomas 563-681(Elsevier, N.Y.). The term “monoclonal antibody” as used herein is notlimited to antibodies produced through hybridoma technology. The term“monoclonal antibody” refers to an antibody that is derived from asingle clone, including any eukaryotic, prokaryotic, or phage clone, andnot the method by which it is produced. Hybridomas are selected, clonedand further screened for desirable characteristics, including robusthybridoma growth, high antibody production and desirable antibodycharacteristics, as discussed in Example 1 below. Hybridomas may becultured and expanded in vivo in syngeneic animals, in animals that lackan immune system, e.g., nude mice, or in cell culture in vitro. Methodsof selecting, cloning and expanding hybridomas are well known to thoseof ordinary skill in the art. In a particular embodiment, the hybridomasare mouse hybridomas. In another embodiment, the hybridomas are producedin a non-human, non-mouse species such as rats, sheep, pigs, goats,cattle or horses. In another embodiment, the hybridomas are humanhybridomas, in which a human non-secretory myeloma is fused with a humancell expressing an antibody that binds a specific antigen.

Recombinant mAbs are also generated from single, isolated lymphocytesusing a procedure referred to in the art as the selected lymphocyteantibody method (SLAM), as described in U.S. Pat. No. 5,627,052; PCTPublication No. WO 92/02551; and Babcock, J. S. et al. (1996) Proc.Natl. Acad. Sci. USA 93:7843-7848. In this method, single cellssecreting antibodies of interest, e.g., lymphocytes derived from animmunized animal, are identified, and, heavy- and light-chain variableregion cDNAs are rescued from the cells by reverse transcriptase-PCR.These variable regions can then be expressed, in the context ofappropriate immunoglobulin constant regions (e.g., human constantregions), in mammalian host cells, such as COS or CHO cells. The hostcells transfected with the amplified immunoglobulin sequences, derivedfrom in vivo selected lymphocytes, can then undergo further analysis andselection in vitro, for example by panning the transfected cells toisolate cells expressing antibodies to the antigen of interest. Theamplified immunoglobulin sequences further can be manipulated in vitro,such as by in vitro affinity maturation methods such as those describedin PCT Publication Nos. WO 97/29131 and WO 00/56772.

Monoclonal antibodies are also produced by immunizing a non-human animalcomprising some, or all, of the human immunoglobulin locus with anantigen of interest. In an embodiment, the non-human animal is aXENOMOUSE transgenic mouse, an engineered mouse strain that compriseslarge fragments of the human immunoglobulin loci and is deficient inmouse antibody production. See, e.g., Green et al. (1994) Nature Genet.7: 13-21 and U.S. Pat. Nos. 5,916,771; 5,939,598; 5,985,615; 5,998,209;6,075,181; 6,091,001; 6,114,598; and 6,130,364. See also PCT PublicationNos. WO 91/10741; WO 94/02602; WO 96/34096; WO 96/33735; WO 98/16654; WO98/24893; WO 98/50433; WO 99/45031; WO 99/53049; WO 00/09560; and WO00/037504. The XENOMOUSE transgenic mouse produces an adult-like humanrepertoire of fully human antibodies, and generates antigen-specifichuman monoclonal antibodies. The XENOMOUSE transgenic mouse containsapproximately 80% of the human antibody repertoire through introductionof megabase sized, germline configuration YAC fragments of the humanheavy chain loci and x light chain loci. See Mendez et al. (1997) NatureGenet. 15: 146-156; Green and Jakobovits (1998) J. Exp. Med. 188:483-495.

In vitro methods also can be used to make the parent antibodies, whereinan antibody library is screened to identify an antibody having thedesired binding specificity. Methods for such screening of recombinantantibody libraries are well known in the art and include methodsdescribed in, for example, Ladner et al., U.S. Pat. No. 5,223,409; PCTPublication Nos. WO 92/18619; WO 91/17271; WO 92/20791; WO 92/15679; WO93/01288; WO 92/01047; WO 92/09690 and WO 97/29131; Fuchs et al. (1991)Bio/Technology 9: 1370-1372; Hay et al. (1992) Hum. Antibod. Hybridomas3: 81-85; Huse et al. (1989) Science 246: 1275-1281; McCafferty et al.(1990) Nature 348: 552-554; Griffiths et al. (1993) EMBO J. 12: 725-734;Hawkins et al. (1992) J. Mol. Biol. 226: 889-896; Clackson et al. (1991)Nature 352: 624-628; Gram et al. (1992) Proc. Natl. Acad. Sci. USA 89:3576-3580; Garrad et al. (1991) Bio/Technology 9: 1373-1377; Hoogenboomet al. (1991) Nucl. Acid Res. 19: 4133-4137; and Barbas et al. (1991)Proc. Natl. Acad. Sci. USA 88: 7978-7982, and U.S. Patent PublicationNo. 2003/0186374.

Parent antibodies can also be generated using various phage displaymethods known in the art. In phage display methods, functional antibodydomains are displayed on the surface of phage particles which carry thepolynucleotide sequences encoding them. In a particular, such phage canbe utilized to display antigen-binding domains expressed from arepertoire or combinatorial antibody library (e.g., human or murine).Phage expressing an antigen binding domain that binds the antigen ofinterest can be selected or identified with antigen, e.g., using labeledantigen or antigen bound or captured to a solid surface or bead. Phageused in these methods are typically filamentous phage including fd andM13 binding domains expressed from phage with Fab, Fv or disulfidestabilized Fv antibody domains recombinantly fused to either the phagegene III or gene VIII protein. Examples of phage display methods thatcan be used include those disclosed in Brinkman et al. (1995) J.Immunol. Methods 182: 41-50; Ames et al. (1995) J. Immunol. Methods 184:177-186; Kettleborough et al. (1994) Eur. J. Immunol. 24: 952-958;Persic et al. (1997) Gene 187: 9-18; Burton et al. (1994) Advances inImmunol. 57: 191-280; PCT Application No. PCT/GB91/01134; PCTPublication Nos. WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO93/11236; WO 95/15982; and WO 95/20401; and U.S. Pat. Nos. 5,698,426;5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047;5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and5,969,108.

As described in the herein references, after phage selection, theantibody coding regions from the phage can be isolated and used togenerate whole antibodies including human antibodies or any otherdesired antigen binding fragment, and expressed in any desired host,including mammalian cells, insect cells, plant cells, yeast, andbacteria, e.g., as described in detail below. For example, techniques toproduce recombinantly Fab, Fab′ and F(ab′)2 fragments can also beemployed using methods known in the art such as those disclosed in PCTPublication No. WO 92/22324; Mullinax et al. (1992) BioTechniques 12(6):864-869; Sawai et al. (1995) AJRI 34: 26-34; and Better et al. (1988)Science 240: 1041-1043. Examples of techniques, which can be used toproduce single-chain Fvs and antibodies, include those described in U.S.Pat. Nos. 4,946,778 and 5,258,498; Huston et al. (1991), MethodsEnzymol. 203:46-88; Shu et al. (1993) Proc. Natl. Acad. Sci. USA 90:7995-7999; and Skerra et al. (1988) Science 240: 1038-1040.

Alternative to screening of recombinant antibody libraries by phagedisplay, other methodologies known in the art for screening largecombinatorial libraries can be applied to the identification of parentantibodies. One type of alternative expression system is one in whichthe recombinant antibody library is expressed as RNA-protein fusions, asdescribed in PCT Publication No. WO 98/31700 and in Roberts, R. W. andSzostak, J. W. (1997) Proc. Natl. Acad. Sci. USA 94:12297-12302. In thissystem, a covalent fusion is created between an mRNA and the peptide orprotein that it encodes by in vitro translation of synthetic mRNAs thatcarry puromycin, a peptidyl acceptor antibiotic, at their 3′ end. Thus,a specific mRNA can be enriched from a complex mixture of mRNAs (e.g., acombinatorial library) based on the properties of the encoded peptide orprotein, e.g., antibody, or portion thereof, such as binding of theantibody, or portion thereof, to the dual specificity antigen. Nucleicacid sequences encoding antibodies, or portions thereof, recovered fromscreening of such libraries can be expressed by recombinant means asdescribed herein (e.g., in mammalian host cells) and, moreover, can besubjected to further affinity maturation by either additional rounds ofscreening of mRNA-peptide fusions in which mutations have beenintroduced into the originally selected sequence(s), or by other methodsfor affinity maturation in vitro of recombinant antibodies, as describedherein.

In another approach the parent antibodies can also be generated usingyeast display methods known in the art. In yeast display methods,genetic methods are used to tether antibody domains to the yeast cellwall and display them on the surface of yeast. In particular, such yeastcan be utilized to display antigen-binding domains expressed from arepertoire or combinatorial antibody library (e.g., human or murine).Examples of yeast display methods that can be used to make the parentantibodies include those disclosed in U.S. Pat. No. 6,699,658.

The antibodies described herein can be further modified to generate CDRgrafted and humanized parent antibodies. CDR-grafted parent antibodiescomprise heavy and light chain variable region sequences from a humanantibody wherein one or more of the CDR regions of V_(H) and/or V_(L)are replaced with CDR sequences of murine antibodies that bind anantigen of interest. A framework sequence from any human antibody mayserve as the template for CDR grafting. However, straight chainreplacement onto such a framework often leads to some loss of bindingaffinity to the antigen. The more homologous a human antibody is to theoriginal murine antibody, the less likely the possibility that combiningthe murine CDRs with the human framework will introduce distortions inthe CDRs that could reduce affinity. Therefore, in an embodiment, thehuman variable framework that is chosen to replace the murine variableframework apart from the CDRs have at least a 65% sequence identity withthe murine antibody variable region framework. In an embodiment, thehuman and murine variable regions apart from the CDRs have at least 70%sequence identify. In a particular embodiment, that the human and murinevariable regions apart from the CDRs have at least 75% sequenceidentity. In another embodiment, the human and murine variable regionsapart from the CDRs have at least 80% sequence identity. Methods forproducing such antibodies are known in the art (see EP 239,400; PCTPublication No. WO 91/09967; and U.S. Pat. Nos. 5,225,539; 5,530,101;and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan(1991) Mol. Immunol. 28(4/5): 489-498; Studnicka et al. (1994) Prot.Engineer. 7(6): 805-814; and Roguska et al. (1994) Proc. Acad. Sci. USA91: 969-973), chain shuffling (U.S. Pat. No. 5,565,352), andanti-idiotypic antibodies.

Humanized antibodies are antibody molecules from non-human species thatbind the desired antigen and have one or more CDRs from the non-humanspecies and framework regions from a human immunoglobulin molecule.Known human Ig sequences are disclosed, e.g.,www.ncbi.nlm.nih.gov/entrez-/query.fcgi; www.atcc.org/phage/hdb.html;www.sciquest.com/; www.abcam.com/;www.antibodyresource.com/onlinecomp.html;www.public.iastate.edu/.about.pedro/research_tools.html;www.mgen.uni-heidelberg.de/SD/IT/IT.html;www.whfreeman.com/immunology/CH-05/kuby05.htm;www.library.thinkquest.org/12429/Immune/Antibody.html;www.hhmi.org/grants/lectures/1996/vlab/;www.path.cam.ac.uk/.about.mrc7/m-ikeimages.html;www.antibodyresource.com/;mcb.harvard.edu/BioLinks/Immuno-logy.html.www.immunologylink.com/;pathbox.wustl.edu/.about.hcenter/index.-html;www.biotech.ufl.edu/.about.hcl/; www.pebio.com/pa/340913/340913.html-;www.nal.usda.gov/awic/pubs/antibody/;www.m.ehime-u.acjp/.about.yasuhito-/Elisa.html;www.biodesign.com/table.asp; www.icnet.uk/axp/facs/davies/lin-ks.html;www.biotech.ufl.edu/.about.fccl/protocol.html;www.isac-net.org/sites_geo.html;aximtl.imt.uni-marburg.de/.about.rek/AEP-Start.html;baserv.uci.kun.nl/.about.jraats/linksl.html;www.recab.uni-hd.de/immuno.bme.nwu.edu/;www.mrc-cpe.cam.ac.uk/imt-doc/pu-blic/INTRO.html;www.ibt.unam.mx/vir/V_mice.html; imgt.cnusc.fr:8104/;www.biochem.ucl.ac.uk/.about.martin/abs/index.html;antibody.bath.ac.uk/; abgen.cvm.tamu.edu/lab/wwwabgen.html;www.unizh.ch/.about.honegger/AHOsem-inar/Slide01.html;www.cryst.bbk.ac.uk/.about.ubcg07s/;www.nimr.mrc.ac.uk/CC/ccaewg/ccaewg.htm;www.path.cam.ac.uk/.about.mrc7/h-umanisation/TAHHP.html;www.ibt.unam.mx/vir/structure/stat_aim.html;www.biosci.missouri.edu/smithgp/index.html;www.cryst.bioc.cam.ac.ukLabo-ut.fmolina/Web-pages/Pept/spottech.html;www.jerini.de/fr roducts.htm; www.patents.ibm.com/ibm.html.; and Kabatet al., Sequences of Proteins of Immunological Interest, U.S. Dept.Health (1983). Such imported sequences can be used to reduceimmunogenicity or reduce, enhance or modify binding, affinity, on-rate,off-rate, avidity, specificity, half-life, or any other suitablecharacteristic, as known in the art.

Framework residues in the human framework regions may be substitutedwith the corresponding residue from the CDR donor antibody to alter,e.g., improve, antigen binding. These framework substitutions areidentified by methods well known in the art, e.g., by modeling of theinteractions of the CDR and framework residues to identify frameworkresidues important for antigen binding and sequence comparison toidentify unusual framework residues at particular positions. (See, e.g.,U.S. Pat. No. 5,585,089; Riechmann et al. (1988) Nature 332:323).Three-dimensional immunoglobulin models are commonly available and arefamiliar to those skilled in the art. Computer programs are availablewhich illustrate and display probable three-dimensional conformationalstructures of selected candidate immunoglobulin sequences. Inspection ofthese displays permits analysis of the likely role of the residues inthe functioning of the candidate immunoglobulin sequence, i.e., theanalysis of residues that influence the ability of the candidateimmunoglobulin to bind its antigen. In this way, FR residues can beselected and combined from the consensus and import sequences so thatthe desired antibody characteristic, such as increased affinity for thetarget antigen(s), is achieved. In general, the CDR residues aredirectly and most substantially involved in influencing antigen binding.Antibodies can be humanized using a variety of techniques known in theart, such as but not limited to those described in Jones et al. (1986)Nature 321: 522; Verhoeyen et al. (1988) Science 239: 1534; Sims et al.(1993) J. Immunol. 151: 2296; Chothia and Lesk (1987) J. Mol. Biol. 196:901; Carter et al. (1992) Proc. Natl. Acad. Sci. USA 89: 4285; Presta etal. (1993) J. Immunol. 151: 2623; Padlan (1991) Mol. Immunol. 28(4/5):489-498; Studnicka et al. (1994) Prot. Engineer. 7(6): 805-814; Roguskaet al., (1994) Proc. Natl. Acad. Sci. USA 91: 969-973; PCT PublicationNo. WO 91/09967: US98/16280; US96/18978; US91/09630; US91/05939;US94/01234; GB89/01334; GB91/01134; GB92/01755; WO90/14443; WO90/14424;and WO90/14430; European Patent Publication Nos. EP 229246; EP 592,106;EP 519,596; and EP 239,400; and U.S. Pat. Nos. 5,565,332; 5,723,323;5,976,862; 5,824,514; 5,817,483; 5,814,476; 5,763,192; 5,723,323;5,766,886; 5,714,352; 6,204,023; 6,180,370; 5,693,762; 5,530,101;5,585,089; 5,225,539; and 4,816,567.

B. Criteria for Selecting Parent Monoclonal Antibodies

An embodiment pertains to selecting parent antibodies with at least oneor more properties desired in the DVD-Ig molecule. In an embodiment, thedesired property is selected from one or more antibody parameters. Inanother embodiment, the antibody parameters are antigen specificity,affinity to antigen, potency, biological function, epitope recognition,stability, solubility, production efficiency, immunogenicity,pharmacokinetics, bioavailability, tissue cross reactivity, ororthologous antigen binding.

B.1. Affinity to Antigen

The desired affinity of a therapeutic mAb may depend upon the nature ofthe antigen, and the desired therapeutic end-point. In an embodiment,monoclonal antibodies have higher affinities (Kd=0.01-0.50 μM) whenblocking a cytokine-cytokine receptor interaction as such interactionsare usually high affinity interactions (e.g., <pM-<nM ranges). In suchinstances, the mAb affinity for its target should be equal to or betterthan the affinity of the cytokine (ligand) for its receptor. On theother hand, mAb with lesser affinity (>nM range) could betherapeutically effective e.g., in clearing circulating potentiallypathogenic proteins e.g., monoclonal antibodies that bind to, sequester,and clear circulating species of A-β amyloid. In other instances,reducing the affinity of an existing high affinity mAb by site-directedmutagenesis or using a mAb with lower affinity for its target could beused to avoid potential side-effects e.g., a high affinity mAb maysequester/neutralize all of its intended target, thereby completelydepleting/eliminating the function(s) of the targeted protein. In thisscenario, a low affinity mAb may sequester/neutralize a fraction of thetarget that may be responsible for the disease symptoms (thepathological or over-produced levels), thus allowing a fraction of thetarget to continue to perform its normal physiological function(s).Therefore, it may be possible to reduce the Kd to adjust dose and/orreduce side-effects. The affinity of the parental mAb might play a rolein appropriately targeting cell surface molecules to achieve desiredtherapeutic out-come. For example, if a target is expressed on cancercells with high density and on normal cells with low density, a loweraffinity mAb will bind a greater number of targets on tumor cells thannormal cells, resulting in tumor cell elimination via ADCC or CDC, andtherefore might have therapeutically desirable effects. Thus selecting amAb with desired affinity may be relevant for both soluble and surfacetargets.

Signaling through a receptor upon interaction with its ligand may dependupon the affinity of the receptor-ligand interaction. Similarly, it isconceivable that the affinity of a mAb for a surface receptor coulddetermine the nature of intracellular signaling and whether the mAb maydeliver an agonist or an antagonist signal. The affinity-based nature ofmAb-mediated signaling may have an impact of its side-effect profile.Therefore, the desired affinity and desired functions of therapeuticmonoclonal antibodies need to be determined carefully by in vitro and invivo experimentation.

The desired Kd of a binding protein (e.g., an antibody) may bedetermined experimentally depending on the desired therapeutic outcome.In an embodiment parent antibodies with affinity (Kd) for a particularantigen equal to, or better than, the desired affinity of the DVD-Ig forthe same antigen are selected. The parent antibodies for a given DVD-Igmolecule can be the same antibody or different antibodies. The antigenbinding affinity and kinetics are assessed by Biacore or another similartechnique. In one embodiment, each parent antibody has a dissociationconstant (Kd) to its antigen of: at most about 10⁻⁷M; at most about10⁻⁸M; at most about 10⁻⁹M; at most about 10⁻¹⁰M; at most about 10⁻¹¹M;at most about 10⁻¹²M; or at most 10⁻¹³M. The first parent antibody fromwhich VD1 is obtained and the second parent antibody from which VD2 isobtained may have similar or different affinity (K_(D)) for therespective antigen. Each parent antibody has an on rate constant (Kon)to the antigen of: at least about 10²M⁻¹s⁻¹; at least about 10³M⁻¹s⁻¹;at least about 10⁴M⁻¹s⁻¹; at least about 10⁵M⁻¹s⁻¹; or at least about10⁶M⁻¹s⁻¹, as measured by surface plasmon resonance. The first parentantibody from which VD1 is obtained and the second parent antibody fromwhich VD2 is obtained may have similar or different on rate constant(Kon) for the respective antigen. In one embodiment, each parentantibody has an off rate constant (Koff) to the antigen of: at mostabout 10⁶M⁻³s⁻¹; at most about 10⁻⁴ s⁻¹; at most about 10⁻⁵ s⁻¹; or atmost about 10⁻⁶ s⁻¹, as measured by surface plasmon resonance. The firstparent antibody from which VD1 is obtained and the second parentantibody from which VD2 is obtained may have similar or different offrate constants (Koff) for the respective antigen.

B.2. Potency

The desired affinity/potency of parental monoclonal antibodies willdepend on the desired therapeutic outcome. For example, forreceptor-ligand (R-L) interactions the affinity (kd) is equal to orbetter than the R-L kd (pM range). For simple clearance of a pathologiccirculating protein, the kd could be in low nM range e.g., clearance ofvarious species of circulating A-β peptide. In addition, the kd willalso depend on whether the target expresses multiple copies of the sameepitope e.g., a mAb targeting conformational epitope in Aβ oligomers.

Where VD1 and VD2 bind the same antigen, but distint epitopes, theDVD-Ig will contain four binding sites for the same antigen, thusincreasing avidity and thereby the apparent kd of the DVD-Ig. In anembodiment, parent antibodies with equal or lower kd than that desiredin the DVD-Ig are chosen. The affinity considerations of a parental mAbmay also depend upon whether the DVD-Ig contains four or more identicalantigen binding sites (i.e., a DVD-Ig from a single mAb). In this case,the apparent kd would be greater than the mAb due to avidity. SuchDVD-Igs can be employed for cross-linking surface receptor, increaseneutralization potency, enhance clearance of pathological proteins, etc.

In an embodiment parent antibodies with neutralization potency forspecific antigen equal to or better than the desired neutralizationpotential of the DVD-Ig for the same antigen are selected. Theneutralization potency can be assessed by a target-dependent bioassaywhere cells of appropriate type produce a measurable signal (i.e.,proliferation or cytokine production) in response to target stimulation,and target neutralization by the mAb can reduce the signal in adose-dependent manner.

B.3. Biological Functions

Monoclonal antibodies can perform potentially several functions. Some ofthese functions are listed in Table 1. These functions can be assessedby both in vitro assays (e.g., cell-based and biochemical assays) and invivo animal models.

TABLE 1 Some Potential Applications For Therapeutic Antibodies Target(Class) Mechanism of Action (target) Soluble Neutralization of activity(e.g., a cytokine) (cytokines, other) Enhance clearance (e.g., Aβoligomers) Increase half-life (e.g., GLP 1) Cell Surface Agonist (e.g.,GLP1 R; EPO R; etc.) (Receptors, other) Antagonist (e.g., integrins;etc.) Cytotoxic (CD 20; etc.) Protein deposits Enhanceclearance/degradation (e.g., Aβ plaques, amyloid deposits)

MAbs with distinct functions described in the examples herein in Table 1can be selected to achieve desired therapeutic outcomes. Two or moreselected parent monoclonal antibodies can then be used in DVD-Ig formatto achieve two distinct functions in a single DVD-Ig molecule. Forexample, a DVD-Ig can be generated by selecting a parent mAb thatneutralizes function of a specific cytokine, and selecting a parent mAbthat enhances clearance of a pathological protein. Similarly, two parentmonoclonal antibodies that recognize two different cell surfacereceptors can be selected, e.g., one mAb with an agonist function on onereceptor and the other mAb with an antagonist function on a differentreceptor. These two selected monoclonal antibodies each with a distinctfunction, can be used to construct a single DVD-Ig molecule that willpossess the two distinct functions (agonist and antagonist) of theselected monoclonal antibodies in a single molecule. Similarly, twoantagonistic monoclonal antibodies to cell surface receptors eachblocking binding of respective receptor ligands (e.g., EGF and IGF), canbe used in a DVD-Ig format. Conversely, an antagonistic anti-receptormAb (e.g., anti-EGFR) and a neutralizing anti-soluble mediator (e.g.,anti-IGF1/2) mAb can be selected to make a DVD-Ig.

B.4. Epitope Recognition

Different regions of proteins may perform different functions. Forexample specific regions of a cytokine interact with the cytokinereceptor to bring about receptor activation whereas other regions of theprotein may be required for stabilizing the cytokine. In this instanceone may select a mAb that binds specifically to the receptor interactingregion(s) on the cytokine and thereby blocks cytokine-receptorinteraction. In some cases, for example, certain chemokine receptorsthat bind multiple ligands, a mAb that binds to the epitope (region onchemokine receptor) that interacts with only one ligand can be selected.In other instances, monoclonal antibodies can bind to epitopes on atarget that are not directly responsible for physiological functions ofthe protein, but binding of a mAb to these regions could eitherinterfere with physiological functions (steric hindrance) or alter theconformation of the protein such that the protein cannot function (mAbto receptors with multiple ligand which alter the receptor conformationsuch that none of the ligand can bind). Anti-cytokine monoclonalantibodies that do not block binding of the cytokine to its receptor,but block signal transduction have also been identified (e.g., 125-2H,an anti-IL-1β mAb).

Examples of epitopes and mAb functions include, but are not limited to,blocking Receptor-Ligand (R-L) interaction (neutralizing mAb that bindsR-interacting site); steric hindrance resulting in diminished or noR-binding. An Ab can bind the target at a site other than a receptorbinding site, but still interfere with receptor binding and functions ofthe target by inducing conformational change and eliminating function(e.g., Xolair), e.g., binding to R but blocking signaling (125-2H).

In an embodiment, the parental mAb needs to target the appropriateepitope for maximum efficacy. Such epitope should be conserved in theDVD-Ig. The binding epitope of a mAb can be determined by severalapproaches, including co-crystallography, limited proteolysis ofmAb-antigen complex plus mass spectrometric peptide mapping (Legros V.et al. (2000) Protein Sci. 9:1002-10), phage displayed peptide libraries(O'Connor, K. H. et al. (2005) J. Immunol. Methods. 299:21-35), as wellas mutagenesis (Wu C. et al. (2003) J. Immunol. 170:5571-7).

B.5. Physicochemical and Pharmaceutical Properties

Therapeutic treatment with antibodies often requires administration ofhigh doses, often several mg/kg (due to a low potency on a mass basis asa consequence of a typically large molecular weight). In order toaccommodate patient compliance and to address adequately chronic diseasetherapies and outpatient treatment, subcutaneous (s.c.) or intramuscular(i.m.) administration of therapeutic mAbs is desirable. For example, themaximum desirable volume for s.c. administration is ˜1.0 mL, andtherefore, concentrations of >100 mg/mL are desirable to limit thenumber of injections per dose. In an embodiment, the therapeuticantibody is administered in one dose. The development of suchformulations is constrained, however, by protein-protein interactions(e.g., aggregation, which potentially increases immunogenicity risks)and by limitations during processing and delivery (e.g., viscosity).Consequently, the large quantities required for clinical efficacy andthe associated development constraints limit full exploitation of thepotential of antibody formulation and s.c. administration in high-doseregimens. It is apparent that the physicochemical and pharmaceuticalproperties of a protein molecule and the protein solution are of utmostimportance, e.g., stability, solubility and viscosity features.

B.5.1. Stability

A “stable” antibody formulation is one in which the antibody thereinessentially retains its physical stability and/or chemical stabilityand/or biological activity upon storage. Stability can be measured at aselected temperature for a selected time period. In an embodiment, theantibody in the formulation is stable at room temperature (about 30° C.)or at 40° C. for at least 1 month and/or stable at about 2-8° C. for atleast 1 year, such as, for at least 2 years. Furthermore, in anembodiment, the formulation is stable following freezing (to, e.g., −70°C.) and thawing of the formulation, hereinafter referred to as a“freeze/thaw cycle.” In another example, a “stable” formulation may beone wherein less than about 10% and less than about 5% of the protein ispresent as an aggregate in the formulation.

A DVD-Ig stable that is in vitro at various temperatures for an extendedtime period is desirable. One can achieve this by rapid screening ofparental mAbs that are stable in vitro at elevated temperature, e.g., at40° C. for 2-4 weeks, and then assess stability. During storage at 2-8°C., the protein reveals stability for at least 12 months, e.g., at least24 months. Stability (% of monomeric, intact molecule) can be assessedusing various techniques such as cation exchange chromatography, sizeexclusion chromatography, SDS-PAGE, as well as bioactivity testing. Fora more comprehensive list of analytical techniques that may be employedto analyze covalent and conformational modifications see Jones, A. J. S.(1993) Analytical methods for the assessment of protein formulations anddelivery systems. In: Cleland, J. L.; Langer, R., editors. Formulationand delivery of peptides and proteins, 1^(st) edition, Washington, ACS,pg. 22-45; and Pearlman, R.; Nguyen, T. H. (1990) Analysis of proteindrugs. In: Lee, V. H., editor. Peptide and protein drug delivery, 1stedition, New York, Marcel Dekker, Inc., pg. 247-301.

Heterogeneity and aggregate formation: stability of the antibody may besuch that the formulation may reveal less than about 10%, such as lessthan about 5%, such as less than about 2%, or, within the range of 0.5%to 1.5% or less in the GMP antibody material that is present asaggregate. Size exclusion chromatography is a method that is sensitive,reproducible, and very robust in the detection of protein aggregates.

In addition to low aggregate levels, the antibody must, in anembodiment, be chemically stable. Chemical stability may be determinedby ion exchange chromatography (e.g., cation or anion exchangechromatography), hydrophobic interaction chromatography, or othermethods such as isoelectric focusing or capillary electrophoresis. Forinstance, chemical stability of the antibody may be such that afterstorage of at least 12 months at 2-8° C. the peak representingunmodified antibody in a cation exchange chromatography may increase notmore than 20%, such as not more than 10%, or not more than 5% ascompared to the antibody solution prior to storage testing.

In an embodiment, the parent antibodies display structural integrity;correct disulfide bond formation, and correct folding. Chemicalinstability due to changes in secondary or tertiary structure of anantibody may impact antibody activity. For instance, stability, asindicated by activity of the antibody may be such that after storage ofat least 12 months at 2-8° C., the activity of the antibody may decreasenot more than 50%, such as not more than 30%, not more than 10%, or notmore than 5% or 1% as compared to the antibody solution prior to storagetesting. Suitable antigen-binding assays can be employed to determineantibody activity.

B.5.2. Solubility

The “solubility” of a mAb correlates with the production of correctlyfolded, monomeric IgG. The solubility of the IgG may therefore beassessed by HPLC. For example, soluble (monomeric) IgG will give rise toa single peak on the HPLC chromatograph, whereas insoluble (e.g.,multimeric and aggregated) will give rise to a plurality of peaks. Aperson skilled in the art will therefore be able to detect an increaseor decrease in solubility of an IgG using routine HPLC techniques. For amore comprehensive list of analytical techniques that may be employed toanalyze solubility (see Jones, A. G. (1993) Dep. Chem. Biochem. Eng.,Univ. Coll. London, London, UK. Editor(s): Shamlou, P. Ayazi. Process.Solid-Liq. Suspensions, 93-117. Publisher: Butterworth-Heinemann,Oxford, UK and Pearlman et al. (1990) Adv. in Parenteral Sci. 4 (Pept.Protein Drug Delivery): 247-301). Solubility of a therapeutic mAb iscritical for formulating to high concentration often required foradequate dosing. As outlined herein, solubilities of >100 mg/mL may berequired to accommodate efficient antibody dosing. For instance,antibody solubility may be not less than about 5 mg/mL in early researchphase, not less than about 25 mg/mL in advanced process science stages,or not less than about 100 mg/mL, or not less than about 150 mg/mL. Itis obvious to a person skilled in the art that the intrinsic propertiesof a protein molecule are important the physico-chemical properties ofthe protein solution, e.g., stability, solubility, viscosity. However, aperson skilled in the art will appreciate that a broad variety ofexcipients exist that may be used as additives to beneficially impactthe characteristics of the final protein formulation. These excipientsmay include: (i) liquid solvents, cosolvents (e.g., alcohols such asethanol); (ii) buffering agents (e.g., phosphate, acetate, citrate, andamino acid buffers); (iii) sugars or sugar alcohols (e.g., sucrose,trehalose, fructose, raffinose, mannitol, sorbitol, and dextrans); (iv)surfactants (e.g., polysorbate 20, 40, 60, 80, and poloxamers); (v)isotonicity modifiers (e.g., salts such as NaCl, sugars, and sugaralcohols); and (vi) others (e.g., preservatives, chelating agents,antioxidants, chelating substances (e.g., EDTA), biodegradable polymers,and carrier molecules (e.g., HSA and PEGs)).

Viscosity is a parameter of high importance with regard to antibodymanufacture and antibody processing (e.g.,diafiltration/ultrafiltration), fill-finish processes (pumping aspects,filtration aspects) and delivery aspects (syringeability, sophisticateddevice delivery). Low viscosities enable the liquid solution of theantibody having a higher concentration. This enables the same dose maybe administered in smaller volumes. Small injection volumes inhere theadvantage of lower pain on injection sensations, and the solutions notnecessarily have to be isotonic to reduce pain on injection in thepatient. The viscosity of the antibody solution may be such that atshear rates of 100 (1/s) antibody solution viscosity is below 200 mPa s,below 125 mPa s, below 70 mPa s, and below 25 mPa s, or even below 10mPa s.

B.5.3. Production Efficiency

The generation of a DVD-Ig that is efficiently expressed in mammaliancells, such as Chinese hamster ovary cells (CHO), will in an embodimentrequire two parental monoclonal antibodies, which are themselvesexpressed efficiently in mammalian cells. The production yield from astable mammalian line (i.e., CHO) should be above about 0.5 g/L, aboveabout 1 g/L, or in the range of about 2 to about 5 g/L or more(Kipriyanov, S. M. and Little, M. (1999) Mol. Biotechnol. 12: 173-201;Carroll, S, and Al-Rubeai, M. (2004) Expert Opin. Biol. Ther. 4:1821-9).

Production of antibodies and Ig fusion proteins in mammalian cells isinfluenced by several factors. Engineering of the expression vector viaincorporation of strong promoters, enhancers and selection markers canmaximize transcription of the gene of interest from an integrated vectorcopy. The identification of vector integration sites that are permissivefor high levels of gene transcription can augment protein expressionfrom a vector (Wurm et al. (2004) Nature Biotechnol. 22(11): 1393-1398).Furthermore, levels of production are affected by the ratio of antibodyheavy and light chains and various steps in the process of proteinassembly and secretion (Jiang et al. (2006) Biotechnol. Prog. 22(1):313-8).

B.6. Immunogenicity

Administration of a therapeutic mAb may result in certain incidence ofan immune response (i.e., the formation of endogenous antibodiesdirected against the therapeutic mAb). Potential elements that mightinduce immunogenicity should be analyzed during selection of theparental monoclonal antibodies, and steps to reduce such risk can betaken to optimize the parental monoclonal antibodies prior to DVD-Igconstruction. Mouse-derived antibodies have been found to be highlyimmunogenic in patients. The generation of chimeric antibodies comprisedof mouse variable and human constant regions presents a logical nextstep to reduce the immunogenicity of therapeutic antibodies (Morrisonand Schlom, 1990). Alternatively, immunogenicity can be reduced bytransferring murine CDR sequences into a human antibody framework(reshaping/CDR grafting/humanization), as described for a therapeuticantibody by Riechmann et al. (1988) Nature 332: 323-327. Another methodis referred to as “resurfacing” or “veneering,” starting with the rodentvariable light and heavy domains, only surface-accessible frameworkamino acids are altered to human ones, while the CDR and buried aminoacids remain from the parental rodent antibody (Roguska et al. (1996)Prot. Engineer 9: 895-904). In another type of humanization, instead ofgrafting the entire CDRs, one technique grafts only the“specificity-determining regions” (SDRs), defined as the subset of CDRresidues that are involved in binding of the antibody to its target(Kashmiri et al. (2005) Methods 36(1): 25-34). This necessitatesidentification of the SDRs either through analysis of availablethree-dimensional structures of antibody-target complexes or mutationalanalysis of the antibody CDR residues to determine which interact withthe target. Alternatively, fully human antibodies may have reducedimmunogenicity compared to murine, chimeric or humanized antibodies.

Another approach to reduce the immunogenicity of therapeutic antibodiesis the elimination of certain specific sequences that are predicted tobe immunogenic. In one approach, after a first generation biologic hasbeen tested in humans and found to be unacceptably immunogenic, theB-cell epitopes can be mapped and then altered to avoid immunedetection. Another approach uses methods to predict and remove potentialT-cell epitopes. Computational methods have been developed to scan andto identify the peptide sequences of biologic therapeutics with thepotential to bind to MHC proteins (Desmet et al. (2005) Proteins 58:53-69). Alternatively a human dendritic cell-based method can be used toidentify CD4⁺ T-cell epitopes in potential protein allergens (Stickleret al. (2000) J. Immunother. 23: 654-60; S. L. Morrison and J. Schlom(1990) Important Adv. Oncol. 3-18; Riechmann et al. (1988) Nature 332:323-327; Roguska et al. (1996) Protein Engineer. 9: 895-904; Kashmiri etal. (2005) Methods 36(1): 25-34; Desmet et al. (2005) Proteins 58:53-69; and Stickler et al. (2000) J. Immunotherapy 23: 654-60.)

B.7. In Vivo Efficacy

To generate a DVD-Ig molecule with desired in vivo efficacy, it isimportant to generate and select mAbs with similarly desired in vivoefficacy when given in combination. However, in some instances theDVD-Ig may exhibit in vivo efficacy that cannot be achieved with thecombination of two separate mAbs. For instance, a DVD-Ig may bring twotargets in close proximity leading to an activity that cannot beachieved with the combination of two separate mAbs. Additional desirablebiological functions are described herein in section B 3. Parentantibodies with characteristics desirable in the DVD-Ig molecule may beselected based on factors such as pharmacokinetic t ½; tissuedistribution; soluble versus cell surface targets; and targetconcentration—soluble/density-surface.

B.8. In Vivo Tissue Distribution

To generate a DVD-Ig molecule with desired in vivo tissue distribution,in an embodiment parent mAbs with similar desired in vivo tissuedistribution profile must be selected. In this regard, the parent mAbscan be the same antibody or different antibodies. Alternatively, basedon the mechanism of the dual-specific targeting strategy, it may atother times not be required to select parent mAbs with the similarlydesired in vivo tissue distribution when given in combination. (e.g., inthe case of a DVD-Ig in which one binding component targets the DVD-Igto a specific site thereby bringing the second binding component to thesame target site). For example, one binding specificity of a DVD-Igcould target pancreas (islet cells) and the other specificity couldbring GLP1 to the pancreas to induce insulin.

B.9. Isotype

To generate a DVD-Ig molecule with desired properties including, but notlimited to, isotype, effector functions, and the circulating half-life,in an embodiment parent mAbs with appropriate Fc-effector functionsdepending on the therapeutic utility and the desired therapeuticend-point are selected. The parent mAbs can be the same antibody ordifferent antibodies. There are five main heavy-chain classes orisotypes, some of which have several sub-types, and these determine theeffector functions of an antibody molecule. These effector functionsreside in the hinge region, CH2 and CH3 domains of the antibodymolecule. However, residues in other parts of an antibody molecule mayhave effects on effector functions as well. The hinge region Fc-effectorfunctions include: (i) antibody-dependent cellular cytotoxicity, (ii)complement (C1q) binding, activation and complement-dependentcytotoxicity (CDC), (iii) phagocytosis/clearance of antigen-antibodycomplexes, and (iv) cytokine release in some instances. TheseFc-effector functions of an antibody molecule are mediated through theinteraction of the Fc-region with a set of class-specific cell surfacereceptors. Antibodies of the IgG1 isotype are most active while IgG2 andIgG4 having minimal or no effector functions. The effector functions ofthe IgG antibodies are mediated through interactions with threestructurally homologous cellular Fc receptor types (and sub-types)(FcgR1, FcgRII and FcgRIII). These effector functions of an IgG1 can beeliminated by mutating specific amino acid residues in the lower hingeregion (e.g., L234A, L235A) that are required for FcgR and C1q binding.Amino acid residues in the Fc region, in particular the CH2-CH3 domains,also determine the circulating half-life of the antibody molecule. ThisFc function is mediated through the binding of the Fc-region to theneonatal Fc receptor (FcRn), which is responsible for recycling ofantibody molecules from the acidic lysosomes back to the generalcirculation.

Whether a mAb should have an active or an inactive isotype will dependon the desired therapeutic end-point for an antibody. Some examples ofusage of isotypes and desired therapeutic outcome are listed below:

-   -   a) If the desired end-point is functional neutralization of a        soluble cytokine, then an inactive isotype may be used;    -   b) If the desired out-come is clearance of a pathological        protein, an active isotype may be used;    -   c) If the desired out-come is clearance of protein aggregates,        an active isotype may be used;    -   d) If the desired outcome is to antagonize a surface receptor,        an inactive isotype is used (Tysabri, IgG4; OKT3, mutated IgG1);    -   e) If the desired outcome is to eliminate target cells, an        active isotype is used (Herceptin, IgG1 (and with enhanced        effector functions); and    -   f) If the desired outcome is to clear proteins from circulation        without entering the CNS, an IgM isotype may be used (e.g.,        clearing circulating Ab peptide species).        The Fc effector functions of a parental mAb can be determined by        various in vitro methods well known in the art.

As discussed, the selection of isotype, and thereby the effectorfunctions will depend upon the desired therapeutic end-point. In caseswhere simple neutralization of a circulating target is desired, forexample, blocking receptor-ligand interactions, the effector functionsmay not be required. In such instances isotypes or mutations in theFc-region of an antibody that eliminate effector functions aredesirable. In other instances, where elimination of target cells is thetherapeutic end-point, for example, elimination of tumor cells, isotypesor mutations or de-fucosylation in the Fc-region that enhance effectorfunctions are desirable (Presta, G. L. (2006) Adv. Drug Deliv. Rev.58:640-656 and Satoh, M. et al. (2006) Expert Opin. Biol. Ther. 6:1161-1173). Similarly, depending up on the therapeutic utility, thecirculating half-life of an antibody molecule can be reduced/prolongedby modulating antibody-FcRn interactions by introducing specificmutations in the Fc region (Dall'Acqua, W. F. et al. (2006) J. Biol.Chem. 281: 23514-23524; Petkova, S. B. (2006) et al., Internat. Immunol.18:1759-1769; Vaccaro, C. et al. (2007) Proc. Natl. Acad. Sci. USA 103:18709-18714).

The published information on the various residues that influence thedifferent effector functions of a normal therapeutic mAb may need to beconfirmed for DVD-Ig. It may be possible that in a DVD-Ig formatadditional (different) Fc-region residues, other than those identifiedfor the modulation of monoclonal antibody effector functions, may beimportant.

Overall, the decision as to which Fc-effector functions (isotype) willbe critical in the final DVD-Ig format will depend upon the diseaseindication, therapeutic target, and desired therapeutic end-point andsafety considerations. Listed below are exemplary appropriate heavychain and light chain constant regions including, but not limited to:

-   -   IgG1—allotype: G1m/z    -   IgG1 mutant—A234, A235    -   IgG2—allotype: G2m(n−)    -   Kappa—Km3    -   Lambda

Fc Receptor and C1q Studies:

The possibility of unwanted antibody-dependent cell-mediatedcytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) byantibody complexing to any overexpressed target on cell membranes can beabrogated by the (for example, L234A, L235A) hinge-region mutations.These substituted amino acids, present in the IgG1 hinge region of mAb,are expected to result in diminished binding of mAb to human Fcreceptors (but not FcRn), as FcgR binding is thought to occur withinoverlapping sites on the IgG1 hinge region. This feature of mAb may leadto an improved safety profile over antibodies containing a wild-typeIgG. Binding of mAb to human Fc receptors can be determined by flowcytometry experiments using cell lines (e.g., THP-1, K562) and anengineered CHO cell line that expresses FcgRIIb (or other FcgRs).Compared to IgG1 control monoclonal antibodies, mAb show reduced bindingto FcgRI and FcgRIIa, whereas binding to FcgRIIb is unaffected. Thebinding and activation of C1q by antigen/IgG immune complexes triggersthe classical complement cascade with consequent inflammatory and/orimmunoregulatory responses. The C1q binding site on IgGs has beenlocalized to residues within the IgG hinge region. C1q binding toincreasing concentrations of mAb was assessed by C1q ELISA. The resultsdemonstrate that mAb is unable to bind to C1q, as expected when comparedto the binding of a wildtype control IgG1. Overall, the L234A, L235Ahinge region mutation abolishes binding of mAb to FcgRI, FcgRIIa and C1qbut does not impact the interaction of mAb with FcgRIIb. These datasuggest that in vivo, mAb with mutant Fc will interact normally with theinhibitory FcgRIIb but will likely fail to interact with the activatingFcgRI and FcgRIIa receptors or C1q.

Human FcRn Binding:

The neonatal receptor (FcRn) is responsible for transport of IgG acrossthe placenta and to control the catabolic half-life of the IgGmolecules. It might be desirable to increase the terminal half-life ofan antibody to improve efficacy, to reduce the dose or frequency ofadministration, or to improve localization to the target. Alternatively,it might be advantageous to do the converse that is, to decrease theterminal half-life of an antibody to reduce whole body exposure or toimprove the target-to-non-target binding ratios. Tailoring theinteraction between IgG and its salvage receptor, FcRn, offers a way toincrease or decrease the terminal half-life of IgG. Proteins in thecirculation, including IgG, are taken up in the fluid phase throughmicropinocytosis by certain cells, such as those of the vascularendothelia. IgG can bind FcRn in endosomes under slightly acidicconditions (pH 6.0-6.5) and can recycle to the cell surface, where it isreleased under almost neutral conditions (pH 7.0-7.4). Mapping of theFc-region-binding site on FcRn80, 16, 17 showed that two histidineresidues that are conserved across species, His310 and His435, areresponsible for the pH dependence of this interaction. Usingphage-display technology, a mouse Fc-region mutation that increasesbinding to FcRn and extends the half-life of mouse IgG was identified(see Victor, G. et al. (1997) Nature Biotechnol. 15(7): 637-640).Fc-region mutations that increase the binding affinity of human IgG forFcRn at pH 6.0, but not at pH 7.4, have also been identified (seeDall'Acqua, William F., et al. (2002) J. Immunol. 169(9): 5171-80).Moreover, in one case, a similar pH-dependent increase in binding (up to27-fold) was also observed for rhesus FcRn, and this resulted in atwofold increase in serum half-life in rhesus monkeys compared with theparent IgG (see Hinton, P. R. et al. (2004) J. Biol. Chem. 279(8),6213-6216). These findings indicate that it is feasible to extend theplasma half-life of antibody therapeutics by tailoring the interactionof the Fc region with FcRn. Conversely, Fc-region mutations thatattenuate interaction with FcRn can reduce antibody half-life.

B.10. Pharmacokinetics (PK)

To generate a DVD-Ig molecule with desired pharmacokinetic profile, inan embodiment parent mAbs with the similarly desired pharmacokineticprofile are selected. One consideration is that immunogenic response tomonoclonal antibodies (i.e., HAHA, human anti-human antibody response;HACA, human anti-chimeric antibody response) further complicates thepharmacokinetics of these therapeutic agents. In an embodiment,monoclonal antibodies with minimal or no immunogenicity are used forconstructing DVD-Ig molecules such that the resulting DVD-Igs will alsohave minimal or no immunogenicity. Some of the factors that determinethe PK of a mAb include, but are not limited to, intrinsic properties ofthe mAb (VH amino acid sequence); immunogenicity; FcRn binding and Fcfunctions.

The PK profile of selected parental monoclonal antibodies can be easilydetermined in rodents as the PK profile in rodents correlates well with(or closely predicts) the PK profile of monoclonal antibodies incynomolgus monkey and humans. The PK profile is determined as describedin Example section 1.2.2.3.A.

After the parental monoclonal antibodies with desired PK characteristics(and other desired functional properties as discussed herein) areselected, the DVD-Ig is constructed. As the DVD-Ig molecules contain twoantigen-binding domains from two parental monoclonal antibodies, the PKproperties of the DVD-Ig are assessed as well. Therefore, whiledetermining the PK properties of the DVD-Ig, PK assays may be employedthat determine the PK profile based on functionality of bothantigen-binding domains derived from the two parent monoclonalantibodies. The PK profile of a DVD-Ig can be determined as described inExample 1.2.2.3.A. Additional factors that may impact the PK profile ofDVD-Ig include the antigen-binding domain (CDR) orientation; linkersize; and Fc/FcRn interactions. PK characteristics of parent antibodiescan be evaluated by assessing the following parameters: absorption,distribution, metabolism and excretion.

Absorption:

To date, administration of therapeutic monoclonal antibodies is viaparenteral routes (e.g., intravenous [IV], subcutaneous [SC], orintramuscular [IM]). Absorption of a mAb into the systemic circulationfollowing either SC or IM administration from the interstitial space isprimarily through the lymphatic pathway. Saturable, presystemic,proteolytic degradation may result in variable absolute bioavailabilityfollowing extravascular administration. Usually, increases in absolutebioavailability with increasing doses of monoclonal antibodies may beobserved due to saturated proteolytic capacity at higher doses. Theabsorption process for a mAb is usually quite slow as the lymph fluiddrains slowly into the vascular system, and the duration of absorptionmay occur over hours to several days. The absolute bioavailability ofmonoclonal antibodies following SC administration generally ranges from50% to 100%. In the case of a transport-mediating structure at theblood-brain barrier targeted by the DVD-Ig construct, circulation timesin plasma may be reduced due to enhanced trans-cellular transport at theblood brain barrier (BBB) into the CNS compartment, where the DVD-Ig isliberated to enable interaction via its second antigen recognition site.

Distribution:

Following IV administration, monoclonal antibodies usually follow abiphasic serum (or plasma) concentration-time profile, beginning with arapid distribution phase, followed by a slow elimination phase. Ingeneral, a biexponential pharmacokinetic model best describes this kindof pharmacokinetic profile. The volume of distribution in the centralcompartment (Vc) for a mAb is usually equal to or slightly larger thanthe plasma volume (2-3 liters). A distinct biphasic pattern in serum(plasma) concentration versus time profile may not be apparent withother parenteral routes of administration, such as IM or SC, because thedistribution phase of the serum (plasma) concentration-time curve ismasked by the long absorption portion. Many factors, includingphysicochemical properties, site-specific and target-oriented receptormediated uptake, binding capacity of tissue, and mAb dose can influencebiodistribution of a mAb. Some of these factors can contribute tononlinearity in biodistribution for a mAb.

Metabolism and Excretion:

Due to the molecular size, intact monoclonal antibodies are not excretedinto the urine via kidney. They are primarily inactivated by metabolism(e.g., catabolism). For IgG-based therapeutic monoclonal antibodies,half-lives typically ranges from hours or 1-2 days to over 20 days. Theelimination of a mAb can be affected by many factors, including, but notlimited to, affinity for the FcRn receptor, immunogenicity of the mAb,the degree of glycosylation of the mAb, the susceptibility for the mAbto proteolysis, and receptor-mediated elimination.

B.11. Tissue Cross-Reactivity Pattern on Human and Tox Species

Identical staining pattern suggests that potential human toxicity can beevaluated in tox species. Tox species are those animal in whichunrelated toxicity is studied.

The individual antibodies are selected to meet two criteria: (1) tissuestaining appropriate for the known expression of the antibody target;and (2) similar staining pattern between human and tox species tissuesfrom the same organ.

Criterion 1: Immunizations and/or antibody selections typically employrecombinant or synthesized antigens (proteins, carbohydrates or othermolecules). Binding to the natural counterpart and counterscreen againstunrelated antigens are often part of the screening funnel fortherapeutic antibodies. However, screening against a multitude ofantigens is often unpractical. Therefore tissue cross-reactivity studieswith human tissues from all major organs serve to rule out unwantedbinding of the antibody to any unrelated antigens.

Criterion 2: Comparative tissue cross reactivity studies with human andtox species tissues (cynomolgus monkey, dog, possibly rodents andothers, the same 36 or 37 tissues are being tested as in the humanstudy) help to validate the selection of a tox species. In the typicaltissue cross-reactivity studies on frozen tissue sections therapeuticantibodies may demonstrate the expected binding to the known antigenand/or to a lesser degree binding to tissues based either on low levelinteractions (unspecific binding, low level binding to similar antigens,low level charge based interactions, etc.). In any case the mostrelevant toxicology animal species is the one with the highest degree ofcoincidence of binding to human and animal tissue.

Tissue cross reactivity studies follow the appropriate regulatoryguidelines including EC CPMP Guideline III/5271/94 “Production andquality control of mAbs” and the 1997 U.S. FDA/CBER “Points to Considerin the Manufacture and Testing of Monoclonal Antibody Products for HumanUse”. Cryosections (5 μm) of human tissues obtained at autopsy or biopsywere fixed and dried on object glass. The peroxidase staining of tissuesections was performed, using the avidin-biotin system. FDA's Guidance“Points to Consider in the Manufacture and Testing of MonoclonalAntibody Products for Human Use”.

Tissue cross reactivity studies are often done in two stages, with thefirst stage including cryosections of 32 tissues (typically: AdrenalGland, Gastrointestinal Tract, Prostate, Bladder, Heart, SkeletalMuscle, Blood Cells, Kidney, Skin, Bone Marrow, Liver, Spinal Cord,Breast, Lung, Spleen, Cerebellum, Lymph Node, Testes, Cerebral Cortex,Ovary, Thymus, Colon, Pancreas, Thyroid, Endothelium, Parathyroid,Ureter, Eye, Pituitary, Uterus, Fallopian Tube and Placenta) from onehuman donor. In the second phase a full cross reactivity study isperformed with up to 38 tissues (including adrenal, blood, blood vessel,bone marrow, cerebellum, cerebrum, cervix, esophagus, eye, heart,kidney, large intestine, liver, lung, lymph node, breast mammary gland,ovary, oviduct, pancreas, parathyroid, peripheral nerve, pituitary,placenta, prostate, salivary gland, skin, small intestine, spinal cord,spleen, stomach, striated muscle, testis, thymus, thyroid, tonsil,ureter, urinary bladder, and uterus) from 3 unrelated adults. Studiesare done typically at minimally two dose levels.

The therapeutic antibody (i.e., test article) and isotype matchedcontrol antibody may be biotinylated for avidin-biotin complex (ABC)detection; other detection methods may include tertiary antibodydetection for a FITC (or otherwise) labeled test article, orprecomplexing with a labeled anti-human IgG for an unlabeled testarticle.

Briefly, cryosections (about 5 μm) of human tissues obtained at autopsyor biopsy are fixed and dried on object glass. The peroxidase stainingof tissue sections is performed, using the avidin-biotin system. First(in case of a precomplexing detection system), the test article isincubated with the secondary biotinylated anti-human IgG and developedinto immune complex. The immune complex at the final concentrations of 2and 10 μg/mL of test article is added onto tissue sections on objectglass and then the tissue sections are reacted for 30 minutes with aavidin-biotin-peroxidase kit. Subsequently, DAB (3,3′-diaminobenzidine),a substrate for the peroxidase reaction, is applied for 4 minutes fortissue staining. Antigen-Sepharose beads are used as positive controltissue sections.

Any specific staining is judged to be either an expected (e.g.,consistent with antigen expression) or unexpected reactivity based uponknown expression of the target antigen in question. Any staining judgedspecific is scored for intensity and frequency. Antigen or serumcompletion or blocking studies can assist further in determining whetherobserved staining is specific or nonspecific.

If two selected antibodies are found to meet the selectioncriteria—appropriate tissue staining, and matching staining betweenhuman and toxicology animal specific tissue—they can be selected forDVD-Ig generation.

The tissue cross-reactivity study has to be repeated with the finalDVD-Ig construct, but while these studies follow the same protocol asoutline herein, they are more complex to evaluate because any bindingcan come from any of the two parent antibodies, and any unexplainedbinding needs to be confirmed with complex antigen competition studies.

It is readily apparent that the complex undertaking of tissuecrossreactivity studies with a multispecific molecule like a DVD-Ig isgreatly simplified if the two parental antibodies are selected for (1)lack of unexpected tissue cross reactivity findings and (2) forappropriate similarity of tissue cross reactivity findings between thecorresponding human and toxicology animal species tissues.

B.12. Specificity and Selectivity

To generate a DVD-Ig molecule with desired specificity and selectivity,one needs to generate and select parent mAbs with the similarly desiredspecificity and selectivity profile. In this regard, parent mAbs can bethe same antibody or different antibodies.

Binding studies for specificity and selectivity with a DVD-Ig can becomplex due to the four or more binding sites, two each for eachantigen. Briefly, binding studies using an enzyme linked immunosorbentassay (ELISA), BIAcore, KinExA, or other interaction studies with aDVD-Ig need to monitor the binding of one, two or more antigens to theDVD-Ig molecule. While BIAcore technology can resolve the sequential,independent binding of multiple antigens, more traditional methods,including ELISA, or more modern techniques, such as KinExA, cannot.Therefore, careful characterization of each parent antibody is critical.After each individual antibody has been characterized for specificity,confirmation of specificity retention of the individual binding sites inthe DVD-Ig molecule is greatly simplified.

It is readily apparent that the complex undertaking of determining thespecificity of a DVD-Ig is greatly simplified if the two parentalantibodies are selected for specificity prior to being combined into aDVD-Ig.

Antigen-antibody interaction studies can take many forms, including manyclassical protein protein interaction studies, ELISA, mass spectrometry,chemical cross-linking, SEC with light scattering, equilibrium dialysis,gel permeation, ultrafiltration, gel chromatography, large-zoneanalytical SEC, micropreparative ultracentrigugation (sedimentationequilibrium), spectroscopic methods, titration microcalorimetry,sedimentation equilibrium (in analytical ultracentrifuge), sedimentationvelocity (in analytical centrifuge), and surface plasmon resonance(including BIAcore). Relevant references include “Current Protocols inProtein Science,” Coligan, J. E. et al. (eds.) Volume 3, chapters 19 and20, published by John Wiley & Sons Inc., and “Current Protocols inImmunology,” Coligan, J. E. et al. (eds.) published by John Wiley & SonsInc., and relevant references included therein.

Cytokine Release in Whole Blood: The interaction of mAb with human bloodcells can be investigated by a cytokine release (Wing, M. G. (1995)Therapeut. Immunol. 2(4): 183-190; “Current Protocols in Pharmacology,”Enna, S. J. et al. (eds.) published by John Wiley & Sons Inc;Madhusudan, S. (2004) Clin. Cancer Res. 10(19): 6528-6534; Cox, J.(2006) Methods 38(4): 274-282; Choi, I. (2001) Eur. J. Immunol. 31(1):94-106). Briefly, various concentrations of mAb are incubated with humanwhole blood for 24 hours. The concentration tested should cover a widerange including final concentrations mimicking typical blood levels inpatients (including but not limited to 100 ng/ml-100 μg/ml). Followingthe incubation, supernatants and cell lysates were analyzed for thepresence of IL-1Rα, TNF-α, IL-1b, IL-6 and IL-8. Cytokine concentrationprofiles generated for mAb were compared to profiles produced by anegative human IgG control and a positive LPS or PHA control. Thecytokine profile displayed by mAb from both cell supernatants and celllysates was comparable to control human IgG. In an embodiment, themonoclonal antibody does not interact with human blood cells tospontaneously release inflammatory cytokines.

Cytokine release studies for a DVD-Ig are complex due to the four ormore binding sites, two each for each antigen. Briefly, cytokine releasestudies as described herein measure the effect of the whole DVD-Igmolecule on whole blood or other cell systems, but can resolve whichportion of the molecule causes cytokine release. Once cytokine releasehas been detected, the purity of the DVD-Ig preparation has to beascertained, because some co-purifying cellular components can causecytokine release on their own. If purity is not the issue, fragmentationof DVD-Ig (including but not limited to removal of Fc portion,separation of binding sites etc.), binding site mutagenesis or othermethods may need to be employed to deconvolute any observations. It isreadily apparent that this complex undertaking is greatly simplified ifthe two parental antibodies are selected for lack of cytokine releaseprior to being combined into a DVD-Ig.

B.13. Cross Reactivity to Other Species for Toxicological Studies

In an embodiment, the individual antibodies are selected with sufficientcross-reactivity to appropriate tox species, for example, cynomolgusmonkey. Parental antibodies need to bind to orthologous species target(i.e., cynomolgus monkey) and elicit appropriate response (modulation,neutralization, activation). In an embodiment, the cross-reactivity(affinity/potency) to orthologous species target should be within10-fold of the human target. In practice, the parental antibodies areevaluated for multiple species, including mouse, rat, dog, monkey (andother non-human primates), as well as disease model species (i.e., sheepfor asthma model). The acceptable cross-reactivity to tox species fromthe perental monoclonal antibodies allows future toxicology studies ofDVD-Ig-Ig in the same species. For that reason, the two parentalmonoclonal antibodies should have acceptable cross-reactivity for acommon tox species, thereby allowing toxicology studies of DVD-Ig in thesame species.

Parent mAbs may be selected from various mAbs that bind specific targetsand are well known in the art. The parent antibodies can be the sameantibody or different antibodies. These include, but are not limited toanti-TNF antibody (U.S. Pat. No. 6,258,562), anti-IL-12 and/oranti-IL-12p40 antibody (U.S. Pat. No. 6,914,128); anti-IL-1β antibody(U.S. Patent Publication No. 2005/0147610), anti-05, anti-CBL,anti-CD147, anti-gp120, anti-VLA-4, anti-CD11a, anti-CD18, anti-VEGF,anti-CD40L, anti CD-40 (e.g., see PCT Publication No. WO 2007/124299)anti-Id, anti-ICAM-1, anti-CXCL13, anti-CD2, anti-EGFR, anti-TGF-beta 2,anti-HGF, anti-cMet, anti DLL-4, anti-NPR1, anti-PLGF, anti-ErbB3,anti-E-selectin, anti-Fact VII, anti-Her2/neu, anti-F gp, anti-CD11/18,anti-CD14, anti-ICAM-3, anti-RON, anti-SOST, anti CD-19, anti-CD80(e.g., see PCT Publication No. WO 2003/039486, anti-CD4, anti-CD3,anti-CD23, anti-beta2-integrin, anti-alpha4beta7, anti-CD52, anti-HLADR, anti-CD22 (e.g., see U.S. Pat. No. 5,789,554), anti-CD20, anti-MIF,anti-CD64 (FcR), anti-TCR alpha beta, anti-CD2, anti-Hep B, anti-CA 125,anti-EpCAM, anti-gp120, anti-CMV, anti-gpIIbIIIa, anti-IgE, anti-CD25,anti-CD33, anti-HLA, anti-IGF1,2, anti IGFR, anti-VNRintegrin,anti-IL-1alpha, anti-IL-1beta, anti-IL-1 receptor, anti-IL-2 receptor,anti-IL-4, anti-IL-4 receptor, anti-IL5, anti-IL-5 receptor, anti-IL-6,anti-IL-8, anti-IL-9, anti-IL-13, anti-IL-13 receptor, anti-IL-17,anti-IL-6R, anti-RANKL, anti-NGF, anti-DKK, anti-alphaVbeta3,anti-IL-17A, anti-IL23p19 and anti-IL-23 (see Presta, L. G. (2005) J.Allergy Clin. Immunol. 116: 731-6 andwww.path.cam.ac.uk/-mrc7/humanisation/antibodies.html).

Parent mAbs may also be selected from various therapeutic antibodiesapproved for use, in clinical trials, or in development for clinicaluse. Such therapeutic antibodies include, but are not limited to,rituximab (Rituxan®, IDEC/Genentech/Roche) (see, for example, U.S. Pat.No. 5,736,137), a chimeric anti-CD20 antibody approved to treatNon-Hodgkin's lymphoma; HuMax-CD20, an anti-CD20 currently beingdeveloped by Genmab, an anti-CD20 antibody described in U.S. Pat. No.5,500,362, AME-133 (Applied Molecular Evolution), hA20 (Immunomedics,Inc.), HumaLYM (Intracel), and PRO70769 (PCT Application No.PCT/US2003/040426), trastuzumab (Herceptin®, Genentech) (see, forexample, U.S. Pat. No. 5,677,171), a humanized anti-Her2/neu antibodyapproved to treat breast cancer; pertuzumab (rhuMab-2C4, Omnitarg®),currently being developed by Genentech; an anti-Her2 antibody (U.S. Pat.No. 4,753,894; cetuximab (Erbitux®, Imclone) (U.S. Pat. No. 4,943,533;PCT Publication No. WO 96/40210), a chimeric anti-EGFR antibody inclinical trials for a variety of cancers; ABX-EGF (U.S. Pat. No.6,235,883), currently being developed by Abgenix-Immunex-Amgen;HuMax-EGFr (U.S. Pat. No. 7,247,301), currently being developed byGenmab; 425, EMD55900, EMD62000, and EMD72000 (Merck KGaA) (U.S. Pat.No. 5,558,864; Murthy, et al. (1987) Arch. Biochem. Biophys. 252(2):549-60; Rodeck, et al. (1987) J. Cell. Biochem. 35(4): 315-20;Kettleborough, et al. (1991) Protein Eng. 4(7): 773-83); ICR62(Institute of Cancer Research) (PCT Publication No. WO 95/20045;Modjtahedi, et al. (1993) J. Cell. Biophys. 22(1-3): 129-46; Modjtahedi,et al. (1993) Br. J. Cancer 67(2): 247-53; Modjtahedi, et al. (1996) Br.J. Cancer 73(2): 228-35; Modjtahedi, et al. (2003) Int. J. Cancer105(2): 273-80); TheraCIM hR3 (YM Biosciences, Canada and Centro deImmunologia Molecular, Cuba (U.S. Pat. No. 5,891,996; U.S. Pat. No.6,506,883; Mateo, et al. (1997) Immunotechnol. 3(1): 71-81); mAb-806(Ludwig Institute for Cancer Research, Memorial Sloan-Kettering)(Jungbluth, et al. (2003) Proc. Natl. Acad. Sci. USA. 100(2): 639-44);KSB-102 (KS Biomedix); MR1-1 (IVAX, National Cancer Institute) (PCTPublication No. WO 01/62931A2); and SC100 (Scancell) (PCT PublicationNo. WO 01/88138); alemtuzumab (Campath®, Millenium), a humanized mAbcurrently approved for treatment of B-cell chronic lymphocytic leukemia;muromonab-CD3 (Orthoclone OKT3®), an anti-CD3 antibody developed byOrtho Biotech/Johnson & Johnson, ibritumomab tiuxetan (Zevalin®), ananti-CD20 antibody developed by IDEC/Schering AG, gemtuzumab ozogamicin(Mylotarg®), an anti-CD33 (p67 protein) antibody developed byCelltech/Wyeth, alefacept (Amevive®), an anti-LFA-3 Fc fusion developedby Biogen), abciximab (ReoPro®), developed by Centocor/Lilly,basiliximab (Simulect®), developed by Novartis, palivizumab (Synagis®),developed by Medimmune, infliximab (Remicade®), an anti-TNFalphaantibody developed by Centocor, adalimumab (Humira®), an anti-TNFalphaantibody developed by Abbott, Humicade®, an anti-TNFalpha antibodydeveloped by Celltech, golimumab (CNTO-148), a fully human TNF antibodydeveloped by Centocor, etanercept (Enbrel®), an p75 TNF receptor Fcfusion developed by Immunex/Amgen, Ienercept, an p55TNF receptor Fcfusion previously developed by Roche, ABX-CBL, an anti-CD147 antibodybeing developed by Abgenix, ABX-IL8, an anti-IL8 antibody beingdeveloped by Abgenix, ABX-MA1, an anti-MUC18 antibody being developed byAbgenix, Pemtumomab (R1549, 90Y-muHMFG1), an anti-MUC1 in development byAntisoma, Therex (R1550), an anti-MUC1 antibody being developed byAntisoma, AngioMab (AS1405), being developed by Antisoma, HuBC-1, beingdeveloped by Antisoma, Thioplatin (AS1407) being developed by Antisoma,Antegren® (natalizumab), an anti-alpha-4-beta-1 (VLA-4) andalpha-4-beta-7 antibody being developed by Biogen, VLA-1 mAb, ananti-VLA-1 integrin antibody being developed by Biogen, LTBR mAb, ananti-lymphotoxin beta receptor (LTBR) antibody being developed byBiogen, CAT-152, an anti-TGF-(32 antibody being developed by CambridgeAntibody Technology, ABT 874 (J695), an anti-IL-12 p40 antibody beingdeveloped by Abbott, CAT-192, an anti-TGFβ1 antibody being developed byCambridge Antibody Technology and Genzyme, CAT-213, an anti-Eotaxin1antibody being developed by Cambridge Antibody Technology, LymphoStat-B®an anti-Blys antibody being developed by Cambridge Antibody Technologyand Human Genome Sciences Inc., TRAIL-R1 mAb, an anti-TRAIL-R1 antibodybeing developed by Cambridge Antibody Technology and Human GenomeSciences, Inc., Avastin® bevacizumab, rhuMAb-VEGF), an anti-VEGFantibody being developed by Genentech, an anti-HER receptor familyantibody being developed by Genentech, Anti-Tissue Factor (ATF), ananti-Tissue Factor antibody being developed by Genentech, Xolair®(Omalizumab), an anti-IgE antibody being developed by Genentech,Raptiva® (Efalizumab), an anti-CD11a antibody being developed byGenentech and Xoma, MLN-O₂ Antibody (formerly LDP-02), being developedby Genentech and Millenium Pharmaceuticals, HuMax CD4, an anti-CD4antibody being developed by Genmab, HuMax-IL15, an anti-IL15 antibodybeing developed by Genmab and Amgen, HuMax-Inflam, being developed byGenmab and Medarex, HuMax-Cancer, an anti-Heparanase I antibody beingdeveloped by Genmab and Medarex and Oxford GcoSciences, HuMax-Lymphoma,being developed by Genmab and Amgen, HuMax-TAC, being developed byGenmab, IDEC-131, and anti-CD40L antibody being developed by IDECPharmaceuticals, IDEC-151 (Clenoliximab), an anti-CD4 antibody beingdeveloped by IDEC Pharmaceuticals, IDEC-114, an anti-CD80 antibody beingdeveloped by IDEC Pharmaceuticals, IDEC-152, an anti-CD23 beingdeveloped by IDEC Pharmaceuticals, anti-macrophage migration factor(MIF) antibodies being developed by IDEC Pharmaceuticals, BEC2, ananti-idiotypic antibody being developed by Imclone, IMC-1C11, ananti-KDR antibody being developed by Imclone, DC101, an anti-flk-1antibody being developed by Imclone, anti-VE cadherin antibodies beingdeveloped by Imclone, CEA-Cide® (Iabetuzumab), an anti-carcinoembryonicantigen (CEA) antibody being developed by Immunomedics, LymphoCide®(Epratuzumab), an anti-CD22 antibody being developed by Immunomedics,AFP-Cide, being developed by Immunomedics, MyelomaCide, being developedby Immunomedics, LkoCide, being developed by Immunomedics, ProstaCide,being developed by Immunomedics, MDX-010, an anti-CTLA4 antibody beingdeveloped by Medarex, MDX-060, an anti-CD30 antibody being developed byMedarex, MDX-070 being developed by Medarex, MDX-018 being developed byMedarex, Osidem® (IDM-1), and anti-Her2 antibody being developed byMedarex and Immuno-Designed Molecules, HuMax®-CD4, an anti-CD4 antibodybeing developed by Medarex and Genmab, HuMax-IL15, an anti-IL15 antibodybeing developed by Medarex and Genmab, CNTO 148, an anti-TNFα antibodybeing developed by Medarex and Centocor/J&J, CNTO 1275, an anti-cytokineantibody being developed by Centocor/J&J, MOR101 and MOR102,anti-intercellular adhesion molecule-1 (ICAM-1) (CD54) antibodies beingdeveloped by MorphoSys, MOR201, an anti-fibroblast growth factorreceptor 3 (FGFR-3) antibody being developed by MorphoSys, Nuvion®(visilizumab), an anti-CD3 antibody being developed by Protein DesignLabs, HuZAF®, an anti-gamma interferon antibody being developed byProtein Design Labs, Anti-α 5β1 Integrin, being developed by ProteinDesign Labs, anti-IL-12, being developed by Protein Design Labs, ING-1,an anti-Ep-CAM antibody being developed by Xoma, Xolair® (Omalizumab) ahumanized anti-IgE antibody developed by Genentech and Novartis, andMLN01, an anti-Beta2 integrin antibody being developed by Xoma. Inanother embodiment, the therapeutics include KRN330 (Kirin); huA33antibody (A33, Ludwig Institute for Cancer Research); CNTO 95 (alpha Vintegrins, Centocor); MEDI-522 (alpha Vβ3 integrin, Medimmune);volociximab (alpha Vβ1 integrin, Biogen/PDL); Human mAb 216 (B cellglycosolated epitope, NCl); BiTE MT103 (bispecific CD19×CD3, Medimmune);4G7×H22 (Bispecific BcellxFcgammaR1, Medarex/Merck KGa); rM28(Bispecific CD28×MAPG, EP Patent No. EP1444268); MDX447 (EMD 82633)(Bispecific CD64×EGFR, Medarex); Catumaxomab (removab) (BispecificEpCAM×anti-CD3, Trion/Fres); Ertumaxomab (bispecific HER2/CD3, FreseniusBiotech); oregovomab (OvaRex) (CA-125, ViRexx); Rencarex® (WX G250)(carbonic anhydrase IX, Wilex); CNTO 888 (CCL2, Centocor); TRC105 (CD105(endoglin), Tracon); BMS-663513 (CD137 agonist, Brystol Myers Squibb);MDX-1342 (CD19, Medarex); Siplizumab (MEDI-507) (CD2, Medimmune);Ofatumumab (Humax-CD20) (CD20, Genmab); Rituximab (Rituxan) (CD20,Genentech); veltuzumab (hA20) (CD20, Immunomedics); Epratuzumab (CD22,Amgen); lumiliximab (IDEC 152) (CD23, Biogen); muromonab-CD3 (CD3,Ortho); HuM291 (CD3 fc receptor, PDL Biopharma); HeFi-1, CD30, NCl);MDX-060 (CD30, Medarex); MDX-1401 (CD30, Medarex); SGN-30 (CD30, SeattleGenentics); SGN-33 (Lintuzumab) (CD33, Seattle Genentics); Zanolimumab(HuMax-CD4) (CD4, Genmab); HCD122 (CD40, Novartis); SGN-40 (CD40,Seattle Genentics); Campathlh (Alemtuzumab) (CD52, Genzyme); MDX-1411(CD70, Medarex); hLL1 (EPB-1) (CD74.38, Immunomedics); Galiximab(IDEC-144) (CD80, Biogen); MT293 (TRC093/D93) (cleaved collagen,Tracon); HuLuc63 (CS1, PDL Pharma); ipilimumab (MDX-010) (CTLA4, BrystolMyers Squibb); Tremelimumab (Ticilimumab, CP-675,2) (CTLA4, Pfizer);HGS-ETR1 (Mapatumumab) (DR4TRAIL-R1 agonist, Human Genome Science/GlaxoSmith Kline); AMG-655 (DR5, Amgen); Apomab (DR5, Genentech); CS-1008(DR5, Daiichi Sankyo); HGS-ETR2 (lexatumumab) (DR5TRAIL-R2 agonist,HGS); Cetuximab (Erbitux) (EGFR, Imclone); IMC-11F8, (EGFR, Imclone);Nimotuzumab (EGFR, YM Bio); Panitumumab (Vectabix) (EGFR, Amgen);Zalutumumab (HuMaxEGFr) (EGFR, Genmab); CDX-110 (EGFRvIII, AVANTImmunotherapeutics); adecatumumab (MT201) (Epcam™, Merck); edrecolomab(Panorex, 17-1A) (Epcam™, Glaxo/Centocor); MORAb-003 (folate receptor a,Morphotech); KW-2871 (ganglioside GD3, Kyowa); MORAb-009 (GP-9,Morphotech); CDX-1307 (MDX-1307) (hCGb, Celldex); Trastuzumab(Herceptin) (HER2, Celldex); Pertuzumab (rhuMAb 2C4) (HER2 (DI),Genentech); apolizumab (HLA-DR beta chain, PDL Pharma); AMG-479 (IGF-1R,Amgen); anti-IGF-1R R1507 (IGF1-R, Roche); CP 751871 (IGF1-R, Pfizer);IMC-A12 (IGF1-R, Imclone); BIIB022 (IGF-1R, Biogen); Mik-beta-1 (IL-2Rb(CD122), Hoffman LaRoche); CNTO 328 (IL6, Centocor); Anti-KIR (1-7F9)(Killer cell Ig-like Receptor (KIR), Novo); Hu3S193 (Lewis (y), Wyeth,Ludwig Institute of Cancer Research); hCBE-11 (LTβR, Biogen); HuHMFG1(MUC1, Antisoma/NCl); RAV12 (N-linked carbohydrate epitope, Raven); CAL(parathyroid hormone-related protein (PTH-rP), University ofCalifornia); CT-011 (PD1, CureTech); MDX-1106 (ono-4538) (PD1,Medarex/Ono); MAb CT-011 (PD1, Curetech); IMC-3G3 (PDGFRa, Imclone);bavituximab (phosphatidylserine, Peregrine); huJ591 (PSMA, CornellResearch Foundation); muJ591 (PSMA, Cornell Research Foundation); GC1008(TGFb (pan) inhibitor (IgG4), Genzyme); Infliximab (Remicade) (TNFα,Centocor); A27.15 (transferrin receptor, Salk Institute, INSERN WO2005/111082); E2.3 (transferrin receptor, Salk Institute); Bevacizumab(Avastin) (VEGF, Genentech); HuMV833 (VEGF, Tsukuba Research Lab, PCTPublication No. WO/2000/034337, University of Texas); IMC-18F1 (VEGFR1,Imclone); IMC-1121 (VEGFR2, Imclone).

C. Construction of DVD Molecules

The dual variable domain immunoglobulin (DVD-Ig) molecule is designedsuch that two different light chain variable domains (VL) from the twoparent monoclonal antibodies, which can be the same or different, arelinked in tandem directly or via a short linker by recombinant DNAtechniques, followed by the light chain constant domain, and optionally,an Fc region. Similarly, the heavy chain comprises two different heavychain variable domains (VH) linked in tandem, followed by the constantdomain CH1 and Fc region (FIG. 1A).

The variable domains can be obtained using recombinant DNA techniquesfrom a parent antibody generated by any one of the methods describedherein. In an embodiment, the variable domain is a murine heavy or lightchain variable domain. In another embodiment, the variable domain is aCDR grafted or a humanized variable heavy or light chain domain. In anembodiment, the variable domain is a human heavy or light chain variabledomain.

In one embodiment the first and second variable domains are linkeddirectly to each other using recombinant DNA techniques. In anotherembodiment the variable domains are linked via a linker sequence. In anembodiment, two variable domains are linked. Three or more variabledomains may also be linked directly or via a linker sequence. Thevariable domains may bind the same antigen or may bind differentantigens. DVD-Ig molecules provided herein may include oneimmunoglobulin variable domain and one non-immunoglobulin variabledomain, such as ligand binding domain of a receptor, or an active domainof an enzyme. DVD-Ig molecules may also comprise two or more non-Igdomains.

The linker sequence may be a single amino acid or a polypeptidesequence. In an embodiment, the linker sequence is AKTTPKLEEGEFSEAR (SEQID NO: 1); AKTTPKLEEGEFSEARV (SEQ ID NO: 2); AKTTPKLGG (SEQ ID NO: 3);SAKTTPKLGG (SEQ ID NO: 4); SAKTTP (SEQ ID NO: 5); RADAAP (SEQ ID NO: 6);RADAAPTVS (SEQ ID NO: 7); RADAAAAGGPGS (SEQ ID NO: 8); RADAAAA(G₄S)₄(SEQ ID NO: 9), SAKTTPKLEEGEFSEARV (SEQ ID NO: 10); ADAAP (SEQ ID NO:11); ADAAPTVSIFPP (SEQ ID NO: 12); TVAAP (SEQ ID NO: 13); TVAAPSVFIFPP(SEQ ID NO: 14); QPKAAP (SEQ ID NO: 15); QPKAAPSVTLFPP (SEQ ID NO: 16);AKTTPP (SEQ ID NO: 17); AKTTPPSVTPLAP (SEQ ID NO: 18); AKTTAP (SEQ IDNO: 19); AKTTAPSVYPLAP (SEQ ID NO: 20); ASTKGP (SEQ ID NO: 21);ASTKGPSVFPLAP (SEQ ID NO: 22), GGGGSGGGGSGGGGS (SEQ ID NO: 23);GENKVEYAPALMALS (SEQ ID NO: 24); GPAKELTPLKEAKVS (SEQ ID NO: 25); orGHEAAAVMQVQYPAS (SEQ ID NO: 26). The choice of linker sequences is basedon crystal structure analysis of several Fab molecules. There is anatural flexible linkage between the variable domain and the CH1/CLconstant domain in Fab or antibody molecular structure. This naturallinkage comprises approximately 10-12 amino acid residues, contributedby 4-6 residues from C-terminus of V domain and 4-6 residues from theN-terminus of CL/CH1 domain. DVD Igs provided herein were generatedusing N-terminal 5-6 amino acid residues, or 11-12 amino acid residues,of CL or CH1 as linker in light chain and heavy chain of DVD-Ig,respectively. The N-terminal residues of the CL or CH1 domain,particularly the first 5-6 amino acid residues, adopt a loopconformation without strong secondary structure, and, therefore, can actas a flexible linker between the two variable domains. The N-terminalresidues of the CL or CH1 domain are a natural extension of the variabledomains, as they are part of the Ig sequences, and, therefore, minimizeto a large extent any immunogenicity potentially arising from thelinkers and junctions.

Other linker sequences may include any sequence of any length of theCL/CH1 domain but not all residues of the CL/CH1 domain (for example,the first 5-12 amino acid residues of the CL/CH1 domains) the lightchain linkers can be from Cκ or Cλ; and the heavy chain linkers can bederived from CH1 of any isotypes, including Cγ1, Cγ2, Cγ3, Cγ4, Cα1,Cα2, Cδ, Cε, and Cμ. Linker sequences may also be derived from otherproteins such as Ig-like proteins, (e.g. TCR, FcR, KIR); G/S basedsequences (e.g., G4S repeats) (SEQ ID NO:29); hinge region-derivedsequences; and other natural sequences from other proteins.

In an embodiment a constant domain is linked to the two linked variabledomains using recombinant DNA techniques. In an embodiment, sequencecomprising linked heavy chain variable domains is linked to a heavychain constant domain and sequence comprising linked light chainvariable domains is linked to a light chain constant domain. In anembodiment, the constant domains are human heavy chain constant domainand human light chain constant domain respectively. In an embodiment,the DVD heavy chain is further linked to an Fc region. The Fc region maybe a native sequence Fc region, or a variant Fc region. In anotherembodiment, the Fc region is a human Fc region. In another embodimentthe Fc region includes Fc region from IgG1, IgG2, IgG3, IgG4, IgA, IgM,IgE, or IgD.

In another embodiment two heavy chain DVD polypeptides and two lightchain DVD polypeptides are combined to form a DVD-Ig molecule. Table 2lists amino acid sequences of VH and VL regions of exemplary antibodiesfor targets useful for treating disease, e.g., for treating cancer. ADVD comprising at least two of the VH and/or VL regions listed in Table2, in any orientation is provided. In some embodiments, VD1 and VD2 areindependently chosen. Therefore, in some embodiments, VD1 and VD2comprise the same SEQ ID NO and, in other embodiments, VD1 and VD2comprise different SEQ ID NOS.

The VH and VL domain sequences provided below comprise complementarydetermining region (CDR) and framework sequences that are either knownin the art or readily discernable using methods known in the art. Insome embodiments, one or more of these CDR and/or framework sequencesare replaced, without loss of function, by other CDR and/or frameworksequences from binding proteins that are known in the art to bind to thesame antigen.

TABLE 2 List of Amino Acid Sequences of VH and VL regions of Antibodiesfor Generating DVD-Igs Sequence SEQ ID ABT Unique Protein123456789012345678901234567890123 No. ID region 4567890 30 AB268VHVH-IL1β EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYD (seq. 1)MSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKG RFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS 31 AB268VL VL-IL1 βDIQMTQSPSSLSASVGDRVTITCRASGNIHNYL (seq. 1)TWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSG SGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR 32 AB269VH VH-IL1 β EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYD (seq. 2)MSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKG RFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVTVSS 33 AB269VL VL-IL1 βDIQMTQSPSSLSASVGDRVTITCRASGNIHNYL (seq. 2)TWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSG SGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR 34 AB270VH VH-IL1 β EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYG (seq. 3)VSWIRQPPGKGLEWLGLIWGGGDTYYNSPLKSR LTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 35 AB270VL VL-IL βDTQVTQSPSSLSASVGDRVTITCITSTDIDVDM (seq. 3)NWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSG SGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKR 36 AB271VH VH-IL1 β EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYG (seq. 4)VSWIRQPPGKGLEWLGLIWGGGDTYYNSPLKSR LTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 37 AB271VL VL-IL1 βDTVVTQSPAFLSVTPGEKVTITCITSTDIDVDM (seq. 4)NWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSG SGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKR 38 AB272VH VH-IL1 β EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYG (seq. 5)VSWIRQAPGKGLEWLGLIWGGGDTYYNSPLKSR LTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 39 AB272VL VL-IL1 βETTVTQSPSSLSASVGDRVTITCITSTDIDVDM (seq. 5)NWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSG SGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKR 40 AB273VH VH-IL17 EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYE (seq. 1)IHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDG RVTLTADESTSTAYMELSSLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSS 41 AB273VL VL-IL17DIQMTQSPSSLSASVGDRVTITCRASSGIISYI (seq. 1)DWFQQKPGKAPKRLIYATFDLASGVPSRFSGSG SGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKR 42 AB274VH VH-IL17 EVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYG (seq. 2)IGWVRQAPGQGLEWMGGITPFFGFADYAQKFQG RVTITADESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSS 43 AB274VL VL-IL17EIVLTQSPDFQSVTPKEKVTITCRASQDIGSEL (seq. 2)HWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSG SGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 44 AB275VH VH-IL17 EVQLVQSGAEVKKPGESVKISCKASGGSFRSYG (seq. 3)ISWVRQAPGQGLEWMGGITHFFGITDYAQKFQG RVTITADESTTTAYMELSGLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSS 45 AB275VL VL-IL17EIVLTQSPDFQSVTPKEKVTITCRASQNIGSEL (seq. 3)HWYQQKPDQSPKLLIKYASHSISGVPSRFSGSG SGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR

Detailed description of specific DVD-Ig molecules capable of bindingspecific targets, and methods of making the same, is provided in theExamples section below.

D. Production of DVD Proteins

Binding proteins provided herein may be produced by any of a number oftechniques known in the art. For example, expression from host cells,wherein expression vector(s) encoding the DVD heavy and DVD light chainsis (are) transfected into a host cell by standard techniques. Thevarious forms of the term “transfection” are intended to encompass awide variety of techniques commonly used for the introduction ofexogenous DNA into a prokaryotic or eukaryotic host cell, e.g.,electroporation, calcium-phosphate precipitation, DEAE-dextrantransfection and the like. Although it is possible to express the DVDproteins in either prokaryotic or eukaryotic host cells, DVD proteinsare expressed in eukaryotic cells, for example, mammalian host cells,because such eukaryotic cells (and in particular mammalian cells) aremore likely than prokaryotic cells to assemble and secrete a properlyfolded and immunologically active DVD protein.

Exemplary mammalian host cells for expressing recombinant antibodiesinclude Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells,described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA77:4216-4220, used with a DHFR selectable marker, e.g., as described inKaufman, R. J. and Sharp, P. A. (1982) Mol. Biol. 159:601-621), NS0myeloma cells, COS cells, SP2 and PER.C6 cells. When recombinantexpression vectors encoding DVD proteins are introduced into mammalianhost cells, the DVD proteins are produced by culturing the host cellsfor a period of time sufficient to allow for expression of the DVDproteins in the host cells or secretion of the DVD proteins into theculture medium in which the host cells are grown. DVD proteins can berecovered from the culture medium using standard protein purificationmethods.

In an exemplary system for recombinant expression of DVD proteins, arecombinant expression vector encoding both the DVD heavy chain and theDVD light chain is introduced into dhfr-CHO cells by calciumphosphate-mediated transfection. Within the recombinant expressionvector, the DVD heavy and light chain genes are each operatively linkedto CMV enhancer/AdMLP promoter regulatory elements to drive high levelsof transcription of the genes. The recombinant expression vector alsocarries a DHFR gene, which allows for selection of CHO cells that havebeen transfected with the vector using methotrexateselection/amplification. The selected transformant host cells arecultured to allow for expression of the DVD heavy and light chains andintact DVD protein is recovered from the culture medium. Standardmolecular biology techniques are used to prepare the recombinantexpression vector, transfect the host cells, select for transformants,culture the host cells and recover the DVD protein from the culturemedium. A method of synthesizing a DVD protein provided herein byculturing a host cell in a suitable culture medium until a DVD proteinis synthesized is provided. The method can further comprise isolatingthe DVD protein from the culture medium.

An important feature of DVD-Ig is that it can be produced and purifiedin a similar way as a conventional antibody. The production of DVD-Igresults in a homogeneous, single major product with desireddual-specific activity, without any sequence modification of theconstant region or chemical modifications of any kind. Other previouslydescribed methods to generate “bi-specific,” “multi-specific,” and“multi-specific multivalent” full length binding proteins do not lead toa single primary product but instead lead to the intracellular orsecreted production of a mixture of assembled inactive, mono-specific,multi-specific, multivalent, full length binding proteins, andmultivalent full length binding proteins with combination of differentbinding sites. As an example, based on the design described by Millerand Presta (PCT Publication No. WO2001/077342(A1), there are 16 possiblecombinations of heavy and light chains. Consequently, only 6.25% ofprotein is likely to be in the desired active form, and not as a singlemajor product or single primary product compared to the other 15possible combinations. Separation of the desired, fully active forms ofthe protein from inactive and partially active forms of the proteinusing standard chromatography techniques, typically used in large scalemanufacturing, is yet to be demonstrated.

Surprisingly, the design of the “dual-specific multivalent full lengthbinding proteins” provided herein leads to a dual variable domain lightchain and a dual variable domain heavy chain which assemble primarily tothe desired “dual-specific multivalent full length binding proteins”.

At least 50%, at least 75% and at least 90% of the assembled, andexpressed dual variable domain immunoglobulin molecules are the desireddual-specific tetravalent protein. This aspect particularly enhancescommercial utility. Therefore, a method to express a dual variabledomain light chain and a dual variable domain heavy chain in a singlecell leading to a single primary product of a “dual-specific tetravalentfull length binding protein” is provided.

Methods of expressing a dual variable domain light chain and a dualvariable domain heavy chain in a single cell leading to a “primaryproduct” of a “dual-specific tetravalent full length binding protein,”where the “primary product” is more than 50% of all assembled protein,comprising a dual variable domain light chain and a dual variable domainheavy chain are provided.

Methods of expressing a dual variable domain light chain and a dualvariable domain heavy chain in a single cell leading to a single“primary product” of a “dual-specific tetravalent full length bindingprotein,” where the “primary product” is more than 75% of all assembledprotein, comprising a dual variable domain light chain and a dualvariable domain heavy chain are provided.

Methods of expressing a dual variable domain light chain and a dualvariable domain heavy chain in a single cell leading to a single“primary product” of a “dual-specific tetravalent full length bindingprotein,” where the “primary product” is more than 90% of all assembledprotein, comprising a dual variable domain light chain and a dualvariable domain heavy chain are provided.

II. Derivatized DVD Binding Proteins

One embodiment provides a labeled binding protein wherein the bindingprotein is derivatized or linked to another functional molecule (e.g.,another peptide or protein). For example, a labeled binding protein canbe derived by functionally linking the binding protein (by chemicalcoupling, genetic fusion, noncovalent association or otherwise) to oneor more other molecular entities, such as another antibody (e.g., abispecific antibody or a diabody), a detectable agent, a cytotoxicagent, a pharmaceutical agent, and/or a protein or peptide that canmediate association of the binding protein with another molecule (suchas a streptavidin core region or a polyhistidine tag).

Useful detectable agents with which the binding protein may bederivatized include fluorescent compounds. Exemplary fluorescentdetectable agents include fluorescein, fluorescein isothiocyanate,rhodamine, 5-dimethylamine-1-napthalenesulfonyl chloride, phycoerythrinand the like. A binding protein may also be derivatized with detectableenzymes, such as alkaline phosphatase, horseradish peroxidase, glucoseoxidase and the like. When a binding protein is derivatized with adetectable enzyme, it is detected by adding additional reagents that theenzyme uses to produce a detectable reaction product. For example, whenthe detectable agent horseradish peroxidase is present, the addition ofhydrogen peroxide and diaminobenzidine leads to a colored reactionproduct, which is detectable. A binding protein may also be derivatizedwith biotin, and detected through indirect measurement of avidin orstreptavidin binding.

A crystallized binding protein and formulations and compositionscomprising such crystals are provided. In one embodiment thecrystallized binding protein has a greater half-life in vivo than thesoluble counterpart of the binding protein. In another embodiment thebinding protein retains biological activity after crystallization.

Crystallized binding protein may be produced according to methods knownin the art and as disclosed in PCT Publication No. WO 02/072636.

A glycosylated binding protein wherein the antibody or antigen-bindingportion thereof comprises one or more carbohydrate residues is provided.Nascent in vivo protein production may undergo further processing, knownas post-translational modification. In particular, sugar (glycosyl)residues may be added enzymatically, a process known as glycosylation.The resulting proteins bearing covalently linked oligosaccharide sidechains are known as glycosylated proteins or glycoproteins. Antibodiesare glycoproteins with one or more carbohydrate residues in the Fcdomain, as well as the variable domain. Carbohydrate residues in the Fcdomain have an important effect on the effector function of the Fcdomain, with minimal effect on antigen binding or half-life of theantibody (Jefferis, R. (2005) Biotechnol. Prog. 21: 11-16). In contrast,glycosylation of the variable domain may have an effect on the antigenbinding activity of the antibody. Glycosylation in the variable domainmay have a negative effect on antibody binding affinity, likely due tosteric hindrance (Co, M. S., et al. (1993) Mol. Immunol. 30:1361-1367),or result in increased affinity for the antigen (Wallick, S. C., et al.(1988) Exp. Med. 168:1099-1109; Wright, A., et al. (1991) EMBO J.10:2717-2723).

One embodiment is directed to generating glycosylation site mutants inwhich the O- or N-linked glycosylation site of the binding protein hasbeen mutated. One skilled in the art can generate such mutants usingstandard well-known technologies. Glycosylation site mutants that retainthe biological activity but have increased or decreased binding activityare also provided.

In still another embodiment, the glycosylation of the antibody orantigen-binding portion is modified. For example, an aglycoslatedantibody can be made (i.e., the antibody lacks glycosylation).Glycosylation can be altered to, for example, increase the affinity ofthe antibody for antigen. Such carbohydrate modifications can beaccomplished by, for example, altering one or more sites ofglycosylation within the antibody sequence. For example, one or moreamino acid substitutions can be made that result in elimination of oneor more variable region glycosylation sites to thereby eliminateglycosylation at that site. Such aglycosylation may increase theaffinity of the antibody for antigen. Such an approach is described infurther detail in PCT Publication WO 2003/016466A2, and U.S. Pat. Nos.5,714,350 and 6,350,861.

Additionally or alternatively, a modified binding protein can be madethat has an altered type of glycosylation, such as a hypofucosylatedantibody having reduced amounts of fucosyl residues (see Kanda, Y. etal. (2007) J. Biotech. 130(3): 300-310.) or an antibody having increasedbisecting GlcNAc structures. Such altered glycosylation patterns havebeen demonstrated to increase the ADCC ability of antibodies. Suchcarbohydrate modifications can be accomplished by, for example,expressing the antibody in a host cell with altered glycosylationmachinery. Cells with altered glycosylation machinery have beendescribed in the art and can be used as host cells in which to expressrecombinant antibodies to thereby produce an antibody with alteredglycosylation. See, for example, Shields, R. L. et al. (2002) J. Biol.Chem. 277:26733-26740; Umana et al. (1999) Nat. Biotech. 17:176-1, aswell as, European Patent No. EP 1,176,195 and PCT Publication Nos. WO03/035835 and WO 99/54342 80.

Protein glycosylation depends on the amino acid sequence of the proteinof interest, as well as the host cell in which the protein is expressed.Different organisms may produce different glycosylation enzymes (e.g.,glycosyltransferases and glycosidases), and have different substrates(nucleotide sugars) available. Due to such factors, proteinglycosylation pattern, and composition of glycosyl residues, may differdepending on the host system in which the particular protein isexpressed. Glycosyl residues may include, but are not limited to,glucose, galactose, mannose, fucose, n-acetylglucosamine and sialicacid. In an embodiment, the glycosylated binding protein comprisesglycosyl residues such that the glycosylation pattern is human.

It is known to those skilled in the art that differing proteinglycosylation may result in differing protein characteristics. Forinstance, the efficacy of a therapeutic protein produced in amicroorganism host, such as yeast, and glycosylated utilizing the yeastendogenous pathway may be reduced compared to that of the same proteinexpressed in a mammalian cell, such as a CHO cell line. Suchglycoproteins may also be immunogenic in humans and show reducedhalf-life in vivo after administration. Specific receptors in humans andother animals may recognize specific glycosyl residues and promote therapid clearance of the protein from the bloodstream. Other adverseeffects may include changes in protein folding, solubility,susceptibility to proteases, trafficking, transport,compartmentalization, secretion, recognition by other proteins orfactors, antigenicity, or allergenicity. Accordingly, a practitioner maychoose a therapeutic protein with a specific composition and pattern ofglycosylation, for example glycosylation composition and patternidentical, or at least similar, to that produced in human cells or inthe species-specific cells of the intended subject animal.

Expressing glycosylated proteins different from that of a host cell maybe achieved by genetically modifying the host cell to expressheterologous glycosylation enzymes. Using techniques known in the art apractitioner may generate antibodies or antigen-binding portions thereofexhibiting human protein glycosylation. For example, yeast strains havebeen genetically modified to express non-naturally occurringglycosylation enzymes such that glycosylated proteins (glycoproteins)produced in these yeast strains exhibit protein glycosylation identicalto that of animal cells, especially human cells (U.S. Pat. Nos.7,449,308 and 7,029,872 and PCT Publication No/WO2005/100584).

In addition to binding proteins, other embodiments are also directed toanti-idiotypic (anti-Id) antibodies specific for such binding proteins.An anti-Id antibody is an antibody, which recognizes unique determinantsgenerally associated with the antigen-binding region of anotherantibody. The anti-Id can be prepared by immunizing an animal with thebinding protein or a CDR containing region thereof. The immunized animalwill recognize, and respond to the idiotypic determinants of theimmunizing antibody and produce an anti-Id antibody. It is readilyapparent that it may be easier to generate anti-idiotypic antibodies tothe two or more parent antibodies incorporated into a DVD-Ig molecule;and confirm binding studies by methods well recognized in the art (e.g.,BIAcore, ELISA) to verify that anti-idiotypic antibodies specific forthe idiotype of each parent antibody also recognize the idiotype (e.g.,antigen binding site) in the context of the DVD-Ig. The anti-idiotypicantibodies specific for each of the two or more antigen binding sites ofa DVD-Ig provide ideal reagents to measure DVD-Ig concentrations of ahuman DVD-Ig in patient serum; DVD-Ig concentration assays can beestablished using a “sandwich assay ELISA format” with an antibody to afirst antigen binding region coated on the solid phase (e.g., BIAcorechip, ELISA plate etc.), rinsing with rinsing buffer, incubating withthe serum sample, rinsing again and ultimately incubating with anotheranti-idiotypic antibody to the another antigen binding site, itselflabeled with an enzyme for quantitation of the binding reaction. In anembodiment, for a DVD-Ig with more than two different binding sites,anti-idiotypic antibodies to the two outermost binding sites (mostdistal and proximal from the constant region) will not only help indetermining the DVD-Ig concentration in human serum but also documentthe integrity of the molecule in vivo. Each anti-Id antibody may also beused as an “immunogen” to induce an immune response in yet anotheranimal, producing a so-called anti-anti-Id antibody.

Further, it will be appreciated by one skilled in the art that a proteinof interest may be expressed using a library of host cells geneticallyengineered to express various glycosylation enzymes, such that memberhost cells of the library produce the protein of interest with variantglycosylation patterns. A practitioner may then select and isolate theprotein of interest with particular novel glycosylation patterns. In anembodiment, the protein having a particularly selected novelglycosylation pattern exhibits improved or altered biologicalproperties.

III. Uses of DVD-Ig

Given their ability to bind to two or more antigens the binding proteinsprovided herein can be used to detect the antigens (e.g., in abiological sample, such as serum or plasma), using a conventionalimmunoassay, such as an enzyme linked immunosorbent assays (ELISA), aradioimmunoassay (RIA) or tissue immunohistochemistry. The DVD-Ig isdirectly or indirectly labeled with a detectable substance to facilitatedetection of the bound or unbound antibody. Suitable detectablesubstances include various enzymes, prosthetic groups, fluorescentmaterials, luminescent materials and radioactive materials. Examples ofsuitable enzymes include horseradish peroxidase, alkaline phosphatase,β-galactosidase, and acetylcholinesterase; examples of suitableprosthetic group complexes include streptavidin/biotin andavidin/biotin; examples of suitable fluorescent materials includeumbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine,dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin;an example of a luminescent material includes luminol; and examples ofsuitable radioactive material include ³H, ¹⁴C, ³⁵S, ⁹⁰Y, ⁹⁹Tc, ¹¹¹In,¹²⁵I, ¹³¹I, ¹⁷⁷Lu, ¹⁶⁶Ho, and ¹⁵³Sm.

In an embodiment, the binding proteins neutralize the activity of theantigens both in vitro and in vivo. Accordingly, such DVD-Igs can beused to inhibit antigen activity, e.g., in a cell culture containing theantigens, in human subjects or in other mammalian subjects havingantigens with which the binding protein cross-reacts. In anotherembodiment, a method for reducing antigen activity in a subjectsuffering from a disease or disorder in which the antigen activity isdetrimental is provided. In some embodiments, the binding protein isadministered to a human subject for therapeutic purposes.

As used herein, the term “a disorder in which antigen activity isdetrimental” is intended to include diseases and other disorders inwhich the presence of the antigen in a subject suffering from thedisorder has been shown to be or is suspected of being eitherresponsible for the pathophysiology of the disorder or a factor thatcontributes to a worsening of the disorder. Accordingly, a disorder inwhich antigen activity is detrimental is a disorder in which reductionof antigen activity is expected to alleviate the symptoms and/orprogression of the disorder. Such disorders may be evidenced, forexample, by an increase in the concentration of the antigen in abiological fluid of a subject suffering from the disorder (e.g., anincrease in the concentration of antigen in serum, plasma, synovialfluid, etc. of the subject). Non-limiting examples of disorders that canbe treated include those disorders discussed below and in the sectionpertaining to pharmaceutical compositions.

The DVD-Igs provided herein may bind one antigen or multiple antigens.Such antigens include, but are not limited to, the targets listed in thefollowing databases. These target databases include those listings:

Therapeutic targets (http://xin.cz3.nus.edu.sg/group/cjttd/ttd.asp);Cytokines and cytokine receptors (http://www.cytokinewebfacts.com/,http://www.copewithcytokines.de/cope.cgi, andhttp://cmbi.bjmu.edu.cn/cmbidata/cgf/CGF_Database/cytokine.medic.kumamoto-u.ac.jp/CFC/indexR.html);Chemokines(http://cytokine.medic.kumamoto-u.ac.jp/CFC/CK/Chemokine.html);Chemokine receptors and GPCRs(http://csp.medic.kumamoto-u.ac.jp/CSP/Receptor.html, andhttp://www.gper.org/7tm/);Olfactory Receptors(http://senselab.med.yale.edu/senselab/ORDB/default.asp);Receptors (http://www.iuphar-db.org/iuphar-rd/list/index.htm);Cancer targets (http://cged.hgc.jp/cgi-bin/input.cgi);Secreted proteins as potential antibody targets(http://spd.cbi.pku.edu.cn/);Protein kinases (http://spd.cbi.pku.edu.cn/), andHuman CD markers(http://contentlabvelocity.com/tools/6/1226/CD_table_final_locked.pdf)and (Zola H, (2005) Blood 106: 3123-6).

DVD-Igs are useful as therapeutic agents to simultaneously block twodifferent targets to enhance efficacy/safety and/or increase patientcoverage. Such targets may include soluble targets (e.g., TNF) and cellsurface receptor targets (e.g., VEGFR and EGFR). It can also be used toinduce redirected cytotoxicity between tumor cells and T cells (e.g.,Her2 and CD3) for cancer therapy, or between autoreactive cell andeffector cells for autoimmune disease or transplantation, or between anytarget cell and effector cell to eliminate disease-causing cells in anygiven disease.

In addition, DVD-Ig can be used to trigger receptor clustering andactivation when it is designed to target two different epitopes on thesame receptor. This may have benefit in making agonistic andantagonistic anti-GPCR therapeutics. In this case, DVD-Ig can be used totarget two different epitopes (including epitopes on both the loopregions and the extracellular domain) on one cell forclustering/signaling (two cell surface molecules) or signaling (on onemolecule). Similarly, a DVD-Ig molecule can be designed to triggerCTLA-4 ligation, and a negative signal by targeting two differentepitopes (or 2 copies of the same epitope) of CTLA-4 extracellulardomain, leading to down regulation of the immune response. CTLA-4 is aclinically validated target for therapeutic treatment of a number ofimmunological disorders. CTLA-4/B7 interactions negatively regulate Tcell activation by attenuating cell cycle progression, IL-2 production,and proliferation of T cells following activation, and CTLA-4 (CD152)engagement can down-regulate T cell activation and promote the inductionof immune tolerance. However, the strategy of attenuating T cellactivation by agonistic antibody engagement of CTLA-4 has beenunsuccessful since CTLA-4 activation requires ligation. The molecularinteraction of CTLA-4/B7 is in “skewed zipper” arrays, as demonstratedby crystal structural analysis (Stamper (2001) Nature 410: 608). Howevernone of the currently available CTLA-4 binding reagents have ligationproperties, including anti-CTLA-4 mAbs. There have been several attemptsto address this issue. In one case, a cell member-bound single chainantibody was generated, and significantly inhibited allogeneic rejectionin mice (Hwang (2002) J. Immunol. 169:633). In a separate case,artificial APC surface-linked single-chain antibody to CTLA-4 wasgenerated and demonstrated to attenuate T cell responses (Griffin (2000)J. Immunol. 164:4433). In both cases, CTLA-4 ligation was achieved byclosely localized member-bound antibodies in artificial systems. Whilethese experiments provide proof-of-concept for immune down-regulation bytriggering CTLA-4 negative signaling, the reagents used in these reportsare not suitable for therapeutic use. To this end, CTLA-4 ligation maybe achieved by using a DVD-Ig molecule, which target two differentepitopes (or 2 copies of the same epitope) of CTLA-4 extracellulardomain. The rationale is that the distance spanning two binding sites ofan IgG, approximately 150-170 Å, is too large for active ligation ofCTLA-4 (30-50 Å between 2 CTLA-4 homodimer). However the distancebetween the two binding sites on DVD-Ig (one arm) is much shorter, alsoin the range of 30-50 Å, allowing proper ligation of CTLA-4.

Similarly, DVD-Ig can target two different members of a cell surfacereceptor complex (e.g., IL-12R alpha and beta). Furthermore, DVD-Ig cantarget CR1 and a soluble protein/pathogen to drive rapid clearance ofthe target soluble protein/pathogen.

Additionally, DVD-Igs provided herein can be employed fortissue-specific delivery (target a tissue marker and a disease mediatorfor enhanced local PK thus higher efficacy and/or lower toxicity),including intracellular delivery (targeting an internalizing receptorand a intracellular molecule), and delivery to the inside of the brain(targeting transferrin receptor and a CNS disease mediator for crossingthe blood-brain barrier). DVD-Ig can also serve as a carrier protein todeliver an antigen to a specific location via binding to anon-neutralizing epitope of that antigen and also to increase thehalf-life of the antigen. Furthermore, DVD-Ig can be designed to eitherbe physically linked to medical devices implanted into patients ortarget these medical devices (see Burke, S. E. et al. (2006) Adv. DrugDeliv. Rev. 58(3): 437-446; Hildebrand, H. F. et al. (2006) Surface andCoatings Technol. 200(22-23): 6318-6324; Wu, P. et al. (2006)Biomaterials 27(11): 2450-2467; Marques, A. P. et al. (2005) Biodegrad.Syst. Tissue Eng. and Regen. Med. 377-397). Briefly, directingappropriate types of cell to the site of medical implant may promotehealing and restoring normal tissue function. Alternatively, inhibitionof mediators (including but not limited to cytokines), released upondevice implantation by a DVD coupled to or target to a device is alsoprovided. For example, stents have been used for years in interventionalcardiology to clear blocked arteries and to improve the flow of blood tothe heart muscle. However, traditional bare metal stents have been knownto cause restenosis (re-narrowing of the artery in a treated area) insome patients and can lead to blood clots. Recently, an anti-CD34antibody coated stent has been described which reduced restenosis andprevents blood clots from occurring by capturing endothelial progenitorcells (EPC) circulating throughout the blood. Endothelial cells arecells that line blood vessels, allowing blood to flow smoothly. The EPCsadhere to the hard surface of the stent forming a smooth layer that notonly promotes healing but prevents restenosis and blood clots,complications previously associated with the use of stents (Aoji et al.(2005) J. Am. Coll. Cardiol. 45(10):1574-9). In addition to improvingoutcomes for patients requiring stents, there are also implications forpatients requiring cardiovascular bypass surgery. For example, aprosthetic vascular conduit (artificial artery) coated with anti-EPCantibodies would eliminate the need to use arteries from patients legsor arms for bypass surgery grafts. This would reduce surgery andanesthesia times, which in turn will reduce coronary surgery deaths.DVD-Ig are designed in such a way that it binds to a cell surface marker(such as CD34) as well as a protein (or an epitope of any kind,including but not limited to proteins, lipids and polysaccharides) thathas been coated on the implanted device to facilitate the cellrecruitment. Such approaches can also be applied to other medicalimplants in general. Alternatively, DVD-Igs can be coated on medicaldevices and upon implantation and releasing all DVDs from the device (orany other need which may require additional fresh DVD-Ig, includingaging and denaturation of the already loaded DVD-Ig) the device could bereloaded by systemic administration of fresh DVD-Ig to the patient,where the DVD-Ig is designed to binds to a target of interest (acytokine, a cell surface marker (such as CD34) etc.) with one set ofbinding sites and to a target coated on the device (including a protein,an epitope of any kind, including but not limited to lipids,polysaccharides and polymers) with the other. This technology has theadvantage of extending the usefulness of coated implants.

A. Use of DVD-Igs in Various Diseases

DVD-Ig molecules provided herein are also useful as therapeuticmolecules to treat various diseases. Such DVD molecules may bind one ormore targets involved in a specific disease. Examples of such targets invarious diseases are described below.

A.1. Human Autoimmune and Inflammatory Response

Many proteins have been implicated in general autoimmune andinflammatory responses, including C5, CCL1 (1-309), CCL11 (eotaxin),CCL13 (mcp-4), CCL15 (MIP-1d), CCL16 (HCC-4), CCL17 (TARC), CCL18(PARC), CCL19, CCL2 (mcp-1), CCL20 (MIP-3a), CCL21 (MIP-2), CCL23(MPIF-1), CCL24 (MPIF-2/eotaxin-2), CCL25 (TECK), CCL26, CCL3 (MIP-1a),CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (mcp-3), CCL8 (mcp-2), CXCL1, CXCL10(1P-10), CXCL11 (1-TAC/IP-9), CXCL12 (SDF1), CXCL13, CXCL14, CXCL2,CXCL3, CXCL5 (ENA-78/LIX), CXCL6 (GCP-2), CXCL9, IL13, IL8, CCL13(mcp-4), CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CX3CR1,IL8RA, XCR1 (CCXCR1), IFNA2, IL10, IL13, IL17C, IL1A, IL1B, IL1F10,IL1F5, IL1F6, IL1F7, IL1F8, IL1F9, IL22, IL5, IL8, IL9, LTA, LTB, MIF,SCYE1 (endothelial Monocyte-activating cytokine), SPP1, TNF, TNFSF5,IFNA2, IL10RA, IL10RB, IL13, IL13RA1, IL5RA, IL9, IL9R, ABCF1, BCL6, C3,C4A, CEBPB, CRP, ICEBERG, IL1R1, IL1RN, IL8RB, LTB4R, TOLLIP, FADD,IRAK1, IRAK2, MYD88, NCK2, TNFAIP3, TRADD, TRAF1, TRAF2, TRAF3, TRAF4,TRAF5, TRAF6, ACVR1, ACVR1B, ACVR2, ACVR2B, ACVRL1, CD28, CD3E, CD3G,CD3Z, CD69, CD80, CD86, CNR1, CTLA4, CYSLTR1, FCER1A, FCER2, FCGR3A,GPR44, HAVCR2, OPRD1, P2RX7, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8,TLR9, TLR10, BLR1, CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11,CCL13, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23,CCL24, CCL25, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9,CX3CL1, CX3CR1, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL10, CXCL11,CXCL12, CXCL13, CXCR4, GPR2, SCYE1, SDF2, XCL1, XCL2, XCR1, AMH, AMHR2,BMPR1A, BMPR1B, BMPR2, C19orf10 (IL27w), CER1, CSF1, CSF2, CSF3,DKFZp451J0118, FGF2, GFI1, IFNA1, IFNB1, IFNG, IGF1, IL1A, IL1B, IL1R1,IL1R2, IL2, IL2RA, IL2RB, IL2RG, IL3, IL4, IL4R, IL5, IL5RA, IL6, IL6R,IL6ST, IL7, IL8, IL8RA, IL8RB, IL9, IL9R, IL10, IL10RA, IL10RB, IL11,IL11RA, IL12A, IL12B, IL12RB1, IL12RB2, IL13, IL13RA1, IL13RA2, IL15,IL15RA, IL16, IL17, IL17R, IL18, IL18R1, IL19, IL20, KITLG, LEP, LTA,LTB, LTB4R, LTB4R2, LTBR, MIF, NPPB, PDGFB, TBX21, TDGF1, TGFA, TGFB1,TGFB1I1, TGFB2, TGFB3, TGFBI, TGFBR1, TGFBR2, TGFBR3, TH1L, TNF,TNFRSF1A, TNFRSF1B, TNFRSF7, TNFRSF8, TNFRSF9, TNFRSF11A, TNFRSF21,TNFSF4, TNFSF5, TNFSF6, TNFSF11, VEGF, ZFPM2, and RNF110 (ZNF144). Inone aspect, DVD-Igs that bind one or more of the targets listed hereinare provided.

DVD Igs capable of binding the following pairs of targets to treatinflammatory disease are contemplated: IL-1β and IL-17.

A.2. Asthma

Allergic asthma is characterized by the presence of eosinophilia, gobletcell metaplasia, epithelial cell alterations, airway hyperreactivity(AHR), and Th2 and Th1 cytokine expression, as well as elevated serumIgE levels. It is now widely accepted that airway inflammation is thekey factor underlying the pathogenesis of asthma, involving a complexinterplay of inflammatory cells such as T cells, B cells, eosinophils,mast cells and macrophages, and of their secreted mediators includingcytokines and chemokines. Corticosteroids are the most importantanti-inflammatory treatment for asthma today, however their mechanism ofaction is non-specific and safety concerns exist, especially in thejuvenile patient population. The development of more specific andtargeted therapies is therefore warranted. There is increasing evidencethat IL-13 in mice mimics many of the features of asthma, including AHR,mucus hypersecretion and airway fibrosis, independently of eosinophilicinflammation (Finotto et al. (2005) Int. Immunol. 17(8): 993-1007;Padilla et al. (2005) J. Immunol. 174(12): 8097-8105).

IL-13 has been implicated as having a pivotal role in causingpathological responses associated with asthma. The development ofanti-IL-13 mAb therapy to reduce the effects of IL-13 in the lung is anexciting new approach that offers considerable promise as a noveltreatment for asthma. However other mediators of differentialimmunological pathways are also involved in asthma pathogenesis, andblocking these mediators, in addition to IL-13, may offer additionaltherapeutic benefit. Such target pairs include, but are not limited to,IL-13 and a pro-inflammatory cytokine, such as tumor necrosis factor-α(TNF-α). TNF-α may amplify the inflammatory response in asthma and maybe linked to disease severity (McDonnell, et al. (2001) Progr. Respir.Res. 31: 247-250). This suggests that blocking both IL-13 and TNF-α mayhave beneficial effects, particularly in severe airway disease. Inanother embodiment the DVD-Ig binds the targets IL-13 and TNFα and isused for treating asthma.

Animal models such as OVA-induced asthma mouse model, where bothinflammation and AHR can be assessed, are known in the art and may beused to determine the ability of various DVD-Ig molecules to treatasthma. Animal models for studying asthma are disclosed in Coffman, etal. (2005) J. Exp. Med. 201(12): 1875-1879; Lloyd et al. (2001) Adv.Immunol. 77: 263-295; Boyce et al. (2005) J. Exp. Med. 201(12):1869-1873; and Snibson et al. (2005) J. Brit. Soc. Allerg. Clin.Immunol. 35(2): 146-52. In addition to routine safety assessments ofthese target pairs, specific tests for the degree of immunosuppressionmay be warranted and helpful in selecting the best target pairs (seeLuster et al. (1994) Toxicology 92(1-3): 229-43; Descotes, et al. (1992)Devel. Biol. Stand. 77: 99-102; Hart et al. (2001) J. Allerg. Clin.Immunol. 108(2): 250-257).

Based on the rationale disclosed herein and using the same evaluationmodel for efficacy and safety other pairs of targets that DVD-Igmolecules can bind and be useful to treat asthma may be determined. Inan embodiment, such targets include, but are not limited to, IL-13 andIL-1beta, since IL-1 beta is also implicated in inflammatory response inasthma; IL-13 and cytokines and chemokines that are involved ininflammation, such as IL-13 and IL-9; IL-13 and IL-4; IL-13 and IL-5;IL-13 and IL-25; IL-13 and TARC; IL-13 and MDC; IL-13 and MIF; IL-13 andTGF-β; IL-13 and LHR agonist; IL-13 and CL25; IL-13 and SPRR2a; IL-13and SPRR2b; and IL-13 and ADAM8. DVD-Igs capable of binding one or moretargets involved in asthma, such as IL-1β and IL-17, are also provided.

A.3. Rheumatoid Arthritis

Rheumatoid arthritis (RA), a systemic disease, is characterized by achronic inflammatory reaction in the synovium of joints and isassociated with degeneration of cartilage and erosion of juxta-articularbone. Many pro-inflammatory cytokines including TNF, chemokines, andgrowth factors are expressed in diseased joints. Systemic administrationof anti-TNF antibody or sTNFR fusion protein to mouse models of RA wasshown to be anti-inflammatory and joint protective. Clinicalinvestigations in which the activity of TNF in RA patients was blockedwith intravenously administered infliximab (Harriman, G. et al. (1999)Ann. Rheum. Dis. 58 (Suppl 1): 161-4), a chimeric anti-TNF mAb, hasprovided evidence that TNF regulates IL-6, IL-8, MCP-1, and VEGFproduction, recruitment of immune and inflammatory cells into joints,angiogenesis, and reduction of blood levels of matrixmetalloproteinases-1 and -3. A better understanding of the inflammatorypathway in rheumatoid arthritis has led to identification of othertherapeutic targets involved in rheumatoid arthritis. Promisingtreatments such as interleukin-6 antagonists (IL-6 receptor antibodyMRA, developed by Chugai, Roche (see Nishimoto, N. et al. (2004)Arthrit. Rheum. 50(6): 1761-1769), CTLA4Ig (abatacept, Genovese, M. etal. (2005) N. Engl. J. Med. 353: 1114-23.), and anti-B cell therapy(rituximab; Okamoto, H. and Kamatani, N. (2004) N. Engl. J. Med. 351:1909), have already been tested in randomized controlled trials over thepast year. Other cytokines have been identified and have been shown tobe of benefit in animal models, including interleukin-15 (therapeuticantibody HuMax-IL_(—)15, AMG 714 (see Baslund, B. et al. (2005) Arthrit.Rheum. 52(9): 2686-2692)), interleukin-17, and interleukin-18, andclinical trials of these agents are currently under way. Dual-specificantibody therapy, combining anti-TNF and another mediator, has greatpotential in enhancing clinical efficacy and/or patient coverage. Forexample, blocking both TNF and VEGF can potentially eradicateinflammation and angiogenesis, both of which are involved inpathophysiology of RA. Blocking other pairs of targets involved in RAincluding, but not limited to: IL-1β and IL-17. In addition to routinesafety assessments of these target pairs, specific tests for the degreeof immunosuppression may be warranted and helpful in selecting the besttarget pairs (see Luster et al. (1994) Toxicol. 92(1-3): 229-43;Descotes et al. (1992) Devel. Biol. Stand. 77: 99-102; Hart et al.(2001) J. Allerg. Clin. Immunol. 108(2): 250-257). Whether a DVD Igmolecule will be useful for the treatment of rheumatoid arthritis can beassessed using pre-clinical animal RA models such as thecollagen-induced arthritis mouse model. Other useful models are alsowell known in the art (see Brand, D. D. (2005) Comp. Med. 55(2):114-22). Based on the cross-reactivity of the parental antibodies forhuman and mouse othologues (e.g., reactivity for human and mouse TNF,human and mouse IL-15, etc.) validation studies in the mouse CIA modelmay be conducted with “matched surrogate antibody” derived DVD-Igmolecules; briefly, a DVD-Ig based on two (or more) mouse targetspecific antibodies may be matched to the extent possible to thecharacteristics of the parental human or humanized antibodies used forhuman DVD-Ig construction (similar affinity, similar neutralizationpotency, similar half-life etc.).

A.4. SLE

The immunopathogenic hallmark of SLE is the polyclonal B cellactivation, which leads to hyperglobulinemia, autoantibody productionand immune complex formation. The fundamental abnormality appears to bethe failure of T cells to suppress the forbidden B cell clones due togeneralized T cell dysregulation. In addition, B and T-cell interactionis facilitated by several cytokines such as IL-10 as well asco-stimulatory molecules such as CD40 and CD40L, B7 and CD28 and CTLA-4,which initiate the second signal. These interactions together withimpaired phagocytic clearance of immune complexes and apoptoticmaterial, perpetuate the immune response with resultant tissue injury.The following targets may be involved in SLE and can potentially be usedfor a DVD-Ig approach for therapeutic intervention: B cell targetedtherapies: CD-20, CD-22, CD-19, CD28, CD4, CD80, HLA-DRA, IL10, IL2,IL4, TNFRSF5, TNFRSF6, TNFSF5, TNFSF6, BLR1, HDAC4, HDAC5, HDAC7A,HDAC9, ICOSL, IGBP1, MS4A1, RGS1, SLA2, CD81, IFNB1, IL10, TNFRSF5,TNFRSF7, TNFSF5, AICDA, BLNK, GALNAC4S-6ST, HDAC4, HDAC5, HDAC7A, HDAC9,IL10, IL11, IL4, INHA, INHBA, KLF6, TNFRSF7, CD28, CD38, CD69, CD80,CD83, CD86, DPP4, FCER2, IL2RA, TNFRSF8, TNFSF7, CD24, CD37, CD40, CD72,CD74, CD79A, CD79B, CR2, IL1R2, ITGA2, ITGA3, MS4A1, ST6GAL1, CD1C,CHST10, HLA-A, HLA-DRA, and NT5E.; co-stimulatory signals: CTLA4 orB7.1/B7.2; inhibition of B cell survival: BlyS or BAFF; Complementinactivation: C5; Cytokine modulation: the key principle is that the netbiologic response in any tissue is the result of a balance between locallevels of proinflammatory or anti-inflammatory cytokines (see Sfikakis,P. P. et al. (2005) Curr. Opin. Rheumatol. 17:550-7). SLE is consideredto be a Th-2 driven disease with documented elevations in serum IL-4,IL-6, IL-10. DVD-Igs that bind one or more of IL-4, IL-6, IL-10, IFN-α,TNF-α, IL-β, or IL-17 are also contemplated. Combination of targetsdiscussed herein will enhance therapeutic efficacy for SLE which can betested in a number of lupus preclinical models (see Peng, S. L. (2004)Methods Mol. Med. 102:227-72). Based on the cross-reactivity of theparental antibodies for human and mouse othologues (e.g., reactivity forhuman and mouse CD20, human and mouse Interferon alpha etc.) validationstudies in a mouse lupus model may be conducted with “matched surrogateantibody” derived DVD-Ig molecules. Briefly, a DVD-Ig based two (ormore) mouse target specific antibodies may be matched to the extentpossible to the characteristics of the parental human or humanizedantibodies used for human DVD-Ig construction (similar affinity, similarneutralization potency, similar half-life etc.).

A.5. Multiple Sclerosis

Multiple sclerosis (MS) is a complex human autoimmune-type disease witha predominantly unknown etiology. Immunologic destruction of myelinbasic protein (MBP) throughout the nervous system is the major pathologyof multiple sclerosis. MS is a disease of complex pathologies, whichinvolves infiltration by CD4+ and CD8+ T cells and of response withinthe central nervous system. Expression in the CNS of cytokines, reactivenitrogen species and costimulator molecules have all been described inMS. Of major consideration are immunological mechanisms that contributeto the development of autoimmunity. In particular, antigen expression,cytokine and leukocyte interactions, and regulatory T-cells, which helpbalance/modulate other T-cells such as Th1 and Th2 cells, are importantareas for therapeutic target identification.

IL-12 is a proinflammatory cytokine that is produced by APC and promotesdifferentiation of Th1 effector cells. IL-12 is produced in thedeveloping lesions of patients with MS as well as in EAE-affectedanimals. Previously it was shown that interference in IL-12 pathwayseffectively prevents EAE in rodents, and that in vivo neutralization ofIL-12p40 using a anti-IL-12 mAb has beneficial effects in themyelin-induced EAE model in common marmosets.

TWEAK is a member of the TNF family, constitutively expressed in thecentral nervous system (CNS), with pro-inflammatory, proliferative orapoptotic effects depending upon cell types. Its receptor, Fn14, isexpressed in CNS by endothelial cells, reactive astrocytes and neurons.TWEAK and Fn14 mRNA expression increased in spinal cord duringexperimental autoimmune encephalomyelitis (EAE). Anti-TWEAK antibodytreatment in myelin oligodendrocyte glycoprotein (MOG) induced EAE inC57BL/6 mice resulted in a reduction of disease severity and leukocyteinfiltration when mice were treated after the priming phase.

DVD Ig molecules capable of binding one or more, for example two,targets such as IL-1β and IL-17 are provided. An embodiment includes adual-specific anti-IL-1β/IL-17 DVD Ig as a therapeutic agent beneficialfor the treatment of MS.

Several animal models for assessing the usefulness of the DVD moleculesto treat MS are known in the art (see Steinman. L. et al. (2005) TrendsImmunol. 26(11): 565-71; Lublin, F. D. et al. (1985) Springer Semin.Immunopathol. 8(3): 197-208; Genain, C. P. et al. (1997) J. Mol. Med.75(3): 187-97; Tuohy, V. K. et al. (1999) J. Exp. Med. 189(7): 1033-42;Owens, T. et al. (1995) Neurol. Clin. 13(1): 51-73; and Hart, B. A. etal. (2005) J. Immunol. 175(7): 4761-8. Based on the cross-reactivity ofthe parental antibodies for human and animal species othologues (e.g.,reactivity for human and mouse IL-12, human and mouse TWEAK etc.),validation studies in the mouse EAE model may be conducted with “matchedsurrogate antibody” derived DVD-Ig molecules. Briefly, a DVD-Ig based ontwo (or more) mouse target specific antibodies may be matched to theextent possible to the characteristics of the parental human orhumanized antibodies used for human DVD-Ig construction (similaraffinity, similar neutralization potency, similar half-life etc.). Thesame concept applies to animal models in other non-rodent species, wherea “matched surrogate antibody” derived DVD-Ig would be selected for theanticipated pharmacology and possibly safety studies. In addition toroutine safety assessments of these target pairs specific tests for thedegree of immunosuppression may be warranted and helpful in selectingthe best target pairs (see Luster et al. (1994) Toxicol. 92(1-3):229-43; Descotes et al. (1992) Devel. Biol. Stand. 77: 99-102; Jones, R.(2000) (Drugs 3(4): 442-6).

A.6. Sepsis

The pathophysiology of sepsis is initiated by the outer membranecomponents of both gram-negative organisms (lipopolysaccharide [LPS],lipid A, endotoxin) and gram-positive organisms (lipoteichoic acid,peptidoglycan). These outer membrane components are able to bind to theCD14 receptor on the surface of monocytes. By virtue of the recentlydescribed toll-like receptors, a signal is then transmitted to the cell,leading to the eventual production of the proinflammatory cytokinestumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1).Overwhelming inflammatory and immune responses are essential features ofseptic shock and play a central part in the pathogenesis of tissuedamage, multiple organ failure, and death induced by sepsis. Cytokines,especially tumor necrosis factor (TNF) and interleukin (IL-1), have beenshown to be critical mediators of septic shock. These cytokines have adirect toxic effect on tissues; they also activate phospholipase A2.These and other effects lead to increased concentrations ofplatelet-activating factor, promotion of nitric oxide synthase activity,promotion of tissue infiltration by neutrophils, and promotion ofneutrophil activity.

The treatment of sepsis and septic shock remains a clinical conundrum,and recent prospective trials with biological response modifiers (i.e.,anti-TNF and anti-MIF) aimed at the inflammatory response have shownonly modest clinical benefit. Recently, interest has shifted towardtherapies aimed at reversing the accompanying periods of immunesuppression. Studies in experimental animals and critically ill patientshave demonstrated that increased apoptosis of lymphoid organs and someparenchymal tissues contribute to this immune suppression, anergy, andorgan system dysfunction. During sepsis syndromes, lymphocyte apoptosiscan be triggered by the absence of IL-2 or by the release ofglucocorticoids, granzymes, or the so-called ‘death’ cytokines: tumornecrosis factor alpha or Fas ligand. Apoptosis proceeds viaauto-activation of cytosolic and/or mitochondrial caspases, which can beinfluenced by the pro- and anti-apoptotic members of the Bcl-2 family.In experimental animals, not only can treatment with inhibitors ofapoptosis prevent lymphoid cell apoptosis; it may also improve outcome.Although clinical trials with anti-apoptotic agents remain distant duein large part to technical difficulties associated with theiradministration and tissue targeting, inhibition of lymphocyte apoptosisrepresents an attractive therapeutic target for the septic patient.Likewise, a dual-specific agent targeting both inflammatory mediator andan apoptotic mediator, may have added benefit. DVD Igs are provided thatare capable of binding one or more targets involved in sepsis, in anembodiment two targets. In some embodiments, the targets are TNF, IL-1,MIF, IL-6, IL-8, IL-18, IL-12, IL-23, FasL, LPS, Toll-like receptors,TLR-4, tissue factor, MIP-2, ADORA2A, CASP1, CASP4, IL-10, IL-1B, NFKB1,PROC, TNFRSF1A, CSF3, CCR3, IL1RN, MIF, NFKB1, PTAFR, TLR2, TLR4, GPR44,HMOX1, midkine, IRAK1, NFKB2, SERPINA1, SERPINE1, or TREM1. The efficacyof such DVD Igs for sepsis can be assessed in preclinical animal modelsknown in the art (see Buras, J. A., et al. (2005) Nat. Rev. Drug Discov.4(10):854-65 and Calandra T, et al. (2000) Nat. Med. 6(2):164-70). In anembodiment, an anti-IL-1β and IL-17 DVD-Ig is used to treat sepsis.

A.7. Neurological Disorders

A.7.1. Neurodegenerative Diseases

Neurodegenerative diseases are either chronic in which case they areusually age-dependent or acute (e.g., stroke, traumatic brain injury,spinal cord injury, etc.). They are characterized by progressive loss ofneuronal functions (neuronal cell death, demyelination), loss ofmobility and loss of memory. Emerging knowledge of the mechanismsunderlying chronic neurodegenerative diseases (e.g., Alzheimer's diseasedisease) show a complex etiology and a variety of factors have beenrecognized to contribute to their development and progression e.g., age,glycemic status, amyloid production and multimerization, accumulation ofadvanced glycation-end products (AGE) which bind to their receptor RAGE(receptor for AGE), increased brain oxidative stress, decreased cerebralblood flow, neuroinflammation including release of inflammatorycytokines and chemokines, neuronal dysfunction and microglialactivation. Thus these chronic neurodegenerative diseases represent acomplex interaction between multiple cell types and mediators. Treatmentstrategies for such diseases are limited and mostly constitute eitherblocking inflammatory processes with non-specific anti-inflammatoryagents (e.g., corticosteroids, COX inhibitors) or agents to preventneuron loss and/or synaptic functions. These treatments fail to stopdisease progression. Recent studies suggest that more targeted therapiessuch as antibodies to soluble A-b peptide (including the A-b oligomericforms) can not only help stop disease progression but may help maintainmemory as well. These preliminary observations suggest that specifictherapies targeting more than one disease mediator (e.g., A-b and apro-inflammatory cytokine, such as TNF) may provide even bettertherapeutic efficacy for chronic neurodegenerative diseases thanobserved with targeting a single disease mechanism (e.g., soluble A-βalone) Several animal models for assessing the usefulness of the DVDmolecules to treat MS are known in the art (see Steinman. L. et al.(2005) Trends Immunol. 26(11): 565-71; Lublin, F. D. et al. (1985)Springer Semin. Immunopathol. 8(3): 197-208; Genain, C. P. et al. (1997)J. Mol. Med. 75(3): 187-97; Tuohy, V. K. et al. (1999) J. Exp. Med.189(7): 1033-42; Owens, T. et al. (1995) Neurol. Clin. 13(1): 51-73; andHart, B. A. et al. (2005) J. Immunol. 175(7): 4761-8. Based on thecross-reactivity of the parental antibodies for human and animal speciesothologues (e.g., reactivity for human and mouse IL-12, human and mouseTWEAK etc.), validation studies in the mouse EAE model may be conductedwith “matched surrogate antibody” derived DVD-Ig molecules. Briefly, aDVD-Ig based on two (or more) mouse target specific antibodies may bematched to the extent possible to the characteristics of the parentalhuman or humanized antibodies used for human DVD-Ig construction(similar affinity, similar neutralization potency, similar half-lifeetc.). The same concept applies to animal models in other non-rodentspecies, where a “matched surrogate antibody” derived DVD-Ig would beselected for the anticipated pharmacology and possibly safety studies.In addition to routine safety assessments of these target pairs specifictests for the degree of immunosuppression may be warranted and helpfulin selecting the best target pairs (see Luster et al. (1994) Toxicol.92(1-3): 229-43; Descotes et al. (1992) Devel. Biol. Stand. 77: 99-102;Jones, R. (2000) (Drugs 3(4): 442-6).

The DVD-Ig molecules can bind one or more targets involved in chronicneurodegenerative diseases such as Alzheimers. Such targets include, butare not limited to, any mediator, soluble or cell surface, implicated inAD pathogenesis e.g AGE (S100 A, amphoterin), pro-inflammatory cytokines(e.g., IL-1), chemokines (e.g., MCP 1), molecules that inhibit nerveregeneration (e.g., Nogo, RGM A), molecules that enhance neurite growth(neurotrophins) and molecules that can mediate transport at the bloodbrain barrier (e.g., transferrin receptor, insulin receptor or RAGE).The efficacy of DVD-Ig molecules can be validated in pre-clinical animalmodels such as the transgenic mice that over-express amyloid precursorprotein or RAGE and develop Alzheimer's disease-like symptoms. Inaddition, DVD-Ig molecules can be constructed and tested for efficacy inthe animal models and the best therapeutic DVD-Ig can be selected fortesting in human patients. DVD-Ig molecules can also be employed fortreatment of other neurodegenerative diseases such as Parkinson'sdisease. Alpha-Synuclein is involved in Parkinson's pathology. A DVD-Igcapable of targeting alpha-synuclein and inflammatory mediators such asTNF, IL-1, MCP-1 can prove effective therapy for Parkinson's disease andare also contemplated. In an embodiment, an anti-IL-1β and IL-17 DVD-Igis used to treat neurodegenerative disease.

A.7.2. Neuronal Regeneration and Spinal Cord Injury

Despite an increase in knowledge of the pathologic mechanisms, spinalcord injury (SCI) is still a devastating condition and represents amedical indication characterized by a high medical need. Most spinalcord injuries are contusion or compression injuries and the primaryinjury is usually followed by secondary injury mechanisms (inflammatorymediators e.g., cytokines and chemokines) that worsen the initial injuryand result in significant enlargement of the lesion area, sometimes morethan 10-fold. These primary and secondary mechanisms in SCI are verysimilar to those in brain injury caused by other means e.g., stroke. Nosatisfying treatment exists and high dose bolus injection ofmethylprednisolone (MP) is the only used therapy within a narrow timewindow of 8 h post injury. This treatment, however, is only intended toprevent secondary injury without causing any significant functionalrecovery. It is heavily criticized for the lack of unequivocal efficacyand severe adverse effects, like immunosuppression with subsequentinfections and severe histopathological muscle alterations. No otherdrugs, biologics or small molecules, stimulating the endogenousregenerative potential are approved, but promising treatment principlesand drug candidates have shown efficacy in animal models of SCI inrecent years. To a large extent the lack of functional recovery in humanSCI is caused by factors inhibiting neurite growth, at lesion sites, inscar tissue, in myelin as well as on injury-associated cells. Suchfactors are the myelin-associated proteins NogoA, OMgp and MAG, RGM A,the scar-associated CSPG (Chondroitin Sulfate Proteoglycans) andinhibitory factors on reactive astrocytes (some semaphorins andephrins). However, at the lesion site not only growth inhibitorymolecules are found but also neurite growth stimulating factors likeneurotrophins, laminin, L1 and others. This ensemble of neurite growthinhibitory and growth promoting molecules may explain that blockingsingle factors, like NogoA or RGM A, resulted in significant functionalrecovery in rodent SCI models, because a reduction of the inhibitoryinfluences could shift the balance from growth inhibition to growthpromotion. However, recoveries observed with blocking a single neuriteoutgrowth inhibitory molecule were not complete. To achieve faster andmore pronounced recoveries either blocking two neurite outgrowthinhibitory molecules, e.g., Nogo and RGM A, or blocking an neuriteoutgrowth inhibitory molecule and enhancing functions of a neuriteoutgrowth enhancing molecule e.g Nogo and neurotrophins, or blocking aneurite outgrowth inhibitory moleclule e.g., Nogo and a pro-inflammatorymolecule e.g., TNF, may be desirable (see McGee, A. W. et al. (2003)Trends Neurosci. 26: 193; Domeniconi, M. et al. (2005) J. Neurol. Sci.233: 43; Makwana1, M. et al. (2005) FEBS J. 272: 2628; Dickson, B. J.(2002) Science 298: 1959; Yu, F. and Teng, H. et al. (2005) J. Neurosci.Res. 79: 273; Karnezis, T. et al. (2004) Nature Neurosci. 7: 736; Xu, G.et al. (2004) J. Neurochem. 91: 1018).

In one aspect, DVD-Igs capable of binding target pairs such as NgR andRGM A; NogoA and RGM A; MAG and RGM A; OMGp and RGM A; RGM A and RGM B;CSPGs and RGM A; aggrecan, midkine, neurocan, versican, phosphacan, Te38and TNF-α; Aβ globulomer-specific antibodies combined with antibodiespromoting dendrite & axon sprouting are provided. Dendrite pathology isa very early sign of AD and it is known that NOGO A restricts dendritegrowth. One can combine one such type of Ab with any of theSCI-candidate (myelin-proteins) Abs. Other DVD-Ig targets may includeany combination of NgR-p75, NgR-Troy, NgR-Nogo66 (Nogo), NgR-Lingo,Lingo-Troy, Lingo-p75, MAG and Omgp. Additionally, targets may alsoinclude any mediator, soluble or cell surface, implicated in inhibitionof neurite e.g., Nogo, Ompg, MAG, RGM A, semaphorins, ephrins, solubleA-b, pro-inflammatory cytokines (e.g., IL-1), chemokines (e.g., MIP 1a),molecules that inhibit nerve regeneration. The efficacy ofanti-nogo/anti-RGM A or similar DVD-Ig molecules can be validated inpre-clinical animal models of spinal cord injury. In addition, theseDVD-Ig molecules can be constructed and tested for efficacy in theanimal models and the best therapeutic DVD-Ig can be selected fortesting in human patients. In addition, DVD-Ig molecules can beconstructed that target two distinct ligand binding sites on a singlereceptor e.g., Nogo receptor, which binds the three ligand Nogo, Ompg,and MAG and RAGE that binds A-b and S100 A. Furthermore, neuriteoutgrowth inhibitors e.g., nogo and nogo receptor, also play a role inpreventing nerve regeneration in immunological diseases like multiplesclerosis. Inhibition of nogo-nogo receptor interaction has been shownto enhance recovery in animal models of multiple sclerosis. Therefore,DVD-Ig molecules that can block the function of one immune mediator,e.g., a cytokine, like IL-12, and a neurite outgrowth inhibitor moleculeeg nogo or RGM may offer faster and greater efficacy than blockingeither an immune or an neurite outgrowth inhibitor molecule alone.

In general, antibodies do not cross the blood brain barrier (BBB) in anefficient and relevant manner. However, in certain neurologic diseases,e.g., stroke, traumatic brain injury, multiple sclerosis, etc., the BBBmay be compromised and allows for increased penetration of DVD-Igs andantibodies into the brain. In other neurological conditions, where BBBleakage is not occurring, one may employ the targeting of endogenoustransport systems, including carrier-mediated transporters such asglucose and amino acid carriers and receptor-mediatedtranscytosis-mediating cell structures/receptors at the vascularendothelium of the BBB, thus enabling trans-BBB transport of the DVD-Ig.Structures at the BBB enabling such transport include but are notlimited to the insulin receptor, transferrin receptor, LRP and RAGE. Inaddition, strategies enable the use of DVD-Igs also as shuttles totransport potential drugs into the CNS including low molecular weightdrugs, nanoparticles and nucleic acids (Coloma, M. J. et al. (2000)Pharm Res. 17(3):266-74; Boado, R. J. et al. (2007) Bioconjug. Chem.18(2):447-55). In an embodiment, an anti-IL-1β and IL-17 DVD-Ig is usedto treat neuronal regeneration and spinal cord injury.

A.8. Oncological Disorders

Monoclonal antibody therapy has emerged as an important therapeuticmodality for cancer (von Mehren, M, et al. (2003) Annu. Rev. Med.54:343-69). Antibodies may exert antitumor effects by inducingapoptosis, redirecting cytotoxicity, interfering with ligand-receptorinteractions, or preventing the expression of proteins that are criticalto the neoplastic phenotype. In addition, antibodies can targetcomponents of the tumor microenvironment, perturbing vital structuressuch as the formation of tumor-associated vasculature. Antibodies canalso target receptors whose ligands are growth factors, such as theepidermal growth factor receptor. The antibody thus inhibits naturalligands that stimulate cell growth from binding to targeted tumor cells.Alternatively, antibodies may induce an anti-idiotype network,complement-mediated cytotoxicity, or antibody-dependent cellularcytotoxicity (ADCC). The use of dual-specific antibody that targets twoseparate tumor mediators will likely give additional benefit compared toa mono-specific therapy. DVD Igs capable of binding the following pairsof targets to treat oncological disease are also contemplated: IL-1β andIL-17.

In another embodiment, the DVD Ig is capable of binding VEGF andphosphatidylserine; VEGF and ErbB3; VEGF and PLGF; VEGF and ROBO4; VEGFand BSG2; VEGF and CDCP1; VEGF and ANPEP; VEGF and c-MET; HER-2 andERB3; HER-2 and BSG2; HER-2 and CDCP1; HER-2 and ANPEP; EGFR and CD64;EGFR and BSG2; EGFR and CDCP1; EGFR and ANPEP; IGF1R and PDGFR; IGF1Rand VEGF; IGF1R and CD20; CD20 and CD74; CD20 and CD30; CD20 and DR4;CD20 and VEGFR2; CD20 and CD52; CD20 and CD4; HGF and c-MET; HGF andNRP1; HGF and phosphatidylserine; ErbB3 and IGF1R; ErbB3 and IGF1,2;c-Met and Her-2; c-Met and NRP1; c-Met and IGF1R; IGF1,2 and PDGFR;IGF1,2 and CD20; IGF1,2 and IGF1R; IGF2 and EGFR; IGF2 and HER2; IGF2and CD20; IGF2 and VEGF; IGF2 and IGF1R; IGF1 and IGF2; PDGFRa andVEGFR2; PDGFRa and PLGF; PDGFRa and VEGF; PDGFRa and c-Met; PDGFRa andEGFR; PDGFRb and VEGFR2; PDGFRb and c-Met; PDGFRb and EGFR; RON andc-Met; RON and MTSP1; RON and MSP; RON and CDCP1; VGFR1 and PLGF; VGFR1and RON; VGFR1 and EGFR; VEGFR2 and PLGF; VEGFR2 and NRP1; VEGFR2 andRON; VEGFR2 and DLL4; VEGFR2 and EGFR; VEGFR2 and ROBO4; VEGFR2 andCD55; LPA and S1P; EPHB2 and RON; CTLA4 and VEGF; CD3 and EPCAM; CD40and IL6; CD40 and IGF; CD40 and CD56; CD40 and CD70; CD40 and VEGFR1;CD40 and DR5; CD40 and DR4; CD40 and APRIL; CD40 and BCMA; CD40 andRANKL; CD28 and MAPG; CD80 and CD40; CD80 and CD30; CD80 and CD33; CD80and CD74; CD80 and CD2; CD80 and CD3; CD80 and CD19; CD80 and CD4; CD80and CD52; CD80 and VEGF; CD80 and DR5; CD80 and VEGFR2; CD22 and CD20;CD22 and CD80; CD22 and CD40; CD22 and CD23; CD22 and CD33; CD22 andCD74; CD22 and CD19; CD22 and DR5; CD22 and DR4; CD22 and VEGF; CD22 andCD52; CD30 and CD20; CD30 and CD22; CD30 and CD23; CD30 and CD40; CD30and VEGF; CD30 and CD74; CD30 and CD19; CD30 and DR5; CD30 and DR4; CD30and VEGFR2; CD30 and CD52; CD30 and CD4; CD138 and RANKL; CD33 and FTL3;CD33 and VEGF; CD33 and VEGFR2; CD33 and CD44; CD33 and DR4; CD33 andDR5; DR4 and CD137; DR4 and IGF1,2; DR4 and IGF1R; DR4 and DR5; DR5 andCD40; DR5 and CD137; DR5 and CD20; DR5 and EGFR; DR5 and IGF1,2; DR5 andIGFR, DR5 and HER-2, and EGFR and DLL4. Other target combinationsinclude one or more members of the EGF/erb-2/erb-3 family. Other targets(one or more) involved in oncological diseases that DVD Igs may bindinclude, but are not limited to: CD52, CD20, CD19, CD3, CD4, CD8, BMP6,IL12A, IL1A, IL1B, IL2, IL24, INHA, TNF, TNFSF10, BMP6, EGF, FGF1,FGF10, FGF11, FGF12, FGF13, FGF14, FGF16, FGF17, FGF18, FGF19, FGF2,FGF20, FGF21, FGF22, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9,GRP, IGF1, IGF2, IL12A, IL1A, IL1B, IL2, INHA, TGFA, TGFB1, TGFB2,TGFB3, VEGF, CDK2, FGF10, FGF18, FGF2, FGF4, FGF7, IGF1R, IL2, BCL2,CD164, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2C, CDKN3, GNRH1,IGFBP6, IL1A, IL1B, ODZ1, PAWR, PLG, TGFB1I1, AR, BRCA1, CDK3, CDK4,CDK5, CDK6, CDK7, CDK9, E2F1, EGFR, ENO1, ERBB2, ESR1, ESR2, IGFBP3,IGFBP6, IL2, INSL4, MYC, NOX5, NR6A1, PAP, PCNA, PRKCQ, PRKD1, PRL,TP53, FGF22, FGF23, FGF9, IGFBP3, IL2, INHA, KLK6, TP53, CHGB, GNRH1,IGF1, IGF2, INHA, INSL3, INSL4, PRL, KLK6, SHBG, NR1D1, NR1H3, NR113,NR2F6, NR4A3, ESR1, ESR2, NR0B1, NR0B2, NR1D2, NR1H2, NR1H4, NR112,NR2C1, NR2C2, NR2E1, NR2E3, NR2F1, NR2F2, NR3C1, NR3C2, NR4A1, NR4A2,NR5A1, NR5A2, NR6A1, PGR, RARB, FGF1, FGF2, FGF6, KLK3, KRT1, APOC1,BRCA1, CHGA, CHGB, CLU, COL1A1, COL6A1, EGF, ERBB2, ERK8, FGF1, FGF10,FGF11, FGF13, FGF14, FGF16, FGF17, FGF18, FGF2, FGF20, FGF21, FGF22,FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, GNRH1, IGF1, IGF2,IGFBP3, IGFBP6, IL12A, IL1A, IL1B, IL2, IL24, INHA, INSL3, INSL4, KLK10,KLK12, KLK13, KLK14, KLK15, KLK3, KLK4, KLK5, KLK6, KLK9, MMP2, MMP9,MSMB, NTN4, ODZ1, PAP, PLAU, PRL, PSAP, SERPINA3, SHBG, TGFA, TIMP3,CD44, CDH1, CDH10, CDH19, CDH20, CDH7, CDH9, CDH1, CDH10, CDH13, CDH18,CDH19, CDH20, CDH7, CDH8, CDH9, ROBO2, CD44, ILK, ITGA1, APC, CD164,COL6A1, MTSS1, PAP, TGFB1I1, AGR2, AIG1, AKAP1, AKAP2, CANT1, CAV1,CDH12, CLDN3, CLN3, CYB5, CYC1, DAB2IP, DES, DNCL1, ELAC2, ENO2, ENO3,FASN, FLJ12584, FLJ25530, GAGEB1, GAGEC1, GGT1, GSTP1, HIP1, HUMCYT2A,IL29, K6HF, KAI1, KRT2A, MIB1, PART1, PATE, PCA3, PIAS2, PIK3CG, PPID,PR1, PSCA, SLC2A2, SLC33A1, SLC43A1, STEAP, STEAP2, TPM1, TPM2, TRPC6,ANGPT1, ANGPT2, ANPEP, ECGF1, EREG, FGF1, FGF2, FIGF, FLT1, JAG1, KDR,LAMA5, NRP1, NRP2, PGF, PLXDC1, STAB1, VEGF, VEGFC, ANGPTL3, BAI1,COL4A3, IL8, LAMA5, NRP1, NRP2, STAB1, ANGPTL4, PECAM1, PF4, PROK2,SERPINF1, TNFAIP2, CCL11, CCL2, CXCL1, CXCL10, CXCL3, CXCL5, CXCL6,CXCL9, IFNA1, IFNB1, IFNG, IL1B, IL6, MDK, EDG1, EFNA1, EFNA3, EFNB2,EGF, EPHB4, FGFR3, HGF, IGF1, ITGB3, PDGFA, TEK, TGFA, TGFB1, TGFB2,TGFBR1, CCL2, CDH5, COL18A1, EDG1, ENG, ITGAV, ITGB3, THBS1, THBS2, BAD,BAG1, BCL2, CCNA1, CCNA2, CCND1, CCNE1, CCNE2, CDH1 (E-cadherin), CDKN1B(p27Kip1), CDKN2A (p161NK4a), COL6A1, CTNNB1 (b-catenin), CTSB(cathepsin B), ERBB2 (Her-2), ESR1, ESR2, F3 (TF), FOSL1 (FRA-1), GATA3,GSN (Gelsolin), IGFBP2, IL2RA, IL6, IL6R, IL6ST (glycoprotein 130),ITGA6 (a6 integrin), JUN, KLK5, KRT19, MAP2K7 (c-Jun), MKI67 (Ki-67),NGFB (NGF), NGFR, NME1 (NM23A), PGR, PLAU (uPA), PTEN, SERPINB5(maspin), SERPINE1 (PAI-1), TGFA, THBS1 (thrombospondin-1), TIE (Tie-1),TNFRSF6 (Fas), TNFSF6 (FasL), TOP2A (topoisomerase lia), TP53, AZGP1(zinc-a-glycoprotein), BPAG1 (plectin), CDKN1A (p21Wap1/Cip1), CLDN7(claudin-7), CLU (clusterin), ERBB2 (Her-2), FGF1, FLRT1 (fibronectin),GABRP (GABAa), GNAS1, ID2, ITGA6 (a6 integrin), ITGB4 (b 4 integrin),KLF5 (GC Box BP), KRT19 (Keratin 19), KRTHB6 (hair-specific type IIkeratin), MACMARCKS, MT3 (metallothionectin-III), MUC1 (mucin), PTGS2(COX-2), RAC2 (p21Rac2), S100A2, SCGB1D2 (lipophilin B), SCGB2A1(mammaglobin 2), SCGB2A2 (mammaglobin 1), SPRR1B (Spr1), THBS1, THBS2,THBS4, and TNFAIP2 (B94), RON, c-Met, CD64, DLL4, PLGF, CTLA4,phophatidylserine, ROBO4, CD80, CD22, CD40, CD23, CD28, CD80, CD55,CD38, CD70, CD74, CD30, CD138, CD56, CD33, CD2, CD137, DR4, DR5, RANKL,VEGFR2, PDGFR, VEGFR1, MTSP1, MSP, EPHB2, EPHA1, EPHA2, EpCAM, PGE2,NKG2D, LPA, SIP, APRIL, BCMA, MAPG, FLT3, PDGFR alpha, PDGFR beta, ROR1,PSMA, PSCA, SCD1, or CD59.

IV. Pharmaceutical Compositions

Pharmaceutical compositions comprising a binding protein and apharmaceutically acceptable carrier are also provided. In someembodiments, the pharmaceutical compositions are for use in, but notlimited to, diagnosing, detecting, or monitoring a disorder, inpreventing (e.g., inhibiting or delaying the onset of a disease,disorder or other condition), treating, managing, or ameliorating of adisorder or one or more symptoms thereof, and/or in research. In aspecific embodiment, a composition comprises one or more bindingproteins provided herein. In another embodiment, the pharmaceuticalcomposition comprises one or more binding proteins provided herein andone or more prophylactic or therapeutic agents other than bindingproteins provided herein for treating a disorder. In an embodiment, theprophylactic or therapeutic agents are useful for or have been orcurrently are being used in the prevention, treatment, management, oramelioration of a disorder or one or more symptoms thereof. Inaccordance with these embodiments, the composition may further comprisea carrier, diluent or excipient.

The binding proteins provided herein can be incorporated intopharmaceutical compositions suitable for administration to a subject.Typically, the pharmaceutical composition comprises a binding proteinprovided herein and a pharmaceutically acceptable carrier. As usedherein, “pharmaceutically acceptable carrier” includes any and allsolvents, dispersion media, coatings, antibacterial and antifungalagents, isotonic and absorption delaying agents, and the like that arephysiologically compatible. Examples of pharmaceutically acceptablecarriers include one or more of water, saline, phosphate bufferedsaline, dextrose, glycerol, ethanol and the like, as well ascombinations thereof. In some embodiments, isotonic agents, for example,sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride, areincluded in the composition. Pharmaceutically acceptable carriers mayfurther comprise minor amounts of auxiliary substances such as wettingor emulsifying agents, preservatives or buffers, which enhance the shelflife or effectiveness of the antibody or antibody portion.

Various delivery systems are known and can be used to administer one ormore antibodies provided herein or the combination of one or moreantibodies provided herein and a prophylactic agent or therapeutic agentuseful for preventing, managing, treating, or ameliorating a disorder orone or more symptoms thereof, e.g., encapsulation in liposomes,microparticles, microcapsules, recombinant cells capable of expressingthe antibody or antibody fragment, receptor-mediated endocytosis (see,e.g., Wu and Wu (1987) J. Biol. Chem. 262:4429-4432), construction of anucleic acid as part of a retroviral or other vector, etc. Methods ofadministering a prophylactic or therapeutic agent provided hereininclude, but are not limited to, parenteral administration (e.g.,intradermal, intramuscular, intraperitoneal, intravenous andsubcutaneous), epidural administration, intratumoral administration, andmucosal administration (e.g., intranasal and oral routes). In addition,pulmonary administration can be employed, e.g., by use of an inhaler ornebulizer, and a formulation with an aerosolizing agent. See, e.g., U.S.Pat. Nos. 6,019,968; 5,985,320; 5,985,309; 5,934,272; 5,874,064;5,855,913; 5,290,540; and 4,880,078; and PCT Publication Nos. WO92/19244; WO 97/32572; WO 97/44013; WO 98/31346; and WO 99/66903. In oneembodiment, a binding protein, combination therapy, or a compositionprovided herein is administered using Alkermes AIR® pulmonary drugdelivery technology (Alkermes, Inc., Cambridge, Mass.). In a specificembodiment, prophylactic or therapeutic agents provided herein areadministered intramuscularly, intravenously, intratumorally, orally,intranasally, pulmonary, or subcutaneously. The prophylactic ortherapeutic agents may be administered by any convenient route, forexample by infusion or bolus injection, by absorption through epithelialor mucocutaneous linings (e.g., oral mucosa, rectal and intestinalmucosa, etc.) and may be administered together with other biologicallyactive agents. Administration can be systemic or local.

In an embodiment, specific binding of antibody-coupled carbon nanotubes(CNTs) to tumor cells in vitro, followed by their highly specificablation with near-infrared (NIR) light can be used to target tumorcells. For example, biotinylated polar lipids can be used to preparestable, biocompatible, noncytotoxic CNT dispersions that are thenattached to one or two different neutralite avidin-derivatized DVD-Igsdirected against one or more tumor antigens (e.g., CD22) (Chakravarty,P. et al. (2008) Proc. Natl. Acad. Sci. USA 105:8697-8702.

In a specific embodiment, it may be desirable to administer theprophylactic or therapeutic agents provided herein locally to the areain need of treatment; this may be achieved by, for example, and not byway of limitation, local infusion, by injection, or by means of animplant, said implant being of a porous or non-porous material,including membranes and matrices, such as sialastic membranes, polymers,fibrous matrices (e.g., Tissuel®), or collagen matrices. In oneembodiment, an effective amount of one or more antibodies providedherein is administered locally to the affected area to a subject toprevent, treat, manage, and/or ameliorate a disorder or a symptomthereof. In another embodiment, an effective amount of one or moreantibodies provided herein is administered locally to the affected areaof a subject in combination with an effective amount of one or moretherapies (e.g., one or more prophylactic or therapeutic agents) otherthan a binding protein provided herein to prevent, treat, manage, and/orameliorate a disorder or one or more symptoms thereof.

In another embodiment, the prophylactic or therapeutic agent can bedelivered in a controlled release or sustained release system. In oneembodiment, a pump may be used to achieve controlled or sustainedrelease (see Langer, supra; Sefton (1987) CRC Crit. Ref. Biomed. Eng.14: 20; Buchwald et al. (1980) Surgery 88: 507; Saudek et al. (1989) N.Engl. J. Med. 321: 574). In another embodiment, polymeric materials canbe used to achieve controlled or sustained release of the therapies ofthe present disclosure (see e.g., Medical Applications of ControlledRelease, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974);Controlled Drug Bioavailability, Drug Product Design and Performance,Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas (1983)J., Macromol. Sci. Rev. Macromol. Chem. 23:61; see also Levy et al.(1985) Science 228: 190; During et al. (1989) Ann. Neurol. 25: 351;Howard et al. (1989) J. Neurosurg. 71: 105); U.S. Pat. Nos. 5,679,377;5,916,597; 5,912,015; 5,989,463; and 5,128,326; and PCT Publication Nos.WO 99/15154; WO 99/20253. Examples of polymers used in sustained releaseformulations include, but are not limited to, poly(2-hydroxy ethylmethacrylate), poly(methyl methacrylate), poly(acrylic acid),poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides(PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol),polyacrylamide, poly(ethylene glycol), polylactides (PLA),poly(lactide-co-glycolides) (PLGA), and polyorthoesters. In anembodiment, the polymer used in a sustained release formulation isinert, free of leachable impurities, stable on storage, sterile, andbiodegradable. In yet another embodiment, a controlled or sustainedrelease system can be placed in proximity of the prophylactic ortherapeutic target, thus requiring only a fraction of the systemic dose(see, e.g., Goodson, in Medical Applications of Controlled Release,supra, vol. 2, pp. 115-138 (1984)).

Controlled release systems are discussed in the review by Langer (1990)Science 249: 1527-1533). Any technique known to one of skill in the artcan be used to produce sustained release formulations comprising one ormore therapeutic agents of the present disclosure. See, e.g., U.S. Pat.No. 4,526,938; PCT Publication Nos. WO 91/05548; WO 96/20698, Ning etal. (1996) Radiotherap. Oncol. 39: 179-189; Song et al. (1995) PDA J.Pharma. Sci. Tech. 50:372-397; Cleek et al. (1997) Pro. Intl Symp.Control. Rel. Bioact. Mater. 24: 853-854, and Lam et al. (1997) Proc.Intl Symp. Control Rel. Bioact. Mater. 24:759-760.

In a specific embodiment, where the composition is a nucleic acidencoding a prophylactic or therapeutic agent, the nucleic acid can beadministered in vivo to promote expression of its encoded prophylacticor therapeutic agent, by constructing it as part of an appropriatenucleic acid expression vector and administering it so that it becomesintracellular, e.g., by use of a retroviral vector (see U.S. Pat. No.4,980,286), or by direct injection, or by use of microparticlebombardment (e.g., a gene gun; Biolistic, Dupont), or coating withlipids or cell-surface receptors or transfecting agents, or byadministering it in linkage to a homeobox-like peptide which is known toenter the nucleus (see, e.g., Joliot et al. (1991) Proc. Natl. Acad.Sci. USA 88:1864-1868). Alternatively, a nucleic acid can be introducedintracellularly and incorporated within host cell DNA for expression byhomologous recombination.

A pharmaceutical composition provided herein may be formulated to becompatible with its intended route of administration. Examples of routesof administration include, but are not limited to, parenteral, e.g.,intravenous, intradermal, subcutaneous, oral, intranasal (e.g.,inhalation), transdermal (e.g., topical), transmucosal, and rectaladministration. In a specific embodiment, the composition is formulatedin accordance with routine procedures as a pharmaceutical compositionadapted for intravenous, subcutaneous, intramuscular, oral, intranasal,or topical administration to human beings. Typically, compositions forintravenous administration are solutions in sterile isotonic aqueousbuffer. Where necessary, the composition may also include a solubilizingagent and a local anesthetic such as lignocamne to ease pain at the siteof the injection.

If the compositions are to be administered topically, the compositionscan be formulated in the form of an ointment, cream, transdermal patch,lotion, gel, shampoo, spray, aerosol, solution, emulsion, or other formwell-known to one of skill in the art. See, e.g., Remington'sPharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms,19th ed., Mack Pub. Co., Easton, Pa. (1995). In an embodiment, fornon-sprayable topical dosage forms, viscous to semi-solid or solid formscomprising a carrier or one or more excipients compatible with topicalapplication and having a dynamic viscosity greater than water areemployed. Suitable formulations include, without limitation, solutions,suspensions, emulsions, creams, ointments, powders, liniments, salves,and the like, which are, if desired, sterilized or mixed with auxiliaryagents (e.g., preservatives, stabilizers, wetting agents, buffers, orsalts) for influencing various properties, such as, for example, osmoticpressure. Other suitable topical dosage forms include sprayable aerosolpreparations wherein the active ingredient, in an embodiment, incombination with a solid or liquid inert carrier, is packaged in amixture with a pressurized volatile (e.g., a gaseous propellant, such asfreon) or in a squeeze bottle. Moisturizers or humectants can also beadded to pharmaceutical compositions and dosage forms if desired.Examples of such additional ingredients are well-known in the art.

If the method comprises intranasal administration of a composition, thecomposition can be formulated in an aerosol form, spray, mist or in theform of drops. In particular, prophylactic or therapeutic agents can beconveniently delivered in the form of an aerosol spray presentation frompressurized packs or a nebuliser, with the use of a suitable propellant(e.g., dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In thecase of a pressurized aerosol the dosage unit may be determined byproviding a valve to deliver a metered amount. Capsules and cartridges(composed of, e.g., gelatin) for use in an inhaler or insufflator may beformulated containing a powder mix of the compound and a suitable powderbase such as lactose or starch.

If the method comprises oral administration, compositions can beformulated orally in the form of tablets, capsules, cachets, gelcaps,solutions, suspensions, and the like. Tablets or capsules can beprepared by conventional means with pharmaceutically acceptableexcipients such as binding agents (e.g., pregelatinised maize starch,polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g.,lactose, microcrystalline cellulose, or calcium hydrogen phosphate);lubricants (e.g., magnesium stearate, talc, or silica); disintegrants(e.g., potato starch or sodium starch glycolate); or wetting agents(e.g., sodium lauryl sulphate). The tablets may be coated by methodswell-known in the art. Liquid preparations for oral administration maytake the form of, but not limited to, solutions, syrups or suspensions,or they may be presented as a dry product for constitution with water orother suitable vehicle before use. Such liquid preparations may beprepared by conventional means with pharmaceutically acceptableadditives such as suspending agents (e.g., sorbitol syrup, cellulosederivatives, or hydrogenated edible fats); emulsifying agents (e.g.,lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oilyesters, ethyl alcohol, or fractionated vegetable oils); andpreservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbicacid). The preparations may also contain buffer salts, flavoring,coloring, and sweetening agents as appropriate. Preparations for oraladministration may be suitably formulated for slow release, controlledrelease, or sustained release of a prophylactic or therapeutic agent(s).

The method provided herein may comprise pulmonary administration, e.g.,by use of an inhaler or nebulizer, of a composition formulated with anaerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968; 5,985,320;5,985,309; 5,934,272; 5,874,064; 5,855,913; 5,290,540; and 4,880,078;and PCT Publication Nos. WO 92/19244; WO 97/32572; WO 97/44013; WO98/31346; and WO 99/66903. In a specific embodiment, a binding protein,combination therapy, and/or composition provided herein is administeredusing Alkermes AIR® pulmonary drug delivery technology (Alkermes, Inc.,Cambridge, Mass.).

The method may comprise administration of a composition formulated forparenteral administration by injection (e.g., by bolus injection orcontinuous infusion). Formulations for injection may be presented inunit dosage form (e.g., in ampoules or in multi-dose containers) with anadded preservative. The compositions may take such forms as suspensions,solutions or emulsions in oily or aqueous vehicles, and may containformulatory agents such as suspending, stabilizing and/or dispersingagents. Alternatively, the active ingredient may be in powder form forconstitution with a suitable vehicle (e.g., sterile pyrogen-free water)before use.

The methods may additionally comprise of administration of compositionsformulated as depot preparations. Such long acting formulations may beadministered by implantation (e.g., subcutaneously or intramuscularly)or by intramuscular injection. Thus, for example, the compositions maybe formulated with suitable polymeric or hydrophobic materials (e.g., asan emulsion in an acceptable oil) or ion exchange resins, or assparingly soluble derivatives (e.g., as a sparingly soluble salt).

The methods provided herein encompass administration of compositionsformulated as neutral or salt forms. Pharmaceutically acceptable saltsinclude those formed with anions such as those derived fromhydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., andthose formed with cations such as those derived from sodium, potassium,ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine,2-ethylamino ethanol, histidine, procaine, etc.

Generally, the ingredients of compositions are supplied eitherseparately or mixed together in unit dosage form, for example, as a drylyophilized powder or water free concentrate in a hermetically sealedcontainer such as an ampoule or sachette indicating the quantity ofactive agent. Where the mode of administration is infusion, compositioncan be dispensed with an infusion bottle containing sterilepharmaceutical grade water or saline. Where the mode of administrationis by injection, an ampoule of sterile water for injection or saline canbe provided so that the ingredients may be mixed prior toadministration.

One or more of the prophylactic or therapeutic agents, or pharmaceuticalcompositions provided herein may be packaged in a hermetically sealedcontainer such as an ampoule or sachette indicating the quantity of theagent. In one embodiment, one or more of the prophylactic or therapeuticagents, or pharmaceutical compositions provided herein is supplied as adry sterilized lyophilized powder or water free concentrate in ahermetically sealed container and can be reconstituted (e.g., with wateror saline) to the appropriate concentration for administration to asubject. In an embodiment, one or more of the prophylactic ortherapeutic agents or pharmaceutical compositions provided herein issupplied as a dry sterile lyophilized powder in a hermetically sealedcontainer at a unit dosage of at least 5 mg, at least 10 mg, at least 15mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg, atleast 75 mg, or at least 100 mg. The lyophilized prophylactic ortherapeutic agents or pharmaceutical compositions provided herein shouldbe stored at between 2° C. and 8° C. in its original container and theprophylactic or therapeutic agents, or pharmaceutical compositionsprovided herein should be administered within 1 week, e.g., within 5days, within 72 hours, within 48 hours, within 24 hours, within 12hours, within 6 hours, within 5 hours, within 3 hours, or within 1 hourafter being reconstituted. In an alternative embodiment, one or more ofthe prophylactic or therapeutic agents or pharmaceutical compositionsprovided herein is supplied in liquid form in a hermetically sealedcontainer indicating the quantity and concentration of the agent. In anembodiment, the liquid form of the administered composition is suppliedin a hermetically sealed container at least 0.25 mg/ml, at least 0.5mg/ml, at least 1 mg/ml, at least 2.5 mg/ml, at least 5 mg/ml, at least8 mg/ml, at least 10 mg/ml, at least 15 mg/kg, at least 25 mg/ml, atleast 50 mg/ml, at least 75 mg/ml or at least 100 mg/ml. The liquid formshould be stored at between 2° C. and 8° C. in its original container.

The binding proteins provided herein can be incorporated into apharmaceutical composition suitable for parenteral administration. In anembodiment, the antibody or antibody-portions will be prepared as aninjectable solution containing 0.1-250 mg/ml binding protein. Theinjectable solution can be composed of either a liquid or lyophilizeddosage form in a flint or amber vial, ampule or pre-filled syringe. Thebuffer can be L-histidine (1-50 mM), optimally 5-10 mM, at pH 5.0 to 7.0(optimally pH 6.0). Other suitable buffers include but are not limitedto, sodium succinate, sodium citrate, sodium phosphate or potassiumphosphate. Sodium chloride can be used to modify the toxicity of thesolution at a concentration of 0-300 mM (optimally 150 mM for a liquiddosage form). Cryoprotectants can be included for a lyophilized dosageform, principally 0-10% sucrose (optimally 0.5-1.0%). Other suitablecryoprotectants include trehalose and lactose. Other suitable bulkingagents include glycine and arginine, either of which can be included ata concentration of 0-0.05%, and polysorbate-80 (optimally included at aconcentration of 0.005-0.01%). Additional surfactants include but arenot limited to polysorbate 20 and BRIJ surfactants. The pharmaceuticalcomposition comprising the binding proteins provided herein prepared asan injectable solution for parenteral administration, can furthercomprise an agent useful as an adjuvant, such as those used to increasethe absorption, or dispersion of a therapeutic protein (e.g., antibody).A particularly useful adjuvant is hyaluronidase, such as Hylenex®(recombinant human hyaluronidase). Addition of hyaluronidase in theinjectable solution improves human bioavailability following parenteraladministration, particularly subcutaneous administration. It also allowsfor greater injection site volumes (i.e., greater than 1 ml) with lesspain and discomfort, and minimum incidence of injection site reactions(see PCT Publication No. WO 2004/078140, and U.S. Patent Publication No.2006/104968).

The compositions provided herein may be in a variety of forms. Theseinclude, for example, liquid, semi-solid and solid dosage forms, such asliquid solutions (e.g., injectable and infusible solutions), dispersionsor suspensions, tablets, pills, powders, liposomes and suppositories.The form chosen depends on the intended mode of administration andtherapeutic application. Typical compositions are in the form ofinjectable or infusible solutions, such as compositions similar to thoseused for passive immunization of humans with other antibodies. Thechosen mode of administration is parenteral (e.g., intravenous,subcutaneous, intraperitoneal, intramuscular). In an embodiment, theantibody is administered by intravenous infusion or injection. Inanother embodiment, the antibody is administered by intramuscular orsubcutaneous injection.

Therapeutic compositions typically must be sterile and stable under theconditions of manufacture and storage. The composition can be formulatedas a solution, microemulsion, dispersion, liposome, or other orderedstructure suitable to high drug concentration. Sterile injectablesolutions can be prepared by incorporating the active compound (i.e.,antibody or antibody portion) in the required amount in an appropriatesolvent with one or a combination of ingredients enumerated herein, asrequired, followed by filtered sterilization. Generally, dispersions areprepared by incorporating the active compound into a sterile vehiclethat contains a basic dispersion medium and the required otheringredients from those enumerated herein. In the case of sterile,lyophilized powders for the preparation of sterile injectable solutions,the methods of preparation are vacuum drying and spray-drying thatyields a powder of the active ingredient plus any additional desiredingredient from a previously sterile-filtered solution thereof. Theproper fluidity of a solution can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.Prolonged absorption of injectable compositions can be brought about byincluding, in the composition, an agent that delays absorption, forexample, monostearate salts and gelatin.

The binding proteins provided herein can be administered by a variety ofmethods known in the art, although for many therapeutic applications, inan embodiment, the route/mode of administration is subcutaneousinjection, intravenous injection or infusion. As will be appreciated bythe skilled artisan, the route and/or mode of administration will varydepending upon the desired results. In certain embodiments, the activecompound may be prepared with a carrier that will protect the compoundagainst rapid release, such as a controlled release formulation,including implants, transdermal patches, and microencapsulated deliverysystems. Biodegradable, biocompatible polymers can be used, such asethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen,polyorthoesters, and polylactic acid. Many methods for the preparationof such formulations are patented or generally known to those skilled inthe art. See, e.g., Sustained and Controlled Release Drug DeliverySystems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

In certain embodiments, a binding protein provided herein may be orallyadministered, for example, with an inert diluent or an assimilableedible carrier. The compound (and other ingredients, if desired) mayalso be enclosed in a hard or soft shell gelatin capsule, compressedinto tablets, or incorporated directly into the subject's diet. For oraltherapeutic administration, the compounds may be incorporated withexcipients and used in the form of ingestible tablets, buccal tablets,troches, capsules, elixirs, suspensions, syrups, wafers, and the like.To administer a compound by other than parenteral administration, it maybe necessary to coat the compound with, or co-administer the compoundwith, a material to prevent its inactivation.

Supplementary active compounds can also be incorporated into thecompositions. In certain embodiments, a binding protein provided hereinis coformulated with and/or coadministered with one or more additionaltherapeutic agents that are useful for treating disorders with a bindingprotein provided herein. For example, a binding protein provided hereinmay be coformulated and/or coadministered with one or more additionalantibodies that bind other targets (e.g., antibodies that bind othercytokines or that bind cell surface molecules). Furthermore, one or moreantibodies provided herein may be used in combination with two or moreof the foregoing therapeutic agents. Such combination therapies mayadvantageously utilize lower dosages of the administered therapeuticagents, thus avoiding possible toxicities or complications associatedwith the various monotherapies.

In certain embodiments, a binding protein is linked to a half-lifeextending vehicle known in the art. Such vehicles include, but are notlimited to, the Fc domain, polyethylene glycol, and dextran. Suchvehicles are described, e.g., in U.S. Pat. No. 6,660,843 and publishedPCT Publication No. WO 99/25044.

In a specific embodiment, nucleic acid sequences encoding a bindingprotein provided herein or another prophylactic or therapeutic agent areadministered to treat, prevent, manage, or ameliorate a disorder or oneor more symptoms thereof by way of gene therapy. Gene therapy refers totherapy performed by the administration to a subject of an expressed orexpressible nucleic acid. In this embodiment, the nucleic acids producetheir encoded antibody or prophylactic or therapeutic agent thatmediates a prophylactic or therapeutic effect.

Any of the methods for gene therapy available in the art can be used.For general reviews of the methods of gene therapy, see Goldspiel et al.(1993) Clinical Pharmacy 12:488-505; Wu and Wu (1991) Biotherapy3:87-95; Tolstoshev (1993) Ann. Rev. Pharmacol. Toxicol. 32:573-596;Mulligan (1993) Science 260:926-932; and Morgan and Anderson (1993) Ann.Rev. Biochem. 62:191-217; May (1993) TIBTECH 11(5):155-215. Methodscommonly known in the art of recombinant DNA technology which can beused are described in Ausubel et al. (eds.), Current Protocols inMolecular Biology, John Wiley &Sons, NY (1993); and Kriegler, GeneTransfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).Detailed descriptions of various methods of gene therapy are disclosedin U.S. Patent Publication No. 20090297514.

The binding proteins provided herein are useful in treating variousdiseases wherein the targets that are recognized by the binding proteinsare detrimental. Such diseases include, but are not limited to,rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, septicarthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis,spondyloarthropathy, systemic lupus erythematosus, Crohn's disease,ulcerative colitis, inflammatory bowel disease, insulin dependentdiabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis,dermatitis scleroderma, graft versus host disease, organ transplantrejection, acute or chronic immune disease associated with organtransplantation, sarcoidosis, atherosclerosis, disseminatedintravascular coagulation, Kawasaki's disease, Grave's disease,nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis,Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys,chronic active hepatitis, uveitis, septic shock, toxic shock syndrome,sepsis syndrome, cachexia, infectious diseases, parasitic diseases,acquired immunodeficiency syndrome, acute transverse myelitis,Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke,primary biliary cirrhosis, hemolytic anemia, malignancies, heartfailure, myocardial infarction, Addison's disease, sporadic,polyglandular deficiency type I and polyglandular deficiency type II,Schmidt's syndrome, adult (acute) respiratory distress syndrome,alopecia, alopecia areata, seronegative arthopathy, arthropathy,Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy,enteropathic synovitis, chlamydia, yersinia and salmonella associatedarthropathy, spondyloarthopathy, atheromatous disease/arteriosclerosis,atopic allergy, autoimmune bullous disease, pemphigus vulgaris,pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmunehaemolytic anaemia, Coombs positive haemolytic anaemia, acquiredpernicious anaemia, juvenile pernicious anaemia, myalgicencephalitis/Royal Free Disease, chronic mucocutaneous candidiasis,giant cell arteritis, primary sclerosing hepatitis, cryptogenicautoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome,Acquired Immunodeficiency Related Diseases, Hepatitis B, Hepatitis C,common varied immunodeficiency (common variable hypogammaglobulinaemia),dilated cardiomyopathy, female infertility, ovarian failure, prematureovarian failure, fibrotic lung disease, cryptogenic fibrosingalveolitis, post-inflammatory interstitial lung disease, interstitialpneumonitis, connective tissue disease associated interstitial lungdisease, mixed connective tissue disease associated lung disease,systemic sclerosis associated interstitial lung disease, rheumatoidarthritis associated interstitial lung disease, systemic lupuserythematosus associated lung disease, dermatomyositis/polymyositisassociated lung disease, Sjögren's disease associated lung disease,ankylosing spondylitis associated lung disease, vasculitic diffuse lungdisease, haemosiderosis associated lung disease, drug-inducedinterstitial lung disease, fibrosis, radiation fibrosis, bronchiolitisobliterans, chronic eosinophilic pneumonia, lymphocytic infiltrativelung disease, postinfectious interstitial lung disease, gouty arthritis,autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmuneor lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibodyhepatitis), autoimmune mediated hypoglycaemia, type B insulin resistancewith acanthosis nigricans, hypoparathyroidism, acute immune diseaseassociated with organ transplantation, chronic immune disease associatedwith organ transplantation, osteoarthrosis, primary sclerosingcholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia,autoimmune neutropaenia, renal disease NOS, glomerulonephritides,microscopic vasulitis of the kidneys, lyme disease, discoid lupuserythematosus, male infertility idiopathic or NOS, sperm autoimmunity,multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonaryhypertension secondary to connective tissue disease, Goodpasture'ssyndrome, pulmonary manifestation of polyarteritis nodosa, acuterheumatic fever, rheumatoid spondylitis, Still's disease, systemicsclerosis, Sjörgren's syndrome, Takayasu's disease/arteritis, autoimmunethrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroiddisease, hyperthyroidism, goitrous autoimmune hypothyroidism(Hashimoto's disease), atrophic autoimmune hypothyroidism, primarymyxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liverdisease, chronic liver diseases, alcoholic cirrhosis, alcohol-inducedliver injury, choleosatatis, idiosyncratic liver disease, Drug-Inducedhepatitis, Non-alcoholic Steatohepatitis, allergy and asthma, group Bstreptococci (GBS) infection, mental disorders (e.g., depression andschizophrenia), Th2 Type and Th1 Type mediated diseases, acute andchronic pain (different forms of pain), and cancers such as lung,breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectalcancer and hematopoietic malignancies (leukemia and lymphoma),Abetalipoprotemia, Acrocyanosis, acute and chronic parasitic orinfectious processes, acute leukemia, acute lymphoblastic leukemia(ALL), acute myeloid leukemia (AML), acute or chronic bacterialinfection, acute pancreatitis, acute renal failure, adenocarcinomas,aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis,allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis,allograft rejection, alpha-l-antitrypsin deficiency, amyotrophic lateralsclerosis, anemia, angina pectoris, anterior horn cell degeneration,anti cd3 therapy, antiphospholipid syndrome, anti-receptorhypersensitivity reactions, aordic and peripheral aneuryisms, aorticdissection, arterial hypertension, arteriosclerosis, arteriovenousfistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrialflutter, atrioventricular block, B cell lymphoma, bone graft rejection,bone marrow transplant (BMT) rejection, bundle branch block, Burkitt'slymphoma, Burns, cardiac arrhythmias, cardiac stun syndrome, cardiactumors, cardiomyopathy, cardiopulmonary bypass inflammation response,cartilage transplant rejection, cerebellar cortical degenerations,cerebellar disorders, chaotic or multifocal atrial tachycardia,chemotherapy associated disorders, chromic myelocytic leukemia (CML),chronic alcoholism, chronic inflammatory pathologies, chroniclymphocytic leukemia (CLL), chronic obstructive pulmonary disease(COPD), chronic salicylate intoxication, colorectal carcinoma,congestive heart failure, conjunctivitis, contact dermatitis, corpulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culturenegative sepsis, cystic fibrosis, cytokine therapy associated disorders,Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever,dermatitis, dermatologic conditions, diabetes, diabetes mellitus,diabetic ateriosclerotic disease, Diffuse Lewy body disease, dilatedcongestive cardiomyopathy, disorders of the basal ganglia, Down'sSyndrome in middle age, drug-induced movement disorders induced by drugswhich block CNS dopamine receptors, drug sensitivity, eczema,encephalomyelitis, endocarditis, endocrinopathy, epiglottitis,epstein-barr virus infection, erythromelalgia, extrapyramidal andcerebellar disorders, familial hematophagocytic lymphohistiocytosis,fetal thymus implant rejection, Friedreich's ataxia, functionalperipheral arterial disorders, fungal sepsis, gas gangrene, gastriculcer, glomerular nephritis, graft rejection of any organ or tissue,gram negative sepsis, gram positive sepsis, granulomas due tointracellular organisms, hairy cell leukemia, Hallerrorden-Spatzdisease, hashimoto's thyroiditis, hay fever, heart transplant rejection,hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolyticthrombocytopenic purpura, hemorrhage, hepatitis (A), His bundlearrythmias, HIV infection/HIV neuropathy, Hodgkin's disease,hyperkinetic movement disorders, hypersensitity reactions,hypersensitivity pneumonitis, hypertension, hypokinetic movementdisorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathicAddison's disease, idiopathic pulmonary fibrosis, antibody mediatedcytotoxicity, Asthenia, infantile spinal muscular atrophy, inflammationof the aorta, influenza a, ionizing radiation exposure,iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury,ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal muscularatrophy, Kaposi's sarcoma, kidney transplant rejection, legionella,leishmaniasis, leprosy, lesions of the corticospinal system, lipedema,liver transplant rejection, lymphederma, malaria, malignant Lymphoma,malignant histiocytosis, malignant melanoma, meningitis,meningococcemia, metabolic/idiopathic, migraine headache, mitochondrialmulti.system disorder, mixed connective tissue disease, monoclonalgammopathy, multiple myeloma, multiple systems degenerations (MencelDejerine-Thomas Shi-Drager and Machado-Joseph), myasthenia gravis,mycobacterium avium intracellulare, mycobacterium tuberculosis,myelodyplastic syndrome, myocardial infarction, myocardial ischemicdisorders, nasopharyngeal carcinoma, neonatal chronic lung disease,nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscularatrophies, neutropenic fever, non-hodgkins lymphoma, occlusion of theabdominal aorta and its branches, occlusive arterial disorders, okt3therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures,organomegaly, osteoporosis, pancreas transplant rejection, pancreaticcarcinoma, paraneoplastic syndrome/hypercalcemia of malignancy,parathyroid transplant rejection, pelvic inflammatory disease, perennialrhinitis, pericardial disease, peripheral atherlosclerotic disease,peripheral vascular disorders, peritonitis, pernicious anemia,pneumocystis carinii pneumonia, pneumonia, POEMS syndrome(polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy,and skin changes syndrome), post perfusion syndrome, post pump syndrome,post-MI cardiotomy syndrome, preeclampsia, Progressive supranucleoPalsy, primary pulmonary hypertension, radiation therapy, Raynaud'sphenomenon and disease, Raynaud's disease, Refsum's disease, regularnarrow QRS tachycardia, renovascular hypertension, reperfusion injury,restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, SenileDementia of Lewy body type, seronegative arthropathies, shock, sicklecell anemia, skin allograft rejection, skin changes syndrome, smallbowel transplant rejection, solid tumors, specific arrythmias, spinalataxia, spinocerebellar degenerations, streptococcal myositis,structural lesions of the cerebellum, Subacute sclerosingpanencephalitis, Syncope, syphilis of the cardiovascular system,systemic anaphalaxis, systemic inflammatory response syndrome, systemiconset juvenile rheumatoid arthritis, T-cell or FAB ALL, Telangiectasia,thromboangitis obliterans, thrombocytopenia, toxicity, transplants,trauma/hemorrhage, type III hypersensitivity reactions, type IVhypersensitivity, unstable angina, uremia, urosepsis, urticaria,valvular heart diseases, varicose veins, vasculitis, venous diseases,venous thrombosis, ventricular fibrillation, viral and fungalinfections, vital encephalitis/aseptic meningitis, vital-associatedhemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease,xenograft rejection of any organ or tissue. (see PCT Publication Nos. WO2002/097048; WO 95/24918; and WO 00/56772).

The DVD-Igs provided herein may also treat one or more of the followingdiseases: Acute coronary syndromes, Acute Idiopathic Polyneuritis, AcuteInflammatory Demyelinating Polyradiculoneuropathy, Acute ischemia, AdultStill's Disease, Alopecia areata, Anaphylaxis, Anti-PhospholipidAntibody Syndrome, Aplastic anemia, Arteriosclerosis, Atopic eczema,Atopic dermatitis, Autoimmune dermatitis, Autoimmune disorder associatedwith Streptococcus infection, Autoimmune hearing loss, AutoimmuneLymphoproliferative Syndrome (ALPS), Autoimmune myocarditis, autoimmunethrombocytopenia (AITP), Blepharitis, Bronchiectasis, Bullouspemphigoid, Cardiovascular Disease, Catastrophic AntiphospholipidSyndrome, Celiac Disease, Cervical Spondylosis, Chronic ischemia,Cicatricial pemphigoid, Clinically isolated Syndrome (CIS) with Risk forMultiple Sclerosis, Conjunctivitis, Childhood Onset PsychiatricDisorder, Chronic obstructive pulmonary disease (COPD), Dacryocystitis,dermatomyositis, Diabetic retinopathy, Diabetes mellitus, Diskherniation, Disk prolaps, Drug induced immune hemolytic anemia,Endocarditis, Endometriosis, endophthalmitis, Erythema multiforme,erythema multiforme major, Gestational pemphigoid, Guillain-BarréSyndrome (GBS), Hay Fever, Hughes Syndrome, Idiopathic Parkinson'sDisease, idiopathic interstitial pneumonia, IgE-mediated Allergy, Immunehemolytic anemia, Inclusion Body Myositis, Infectious ocularinflammatory disease, Inflammatory demyelinating disease, Inflammatoryheart disease, Inflammatory kidney disease, IPF/UIP, Iritis, Keratitis,Keratojuntivitis sicca, Kussmaul disease or Kussmaul-Meier Disease,Landry's Paralysis, Langerhan's Cell Histiocytosis, Livedo reticularis,Macular Degeneration, malignancies, Microscopic Polyangiitis, MorbusBechterev, Motor Neuron Disorders, Mucous membrane pemphigoid, MultipleOrgan failure, Myasthenia Gravis, Myelodysplastic Syndrome, Myocarditis,Nerve Root Disorders, Neuropathy, Non-A Non-B Hepatitis, Optic Neuritis,Osteolysis, Ovarian cancer, Pauciarticular JRA, peripheral arteryocclusive disease (PAOD), peripheral vascular disease (PVD), peripheralartery disease (PAD), Phlebitis, Polyarteritis nodosa (or periarteritisnodosa), Polychondritis, Polymyalgia Rheumatica, Poliosis, PolyarticularJRA, Polyendocrine Deficiency Syndrome, Polymyositis, polymyalgiarheumatica (PMR), Post-Pump Syndrome, primary parkinsonism, prostate andrectal cancer and hematopoietic malignancies (leukemia and lymphoma),Prostatitis, Pure red cell aplasia, Primary Adrenal Insufficiency,Recurrent Neuromyelitis Optica, Restenosis, Rheumatic heart disease,SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis),Scleroderma, Secondary Amyloidosis, Shock lung, Scleritis, Sciatica,Secondary Adrenal Insufficiency, Silicone associated connective tissuedisease, Sneddon-Wilkinson Dermatosis, spondilitis ankylosans,Stevens-Johnson Syndrome (SJS), Systemic inflammatory response syndrome,Temporal arteritis, toxoplasmic retinitis, toxic epidermal necrolysis,Transverse myelitis, TRAPS (Tumor Necrosis Factor Receptor, Type 1allergic reaction, Type II Diabetes, Urticaria, Usual interstitialpneumonia (UIP), Vasculitis, Vernal conjunctivitis, viral retinitis,Vogt-Koyanagi-Harada syndrome (VKH syndrome), Wet macular degeneration,and Wound healing.

The binding proteins provided herein can be used to treat humanssuffering from autoimmune diseases, in particular those associated withinflammation, including, rheumatoid arthritis, spondylitis, allergy,autoimmune diabetes, autoimmune uveitis. In an embodiment, the bindingproteins or antigen-binding portions thereof, are used to treatrheumatoid arthritis, Crohn's disease, multiple sclerosis, insulindependent diabetes mellitus and psoriasis.

In an embodiment, diseases that can be treated or diagnosed with thecompositions and methods provided herein include, but are not limitedto, primary and metastatic cancers, including carcinomas of breast,colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach,pancreas, liver, gallbladder and bile ducts, small intestine, urinarytract (including kidney, bladder and urothelium), female genital tract(including cervix, uterus, and ovaries as well as choriocarcinoma andgestational trophoblastic disease), male genital tract (includingprostate, seminal vesicles, testes and germ cell tumors), endocrineglands (including the thyroid, adrenal, and pituitary glands), and skin,as well as hemangiomas, melanomas, sarcomas (including those arisingfrom bone and soft tissues as well as Kaposi's sarcoma), tumors of thebrain, nerves, eyes, and meninges (including astrocytomas, gliomas,glioblastomas, retinoblastomas, neuromas, neuroblastomas, Schwannomas,and meningiomas), solid tumors arising from hematopoietic malignanciessuch as leukemias, and lymphomas (both Hodgkin's and non-Hodgkin'slymphomas).

In an embodiment, the antibodies provided herein, or antigen-bindingportions thereof, are used to treat cancer, prevention, or inhibitmetastases from the tumors described herein either when used alone or incombination with radiotherapy and/or other chemotherapeutic agents.

The antibodies provided herein, or antigen binding portions thereof, maybe combined with agents that include but are not limited to,antineoplastic agents, radiotherapy, chemotherapy such as DNA alkylatingagents, cisplatin, carboplatin, anti-tubulin agents, paclitaxel,docetaxel, taxol, doxorubicin, gemcitabine, gemzar, anthracyclines,adriamycin, topoisomerase I inhibitors, topoisomerase II inhibitors,5-fluorouracil (5-FU), leucovorin, irinotecan, receptor tyrosine kinaseinhibitors (e.g., erlotinib, gefitinib), COX-2 inhibitors (e.g.,celecoxib), kinase inhibitors, and siRNAs.

A binding protein also can be administered with one or more additionaltherapeutic agents useful in the treatment of various diseases.

A binding protein provided herein can be used alone or in combination totreat such diseases. It should be understood that the binding proteinscan be used alone or in combination with an additional agent, e.g., atherapeutic agent, said additional agent being selected by the skilledartisan for its intended purpose. For example, the additional agent canbe a therapeutic agent art-recognized as being useful to treat thedisease or condition being treated by the antibody. The additional agentalso can be an agent that imparts a beneficial attribute to thetherapeutic composition e.g., an agent which affects the viscosity ofthe composition.

It should further be understood that the combinations include thosecombinations useful for their intended purpose. The agents set forthbelow are illustrative and are not intended to be limited. Thecombinations can be the antibodies provided herein and at least oneadditional agent selected from the lists below. The combination can alsoinclude more than one additional agent, e.g., two or three additionalagents if the combination is such that the formed composition canperform its intended function.

Combinations to treat autoimmune and inflammatory diseases arenon-steroidal anti-inflammatory drug(s) also referred to as NSAIDS whichinclude drugs like ibuprofen. Other combinations are corticosteroidsincluding prednisolone; the well known side-effects of steroid use canbe reduced or even eliminated by tapering the steroid dose required whentreating patients in combination with the DVD Igs provided herein.Non-limiting examples of therapeutic agents for rheumatoid arthritiswith which an antibody, or antibody portion, provided herein can becombined include the following: cytokine suppressive anti-inflammatorydrug(s) (CSAIDs); antibodies to or antagonists of other human cytokinesor growth factors, for example, TNF, LT, IL-1, IL-2, IL-3, IL-4, IL-5,IL-6, IL-7, IL-8, IL-15, IL-16, IL-18, IL-21, IL-23, interferons,EMAP-II, GM-CSF, FGF, and PDGF. Binding proteins provided herein, orantigen binding portions thereof, can be combined with antibodies tocell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30,CD40, CD45, CD69, CD80 (B7.1), CD86 (B7.2), CD90, and CTLA or theirligands including CD154 (gp39 or CD40L).

Combinations of therapeutic agents may interfere at different points inthe autoimmune and subsequent inflammatory cascade; examples include TNFantagonists like chimeric, humanized or human TNF antibodies,ADALIMUMAB, (PCT Publication No. WO 97/29131), CA2 (Remicade™), CDP 571,and soluble p55 or p75 TNF receptors, derivatives, thereof, (p75TNFR1gG(Enbrel™) or p55TNFR1gG (Lenercept), and also TNFα converting enzyme(TACE) inhibitors; similarly IL-1 inhibitors (Interleukin-1-convertingenzyme inhibitors, IL-1RA etc.) may be effective for the same reason.Other combinations include Interleukin 11. Yet another combinationincludes key players of the autoimmune response which may act parallelto, dependent on, or in concert with, IL-12 function, especially IL-1βantagonists including IL-1β antibodies, soluble IL-1β receptors, andIL-1β binding proteins. It has been shown that IL-12 and IL-1β haveoverlapping but distinct functions and a combination of antagonists toboth may be most effective. Yet another combination is non-depletinganti-CD4 inhibitors. Yet other combinations include antagonists of theco-stimulatory pathway CD80 (B7.1) or CD86 (B7.2) including antibodies,soluble receptors and antagonistic ligands.

The binding proteins provided herein may also be combined with agents,such as methotrexate, 6-MP, azathioprine sulphasalazine, mesalazine,olsalazine chloroquinine/hydroxychloroquine, pencillamine,aurothiomalate (intramuscular and oral), azathioprine, cochicine,corticosteroids (oral, inhaled and local injection), beta-2adrenoreceptor agonists (salbutamol, terbutaline, salmeteral), xanthines(theophylline, aminophylline), cromoglycate, nedocromil, ketotifen,ipratropium and oxitropium, cyclosporin, FK506, rapamycin, mycophenolatemofetil, leflunomide, NSAIDs, for example, ibuprofen, corticosteroidssuch as prednisolone, phosphodiesterase inhibitors, adensosine agonists,antithrombotic agents, complement inhibitors, adrenergic agents, agentswhich interfere with signalling by proinflammatory cytokines, such asTNF-α or IL-1 (e.g., IRAK, NIK, IKK, p38 or MAP kinase inhibitors),IL-1β converting enzyme inhibitors, TNFα-converting enzyme (TACE)inhibitors, T-cell signalling inhibitors, such as kinase inhibitors,metalloproteinase inhibitors, sulfasalazine, azathioprine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors and derivatives thereof (e.g., soluble p55 or p75 TNFreceptors and the derivatives p75TNFRIgG (Enbrel™ and p55TNFRIgG(Lenercept)), sIL-1RI, sIL-1RII, and sIL-6R), antiinflammatory cytokines(e.g., IL-4, IL-10, IL-11, IL-13 and TGFβ), celecoxib, folic acid,hydroxychloroquine sulfate, rofecoxib, etanercept, infliximab, naproxen,valdecoxib, sulfasalazine, methylprednisolone, meloxicam,methylprednisolone acetate, gold sodium thiomalate, aspirin,triamcinolone acetonide, propoxyphene napsylate/apap, folate,nabumetone, diclofenac, piroxicam, etodolac, diclofenac sodium,oxaprozin, oxycodone hcl, hydrocodone bitartrate/apap, diclofenacsodium/misoprostol, fentanyl, anakinra, human recombinant, tramadol hcl,salsalate, sulindac, cyanocobalamin/fa/pyridoxine, acetaminophen,alendronate sodium, prednisolone, morphine sulfate, lidocainehydrochloride, indomethacin, glucosamine sulf/chondroitin, amitriptylinehcl, sulfadiazine, oxycodone hcl/acetaminophen, olopatadine hcl,misoprostol, naproxen sodium, omeprazole, cyclophosphamide, rituximab,IL-1 TRAP, MRA, CTLA4-IG, IL-1β BP, anti-IL-18, Anti-IL15, BIRB-796,SC10-469, VX-702, AMG-548, VX-740, Roflumilast, IC-485, CDC-801, andMesopram. Combinations include methotrexate or leflunomide and inmoderate or severe rheumatoid arthritis cases, cyclosporine.

Nonlimiting additional agents, which can also be used in combinationwith a binding protein to treat rheumatoid arthritis include, but arenot limited to, the following: non-steroidal anti-inflammatory drug(s)(NSAIDs); cytokine suppressive anti-inflammatory drug(s) (CSAIDs);CDP-571/BAY-10-3356 (humanized anti-TNFα antibody; Celltech/Bayer);cA2/infliximab (chimeric anti-TNFα antibody; Centocor); 75kdTNFR-IgG/etanercept (75 kD TNF receptor-IgG fusion protein; Immunex;see e.g., (1994) Arthr. Rheum. 37: S295; (1996) J. Invest. Med. 44:235A); 55 kdTNF-IgG (55 kD TNF receptor-IgG fusion protein;Hoffmann-LaRoche); IDEC-CE9.1/SB 210396 (non-depleting primatizedanti-CD4 antibody; IDEC/SmithKline; see e.g., (1995) Arthr. Rheum. 38:S185); DAB 486-IL-2 and/or DAB 389-IL-2 (IL-2 fusion proteins; Seragen;see e.g., (1993) Arthrit. Rheum. 36: 1223); Anti-Tac (humanizedanti-IL-2Rα; Protein Design Labs/Roche); IL-4 (anti-inflammatorycytokine; DNAX/Schering); IL-10 (SCH 52000; recombinant IL-10,anti-inflammatory cytokine; DNAX/Schering); IL-4; IL-10 and/or IL-4agonists (e.g., agonist antibodies); IL-1RA (IL-1 receptor antagonist;Synergen/Amgen); anakinra (Kineret®/Amgen); TNF-bp/s-TNF (soluble TNFbinding protein; see e.g., (1996) Arthr. Rheum. 39(9 (supplement)):S284; (1995) Amer. J. Physiol.-Heart and Circ. Physiol. 268: 37-42);R973401 (phosphodiesterase Type IV inhibitor; see e.g., (1996) Arthr.Rheum. 39(9 (supplement): S282); MK-966 (COX-2 Inhibitor; see e.g.,(1996) Arthr. Rheum. 39(9 (supplement): S81); Iloprost (see e.g., (1996)Arthr. Rheum. 39(9 (supplement): S82); methotrexate; thalidomide (seee.g., (1996) Arthr. Rheum. 39(9 (supplement): S282) andthalidomide-related drugs (e.g., Celgen); leflunomide (anti-inflammatoryand cytokine inhibitor; see e.g., (1996) Arthr. Rheum. 39(9(supplement): S131; (1996) Inflamm. Res. 45: 103-107); tranexamic acid(inhibitor of plasminogen activation; see e.g., (1996) Arthr. Rheum.39(9 (supplement): S284); T-614 (cytokine inhibitor; see e.g., (1996)Arthr. Rheum. 39(9 (supplement): S282); prostaglandin E1 (see e.g.,(1996) Arthr. Rheum. 39(9 (supplement): S282); Tenidap (non-steroidalanti-inflammatory drug; see e.g., (1996) Arthr. Rheum. 39(9(supplement): S280); Naproxen (non-steroidal anti-inflammatory drug; seee.g., (1996) Neuro. Report 7: 1209-1213); Meloxicam (non-steroidalanti-inflammatory drug); Ibuprofen (non-steroidal anti-inflammatorydrug); Piroxicam (non-steroidal anti-inflammatory drug); Diclofenac(non-steroidal anti-inflammatory drug); Indomethacin (non-steroidalanti-inflammatory drug); Sulfasalazine (see e.g., (1996) Arthr. Rheum.39(9 (supplement): S281); Azathioprine (see e.g., (1996) Arthr. Rheum.39(9 (supplement): S281); ICE inhibitor (inhibitor of the enzymeinterleukin-1β converting enzyme); zap-70 and/or Ick inhibitor(inhibitor of the tyrosine kinase zap-70 or Ick); VEGF inhibitor and/orVEGF-R inhibitor (inhibitors of vascular endothelial cell growth factoror vascular endothelial cell growth factor receptor; inhibitors ofangiogenesis); corticosteroid anti-inflammatory drugs (e.g., SB203580);TNF-convertase inhibitors; anti-IL-12 antibodies; anti-IL-1β antibodies;interleukin-11 (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S296);interleukin-13 (see e.g., (1996) Arthr. Rheum. 39(9 (supplement): S308);interleukin-17 inhibitors (see e.g., (1996) Arthr. Rheum. 39(9(supplement): S120); gold; penicillamine; chloroquine; chlorambucil;hydroxychloroquine; cyclosporine; cyclophosphamide; total lymphoidirradiation; anti-thymocyte globulin; anti-CD4 antibodies; CD5-toxins;orally-administered peptides and collagen; lobenzarit disodium; CytokineRegulating Agents (CRAB) HP228 and HP466 (Houghten Pharmaceuticals,Inc.); ICAM-1 antisense phosphorothioate oligo-deoxynucleotides (ISIS2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10;T Cell Sciences, Inc.); prednisone; orgotein; glycosaminoglycanpolysulphate; minocycline; anti-IL2R antibodies; marine and botanicallipids (fish and plant seed fatty acids; see e.g., DeLuca et al. (1995)Rheum. Dis. Clin. North Am. 21: 759-777); auranofin; phenylbutazone;meclofenamic acid; flufenamic acid; intravenous immune globulin;zileuton; azaribine; mycophenolic acid (RS-61443); tacrolimus (FK-506);sirolimus (rapamycin); amiprilose (therafectin); cladribine(2-chlorodeoxyadenosine); methotrexate; bcl-2 inhibitors (see Bruncko,M. et al. (2007) J. Med. Chem. 50(4): 641-662); and antivirals andimmune-modulating agents.

In one embodiment, the binding protein or antigen-binding portionthereof, is administered in combination with one of the following agentsfor the treatment of rheumatoid arthritis: small molecule inhibitor ofKDR, small molecule inhibitor of Tie-2; methotrexate; prednisone;celecoxib; folic acid; hydroxychloroquine sulfate; rofecoxib;etanercept; infliximab; leflunomide; naproxen; valdecoxib;sulfasalazine; methylprednisolone; ibuprofen; meloxicam;methylprednisolone acetate; gold sodium thiomalate; aspirin;azathioprine; triamcinolone acetonide; propoxyphene napsylate/apap;folate; nabumetone; diclofenac; piroxicam; etodolac; diclofenac sodium;oxaprozin; oxycodone hcl; hydrocodone bitartrate/apap; diclofenacsodium/misoprostol; fentanyl; anakinra, human recombinant; tramadol hcl;salsalate; sulindac; cyanocobalamin/fa/pyridoxine; acetaminophen;alendronate sodium; prednisolone; morphine sulfate; lidocainehydrochloride; indomethacin; glucosamine sulfate/chondroitin;cyclosporine; amitriptyline hcl; sulfadiazine; oxycodonehcl/acetaminophen; olopatadine hcl; misoprostol; naproxen sodium;omeprazole; mycophenolate mofetil; cyclophosphamide; rituximab; IL-1TRAP; MRA; CTLA4-IG; IL-1β BP; IL-12/23; anti-IL 18; anti-IL 15;BIRB-796; SC10-469; VX-702; AMG-548; VX-740; Roflumilast; IC-485;CDC-801; and mesopram.

Non-limiting examples of therapeutic agents for inflammatory boweldisease with which a binding protein provided herein can be combinedinclude the following: budenoside; epidermal growth factor;corticosteroids; cyclosporin, sulfasalazine; aminosalicylates;6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors;mesalamine; olsalazine; balsalazide; antioxidants; thromboxaneinhibitors; IL-1 receptor antagonists; anti-IL-1βmAbs; anti-IL-6 mAbs;growth factors; elastase inhibitors; pyridinyl-imidazole compounds; andantibodies to, or antagonists of, other human cytokines or growthfactors, for example, TNF, LT, IL-1, IL-2, IL-6, IL-7, IL-8, IL-15,IL-16, IL-17, IL-18, EMAP-II, GM-CSF, FGF, and PDGF. Antibodies providedherein, or antigen binding portions thereof, can be combined withantibodies to cell surface molecules such as CD2, CD3, CD4, CD8, CD25,CD28, CD30, CD40, CD45, CD69, and CD90 and their ligands. The antibodiesprovided herein, or antigen binding portions thereof, may also becombined with agents, such as methotrexate, cyclosporin, FK506,rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, such asibuprofen, corticosteroids such as prednisolone, phosphodiesteraseinhibitors, adenosine agonists, antithrombotic agents, complementinhibitors, adrenergic agents, agents which interfere with signalling byproinflammatory cytokines such as TNFα or IL-1 (e.g., IRAK, NIK, IKK,p38 or MAP kinase inhibitors), IL-1β converting enzyme inhibitors, TNFαconverting enzyme inhibitors, T-cell signalling inhibitors such askinase inhibitors, metalloproteinase inhibitors, sulfasalazine,azathioprine, 6-mercaptopurines, angiotensin converting enzymeinhibitors, soluble cytokine receptors and derivatives thereof (e.g.,soluble p55 or p75 TNF receptors, sIL-1RI, sIL-1RII, and sIL-6R) andantiinflammatory cytokines (e.g., IL-4, IL-10, IL-11, IL-13 and TGFβ),and bcl-2 inhibitors.

Examples of therapeutic agents for Crohn's disease in which a bindingprotein can be combined include the following: TNF antagonists, forexample, anti-TNF antibodies, ADALIMUMAB (PCT Publication No. WO97/29131; HUMIRA), CA2 (REMICADE), CDP 571, TNFR-Ig constructs,(p75TNFRIgG (ENBREL) and p55TNFRIgG (LENERCEPT)) inhibitors and PDE4inhibitors. Antibodies provided herein, or antigen binding portionsthereof, can be combined with corticosteroids, for example, budenosideand dexamethasone. Binding proteins provided herein, or antigen bindingportions thereof, may also be combined with agents such assulfasalazine, 5-aminosalicylic acid and olsalazine, and agents whichinterfere with synthesis or action of proinflammatory cytokines such asIL-1, for example, IL-1β converting enzyme inhibitors and IL-1ra.Antibodies provided herein or antigen binding portion thereof may alsobe used with T cell signaling inhibitors, for example, tyrosine kinaseinhibitors 6-mercaptopurines. Binding proteins provided herein, orantigen binding portions thereof, can be combined with IL-11. Bindingproteins provided herein, or antigen binding portions thereof, can becombined with mesalamine, prednisone, azathioprine, mercaptopurine,infliximab, methylprednisolone sodium succinate, diphenoxylate/atropsulfate, loperamide hydrochloride, methotrexate, omeprazole, folate,ciprofloxacin/dextrose-water, hydrocodone bitartrate/apap, tetracyclinehydrochloride, fluocinonide, metronidazole, thimerosal/boric acid,cholestyramine/sucrose, ciprofloxacin hydrochloride, hyoscyaminesulfate, meperidine hydrochloride, midazolam hydrochloride, oxycodonehcl/acetaminophen, promethazine hydrochloride, sodium phosphate,sulfamethoxazole/trimethoprim, celecoxib, polycarbophil, propoxyphenenapsylate, hydrocortisone, multivitamins, balsalazide disodium, codeinephosphate/apap, colesevelam hcl, cyanocobalamin, folic acid,levofloxacin, methylprednisolone, natalizumab and interferon-gamma

Non-limiting examples of therapeutic agents for multiple sclerosis withwhich binding proteins provided herein can be combined include thefollowing: corticosteroids; prednisolone; methylprednisolone;azathioprine; cyclophosphamide; cyclosporine; methotrexate;4-aminopyridine; tizanidine; interferon-β1a (AVONEX; Biogen);interferon-β1b (BETASERON; Chiron/Berlex); interferon α-n3) (InterferonSciences/Fujimoto), interferon-α (Alfa Wassermann/J&J), interferonβ1A-1F (Serono/Inhale Therapeutics), Peginterferon α 2b(Enzon/Schering-Plough), Copolymer 1 (Cop-1; COPAXONE; TevaPharmaceutical Industries, Inc.); hyperbaric oxygen; intravenousimmunoglobulin; clabribine; antibodies to or antagonists of other humancytokines or growth factors and their receptors, for example, TNF, LT,IL-1, IL-2, IL-6, IL-7, IL-8, IL-23, IL-15, IL-16, IL-18, EMAP-II,GM-CSF, FGF, and PDGF. Binding proteins provided herein can be combinedwith antibodies to cell surface molecules such as CD2, CD3, CD4, CD8,CD19, CD20, CD25, CD28, CD30, CD40, CD45, CD69, CD80, CD86, CD90 ortheir ligands. Binding proteins provided herein, may also be combinedwith agents, such as methotrexate, cyclosporine, FK506, rapamycin,mycophenolate mofetil, leflunomide, NSAIDs, for example, ibuprofen,corticosteroids such as prednisolone, phosphodiesterase inhibitors,adensosine agonists, antithrombotic agents, complement inhibitors,adrenergic agents, agents which interfere with signalling byproinflammatory cytokines such as TNFα or IL-1 (e.g., IRAK, NIK, IKK,p38 or MAP kinase inhibitors), IL-113 converting enzyme inhibitors, TACEinhibitors, T-cell signaling inhibitors such as kinase inhibitors,metalloproteinase inhibitors, sulfasalazine, azathioprine,6-mercaptopurines, angiotensin converting enzyme inhibitors, solublecytokine receptors and derivatives thereof (e.g., soluble p55 or p75 TNFreceptors, sIL-1RI, sIL-1RII, and sIL-6R), antiinflammatory cytokines(e.g., IL-4, IL-10, IL-13 and TGFβ) and bcl-2 inhibitors.

Examples of therapeutic agents for multiple sclerosis in which bindingproteins provided herein can be combined include interferon-β, forexample, IFNβ1a and IFNβ1b; copaxone, corticosteroids, caspaseinhibitors, for example inhibitors of caspase-1, IL-1 inhibitors, TNFinhibitors, and antibodies to CD40 ligand and CD80.

The binding proteins provided herein, may also be combined with agents,such as alemtuzumab, dronabinol, Unimed, daclizumab, mitoxantrone,xaliproden hydrochloride, fampridine, glatiramer acetate, natalizumab,sinnabidol, a-immunokine NNSO3, ABR-215062, AnergiX.MS, chemokinereceptor antagonists, BBR-2778, calagualine, CPI-1189, LEM (liposomeencapsulated mitoxantrone), THC.CBD (cannabinoid agonist) MBP-8298,mesopram (PDE4 inhibitor), MNA-715, anti-IL-6 receptor antibody,neurovax, pirfenidone allotrap 1258 (RDP-1258), sTNF-R1, talampanel,teriflunomide, TGF-beta2, tiplimotide, VLA-4 antagonists (for example,TR-14035, VLA4 Ultrahaler, Antegran-ELAN/Biogen), interferon gammaantagonists, and IL-4 agonists.

Non-limiting examples of therapeutic agents for Angina with whichbinding proteins provided herein can be combined include the following:aspirin, nitroglycerin, isosorbide mononitrate, metoprolol succinate,atenolol, metoprolol tartrate, amlodipine besylate, diltiazemhydrochloride, isosorbide dinitrate, clopidogrel bisulfate, nifedipine,atorvastatin calcium, potassium chloride, furosemide, simvastatin,verapamil hcl, digoxin, propranolol hydrochloride, carvedilol,lisinopril, spironolactone, hydrochlorothiazide, enalapril maleate,nadolol, ramipril, enoxaparin sodium, heparin sodium, valsartan, sotalolhydrochloride, fenofibrate, ezetimibe, bumetanide, losartan potassium,lisinopril/hydrochlorothiazide, felodipine, captopril, and bisoprololfumarate.

Non-limiting examples of therapeutic agents for Ankylosing Spondylitiswith which binding proteins provided herein can be combined include thefollowing: ibuprofen, diclofenac and misoprostol, naproxen, meloxicam,indomethacin, diclofenac, celecoxib, rofecoxib, Sulfasalazine,Methotrexate, azathioprine, minocyclin, prednisone, etanercept, andinfliximab.

Non-limiting examples of therapeutic agents for Asthma with whichbinding proteins provided herein can be combined include the following:albuterol, salmeterol/fluticasone, montelukast sodium, fluticasonepropionate, budesonide, prednisone, salmeterol xinafoate, levalbuterolhcl, albuterol sulfate/ipratropium, prednisolone sodium phosphate,triamcinolone acetonide, beclomethasone dipropionate, ipratropiumbromide, azithromycin, pirbuterol acetate, prednisolone, theophyllineanhydrous, methylprednisolone sodium succinate, clarithromycin,zafirlukast, formoterol fumarate, influenza virus vaccine,methylprednisolone, amoxicillin trihydrate, flunisolide, allergyinjection, cromolyn sodium, fexofenadine hydrochloride,flunisolide/menthol, amoxicillin/clavulanate, levofloxacin, inhalerassist device, guaifenesin, dexamethasone sodium phosphate, moxifloxacinhcl, doxycycline hyclate, guaifenesin/d-methorphan,p-ephedrine/cod/chlorphenir, gatifloxacin, cetirizine hydrochloride,mometasone furoate, salmeterol xinafoate, benzonatate, cephalexin,pe/hydrocodone/chlorphenir, cetirizine hcl/pseudoephed,phenylephrine/cod/promethazine, codeine/promethazine, cefprozil,dexamethasone, guaifenesin/pseudoephedrine,chlorpheniramine/hydrocodone, nedocromil sodium, terbutaline sulfate,epinephrine, methylprednisolone, and metaproterenol sulfate.

Non-limiting examples of therapeutic agents for COPD with which bindingproteins provided herein can be combined include the following:albuterol sulfate/ipratropium, ipratropium bromide,salmeterol/fluticasone, albuterol, salmeterol xinafoate, fluticasonepropionate, prednisone, theophylline anhydrous, methylprednisolonesodium succinate, montelukast sodium, budesonide, formoterol fumarate,triamcinolone acetonide, levofloxacin, guaifenesin, azithromycin,beclomethasone dipropionate, levalbuterol hcl, flunisolide, ceftriaxonesodium, amoxicillin trihydrate, gatifloxacin, zafirlukast,amoxicillin/clavulanate, flunisolide/menthol,chlorpheniramine/hydrocodone, metaproterenol sulfate,methylprednisolone, mometasone furoate, p-ephedrine/cod/chlorphenir,pirbuterol acetate, p-ephedrine/loratadine, terbutaline sulfate,tiotropium bromide, (R,R)-formoterol, TgAAT, Cilomilast, andRoflumilast.

Non-limiting examples of therapeutic agents for HCV with which bindingproteins provided herein can be combined include the following:Interferon-alpha-2a, Interferon-alpha-2b, Interferon-alpha con1,Interferon-alpha-n1, Pegylated interferon-alpha-2a, Pegylatedinterferon-alpha-2b, ribavirin, Peginterferon alfa-2b+ribavirin,Ursodeoxycholic Acid, Glycyrrhizic Acid, Thymalfasin, Maxamine, VX-497and any compounds that are used to treat HCV through intervention withthe following targets: HCV polymerase, HCV protease, HCV helicase, andHCV IRES (internal ribosome entry site).

Non-limiting examples of therapeutic agents for Idiopathic PulmonaryFibrosis with which binding proteins provided herein can be combinedinclude the following: prednisone, azathioprine, albuterol, colchicine,albuterol sulfate, digoxin, gamma interferon, methylprednisolone sodsucc, lorazepam, furosemide, lisinopril, nitroglycerin, spironolactone,cyclophosphamide, ipratropium bromide, actinomycin d, alteplase,fluticasone propionate, levofloxacin, metaproterenol sulfate, morphinesulfate, oxycodone hcl, potassium chloride, triamcinolone acetonide,tacrolimus anhydrous, calcium, interferon-alpha, methotrexate,mycophenolate mofetil, and Interferon-gamma-1β.

Non-limiting examples of therapeutic agents for Myocardial Infarctionwith which binding proteins provided herein can be combined include thefollowing: aspirin, nitroglycerin, metoprolol tartrate, enoxaparinsodium, heparin sodium, clopidogrel bisulfate, carvedilol, atenolol,morphine sulfate, metoprolol succinate, warfarin sodium, lisinopril,isosorbide mononitrate, digoxin, furosemide, simvastatin, ramipril,tenecteplase, enalapril maleate, torsemide, retavase, losartanpotassium, quinapril hcl/mag carb, bumetanide, alteplase, enalaprilat,amiodarone hydrochloride, tirofiban hcl m-hydrate, diltiazemhydrochloride, captopril, irbesartan, valsartan, propranololhydrochloride, fosinopril sodium, lidocaine hydrochloride, eptifibatide,cefazolin sodium, atropine sulfate, aminocaproic acid, spironolactone,interferon, sotalol hydrochloride, potassium chloride, docusate sodium,dobutamine hcl, alprazolam, pravastatin sodium, atorvastatin calcium,midazolam hydrochloride, meperidine hydrochloride, isosorbide dinitrate,epinephrine, dopamine hydrochloride, bivalirudin, rosuvastatin,ezetimibe/simvastatin, avasimibe, and cariporide.

Non-limiting examples of therapeutic agents for Psoriasis with whichbinding proteins provided herein can be combined include the following:small molecule inhibitor of KDR, small molecule inhibitor of Tie-2,calcipotriene, clobetasol propionate, triamcinolone acetonide,halobetasol propionate, tazarotene, methotrexate, fluocinonide,betamethasone diprop augmented, fluocinolone acetonide, acitretin, tarshampoo, betamethasone valerate, mometasone furoate, ketoconazole,pramoxine/fluocinolone, hydrocortisone valerate, flurandrenolide, urea,betamethasone, clobetasol propionate/emoll, fluticasone propionate,azithromycin, hydrocortisone, moisturizing formula, folic acid,desonide, pimecrolimus, coal tar, diflorasone diacetate, etanerceptfolate, lactic acid, methoxsalen, hc/bismuth subgal/znox/resor,methylprednisolone acetate, prednisone, sunscreen, halcinonide,salicylic acid, anthralin, clocortolone pivalate, coal extract, coaltar/salicylic acid, coal tar/salicylic acid/sulfur, desoximetasone,diazepam, emollient, fluocinonide/emollient, mineral oil/castor oil/nalact, mineral oil/peanut oil, petroleum/isopropyl myristate, psoralen,salicylic acid, soap/tribromsalan, thimerosal/boric acid, celecoxib,infliximab, cyclosporine, alefacept, efalizumab, tacrolimus,pimecrolimus, PUVA, UVB, and sulfasalazine.

Non-limiting examples of therapeutic agents for Psoriatic Arthritis withwhich binding proteins provided herein can be combined include thefollowing: methotrexate, etanercept, rofecoxib, celecoxib, folic acid,sulfasalazine, naproxen, leflunomide, methylprednisolone acetate,indomethacin, hydroxychloroquine sulfate, prednisone, sulindac,betamethasone diprop augmented, infliximab, methotrexate, folate,triamcinolone acetonide, diclofenac, dimethylsulfoxide, piroxicam,diclofenac sodium, ketoprofen, meloxicam, methylprednisolone,nabumetone, tolmetin sodium, calcipotriene, cyclosporine, diclofenacsodium/misoprostol, fluocinonide, glucosamine sulfate, gold sodiumthiomalate, hydrocodone bitartrate/apap, ibuprofen, risedronate sodium,sulfadiazine, thioguanine, valdecoxib, alefacept, efalizumab and bcl-2inhibitors.

Non-limiting examples of therapeutic agents for Restenosis with whichbinding proteins provided herein can be combined include the following:sirolimus, paclitaxel, everolimus, tacrolimus, Zotarolimus, andacetaminophen.

Non-limiting examples of therapeutic agents for Sciatica with whichbinding proteins provided herein can be combined include the following:hydrocodone bitartrate/apap, rofecoxib, cyclobenzaprine hcl,methylprednisolone, naproxen, ibuprofen, oxycodone hcl/acetaminophen,celecoxib, valdecoxib, methylprednisolone acetate, prednisone, codeinephosphate/apap, tramadol hcl/acetaminophen, metaxalone, meloxicam,methocarbamol, lidocaine hydrochloride, diclofenac sodium, gabapentin,dexamethasone, carisoprodol, ketorolac tromethamine, indomethacin,acetaminophen, diazepam, nabumetone, oxycodone hcl, tizanidine hcl,diclofenac sodium/misoprostol, propoxyphene napsylate/apap,asa/oxycod/oxycodone ter, ibuprofen/hydrocodone bit, tramadol hcl,etodolac, propoxyphene hcl, amitriptyline hcl, carisoprodol/codeinephos/asa, morphine sulfate, multivitamins, naproxen sodium, orphenadrinecitrate, and temazepam.

Examples of therapeutic agents for SLE (Lupus) in which binding proteinsprovided herein can be combined include the following: NSAIDS, forexample, diclofenac, naproxen, ibuprofen, piroxicam, indomethacin; COX2inhibitors, for example, Celecoxib, rofecoxib, valdecoxib;anti-malarials, for example, hydroxychloroquine; Steroids, for example,prednisone, prednisolone, budenoside, dexamethasone; Cytotoxics, forexample, azathioprine, cyclophosphamide, mycophenolate mofetil,methotrexate; and inhibitors of PDE4 or a purine synthesis inhibitor,for example Cellcept. Binding proteins provided herein may also becombined with agents such as sulfasalazine, 5-aminosalicylic acid,olsalazine, Imuran and agents which interfere with synthesis, productionor action of proinflammatory cytokines such as IL-1, for example,caspase inhibitors like IL-1β converting enzyme inhibitors and IL-1ra.Binding proteins provided herein may also be used with T cell signalinginhibitors, for example, tyrosine kinase inhibitors; or molecules thattarget T cell activation molecules, for example, CTLA-4-IgG or anti-B7family antibodies, and anti-PD-1 family antibodies. Binding proteinsprovided herein can be combined with IL-11 or anti-cytokine antibodies,for example, fonotolizumab (anti-IFNg antibody), or anti-receptorreceptor antibodies, for example, anti-IL-6 receptor antibody andantibodies to B-cell surface molecules. Antibodies provided herein orantigen binding portion thereof may also be used with LJP 394(abetimus), agents that deplete or inactivate B-cells, for example,Rituximab (anti-CD20 antibody), lymphostat-B (anti-BlyS antibody), TNFantagonists, for example, anti-TNF antibodies, Adalimumab (PCTPublication No. WO 97/29131; HUMIRA), CA2 (REMICADE), CDP 571, TNFR-Igconstructs, (p75TNFRIgG (ENBREL) and p55TNFRIgG (LENERCEPT)) and bcl-2inhibitors, because bcl-2 overexpression in transgenic mice has beendemonstrated to cause a lupus like phenotype (see Marquina, R. et al.(2004) J. Immunol. 172(11): 7177-7185), therefore inhibition is expectedto have therapeutic effects.

The pharmaceutical compositions provided herein may include a“therapeutically effective amount” or a “prophylactically effectiveamount” of a binding protein provided herein. A “therapeuticallyeffective amount” refers to an amount effective, at dosages and forperiods of time necessary, to achieve the desired therapeutic result. Atherapeutically effective amount of the binding protein may bedetermined by a person skilled in the art and may vary according tofactors such as the disease state, age, sex, and weight of theindividual, and the ability of the binding protein to elicit a desiredresponse in the individual. A therapeutically effective amount is alsoone in which any toxic or detrimental effects of the antibody, orantibody portion, are outweighed by the therapeutically beneficialeffects. A “prophylactically effective amount” refers to an amounteffective, at dosages and for periods of time necessary, to achieve thedesired prophylactic result. Typically, since a prophylactic dose isused in subjects prior to or at an earlier stage of disease, theprophylactically effective amount will be less than the therapeuticallyeffective amount.

Dosage regimens may be adjusted to provide the optimum desired response(e.g., a therapeutic or prophylactic response). For example, a singlebolus may be administered, several divided doses may be administeredover time or the dose may be proportionally reduced or increased asindicated by the exigencies of the therapeutic situation. It isespecially advantageous to formulate parenteral compositions in dosageunit form for ease of administration and uniformity of dosage. Dosageunit form as used herein refers to physically discrete units suited asunitary dosages for the mammalian subjects to be treated; each unitcontaining a predetermined quantity of active compound calculated toproduce the desired therapeutic effect in association with the requiredpharmaceutical carrier. The specification for the dosage unit forms aredictated by and directly dependent on (a) the unique characteristics ofthe active compound and the particular therapeutic or prophylacticeffect to be achieved, and (b) the limitations inherent in the art ofcompounding such an active compound for the treatment of sensitivity inindividuals.

An exemplary, non-limiting range for a therapeutically orprophylactically effective amount of a binding protein provided hereinis 0.1-20 mg/kg, for example, 1-10 mg/kg. It is to be noted that dosagevalues may vary with the type and severity of the condition to bealleviated. It is to be further understood that for any particularsubject, specific dosage regimens should be adjusted over time accordingto the individual need and the professional judgment of the personadministering or supervising the administration of the compositions, andthat dosage ranges set forth herein are exemplary only and are notintended to limit the scope or practice of the claimed composition.

V. Diagnostics

The disclosure herein also provides diagnostic applications. This isfurther elucidated below.

A. Method of Assay

The present disclosure also provides a method for determining thepresence, amount or concentration of an analyte (or a fragment thereof)in a test sample using at least one DVD-Ig as described herein. Anysuitable assay as is known in the art can be used in the method.Examples include, but are not limited to, immunoassay, such as sandwichimmunoassay (e.g., monoclonal, polyclonal and/or DVD-Ig sandwichimmunoassays or any variation thereof (e.g., monoclonal/DVD-Ig,DVD-Ig/polyclonal, etc.), including radioisotope detection(radioimmunoassay (RIA)) and enzyme detection (enzyme immunoassay (EIA)or enzyme-linked immunosorbent assay (ELISA) (e.g., Quantikine ELISAassays, R&D Systems, Minneapolis, Minn.))), competitive inhibitionimmunoassay (e.g., forward and reverse), fluorescence polarizationimmunoassay (FPIA), enzyme multiplied immunoassay technique (EMIT),bioluminescence resonance energy transfer (BRET), and homogeneouschemiluminescent assay, etc. In a SELDI-based immunoassay, a capturereagent that specifically binds an analyte (or a fragment thereof) ofinterest is attached to the surface of a mass spectrometry probe, suchas a pre-activated protein chip array. The analyte (or a fragmentthereof) is then specifically captured on the biochip, and the capturedanalyte (or a fragment thereof) is detected by mass spectrometry.Alternatively, the analyte (or a fragment thereof) can be eluted fromthe capture reagent and detected by traditional MALDI (matrix-assistedlaser desorption/ionization) or by SELDI. A chemiluminescentmicroparticle immunoassay, in particular one employing the ARCHITECT®automated analyzer (Abbott Laboratories, Abbott Park, Ill.), is anexample of a preferred immunoassay.

Methods well-known in the art for collecting, handling and processingurine, blood, serum and plasma, and other body fluids, are used in thepractice of the present disclosure, for instance, when a DVD-Ig asdescribed herein is employed as an immunodiagnostic reagent and/or in ananalyte immunoassay kit. The test sample can comprise further moietiesin addition to the analyte of interest, such as antibodies, antigens,haptens, hormones, drugs, enzymes, receptors, proteins, peptides,polypeptides, oligonucleotides and/or polynucleotides. For example, thesample can be a whole blood sample obtained from a subject. It can benecessary or desired that a test sample, particularly whole blood, betreated prior to immunoassay as described herein, e.g., with apretreatment reagent. Even in cases where pretreatment is not necessary(e.g., most urine samples), pretreatment optionally can be done (e.g.,as part of a regimen on a commercial platform).

The pretreatment reagent can be any reagent appropriate for use with theimmunoassay and kits provided herein. The pretreatment optionallycomprises: (a) one or more solvents (e.g., methanol and ethylene glycol)and optionally, salt, (b) one or more solvents and salt, and optionally,detergent, (c) detergent, or (d) detergent and salt. Pretreatmentreagents are known in the art, and such pretreatment can be employed,e.g., as used for assays on Abbott TDx, AxSYM®, and ARCHITECT® analyzers(Abbott Laboratories, Abbott Park, Ill.), as described in the literature(see, e.g., Yatscoff et al., (1990) Clin. Chem. 36: 1969-1973 andWallemacq et al. (1999) Clin. Chem. 45: 432-435), and/or as commerciallyavailable. Additionally, pretreatment can be done as described in U.S.Pat. No. 5,135,875, EU Patent Publication No. EU0471293, U.S. Pat. No.6,660,843, and U.S. Patent Application No. 20080020401. The pretreatmentreagent can be a heterogeneous agent or a homogeneous agent.

With use of a heterogeneous pretreatment reagent, the pretreatmentreagent precipitates analyte binding protein (e.g., protein that canbind to an analyte or a fragment thereof) present in the sample. Such apretreatment step comprises removing any analyte binding protein byseparating from the precipitated analyte binding protein the supernatantof the mixture formed by addition of the pretreatment agent to sample.In such an assay, the supernatant of the mixture absent any bindingprotein is used in the assay, proceeding directly to the antibodycapture step.

With use of a homogeneous pretreatment reagent there is no suchseparation step. The entire mixture of test sample and pretreatmentreagent are contacted with a labeled specific binding partner foranalyte (or a fragment thereof), such as a labeled anti-analyte antibody(or an antigenically reactive fragment thereof). The pretreatmentreagent employed for such an assay typically is diluted in thepretreated test sample mixture, either before or during capture by thefirst specific binding partner. Despite such dilution, a certain amountof the pretreatment reagent is still present (or remains) in the testsample mixture during capture. In one embodiment, the labeled specificbinding partner can be a DVD-Ig (or a fragment, a variant, or a fragmentof a variant thereof).

In a heterogeneous format, after the test sample is obtained from asubject, a first mixture is prepared. The mixture contains the testsample being assessed for an analyte (or a fragment thereof) and a firstspecific binding partner, wherein the first specific binding partner andany analyte contained in the test sample form a first specific bindingpartner-analyte complex. Preferably, the first specific binding partneris an anti-analyte antibody or a fragment thereof. The first specificbinding partner can be a DVD-Ig (or a fragment, a variant, or a fragmentof a variant thereof) as described herein. The order in which the testsample and the first specific binding partner are added to form themixture is not critical. Preferably, the first specific binding partneris immobilized on a solid phase. The solid phase used in the immunoassay(for the first specific binding partner and, optionally, the secondspecific binding partner) can be any solid phase known in the art, suchas, but not limited to, a magnetic particle, a bead, a test tube, amicrotiter plate, a cuvette, a membrane, a scaffolding molecule, a film,a filter paper, a disc and a chip.

After the mixture containing the first specific binding partner-analytecomplex is formed, any unbound analyte is removed from the complex usingany technique known in the art. For example, the unbound analyte can beremoved by washing. Desirably, however, the first specific bindingpartner is present in excess of any analyte present in the test sample,such that all analyte that is present in the test sample is bound by thefirst specific binding partner.

After any unbound analyte is removed, a second specific binding partneris added to the mixture to form a first specific bindingpartner-analyte-second specific binding partner complex. The secondspecific binding partner is preferably an anti-analyte antibody thatbinds to an epitope on analyte that differs from the epitope on analytebound by the first specific binding partner. Moreover, also preferably,the second specific binding partner is labeled with or contains adetectable label as described above. The second specific binding partnercan be a DVD-Ig (or a fragment, a variant, or a fragment of a variantthereof) as described herein.

Any suitable detectable label as is known in the art can be used. Forexample, the detectable label can be a radioactive label (such as ³H,¹²⁵I, ³⁵S, ¹⁴C, ³²P, and ³³P), an enzymatic label (such as horseradishperoxidase, alkaline peroxidase, glucose 6-phosphate dehydrogenase, andthe like), a chemiluminescent label (such as acridinium esters,thioesters, or sulfonamides; luminol, isoluminol, phenanthridiniumesters, and the like), a fluorescent label (such as fluorescein (e.g.,5-fluorescein, 6-carboxyfluorescein, 3′6-carboxyfluorescein,5(6)-carboxyfluorescein, 6-hexachloro-fluorescein,6-tetrachlorofluorescein, fluorescein isothiocyanate, and the like)),rhodamine, phycobiliproteins, R-phycoerythrin, quantum dots (e.g., zincsulfide-capped cadmium selenide), a thermometric label, or animmuno-polymerase chain reaction label. An introduction to labels,labeling procedures and detection of labels is found in Polak and VanNoorden, Introduction to Immunocytochemistry, 2^(nd) ed., SpringerVerlag, N.Y. (1997), and in Haugland, Handbook of Fluorescent Probes andResearch Chemicals (1996), which is a combined handbook and cataloguepublished by Molecular Probes, Inc., Eugene, Oreg. A fluorescent labelcan be used in FPIA (see, e.g., U.S. Pat. Nos. 5,593,896; 5,573,904;5,496,925; 5,359,093; and 5,352,803. An acridinium compound can be usedas a detectable label in a homogeneous or heterogeneous chemiluminescentassay (see, e.g., Adamczyk et al. (2006) Bioorg. Med. Chem. Lett. 16:1324-1328; Adamczyk et al. (2004) Bioorg. Med. Chem. Lett. 4: 2313-2317;Adamczyk et al. (2004) Biorg. Med. Chem. Lett. 14: 3917-3921; andAdamczyk et al. (2003) Org. Lett. 5: 3779-3782).

A preferred acridinium compound is an acridinium-9-carboxamide. Methodsfor preparing acridinium 9-carboxamides are described in Mattingly(1991) J. Biolumin. Chemilumin. 6: 107-114; Adamczyk et al. (1998) J.Org. Chem. 63: 5636-5639; Adamczyk et al. (1999) Tetrahedron 55:10899-10914; Adamczyk et al. (1999) Org. Lett. 1: 779-781; Adamczyk etal. (2000) Biocon. Chem. 11: 714-724; Mattingly et al., In LuminescenceBiotechnology Instruments and Applications; Dyke, K. V. Ed.; CRC Press:Boca Raton, pp. 77-105 (2002); Adamczyk et al. (2003) Org. Lett. 5:3779-3782; and U.S. Pat. Nos. 5,468,646; 5,543,524; and 5,783,699.Another preferred acridinium compound is an acridinium-9-carboxylatearyl ester. An example of an acridinium-9-carboxylate aryl ester is10-methyl-9-(phenoxycarbonyl)acridinium fluorosulfonate (available fromCayman Chemical, Ann Arbor, Mich.). Methods for preparing acridinium9-carboxylate aryl esters are described in McCapra et al. (1965)Photochem. Photobiol. 4: 1111-21; Razavi et al. (2000) Luminescence 15:245-249; Razavi et al. (2000) Luminescence 15: 239-244; and U.S. Pat.No. 5,241,070. Further details regarding acridinium-9-carboxylate arylester and its use are set forth in US Patent Publication No.20080248493.

Chemiluminescent assays (e.g., using acridinium as described above orother chemiluminescent agents) can be performed in accordance with themethods described in Adamczyk et al. (2006) Anal. Chim. Acta 579(1):61-67. While any suitable assay format can be used, a microplatechemiluminometer (Mithras LB-940, Berthold Technologies U.S.A., LLC, OakRidge, Tenn.) enables the assay of multiple samples of small volumesrapidly.

The order in which the test sample and the specific binding partner(s)are added to form the mixture for chemiluminescent assay is notcritical. If the first specific binding partner is detectably labeledwith a chemiluminescent agent such as an acridinium compound, detectablylabeled first specific binding partner-analyte complexes form.Alternatively, if a second specific binding partner is used and thesecond specific binding partner is detectably labeled with achemiluminescent agent such as an acridinium compound, detectablylabeled first specific binding partner-analyte-second specific bindingpartner complexes form. Any unbound specific binding partner, whetherlabeled or unlabeled, can be removed from the mixture using anytechnique known in the art, such as washing.

Hydrogen peroxide can be generated in situ in the mixture or provided orsupplied to the mixture (e.g., the source of the hydrogen peroxide beingone or more buffers or other solutions that are known to containhydrogen peroxide) before, simultaneously with, or after the addition ofan above-described acridinium compound. Hydrogen peroxide can begenerated in situ in a number of ways such as would be apparent to oneskilled in the art.

Upon the simultaneous or subsequent addition of at least one basicsolution to the sample, a detectable signal, namely, a chemiluminescentsignal, indicative of the presence of analyte is generated. The basicsolution contains at least one base and has a pH greater than or equalto 10, preferably, greater than or equal to 12. Examples of basicsolutions include, but are not limited to, sodium hydroxide, potassiumhydroxide, calcium hydroxide, ammonium hydroxide, magnesium hydroxide,sodium carbonate, sodium bicarbonate, calcium hydroxide, calciumcarbonate, and calcium bicarbonate. The amount of basic solution addedto the sample depends on the concentration of the basic solution. Basedon the concentration of the basic solution used, one skilled in the artcan easily determine the amount of basic solution to add to the sample.

The chemiluminescent signal that is generated can be detected usingroutine techniques known to those skilled in the art. Based on theintensity of the signal generated, the amount of analyte in the samplecan be quantified. Specifically, the amount of analyte in the sample isproportional to the intensity of the signal generated. The amount ofanalyte present can be quantified by comparing the amount of lightgenerated to a standard curve for analyte or by comparison to areference standard. The standard curve can be generated using serialdilutions or solutions of known concentrations of analyte by massspectroscopy, gravimetric methods, and other techniques known in theart. While the above is described with emphasis on use of an acridiniumcompound as the chemiluminescent agent, one of ordinary skill in the artcan readily adapt this description for use of other chemiluminescentagents.

Analyte immunoassays generally can be conducted using any format knownin the art, such as, but not limited to, a sandwich format.Specifically, in one immunoassay format, at least two antibodies areemployed to separate and quantify analyte, such as human analyte, or afragment thereof in a sample. More specifically, the at least twoantibodies bind to different epitopes on an analyte (or a fragmentthereof) forming an immune complex, which is referred to as a“sandwich.” Generally, in the immunoassays one or more antibodies can beused to capture the analyte (or a fragment thereof) in the test sample(these antibodies are frequently referred to as a “capture” antibody or“capture” antibodies) and one or more antibodies can be used to bind adetectable (namely, quantifiable) label to the sandwich (theseantibodies are frequently referred to as the “detection antibody,” the“detection antibodies,” the “conjugate,” or the “conjugates”). Thus, inthe context of a sandwich immunoassay format, a binding protein or aDVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) asdescribed herein can be used as a capture antibody, a detectionantibody, or both. For example, one binding protein or DVD-Ig having adomain that can bind a first epitope on an analyte (or a fragmentthereof) can be used as a capture agent and/or another binding proteinor DVD-Ig having a domain that can bind a second epitope on an analyte(or a fragment thereof) can be used as a detection agent. In thisregard, a binding protein or a DVD-Ig having a first domain that canbind a first epitope on an analyte (or a fragment thereof) and a seconddomain that can bind a second epitope on an analyte (or a fragmentthereof) can be used as a capture agent and/or a detection agent.Alternatively, one binding protein or DVD-Ig having a first domain thatcan bind an epitope on a first analyte (or a fragment thereof) and asecond domain that can bind an epitope on a second analyte (or afragment thereof) can be used as a capture agent and/or a detectionagent to detect, and optionally quantify, two or more analytes. In theevent that an analyte can be present in a sample in more than one form,such as a monomeric form and a dimeric/multimeric form, which can behomomeric or heteromeric, one binding protein or DVD-Ig having a domainthat can bind an epitope that is only exposed on the monomeric form andanother binding protein or DVD-Ig having a domain that can bind anepitope on a different part of a dimeric/multimeric form can be used ascapture agents and/or detection agents, thereby enabling the detection,and optional quantification, of different forms of a given analyte.Furthermore, employing binding proteins or DVD-Igs with differentialaffinities within a single binding protein or DVD-Ig and/or betweenbinding proteins or DVD-Igs can provide an avidity advantage. In thecontext of immunoassays as described herein, it generally may be helpfulor desired to incorporate one or more linkers within the structure of abinding protein or a DVD-Ig. When present, optimally the linker shouldbe of sufficient length and structural flexibility to enable binding ofan epitope by the inner domains as well as binding of another epitope bythe outer domains. In this regard, when a binding protein or a DVD-Igcan bind two different analytes and one analyte is larger than theother, desirably the larger analyte is bound by the outer domains.

Generally speaking, a sample being tested for (for example, suspected ofcontaining) analyte (or a fragment thereof) can be contacted with atleast one capture agent (or agents) and at least one detection agent(which can be a second detection agent or a third detection agent oreven a successively numbered agent, e.g., as where the capture and/ordetection agent comprises multiple agents) either simultaneously orsequentially and in any order. For example, the test sample can be firstcontacted with at least one capture agent and then (sequentially) withat least one detection agent. Alternatively, the test sample can befirst contacted with at least one detection agent and then(sequentially) with at least one capture agent. In yet anotheralternative, the test sample can be contacted simultaneously with acapture agent and a detection agent.

In the sandwich assay format, a sample suspected of containing analyte(or a fragment thereof) is first brought into contact with at least onefirst capture agent under conditions that allow the formation of a firstagent/analyte complex. If more than one capture agent is used, a firstcapture agent/analyte complex comprising two or more capture agents isformed. In a sandwich assay, the agents, i.e., preferably, the at leastone capture agent, are used in molar excess amounts of the maximumamount of analyte (or a fragment thereof) expected in the test sample.For example, from about 5 μg to about 1 mg of agent per mL of buffer(e.g., microparticle coating buffer) can be used.

Competitive inhibition immunoassays, which are often used to measuresmall analytes because binding by only one antibody (i.e., a bindingprotein and/or a DVD-Ig in the context of the present disclosure) isrequired, comprise sequential and classic formats. In a sequentialcompetitive inhibition immunoassay a capture agent to an analyte ofinterest is coated onto a well of a microtiter plate or other solidsupport. When the sample containing the analyte of interest is added tothe well, the analyte of interest binds to the capture agent. Afterwashing, a known amount of labeled (e.g., biotin or horseradishperoxidase (HRP)) analyte capable of binding the capture antibody isadded to the well. A substrate for an enzymatic label is necessary togenerate a signal. An example of a suitable substrate for HRP is3,3′,5,5′-tetramethylbenzidine (TMB). After washing, the signalgenerated by the labeled analyte is measured and is inverselyproportional to the amount of analyte in the sample. In a classiccompetitive inhibition immunoassay typically an antibody (i.e., abinding protein and/or a DVD-Ig in the context of the presentdisclosure) to an analyte of interest is coated onto a solid support(e.g., a well of a microtiter plate). However, unlike the sequentialcompetitive inhibition immunoassay, the sample and the labeled analyteare added to the well at the same time. Any analyte in the samplecompetes with labeled analyte for binding to the capture agent. Afterwashing, the signal generated by the labeled analyte is measured and isinversely proportional to the amount of analyte in the sample. Ofcourse, there are many variations of these formats—e.g., such as whenbinding to the solid substrate takes place, whether the format isone-step, two-step, delayed two-step, and the like—and these would berecognized by one of ordinary skill in the art.

Optionally, prior to contacting the test sample with the at least onecapture agent (for example, the first capture agent), the at least onecapture agent can be bound to a solid support, which facilitates theseparation of the first agent/analyte (or a fragment thereof) complexfrom the test sample. The substrate to which the capture agent is boundcan be any suitable solid support or solid phase that facilitatesseparation of the capture agent-analyte complex from the sample.

Examples include a well of a plate, such as a microtiter plate, a testtube, a porous gel (e.g., silica gel, agarose, dextran, or gelatin), apolymeric film (e.g., polyacrylamide), beads (e.g., polystyrene beads ormagnetic beads), a strip of a filter/membrane (e.g., nitrocellulose ornylon), microparticles (e.g., latex particles, magnetizablemicroparticles (e.g., microparticles having ferric oxide or chromiumoxide cores and homo- or hetero-polymeric coats and radii of about 1-10microns). The substrate can comprise a suitable porous material with asuitable surface affinity to bind antigens and sufficient porosity toallow access by detection antibodies. A microporous material isgenerally preferred, although a gelatinous material in a hydrated statecan be used. Such porous substrates are preferably in the form of sheetshaving a thickness of about 0.01 to about 0.5 mm, preferably about 0.1mm. While the pore size may vary quite a bit, preferably the pore sizeis from about 0.025 to about 15 microns, more preferably from about 0.15to about 15 microns. The surface of such substrates can be passivelycoated or activated by chemical processes that cause covalent linkage ofan antibody to the substrate. Irreversible binding, generally byadsorption through hydrophobic forces, of the antigen or the antibody tothe substrate results; alternatively, a chemical coupling agent or othermeans can be used to bind covalently the antibody to the substrate,provided that such binding does not interfere with the ability of theantibody to bind to analyte. Alternatively, the antibody (i.e., bindingprotein and/or DVD-Ig in the context of the present disclosure) can bebound with microparticles, which have been previously coated withstreptavidin (e.g., DYNAL® Magnetic Beads, Invitrogen, Carlsbad, Calif.)or biotin (e.g., using Power-Bind™-SA-MP streptavidin-coatedmicroparticles (Seradyn, Indianapolis, Ind.)) or anti-species-specificmonoclonal antibodies (i.e., binding proteins and/or DVD-Igs in thecontext of the present disclosure). If necessary or desired, thesubstrate (e.g., for the label) can be derivatized to allow reactivitywith various functional groups on the antibody (i.e., binding protein orDVD-Ig in the context of the present disclosure). Such derivatizationrequires the use of certain coupling agents, examples of which include,but are not limited to, maleic anhydride, N-hydroxysuccinimide, and1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. If desired, one or morecapture agents, such as antibodies (or fragments thereof) (i.e., bindingproteins and/or DVD-Igs in the context of the present disclosure), eachof which is specific for analyte(s) can be attached to solid phases indifferent physical or addressable locations (e.g., such as in a biochipconfiguration (see, e.g., U.S. Pat. No. 6,225,047; PCT Publication No.WO 99/51773; U.S. Pat. No. 6,329,209; PCT Publication No. WO 00/56934,and U.S. Pat. No. 5,242,828). If the capture agent is attached to a massspectrometry probe as the solid support, the amount of analyte bound tothe probe can be detected by laser desorption ionization massspectrometry. Alternatively, a single column can be packed withdifferent beads, which are derivatized with the one or more captureagents, thereby capturing the analyte in a single place (see,antibody-derivatized, bead-based technologies, e.g., the xMAP technologyof Luminex (Austin, Tex.)).

After the test sample being assayed for analyte (or a fragment thereof)is brought into contact with the at least one capture agent (forexample, the first capture agent), the mixture is incubated in order toallow for the formation of a first capture agent (or multiple captureagent)-analyte (or a fragment thereof) complex. The incubation can becarried out at a pH of from about 4.5 to about 10.0, at a temperature offrom about 2° C. to about 45° C., and for a period from at least aboutone (1) minute to about eighteen (18) hours, preferably from about 1 toabout 24 minutes, most preferably for about 4 to about 18 minutes. Theimmunoassay described herein can be conducted in one step (meaning thetest sample, at least one capture agent and at least one detection agentare all added sequentially or simultaneously to a reaction vessel) or inmore than one step, such as two steps, three steps, etc.

After formation of the (first or multiple) capture agent/analyte (or afragment thereof) complex, the complex is then contacted with at leastone detection agent under conditions which allow for the formation of a(first or multiple) capture agent/analyte (or a fragment thereof)/seconddetection agent complex). While captioned for clarity as the “second”agent (e.g., second detection agent), in fact, where multiple agents areused for capture and/or detection, the at least one detection agent canbe the second, third, fourth, etc., agents used in the immunoassay. Ifthe capture agent/analyte (or a fragment thereof) complex is contactedwith more than one detection agent, then a (first or multiple) captureagent/analyte (or a fragment thereof)/(multiple) detection agent complexis formed. As with the capture agent (e.g., the first capture agent),when the at least one (e.g., second and any subsequent) detection agentis brought into contact with the capture agent/analyte (or a fragmentthereof) complex, a period of incubation under conditions similar tothose described above is required for the formation of the (first ormultiple) capture agent/analyte (or a fragment thereof)/(second ormultiple) detection agent complex. Preferably, at least one detectionagent contains a detectable label. The detectable label can be bound tothe at least one detection agent (e.g., the second detection agent)prior to, simultaneously with, or after the formation of the (first ormultiple) capture agent/analyte (or a fragment thereof)/(second ormultiple) detection agent complex. Any detectable label known in the artcan be used (see discussion above, including of the Polak and VanNoorden (1997) and Haugland (1996) references).

The detectable label can be bound to the agents either directly orthrough a coupling agent. An example of a coupling agent that can beused is EDAC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide,hydrochloride), which is commercially available from Sigma-Aldrich, St.Louis, Mo. Other coupling agents that can be used are known in the art.Methods for binding a detectable label to an antibody are known in theart. Additionally, many detectable labels can be purchased orsynthesized that already contain end groups that facilitate the couplingof the detectable label to the agent, such as CPSP-Acridinium Ester(i.e., 9-[N-tosyl-N-(3-carboxypropyl)]-10-(3-sulfopropyl)acridiniumcarboxamide) or SPSP-Acridinium Ester (i.e.,N10-(3-sulfopropyl)-N-(3-sulfopropyl)-acridinium-9-carboxamide).

The (first or multiple) capture agent/analyte/(second or multiple)detection agent complex can be, but does not have to be, separated fromthe remainder of the test sample prior to quantification of the label.For example, if the at least one capture agent (e.g., the first captureagent, such as a binding protein and/or a DVD-Ig in accordance with thepresent disclosure) is bound to a solid support, such as a well or abead, separation can be accomplished by removing the fluid (of the testsample) from contact with the solid support. Alternatively, if the atleast first capture agent is bound to a solid support, it can besimultaneously contacted with the analyte-containing sample and the atleast one second detection agent to form a first (multiple)agent/analyte/second (multiple) agent complex, followed by removal ofthe fluid (test sample) from contact with the solid support. If the atleast one first capture agent is not bound to a solid support, then the(first or multiple) capture agent/analyte/(second or multiple) detectionagent complex does not have to be removed from the test sample forquantification of the amount of the label.

After formation of the labeled capture agent/analyte/detection agentcomplex (e.g., the first capture agent/analyte/second detection agentcomplex), the amount of label in the complex is quantified usingtechniques known in the art. For example, if an enzymatic label is used,the labeled complex is reacted with a substrate for the label that givesa quantifiable reaction such as the development of color. If the labelis a radioactive label, the label is quantified using appropriate means,such as a scintillation counter. If the label is a fluorescent label,the label is quantified by stimulating the label with a light of onecolor (which is known as the “excitation wavelength”) and detectinganother color (which is known as the “emission wavelength”) that isemitted by the label in response to the stimulation. If the label is achemiluminescent label, the label is quantified by detecting the lightemitted either visually or by using luminometers, x-ray film, high speedphotographic film, a CCD camera, etc. Once the amount of the label inthe complex has been quantified, the concentration of analyte or afragment thereof in the test sample is determined by appropriate means,such as by use of a standard curve that has been generated using serialdilutions of analyte or a fragment thereof of known concentration. Otherthan using serial dilutions of analyte or a fragment thereof, thestandard curve can be generated gravimetrically, by mass spectroscopyand by other techniques known in the art.

In a chemiluminescent microparticle assay employing the ARCHITECT®analyzer, the conjugate diluent pH should be about 6.0+/−0.2, themicroparticle coating buffer should be maintained at about roomtemperature (i.e., at from about 17 to about 27° C.), the microparticlecoating buffer pH should be about 6.5+/−0.2, and the microparticlediluent pH should be about 7.8+/−0.2. Solids preferably are less thanabout 0.2%, such as less than about 0.15%, less than about 0.14%, lessthan about 0.13%, less than about 0.12%, or less than about 0.11%, suchas about 0.10%.

FPIAs are based on competitive binding immunoassay principles. Afluorescently labeled compound, when excited by a linearly polarizedlight, will emit fluorescence having a degree of polarization inverselyproportional to its rate of rotation. When a fluorescently labeledtracer-antibody complex is excited by a linearly polarized light, theemitted light remains highly polarized because the fluorophore isconstrained from rotating between the time light is absorbed and thetime light is emitted. When a “free” tracer compound (i.e., a compoundthat is not bound to an antibody) is excited by linearly polarizedlight, its rotation is much faster than the correspondingtracer-antibody conjugate (or tracer-binding protein and/ortracer-DVD-Ig in accordance with the present disclosure) produced in acompetitive binding immunoassay. FPIAs are advantageous over RIAsinasmuch as there are no radioactive substances requiring specialhandling and disposal. In addition, FPIAs are homogeneous assays thatcan be easily and rapidly performed.

In view of the above, a method of determining the presence, amount, orconcentration of analyte (or a fragment thereof) in a test sample isprovided. The method comprises assaying the test sample for an analyte(or a fragment thereof) by an assay (i) employing (i′) at least one ofan antibody, a fragment of an antibody that can bind to an analyte, avariant of an antibody that can bind to an analyte, a fragment of avariant of an antibody that can bind to an analyte, a binding protein asdisclosed herein, and a DVD-Ig (or a fragment, a variant, or a fragmentof a variant thereof) that can bind to an analyte, and (ii′) at leastone detectable label and (ii) comprising comparing a signal generated bythe detectable label as a direct or indirect indication of the presence,amount or concentration of analyte (or a fragment thereof) in the testsample to a signal generated as a direct or indirect indication of thepresence, amount or concentration of analyte (or a fragment thereof) ina control or calibrator. The calibrator is optionally part of a seriesof calibrators, in which each of the calibrators differs from the othercalibrators by the concentration of analyte.

The method can comprise (i) contacting the test sample with at least onefirst specific binding partner for analyte (or a fragment thereof)comprising an antibody, a fragment of an antibody that can bind to ananalyte, a variant of an antibody that can bind to an analyte, afragment of a variant of an antibody that can bind to an analyte, abinding protein as disclosed herein, or a DVD-Ig (or a fragment, avariant, or a fragment of a variant thereof) that can bind to an analyteso as to form a first specific binding partner/analyte (or fragmentthereof) complex, (ii) contacting the first specific bindingpartner/analyte (or fragment thereof) complex with at least one secondspecific binding partner for analyte (or fragment thereof) comprising adetectably labeled anti-analyte antibody, a detectably labeled fragmentof an anti-analyte antibody that can bind to analyte, a detectablylabeled variant of an anti-analyte antibody that can bind to analyte, adetectably labeled fragment of a variant of an anti-analyte antibodythat can bind to analyte, a detectably labeled binding protein asdisclosed herein that can bind to analyte, or a detectably labeledDVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) soas to form a first specific binding partner/analyte (or fragmentthereof)/second specific binding partner complex, and (iii) determiningthe presence, amount or concentration of analyte in the test sample bydetecting or measuring the signal generated by the detectable label inthe first specific binding partner/analyte (or fragment thereof)/secondspecific binding partner complex formed in (ii). A method in which atleast one first specific binding partner for analyte (or a fragmentthereof) and/or at least one second specific binding partner for analyte(or a fragment thereof) is a binding protein as disclosed herein or aDVD-Ig (or a fragment, a variant, or a fragment of a variant thereof) asdescribed herein can be preferred.

Alternatively, the method can comprise contacting the test sample withat least one first specific binding partner for analyte (or a fragmentthereof) comprising an antibody, a fragment of an antibody that can bindto an analyte, a variant of an antibody that can bind to an analyte, afragment of a variant of an antibody that can bind to an analyte, abinding protein as disclosed herein, or a DVD-Ig (or a fragment, avariant, or a fragment of a variant thereof) and simultaneously orsequentially, in either order, contacting the test sample with at leastone second specific binding partner, which can compete with analyte (ora fragment thereof) for binding to the at least one first specificbinding partner, wherein the binding partner is a detectably labeledanalyte, a detectably labeled fragment of analyte that can bind to thefirst specific binding partner, a detectably labeled variant of analytethat can bind to the first specific binding partner, or a detectablylabeled fragment of a variant of analyte that can bind to the firstspecific binding partner. Any analyte (or a fragment thereof) present inthe test sample and the at least one second specific binding partnercompete with each other to form a first specific binding partner/analyte(or fragment thereof) complex and a first specific bindingpartner/second specific binding partner complex, respectively. Themethod further comprises determining the presence, amount orconcentration of analyte in the test sample by detecting or measuringthe signal generated by the detectable label in the first specificbinding partner/second specific binding partner complex formed in (ii),wherein the signal generated by the detectable label in the firstspecific binding partner/second specific binding partner complex isinversely proportional to the amount or concentration of analyte in thetest sample.

The above methods can further comprise diagnosing, prognosticating, orassessing the efficacy of a therapeutic/prophylactic treatment of apatient from whom the test sample was obtained. If the method furthercomprises assessing the efficacy of a therapeutic/prophylactic treatmentof the patient from whom the test sample was obtained, the methodoptionally further comprises modifying the therapeutic/prophylactictreatment of the patient as needed to improve efficacy. The method canbe adapted for use in an automated system or a semi-automated system.

More specifically, a method of determining the presence, amount orconcentration of an antigen (or a fragment thereof) in a test sample isprovided. The method comprises assaying the test sample for the antigen(or a fragment thereof) by an immunoassay. The immunoassay (i) employsat least one binding protein and at least one detectable label and (ii)comprises comparing a signal generated by the detectable label as adirect or indirect indication of the presence, amount or concentrationof the antigen (or a fragment thereof) in the test sample to a signalgenerated as a direct or indirect indication of the presence, amount orconcentration of the antigen (or a fragment thereof) in a control or acalibrator. The calibrator is optionally part of a series of calibratorsin which each of the calibrators differs from the other calibrators inthe series by the concentration of the antigen (or a fragment thereof).One of the at least one binding protein (i′) comprises a polypeptidechain comprising VD1-(X1)n-VD2-C—(X2)n, in which VD1 is a first heavychain variable domain obtained from a first parent antibody (or antigenbinding portion thereof), VD2 is a second heavy chain variable domainobtained from a second parent antibody (or antigen binding portionthereof), which can be the same as or different from the first parentantibody, C is a heavy chain constant domain, (X1)n is a linker, whichis optionally present and, when present, is other than CH1, and (X2)n isan Fc region, which is optionally present, and (ii′) can bind a pair ofantigens. The method can comprise (i) contacting the test sample with atleast one capture agent, which binds to an epitope on the antigen (or afragment thereof) so as to form a capture agent/antigen (or a fragmentthereof) complex, (ii) contacting the capture agent/antigen (or afragment thereof) complex with at least one detection agent, whichcomprises a detectable label and binds to an epitope on the antigen (ora fragment thereof) that is not bound by the capture agent, to form acapture agent/antigen (or a fragment thereof)/detection agent complex,and (iii) determining the presence, amount or concentration of theantigen (or a fragment thereof) in the test sample based on the signalgenerated by the detectable label in the capture agent/antigen (or afragment thereof)/detection agent complex formed in (ii), wherein atleast one capture agent and/or at least one detection agent is the atleast one binding protein. Alternatively, the method can comprise (i)contacting the test sample with at least one capture agent, which bindsto an epitope on the antigen (or a fragment thereof) so as to form acapture agent/antigen (or a fragment thereof) complex, andsimultaneously or sequentially, in either order, contacting the testsample with detectably labeled antigen (or a fragment thereof), whichcan compete with any antigen (or a fragment thereof) in the test samplefor binding to the at least one capture agent, wherein any antigen (or afragment thereof) present in the test sample and the detectably labeledantigen compete with each other to form a capture agent/antigen (or afragment thereof) complex and a capture agent/detectably labeled antigen(or a fragment thereof) complex, respectively, and (ii) determining thepresence, amount or concentration of the antigen (or a fragment thereof)in the test sample based on the signal generated by the detectable labelin the capture agent/detectably labeled antigen (or a fragment thereof)complex formed in (ii), wherein at least one capture agent is the atleast one binding protein and wherein the signal generated by thedetectable label in the capture agent/detectably labeled antigen (or afragment thereof) complex is inversely proportional to the amount orconcentration of antigen (or a fragment thereof) in the test sample. Thetest sample can be from a patient, in which case the method can furthercomprise diagnosing, prognosticating, or assessing the efficacy oftherapeutic/prophylactic treatment of the patient. If the method furthercomprises assessing the efficacy of therapeutic/prophylactic treatmentof the patient, the method optionally further comprises modifying thetherapeutic/prophylactic treatment of the patient as needed to improveefficacy. The method can be adapted for use in an automated system or asemi-automated system.

Another method of determining the presence, amount or concentration ofan antigen (or a fragment thereof) in a test sample is provided. Themethod comprises assaying the test sample for the antigen (or a fragmentthereof) by an immunoassay. The immunoassay (i) employs at least onebinding protein and at least one detectable label and (ii) comprisescomparing a signal generated by the detectable label as a direct orindirect indication of the presence, amount or concentration of theantigen (or a fragment thereof) in the test sample to a signal generatedas a direct or indirect indication of the presence, amount orconcentration of the antigen (or a fragment thereof) in a control or acalibrator. The calibrator is optionally part of a series of calibratorsin which each of the calibrators differs from the other calibrators inthe series by the concentration of the antigen (or a fragment thereof).One of the at least one binding protein (i′) comprises a polypeptidechain comprising VD1-(X1)n-VD2-C—(X2)n, in which VD1 is a first lightchain variable domain obtained from a first parent antibody (or antigenbinding portion thereof), VD2 is a second light chain variable domainobtained from a second parent antibody (or antigen binding portionthereof), which can be the same as or different from the first parentantibody, C is a light chain constant domain, (X1)n is a linker, whichis optionally present and, when present, is other than CH1, and (X2)n isan Fc region, which is optionally present, and (ii′) can bind a pair ofantigens. The method can comprise (i) contacting the test sample with atleast one capture agent, which binds to an epitope on the antigen (or afragment thereof) so as to form a capture agent/antigen (or a fragmentthereof) complex, (ii) contacting the capture agent/antigen (or afragment thereof) complex with at least one detection agent, whichcomprises a detectable label and binds to an epitope on the antigen (ora fragment thereof) that is not bound by the capture agent, to form acapture agent/antigen (or a fragment thereof)/detection agent complex,and (iii) determining the presence, amount or concentration of theantigen (or a fragment thereof) in the test sample based on the signalgenerated by the detectable label in the capture agent/antigen (or afragment thereof)/detection agent complex formed in (ii), wherein atleast one capture agent and/or at least one detection agent is the atleast one binding protein. Alternatively, the method can comprise (i)contacting the test sample with at least one capture agent, which bindsto an epitope on the antigen (or a fragment thereof) so as to form acapture agent/antigen (or a fragment thereof) complex, andsimultaneously or sequentially, in either order, contacting the testsample with detectably labeled antigen (or a fragment thereof), whichcan compete with any antigen (or a fragment thereof) in the test samplefor binding to the at least one capture agent, wherein any antigen (or afragment thereof) present in the test sample and the detectably labeledantigen compete with each other to form a capture agent/antigen (or afragment thereof) complex and a capture agent/detectably labeled antigen(or a fragment thereof) complex, respectively, and (ii) determining thepresence, amount or concentration of the antigen (or a fragment thereof)in the test sample based on the signal generated by the detectable labelin the capture agent/detectably labeled antigen (or a fragment thereof)complex formed in (ii), wherein at least one capture agent is the atleast one binding protein and wherein the signal generated by thedetectable label in the capture agent/detectably labeled antigen (or afragment thereof) complex is inversely proportional to the amount orconcentration of antigen (or a fragment thereof) in the test sample. Ifthe test sample is from a patient, the method can further comprisediagnosing, prognosticating, or assessing the efficacy oftherapeutic/prophylactic treatment of the patient. If the method furthercomprises assessing the efficacy of therapeutic/prophylactic treatmentof the patient, the method optionally further comprises modifying thetherapeutic/prophylactic treatment of the patient as needed to improveefficacy. The method can be adapted for use in an automated system or asemi-automated system.

Yet another method of determining the presence, amount or concentrationof an antigen (or a fragment thereof) in a test sample is provided. Themethod comprises assaying the test sample for the antigen (or a fragmentthereof) by an immunoassay. The immunoassay (i) employs at least onebinding protein and at least one detectable label and (ii) comprisescomparing a signal generated by the detectable label as a direct orindirect indication of the presence, amount or concentration of theantigen (or a fragment thereof) in the test sample to a signal generatedas a direct or indirect indication of the presence, amount orconcentration of the antigen (or a fragment thereof) in a control or acalibrator. The calibrator is optionally part of a series of calibratorsin which each of the calibrators differs from the other calibrators inthe series by the concentration of the antigen (or a fragment thereof).One of the at least one binding protein (i′) comprises a firstpolypeptide chain and a second polypeptide chain, wherein the firstpolypeptide chain comprises a first VD1-(X1)n-VD2-C—(X2)n, in which VD1is a first heavy chain variable domain obtained from a first parentantibody (or antigen binding portion thereof), VD2 is a second heavychain variable domain obtained from a second parent antibody (or antigenbinding portion thereof), which can be the same as or different from thefirst parent antibody, C is a heavy chain constant domain, (X1)n is alinker, which is optionally present and, when present, is other thanCH1, and (X2)n is an Fc region, which is optionally present, and whereinthe second polypeptide chain comprises a second VD1-(X1)n-VD2-C—(X2)n,in which VD1 is a first light chain variable domain obtained from afirst parent antibody (or antigen binding portion thereof), VD2 is asecond light chain variable domain obtained from a second parentantibody (or antigen binding portion thereof), which can be the same asor different from the first parent antibody, C is a light chain constantdomain, (X1)n is a linker, which is optionally present and, whenpresent, is other than CH1, and (X2)n is an Fc region, which isoptionally present, and (ii′) can bind a pair of antigens. The methodcan comprise (i) contacting the test sample with at least one captureagent, which binds to an epitope on the antigen (or a fragment thereof)so as to form a capture agent/antigen (or a fragment thereof) complex,(ii) contacting the capture agent/antigen (or a fragment thereof)complex with at least one detection agent, which comprises a detectablelabel and binds to an epitope on the antigen (or a fragment thereof)that is not bound by the capture agent, to form a capture agent/antigen(or a fragment thereof)/detection agent complex, and (iii) determiningthe presence, amount or concentration of the antigen (or a fragmentthereof) in the test sample based on the signal generated by thedetectable label in the capture agent/antigen (or a fragmentthereof)/detection agent complex formed in (ii), wherein at least onecapture agent and/or at least one detection agent is the at least onebinding protein. Alternatively, the method can comprise (i) contactingthe test sample with at least one capture agent, which binds to anepitope on the antigen (or a fragment thereof) so as to form a captureagent/antigen (or a fragment thereof) complex, and simultaneously orsequentially, in either order, contacting the test sample withdetectably labeled antigen (or a fragment thereof), which can competewith any antigen (or a fragment thereof) in the test sample for bindingto the at least one capture agent, wherein any antigen (or a fragmentthereof) present in the test sample and the detectably labeled antigencompete with each other to form a capture agent/antigen (or a fragmentthereof) complex and a capture agent/detectably labeled antigen (or afragment thereof) complex, respectively, and (ii) determining thepresence, amount or concentration of the antigen (or a fragment thereof)in the test sample based on the signal generated by the detectable labelin the capture agent/detectably labeled antigen (or a fragment thereof)complex formed in (ii), wherein at least one capture agent is the atleast one binding protein and wherein the signal generated by thedetectable label in the capture agent/detectably labeled antigen (or afragment thereof) complex is inversely proportional to the amount orconcentration of antigen (or a fragment thereof) in the test sample. Ifthe test sample is from a patient, the method can further comprisediagnosing, prognosticating, or assessing the efficacy oftherapeutic/prophylactic treatment of the patient. If the method furthercomprises assessing the efficacy of therapeutic/prophylactic treatmentof the patient, the method optionally further comprises modifying thetherapeutic/prophylactic treatment of the patient as needed to improveefficacy. The method can be adapted for use in an automated system or asemi-automated system.

Still yet another method of determining the presence, amount orconcentration of an antigen (or a fragment thereof) in a test sample isprovided. The method comprises assaying the test sample for the antigen(or a fragment thereof) by an immunoassay. The immunoassay (i) employsat least one DVD-Ig that can bind two antigens and at least onedetectable label and (ii) comprises comparing a signal generated by thedetectable label as a direct or indirect indication of the presence,amount or concentration of the antigen (or a fragment thereof) in thetest sample to a signal generated as a direct or indirect indication ofthe presence, amount or concentration of the antigen (or a fragmentthereof) in a control or a calibrator. The calibrator is optionally partof a series of calibrators in which each of the calibrators differs fromthe other calibrators in the series by the concentration of the antigen(or a fragment thereof). One of the at least one DVD-Ig (i′) comprisesfour polypeptide chains, wherein the first and third polypeptide chainscomprise a first VD1-(X1)n-VD2-C—(X2)n, in which VD1 is a first heavychain variable domain obtained from a first parent antibody (or antigenbinding portion thereof), VD2 is a second heavy chain variable domainobtained from a second parent antibody (or antigen binding portionthereof), which can be the same as or different from the first parentantibody, C is a heavy chain constant domain, (X1)n is a linker, whichis optionally present and, when present, is other than CH1, and (X2)n isan Fc region, which is optionally present, and wherein the second andfourth polypeptide chains comprise a second VD1-(X1)n-VD2-C—(X2)n, inwhich VD1 is a first light chain variable domain obtained from a firstparent antibody (or antigen binding portion thereof), VD2 is a secondlight chain variable domain obtained from a second parent antibody (orantigen binding portion thereof), which can be the same as or differentfrom the first parent antibody, C is a light chain constant domain,(X1)n is a linker, which is optionally present and, when present, isother than CH1, and (X2)n is an Fc region, which is optionally present,and (ii′) can bind two antigens (or fragments thereof). The method cancomprise (i) contacting the test sample with at least one capture agent,which binds to an epitope on the antigen (or a fragment thereof) so asto form a capture agent/antigen (or a fragment thereof) complex, (ii)contacting the capture agent/antigen (or a fragment thereof) complexwith at least one detection agent, which comprises a detectable labeland binds to an epitope on the antigen (or a fragment thereof) that isnot bound by the capture agent, to form a capture agent/antigen (or afragment thereof)/detection agent complex, and (iii) determining thepresence, amount or concentration of the antigen (or a fragment thereof)in the test sample based on the signal generated by the detectable labelin the capture agent/antigen (or a fragment thereof)/detection agentcomplex formed in (ii), wherein at least one capture agent and/or atleast one detection agent is the at least one DVD-Ig. Alternatively, themethod can comprise (i) contacting the test sample with at least onecapture agent, which binds to an epitope on the antigen (or a fragmentthereof) so as to form a capture agent/antigen (or a fragment thereof)complex, and simultaneously or sequentially, in either order, contactingthe test sample with detectably labeled antigen (or a fragment thereof),which can compete with any antigen (or a fragment thereof) in the testsample for binding to the at least one capture agent, wherein anyantigen (or a fragment thereof) present in the test sample and thedetectably labeled antigen compete with each other to form a captureagent/antigen (or a fragment thereof) complex and a captureagent/detectably labeled antigen (or a fragment thereof) complex,respectively, and (ii) determining the presence, amount or concentrationof the antigen (or a fragment thereof) in the test sample based on thesignal generated by the detectable label in the capture agent/detectablylabeled antigen (or a fragment thereof) complex formed in (ii), whereinat least one capture agent is the at least one DVD-Ig and wherein thesignal generated by the detectable label in the capture agent/detectablylabeled antigen (or a fragment thereof) complex is inverselyproportional to the amount or concentration of antigen (or a fragmentthereof) in the test sample. If the test sample is from a patient, themethod can further comprise diagnosing, prognosticating, or assessingthe efficacy of therapeutic/prophylactic treatment of the patient. Ifthe method further comprises assessing the efficacy oftherapeutic/prophylactic treatment of the patient, the method optionallyfurther comprises modifying the therapeutic/prophylactic treatment ofthe patient as needed to improve efficacy. The method can be adapted foruse in an automated system or a semi-automated system.

With regard to the methods of assay (and kit therefor), it may bepossible to employ commercially available anti-analyte antibodies ormethods for production of anti-analyte as described in the literature.Commercial supplies of various antibodies include, but are not limitedto, Santa Cruz Biotechnology Inc. (Santa Cruz, Calif.), GenWay Biotech,Inc. (San Diego, Calif.), and R&D Systems (RDS; Minneapolis, Minn.).

Generally, a predetermined level can be employed as a benchmark againstwhich to assess results obtained upon assaying a test sample for analyteor a fragment thereof, e.g., for detecting disease or risk of disease.Generally, in making such a comparison, the predetermined level isobtained by running a particular assay a sufficient number of times andunder appropriate conditions such that a linkage or association ofanalyte presence, amount or concentration with a particular stage orendpoint of a disease, disorder or condition or with particular clinicalindicia can be made. Typically, the predetermined level is obtained withassays of reference subjects (or populations of subjects). The analytemeasured can include fragments thereof, degradation products thereof,and/or enzymatic cleavage products thereof.

In particular, with respect to a predetermined level as employed formonitoring disease progression and/or treatment, the amount orconcentration of analyte or a fragment thereof may be “unchanged,”“favorable” (or “favorably altered”), or “unfavorable” (or “unfavorablyaltered”). “Elevated” or “increased” refers to an amount or aconcentration in a test sample that is higher than a typical or normallevel or range (e.g., predetermined level), or is higher than anotherreference level or range (e.g., earlier or baseline sample). The term“lowered” or “reduced” refers to an amount or a concentration in a testsample that is lower than a typical or normal level or range (e.g.,predetermined level), or is lower than another reference level or range(e.g., earlier or baseline sample). The term “altered” refers to anamount or a concentration in a sample that is altered (increased ordecreased) over a typical or normal level or range (e.g., predeterminedlevel), or over another reference level or range (e.g., earlier orbaseline sample).

The typical or normal level or range for analyte is defined inaccordance with standard practice. Because the levels of analyte in someinstances will be very low, a so-called altered level or alteration canbe considered to have occurred when there is any net change as comparedto the typical or normal level or range, or reference level or range,that cannot be explained by experimental error or sample variation.Thus, the level measured in a particular sample will be compared withthe level or range of levels determined in similar samples from aso-called normal subject. In this context, a “normal subject” is anindividual with no detectable disease, for example, and a “normal”(sometimes termed “control”) patient or population is/are one(s) thatexhibit(s) no detectable disease, respectively, for example.Furthermore, given that analyte is not routinely found at a high levelin the majority of the human population, a “normal subject” can beconsidered an individual with no substantial detectable increased orelevated amount or concentration of analyte, and a “normal” (sometimestermed “control”) patient or population is/are one(s) that exhibit(s) nosubstantial detectable increased or elevated amount or concentration ofanalyte. An “apparently normal subject” is one in which analyte has notyet been or currently is being assessed. The level of an analyte is saidto be “elevated” when the analyte is normally undetectable (e.g., thenormal level is zero, or within a range of from about 25 to about 75percentiles of normal populations), but is detected in a test sample, aswell as when the analyte is present in the test sample at a higher thannormal level. Thus, inter alia, the disclosure provides a method ofscreening for a subject having, or at risk of having, a particulardisease, disorder, or condition. The method of assay can also involvethe assay of other markers and the like.

Accordingly, the methods described herein also can be used to determinewhether or not a subject has or is at risk of developing a givendisease, disorder or condition. Specifically, such a method can comprisethe steps of:

(a) determining the concentration or amount in a test sample from asubject of analyte (or a fragment thereof) (e.g., using the methodsdescribed herein, or methods known in the art); and

(b) comparing the concentration or amount of analyte (or a fragmentthereof) determined in step (a) with a predetermined level, wherein, ifthe concentration or amount of analyte determined in step (a) isfavorable with respect to a predetermined level, then the subject isdetermined not to have or be at risk for a given disease, disorder orcondition. However, if the concentration or amount of analyte determinedin step (a) is unfavorable with respect to the predetermined level, thenthe subject is determined to have or be at risk for a given disease,disorder or condition.

Additionally, provided herein is method of monitoring the progression ofdisease in a subject. Optimally the method comprising the steps of:

(a) determining the concentration or amount in a test sample from asubject of analyte;

(b) determining the concentration or amount in a later test sample fromthe subject of analyte; and

(c) comparing the concentration or amount of analyte as determined instep (b) with the concentration or amount of analyte determined in step(a), wherein if the concentration or amount determined in step (b) isunchanged or is unfavorable when compared to the concentration or amountof analyte determined in step (a), then the disease in the subject isdetermined to have continued, progressed or worsened. By comparison, ifthe concentration or amount of analyte as determined in step (b) isfavorable when compared to the concentration or amount of analyte asdetermined in step (a), then the disease in the subject is determined tohave discontinued, regressed or improved.

Optionally, the method further comprises comparing the concentration oramount of analyte as determined in step (b), for example, with apredetermined level. Further, optionally the method comprises treatingthe subject with one or more pharmaceutical compositions for a period oftime if the comparison shows that the concentration or amount of analyteas determined in step (b), for example, is unfavorably altered withrespect to the predetermined level.

Still further, the methods can be used to monitor treatment in a subjectreceiving treatment with one or more pharmaceutical compositions.Specifically, such methods involve providing a first test sample from asubject before the subject has been administered one or morepharmaceutical compositions. Next, the concentration or amount in afirst test sample from a subject of analyte is determined (e.g., usingthe methods described herein or as known in the art). After theconcentration or amount of analyte is determined, optionally theconcentration or amount of analyte is then compared with a predeterminedlevel. If the concentration or amount of analyte as determined in thefirst test sample is lower than the predetermined level, then thesubject is not treated with one or more pharmaceutical compositions.However, if the concentration or amount of analyte as determined in thefirst test sample is higher than the predetermined level, then thesubject is treated with one or more pharmaceutical compositions for aperiod of time. The period of time that the subject is treated with theone or more pharmaceutical compositions can be determined by one skilledin the art (for example, the period of time can be from about seven (7)days to about two years, preferably from about fourteen (14) days toabout one (1) year).

During the course of treatment with the one or more pharmaceuticalcompositions, second and subsequent test samples are then obtained fromthe subject. The number of test samples and the time in which said testsamples are obtained from the subject are not critical. For example, asecond test sample could be obtained seven (7) days after the subject isfirst administered the one or more pharmaceutical compositions, a thirdtest sample could be obtained two (2) weeks after the subject is firstadministered the one or more pharmaceutical compositions, a fourth testsample could be obtained three (3) weeks after the subject is firstadministered the one or more pharmaceutical compositions, a fifth testsample could be obtained four (4) weeks after the subject is firstadministered the one or more pharmaceutical compositions, etc.

After each second or subsequent test sample is obtained from thesubject, the concentration or amount of analyte is determined in thesecond or subsequent test sample is determined (e.g., using the methodsdescribed herein or as known in the art). The concentration or amount ofanalyte as determined in each of the second and subsequent test samplesis then compared with the concentration or amount of analyte asdetermined in the first test sample (e.g., the test sample that wasoriginally optionally compared to the predetermined level). If theconcentration or amount of analyte as determined in step (c) isfavorable when compared to the concentration or amount of analyte asdetermined in step (a), then the disease in the subject is determined tohave discontinued, regressed or improved, and the subject shouldcontinue to be administered the one or pharmaceutical compositions ofstep (b). However, if the concentration or amount determined in step (c)is unchanged or is unfavorable when compared to the concentration oramount of analyte as determined in step (a), then the disease in thesubject is determined to have continued, progressed or worsened, and thesubject should be treated with a higher concentration of the one or morepharmaceutical compositions administered to the subject in step (b) orthe subject should be treated with one or more pharmaceuticalcompositions that are different from the one or more pharmaceuticalcompositions administered to the subject in step (b). Specifically, thesubject can be treated with one or more pharmaceutical compositions thatare different from the one or more pharmaceutical compositions that thesubject had previously received to decrease or lower said subject'sanalyte level.

Generally, for assays in which repeat testing may be done (e.g.,monitoring disease progression and/or response to treatment), a secondor subsequent test sample is obtained at a period in time after thefirst test sample has been obtained from the subject. Specifically, asecond test sample from the subject can be obtained minutes, hours,days, weeks or years after the first test sample has been obtained fromthe subject. For example, the second test sample can be obtained fromthe subject at a time period of about 1 minute, about 5 minutes, about10 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about60 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours,about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours,about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours,about 24 hours, about 2 days, about 3 days, about 4 days, about 5 days,about 6 days, about 7 days, about 2 weeks, about 3 weeks, about 4 weeks,about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks,about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks,about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks,about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks,about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks,about 50 weeks, about 51 weeks, about 52 weeks, about 1.5 years, about 2years, about 2.5 years, about 3.0 years, about 3.5 years, about 4.0years, about 4.5 years, about 5.0 years, about 5.5. years, about 6.0years, about 6.5 years, about 7.0 years, about 7.5 years, about 8.0years, about 8.5 years, about 9.0 years, about 9.5 years or about 10.0years after the first test sample from the subject is obtained.

When used to monitor disease progression, the above assay can be used tomonitor the progression of disease in subjects suffering from acuteconditions. Acute conditions, also known as critical care conditions,refer to acute, life-threatening diseases or other critical medicalconditions involving, for example, the cardiovascular system orexcretory system. Typically, critical care conditions refer to thoseconditions requiring acute medical intervention in a hospital-basedsetting (including, but not limited to, the emergency room, intensivecare unit, trauma center, or other emergent care setting) oradministration by a paramedic or other field-based medical personnel.For critical care conditions, repeat monitoring is generally done withina shorter time frame, namely, minutes, hours or days (e.g., about 1minute, about 5 minutes, about 10 minutes, about 15 minutes, about 30minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours,about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours,about 22 hours, about 23 hours, about 24 hours, about 2 days, about 3days, about 4 days, about 5 days, about 6 days or about 7 days), and theinitial assay likewise is generally done within a shorter timeframe,e.g., about minutes, hours or days of the onset of the disease orcondition.

The assays also can be used to monitor the progression of disease insubjects suffering from chronic or non-acute conditions. Non-criticalcare or, non-acute conditions, refers to conditions other than acute,life-threatening disease or other critical medical conditions involving,for example, the cardiovascular system and/or excretory system.Typically, non-acute conditions include those of longer-term or chronicduration. For non-acute conditions, repeat monitoring generally is donewith a longer timeframe, e.g., hours, days, weeks, months or years(e.g., about 1 hour, about 2 hours, about 3 hours, about 4 hours, about5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours,about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours,about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23hours, about 24 hours, about 2 days, about 3 days, about 4 days, about 5days, about 6 days, about 7 days, about 2 weeks, about 3 weeks, about 4weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks,about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks,about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks,about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks,about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks,about 50 weeks, about 51 weeks, about 52 weeks, about 1.5 years, about 2years, about 2.5 years, about 3.0 years, about 3.5 years, about 4.0years, about 4.5 years, about 5.0 years, about 5.5. years, about 6.0years, about 6.5 years, about 7.0 years, about 7.5 years, about 8.0years, about 8.5 years, about 9.0 years, about 9.5 years or about 10.0years), and the initial assay likewise generally is done within a longertime frame, e.g., about hours, days, months or years of the onset of thedisease or condition.

Furthermore, the above assays can be performed using a first test sampleobtained from a subject where the first test sample is obtained from onesource, such as urine, serum or plasma. Optionally, the above assays canthen be repeated using a second test sample obtained from the subjectwhere the second test sample is obtained from another source. Forexample, if the first test sample was obtained from urine, the secondtest sample can be obtained from serum or plasma. The results obtainedfrom the assays using the first test sample and the second test samplecan be compared. The comparison can be used to assess the status of adisease or condition in the subject.

Moreover, the present disclosure also relates to methods of determiningwhether a subject predisposed to or suffering from a given disease,disorder or condition will benefit from treatment. In particular, thedisclosure relates to analyte companion diagnostic methods and products.Thus, the method of “monitoring the treatment of disease in a subject”as described herein further optimally also can encompass selecting oridentifying candidates for therapy.

Thus, in particular embodiments, the disclosure also provides a methodof determining whether a subject having, or at risk for, a givendisease, disorder or condition is a candidate for therapy. Generally,the subject is one who has experienced some symptom of a given disease,disorder or condition or who has actually been diagnosed as having, orbeing at risk for, a given disease, disorder or condition, and/or whodemonstrates an unfavorable concentration or amount of analyte or afragment thereof, as described herein.

The method optionally comprises an assay as described herein, whereanalyte is assessed before and following treatment of a subject with oneor more pharmaceutical compositions (e.g., particularly with apharmaceutical related to a mechanism of action involving analyte), withimmunosuppressive therapy, or by immunoabsorption therapy, or whereanalyte is assessed following such treatment and the concentration orthe amount of analyte is compared against a predetermined level. Anunfavorable concentration of amount of analyte observed followingtreatment confirms that the subject will not benefit from receivingfurther or continued treatment, whereas a favorable concentration oramount of analyte observed following treatment confirms that the subjectwill benefit from receiving further or continued treatment. Thisconfirmation assists with management of clinical studies, and provisionof improved patient care.

It goes without saying that, while certain embodiments herein areadvantageous when employed to assess a given disease, disorder orcondition as discussed herein, the assays and kits can be employed toassess analyte in other diseases, disorders and conditions. The methodof assay can also involve the assay of other markers and the like.

The method of assay also can be used to identify a compound thatameliorates a given disease, disorder or condition. For example, a cellthat expresses analyte can be contacted with a candidate compound. Thelevel of expression of analyte in the cell contacted with the compoundcan be compared to that in a control cell using the method of assaydescribed herein.

B. Kit

A kit for assaying a test sample for the presence, amount orconcentration of an analyte (or a fragment thereof) in a test sample isalso provided. The kit comprises at least one component for assaying thetest sample for the analyte (or a fragment thereof) and instructions forassaying the test sample for the analyte (or a fragment thereof). The atleast one component for assaying the test sample for the analyte (or afragment thereof) can include a composition comprising a binding proteinas disclosed herein and/or an anti-analyte DVD-Ig (or a fragment, avariant, or a fragment of a variant thereof), which is optionallyimmobilized on a solid phase.

The kit can comprise at least one component for assaying the test samplefor an analyte by immunoassay, e.g., chemiluminescent microparticleimmunoassay, and instructions for assaying the test sample for ananalyte by immunoassay, e.g., chemiluminescent microparticleimmunoassay. For example, the kit can comprise at least one specificbinding partner for an analyte, such as an anti-analyte,monoclonal/polyclonal antibody (or a fragment thereof that can bind tothe analyte, a variant thereof that can bind to the analyte, or afragment of a variant that can bind to the analyte) a binding protein asdisclosed herein or an anti-analyte DVD-Ig (or a fragment, a variant, ora fragment of a variant thereof), either of which can be detectablylabeled. Alternatively or additionally, the kit can comprise detectablylabeled analyte (or a fragment thereof that can bind to an anti-analyte,monoclonal/polyclonal antibody a binding protein as disclosed herein, oran anti-analyte DVD-Ig (or a fragment, a variant, or a fragment of avariant thereof)), which can compete with any analyte in a test samplefor binding to an anti-analyte, monoclonal/polyclonal antibody (or afragment thereof that can bind to the analyte, a variant thereof thatcan bind to the analyte, or a fragment of a variant that can bind to theanalyte), a binding protein as disclosed herein, or an anti-analyteDVD-Ig (or a fragment, a variant, or a fragment of a variant thereof),either of which can be immobilized on a solid support. The kit cancomprise a calibrator or control, e.g., isolated or purified analyte.The kit can comprise at least one container (e.g., tube, microtiterplates or strips, which can be already coated with a first specificbinding partner, for example) for conducting the assay, and/or a buffer,such as an assay buffer or a wash buffer, either one of which can beprovided as a concentrated solution, a substrate solution for thedetectable label (e.g., an enzymatic label), or a stop solution.Preferably, the kit comprises all components, i.e., reagents, standards,buffers, diluents, etc., which are necessary to perform the assay. Theinstructions can be in paper form or computer-readable form, such as adisk, CD, DVD, or the like.

More specifically, provided is a kit for assaying a test sample for anantigen (or a fragment thereof). The kit comprises at least onecomponent for assaying the test sample for an antigen (or a fragmentthereof) and instructions for assaying the test sample for an antigen(or a fragment thereof), wherein the at least one component includes atleast one composition comprising a binding protein, which (i′) comprisesa polypeptide chain comprising VD1-(X1)n-VD2-C—(X2)n, in which VD1 is afirst heavy chain variable domain obtained from a first parent antibody(or antigen binding portion thereof), VD2 is a second heavy chainvariable domain obtained from a second parent antibody (or antigenbinding portion thereof), which can be same as or different from thefirst parent antibody, C is a heavy chain constant domain, (X1)n is alinker, which is optionally present and, when present, is other thanCH1, and (X2)n is an Fc region, which is optionally present, and (ii′)can bind a pair of antigens, wherein the binding protein is optionallydetectably labeled.

Further provided is another kit for assaying a test sample for anantigen (or a fragment thereof). The kit comprises at least onecomponent for assaying the test sample for an antigen (or a fragmentthereof) and instructions for assaying the test sample for an antigen(or a fragment thereof), wherein the at least one component includes atleast one composition comprising a binding protein, which (i′) comprisesa polypeptide chain comprising VD1-(X1)n-VD2-C—(X2)n, in which VD1 is afirst light chain variable domain obtained from a first parent antibody(or antigen binding portion thereof), VD2 is a second light chainvariable domain obtained from a second parent antibody (or antigenbinding portion thereof), which can be the same as or different from thefirst parent antibody, C is a light chain constant domain, (X1)n is alinker, which is optionally present and, when present, is other thanCH1, and (X2)n is an Fc region, which is optionally present, and (ii′)can bind a pair of antigens, wherein the binding protein is optionallydetectably labeled.

Still further provided is another kit for assaying a test sample for anantigen (or a fragment thereof). The kit comprises at least onecomponent for assaying the test sample for an antigen (or a fragmentthereof) and instructions for assaying the test sample for an antigen(or a fragment thereof), wherein the at least one component includes atleast one composition comprising a binding protein, which (i′) comprisesa first polypeptide chain and a second polypeptide chain, wherein thefirst polypeptide chain comprises a first VD1-(X1)n-VD2-C—(X2)n, inwhich VD1 is a first heavy chain variable domain obtained from a firstparent antibody (or antigen binding portion thereof), VD2 is a secondheavy chain variable domain obtained from a second parent antibody (orantigen binding portion thereof), which can be the same as or differentfrom the first parent antibody, C is a heavy chain constant domain,(X1)n is a linker, which is optionally present and, when present, isother than CH1, and (X2)n is an Fc region, which is optionally present,and wherein the second polypeptide chain comprises a secondVD1-(X1)n-VD2-C—(X2)n, in which VD1 is a first light chain variabledomain obtained from a first parent antibody (or antigen binding portionthereof), VD2 is a second light chain variable domain obtained from asecond parent antibody (or antigen binding portion thereof), which canbe the same as or different from the first parent antibody, C is a lightchain constant domain, (X1)n is a linker, which is optionally presentand, when present, is other than CH1, and (X2)n is an Fc region, whichis optionally present, and (ii′) can bind a pair of antigens, whereinthe binding protein is optionally detectably labeled.

Even still further provided is another kit for assaying a test samplefor an antigen (or a fragment thereof). The kit comprises at least onecomponent for assaying the test sample for an antigen (or a fragmentthereof) and instructions for assaying the test sample for an antigen(or a fragment thereof), wherein the at least one component includes atleast one composition comprising a DVD-Ig, which (i′) comprises fourpolypeptide chains, wherein the first and third polypeptide chainscomprise a first VD1-(X1)n-VD2-C—(X2)n, in which VD1 is a first heavychain variable domain obtained from a first parent antibody (or antigenbinding portion thereof), VD2 is a second heavy chain variable domainobtained from a second parent antibody (or antigen binding portionthereof), which can be the same as or different from the first parentantibody, C is a heavy chain constant domain, (X1)n is a linker, whichis optionally present and, when present, is other than CH1, and (X2)n isan Fc region, which is optionally present, and wherein the second andfourth polypeptide chains comprise a second VD1-(X1)n-VD2-C—(X2)n, inwhich VD1 is a first light chain variable domain obtained from a firstparent antibody (or antigen binding portion thereof), VD2 is a secondlight chain variable domain obtained from a second parent antibody (orantigen binding portion thereof), which can be the same as or differentfrom the first parent antibody, C is a light chain constant domain,(X1)n is a linker, which is optionally present and, when present, isother than CH1, and (X2)n is an Fc region, which is optionally present,and (ii′) can bind two antigens (or fragments thereof), wherein theDVD-Ig is optionally detectably labeled.

Any antibodies, such as an anti-analyte antibody, any binding proteinsas disclosed herein, any anti-analyte DVD-Igs, or tracers canincorporate a detectable label as described herein, such as afluorophore, a radioactive moiety, an enzyme, a biotin/avidin label, achromophore, a chemiluminescent label, or the like, or the kit caninclude reagents for carrying out detectable labeling. The antibodies,calibrators and/or controls can be provided in separate containers orpre-dispensed into an appropriate assay format, for example, intomicrotiter plates.

Optionally, the kit includes quality control components (for example,sensitivity panels, calibrators, and positive controls). Preparation ofquality control reagents is well-known in the art and is described oninsert sheets for a variety of immunodiagnostic products. Sensitivitypanel members optionally are used to establish assay performancecharacteristics, and further optionally are useful indicators of theintegrity of the immunoassay kit reagents, and the standardization ofassays.

The kit can also optionally include other reagents required to conduct adiagnostic assay or facilitate quality control evaluations, such asbuffers, salts, enzymes, enzyme co-factors, enzyme substrates, detectionreagents, and the like. Other components, such as buffers and solutionsfor the isolation and/or treatment of a test sample (e.g., pretreatmentreagents), also can be included in the kit. The kit can additionallyinclude one or more other controls. One or more of the components of thekit can be lyophilized, in which case the kit can further comprisereagents suitable for the reconstitution of the lyophilized components.

The various components of the kit optionally are provided in suitablecontainers as necessary, e.g., a microtiter plate. The kit can furtherinclude containers for holding or storing a sample (e.g., a container orcartridge for a urine sample). Where appropriate, the kit optionallyalso can contain reaction vessels, mixing vessels, and other componentsthat facilitate the preparation of reagents or the test sample. The kitcan also include one or more instruments for assisting with obtaining atest sample, such as a syringe, pipette, forceps, measured spoon, or thelike.

If the detectable label is at least one acridinium compound, the kit cancomprise at least one acridinium-9-carboxamide, at least oneacridinium-9-carboxylate aryl ester, or any combination thereof. If thedetectable label is at least one acridinium compound, the kit also cancomprise a source of hydrogen peroxide, such as a buffer, a solution,and/or at least one basic solution. If desired, the kit can contain asolid phase, such as a magnetic particle, bead, test tube, microtiterplate, cuvette, membrane, scaffolding molecule, film, filter paper, discor chip.

C. Adaptation of Kit and Method

The kit (or components thereof), as well as the method of determiningthe presence, amount or concentration of an analyte in a test sample byan assay, such as an immunoassay as described herein, can be adapted foruse in a variety of automated and semi-automated systems (includingthose wherein the solid phase comprises a microparticle), as described,e.g., in U.S. Pat. Nos. 5,089,424 and 5,006,309, and as commerciallymarketed, e.g., by Abbott Laboratories (Abbott Park, Ill.) asARCHITECT®.

Some of the differences between an automated or semi-automated system ascompared to a non-automated system (e.g., ELISA) include the substrateto which the first specific binding partner (e.g., an anti-analyte,monoclonal/polyclonal antibody (or a fragment thereof, a variantthereof, or a fragment of a variant thereof), a binding protein asdisclosed herein, or an anti-analyte DVD-Ig (or a fragment thereof, avariant thereof, or a fragment of a variant thereof) is attached; eitherway, sandwich formation and analyte reactivity can be impacted), and thelength and timing of the capture, detection and/or any optional washsteps. Whereas a non-automated format, such as an ELISA, may require arelatively longer incubation time with sample and capture reagent (e.g.,about 2 hours), an automated or semi-automated format (e.g., ARCHITECT®,Abbott Laboratories) may have a relatively shorter incubation time(e.g., approximately 18 minutes for ARCHITECT®). Similarly, whereas anon-automated format, such as an ELISA, may incubate a detectionantibody, such as the conjugate reagent, for a relatively longerincubation time (e.g., about 2 hours), an automated or semi-automatedformat (e.g., ARCHITECT®) may have a relatively shorter incubation time(e.g., approximately 4 minutes for the ARCHITECT®).

Other platforms available from Abbott Laboratories include, but are notlimited to, AxSYM®, IMx® (see, e.g., U.S. Pat. No. 5,294,404), PRISM®,EIA (bead), and Quantum™ II, as well as other platforms. Additionally,the assays, kits and kit components can be employed in other formats,for example, on electrochemical or other hand-held or point-of-careassay systems. The present disclosure is, for example, applicable to thecommercial Abbott Point of Care (i-STAT®, Abbott Laboratories)electrochemical immunoassay system that performs sandwich immunoassays.Immunosensors and their methods of manufacture and operation insingle-use test devices are described, for example in, U.S. Pat. Nos.5,063,081; 7,419,821; and 7,682,833; and U.S. Patent Publication Nos.20040018577 and 20060160164.

In particular, with regard to the adaptation of an analyte assay to theI-STAT® system, the following configuration is preferred. Amicrofabricated silicon chip is manufactured with a pair of goldamperometric working electrodes and a silver-silver chloride referenceelectrode. On one of the working electrodes, polystyrene beads (0.2 mmdiameter) with immobilized anti-analyte, monoclonal/polyclonal antibody(or a fragment thereof, a variant thereof, or a fragment of a variantthereof), a binding protein as disclosed herein, or anti-analyte DVD-Ig(or a fragment thereof, a variant thereof, or a fragment of a variantthereof), are adhered to a polymer coating of patterned polyvinylalcohol over the electrode. This chip is assembled into an I-STAT®cartridge with a fluidics format suitable for immunoassay. On a portionof the wall of the sample-holding chamber of the cartridge there is alayer comprising a specific binding partner for an analyte, such as ananti-analyte, monoclonal/polyclonal antibody (or a fragment thereof, avariant thereof, or a fragment of a variant thereof that can bind theanalyte), a binding protein as disclosed herein, or an anti-analyteDVD-Ig (or a fragment thereof, a variant thereof, or a fragment of avariant thereof that can bind the analyte), either of which can bedetectably labeled. Within the fluid pouch of the cartridge is anaqueous reagent that includes p-aminophenol phosphate.

In operation, a sample suspected of containing an analyte is added tothe holding chamber of the test cartridge, and the cartridge is insertedinto the I-STAT®reader. After the specific binding partner for ananalyte has dissolved into the sample, a pump element within thecartridge forces the sample into a conduit containing the chip. Here itis oscillated to promote formation of the sandwich. In the penultimatestep of the assay, fluid is forced out of the pouch and into the conduitto wash the sample off the chip and into a waste chamber. In the finalstep of the assay, the alkaline phosphatase label reacts withp-aminophenol phosphate to cleave the phosphate group and permit theliberated p-aminophenol to be electrochemically oxidized at the workingelectrode. Based on the measured current, the reader is able tocalculate the amount of analyte in the sample by means of an embeddedalgorithm and factory-determined calibration curve.

It further goes without saying that the methods and kits as describedherein necessarily encompass other reagents and methods for carrying outthe immunoassay. For instance, encompassed are various buffers such asare known in the art and/or which can be readily prepared or optimizedto be employed, e.g., for washing, as a conjugate diluent, microparticlediluent, and/or as a calibrator diluent. An exemplary conjugate diluentis ARCHITECT® conjugate diluent employed in certain kits (AbbottLaboratories, Abbott Park, Ill.) and containing2-(N-morpholino)ethanesulfonic acid (MES), a salt, a protein blocker, anantimicrobial agent, and a detergent. An exemplary calibrator diluent isARCHITECT® human calibrator diluent employed in certain kits (AbbottLaboratories, Abbott Park, Ill.), which comprises a buffer containingMES, other salt, a protein blocker, and an antimicrobial agent.Additionally, as described in U.S. Patent Application No. 61/142,048filed Dec. 31, 2008, improved signal generation may be obtained, e.g.,in an I-Stat cartridge format, using a nucleic acid sequence linked tothe signal antibody as a signal amplifier.

EXEMPLIFICATION

It will be readily apparent to those skilled in the art that othersuitable modifications and adaptations of the methods described hereinare obvious and may be made using suitable equivalents without departingfrom the scope or the embodiments disclosed herein. Having now describedseveral embodiments in detail, the same will be more clearly understoodby reference to the following examples, which are included for purposesof illustration only and are not intended to be limiting of the claims.

EXAMPLES Example 1 Design, Construction, and Analysis of a DVD-IgExample 1.1 Assays Used to Identify and Characterize Parent Antibodiesand DVD-Ig

The following assays are used throughout the Examples to identify andcharacterize parent antibodies and DVD-Ig, unless otherwise stated.

Example 1.1.1 Assays Used to Determine Binding and Affinity of ParentAntibodies and DVD-Ig for their Target Antigen(s) Example 1.1.1A DirectBind ELISA

Enzyme Linked Immunosorbent Assays to screen for antibodies that bind adesired target antigen are performed as follows. High bind ELISA plates(Corning Costar #3369, Acton, Mass.) are coated with 1004/well of 10μg/ml of desired target antigen (R&D Systems, Minneapolis, Minn.) ordesired target antigen extra-cellular domain/FC fusion protein (R&DSystems, Minneapolis, Minn.) or monoclonal mouse anti-polyHistidineantibody (R&D Systems #MAB050, Minneapolis, Minn.) in phosphate bufferedsaline (10×PBS, Abbott Bioresearch Center, Media Prep#MPS-073,Worcester, Mass.) overnight at 4° C. Plates are washed four times withPBS containing 0.02% Tween 20. Plates are blocked by the addition of 300μL/well blocking solution (non-fat dry milk powder, various retailsuppliers, diluted to 2% in PBS) for ½ hour at room temperature. Platesare washed four times after blocking with PBS containing 0.02% Tween 20.

Alternatively, one hundred microliters per well of 10 μg/ml of Histidine(His) tagged desired target antigen (R&D Systems, Minneapolis, Minn.)are added to ELISA plates coated with monoclonal mouseanti-polyHistidine antibody as described above and incubated for 1 hourat room temperature. Wells are washed four times with PBS containing0.02% Tween 20.

One hundred microliters of antibody or DVD-Ig preparations diluted inblocking solution as described above is added to the desired targetantigen plate or desired target antigen/FC fusion plate or theanti-polyHistidine antibody/His tagged desired target antigen plateprepared as described above and incubated for 1 hour at roomtemperature. Wells are washed four times with PBS containing 0.02% Tween20.

One hundred microliters of 10 ng/mL goat anti-human IgG-FC specific HRPconjugated antibody (Southern Biotech #2040-05, Birmingham, Ala.) isadded to each well of the desired target antigen plate oranti-polyHistidine antibody/Histidine tagged desired target antigenplate. Alternatively, one hundred microliters of 10 ng/mL goatanti-human IgG-kappa light chain specific HRP conjugated antibody(Southern Biotech #2060-05 Birmingham, Ala.) is added to each well ofthe desired target antigen/FC fusion plate and incubated for 1 hour atroom temperature. Plates are washed 4 times with PBS containing 0.02%Tween 20.

One hundred microliters of enhanced TMB solution (Neogen Corp. #308177,K Blue, Lexington, Ky.) is added to each well and incubated for 10minutes at room temperature. The reaction is stopped by the addition of50 μL 1N sulphuric acid. Plates are read spectrophotometrically at awavelength of 450 nm.

Example 1.1.1.B Capture ELISA

ELISA plates (Nunc, MaxiSorp, Rochester, N.Y.) are incubated overnightat 4° C. with anti-human Fc antibody (5 μg/ml in PBS, JacksonImmunoresearch, West Grove, Pa.). Plates are washed three times inwashing buffer (PBS containing 0.05% Tween 20), and blocked for 1 hourat 25° C. in blocking buffer (PBS containing 1% BSA). Wells are washedthree times, and serial dilutions of each antibody or DVD-Ig in PBScontaining 0.1% BSA are added to the wells and incubated at 25° C. for 1hour. The wells are washed three times, and biotinylated antigen (2 nM)is added to the plates and incubated for 1 hour at 25° C. The wells arethree times, and then incubated for 1 hour at 25° C. withstreptavidin-HRP (KPL #474-3000, Gaithersburg, Md.). The wells arewashed three times, and 100 μl of ULTRA-TMB ELISA (Pierce, Rockford,Ill.) are added per well. Following color development the reaction isstopped with 1N HCL and absorbance at 450 nM is measured.

Example 1.1.1.C IgG-Fc Capture ELISA

96-well Nunc-Immuno plates are coated with 2 μg/mL goat-anti-human IgGFc specific antibody (Jackson Immunoresearch #109-055-098, West Grove,Pa., 50 μL/well) in PBS (Gibco #10010-023 from Invitrogen, Grand Island,N.Y.), and incubated overnight at 4° C. Plates are washed three timeswith washing buffer (PBS, 0.05% Tween 20) and subsequently blocked with100 uL/well of blocking buffer (PBS, 2% BSA) for one hour at roomtemperature. Plates are washed three times and incubated with 50 μL/wellof a 1 μg/mL solution of the appropriate antibody or DVD-Ig for one hourat room temperature. After the one hour incubation, the plates arewashed three times and incubated with 50 μL/well of his-tagged,recombinant antigen protein (R&D Systems, Minneapolis, Minn., 1000 nM to0 nM final dose range) for one hour at room temperature. Plates arewashed three times, and 50 μL/well of a rabbit-anti-His tag-HRP antibody(Abcam ab1187, Cambridge, Mass., diluted at 1:10,000 in 2% BSA/PBSsolution) is added and plates are incubated at room temperature for onehour. After the final wash, 50 μl/well of TMB substrate (Pierce #34028,Rockford, Ill.) is added, and the reaction is terminated after fiveminutes using 50 μl/well of 2N H2SO4. The absorbance is read at 450 nm(Spectra Max Plus plate reader, Molecular Devices, Sunnyvale, Calif.).EC50s are calculated in GraphPad Prism 4.03.

Example 1.1.1.D Affinity Determination Using BIACORE Technology

TABLE 3 Reagent Used in Biacore Analyses Assay Antigen VendorDesignation Vendor Catalog # IL-1β Recombinant Human IL-1β R&D 201-LBsystems IL-17 Recombinant Human IL-17 R&D 317-IL systems

BIACORE Methods:

The BIACORE assay (Biacore, Inc, Piscataway, N.J.) determines theaffinity of antibodies or DVD-Ig with kinetic measurements of on-rateand off-rate constants. Binding of antibodies or DVD-Ig to a targetantigen (for example, a purified recombinant target antigen) wasdetermined by surface plasmon resonance-based measurements with aBiacore® 1000 or 3000 instrument (Biacore® AB, Uppsala, Sweden) usingrunning HBS-EP (10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM EDTA, and 0.005%surfactant P20) at 25° C. All chemicals were obtained from Biacore® AB(Uppsala, Sweden) or otherwise from a different source as described inthe text. For example, approximately 5000 RU of goat anti-mouse IgG,(Fcγ), fragment specific polyclonal antibody (Pierce Biotechnology Inc,Rockford, Ill.) diluted in 10 mM sodium acetate (pH 4.5) was directlyimmobilized across a CM5 research grade biosensor chip using a standardamine coupling kit according to manufacturer's instructions andprocedures at 25 μg/ml. Unreacted moieties on the biosensor surface wereblocked with ethanolamine. Modified carboxymethyl dextran surface inflowcell 2 and 4 was used as a reaction surface. Unmodifiedcarboxymethyl dextran without goat anti-mouse IgG in flow cell 1 and 3was used as the reference surface. For kinetic analysis, rate equationsderived from the 1:1 Langmuir binding model were fitted simultaneouslyto association and dissociation phases of all eight injections (usingglobal fit analysis) with the use of Biaevaluation 4.0.1 software.Purified antibodies or DVD-Ig were diluted in HEPES-buffered saline forcapture across goat anti-mouse IgG specific reaction surfaces.Antibodies or DVD-Ig to be captured as a ligand (25 μg/ml) were injectedover reaction matrices at a flow rate of 5 μl/min. The association anddissociation rate constants, k_(on) (M⁻¹s⁻¹) and k_(off) (s⁻¹) weredetermined under a continuous flow rate of 25 μl/min. Rate constantswere derived by making kinetic binding measurements at different antigenconcentrations ranging from 10-200 nM. The equilibrium dissociationconstant (M) of the reaction between antibodies or DVD-Igs and thetarget antigen was then calculated from the kinetic rate constants bythe following formula: K_(D)=k_(off)/k_(on). Binding was recorded as afunction of time and kinetic rate constants are calculated. In thisassay, on-rates as fast as 10⁶M⁻¹s⁻¹ and off-rates as slow as 10⁻⁶s⁻¹can be measured.

TABLE 4 BIACORE Analysis of Parental Antibodies and DVD ConstructsN-Terminal C-Terminal Parent Variable Variable Antibody or Domain Domaink_(on) k_(off) K_(D) DVD-Ig ID (VD) (VD) (M−1s−1) (s−1) (M) AB268 IL-1B(seq. 1) 9.80E+05 4.20E−05 4.30E−11 AB273 IL-17 (seq. 1) 7.30E+041.00E−05 1.40E−10 DVD1262 IL-1B (seq. 1) 1.40E+06 4.80E−05 3.30E−11DVD1262 IL-17 (seq. 1) 8.50E+03 1.00E−04 1.20E−08 DVD1263 IL-17 (seq. 1)1.30E+05 7.80E−06 6.10E−11 DVD1263 IL-1B (seq. 1) 8.90E+05 1.50E−041.70E−10 AB269 IL-1B (seq. 2) 6.50E+05 4.60E−05 7.10E−11 AB273 IL-17(seq. 1) 7.30E+04 1.00E−05 1.40E−10 DVD1264 IL-1B (seq. 2) 9.40E+052.20E−05 2.40E−11 DVD1264 IL-17 (seq. 1) 3.70E+04 1.10E−05 3.00E−10DVD1265 IL-17 (seq. 1) 1.20E+05 1.10E−05 9.60E−11 DVD1265 IL-1B (seq. 2)3.40E+06 3.00E−04 8.80E−11 AB270 IL-1B (seq. 1) 6.50E+06 5.80E−048.90E−11 AB273 IL-17 (seq. 1) 7.30E+04 1.00E−05 1.40E−10 DVD1266 IL-1B(seq. 1) 6.00E+06 4.60E−04 7.70E−11 DVD1266 IL-17 (seq. 1) — — — DVD1267IL-17 (seq. 1) 1.50E+05 1.00E−05 6.60E−11 DVD1267 IL-1B (seq. 1)3.70E+05 4.10E−04 1.10E−09 AB271 IL-1B (seq. 4) 5.10E+06 5.50E−041.10E−10 AB273 IL-17 (seq. 1) 7.30E+04 1.00E−05 1.40E−10 DVD1268 IL-1B(seq. 4) 8.50E+06 5.70E−04 6.70E−11 DVD1268 IL-17 (seq. 1) 5.10E+04  <1E−06 <2.0E−11 DVD1269 IL-17 (seq. 1) 1.60E+05 5.00E−06 3.20E−11DVD1269 IL-1B (seq. 4) 4.00E+05 4.30E−04 1.10E−09 AB272 IL-1B (seq. 5)3.90E+06 5.30E−04 1.40E−10 AB273 IL-17 (seq. 1) 7.30E+04 1.00E−051.40E−10 DVD1270 IL-1B (seq. 5) 5.30E+06 5.40E−04 1.00E−10 DVD1270 IL-17(seq. 1) — — — DVD1271 IL-17 (seq. 1) 1.10E+05 1.20E−05 1.10E−10 DVD1271IL-1B (seq. 5) 3.20E+05 7.10E−04 2.20E−09 AB268 IL-1B (seq. 1) 9.80E+054.20E−05 4.30E−11 AB274 IL-17 (seq. 2) 5.50E+04 2.00E−05 3.60E−10DVD1272 IL-1B (seq. 1) 1.50E+06 4.50E−05 3.00E−11 DVD1272 IL-17 (seq. 2)— — — DVD1273 IL-17 (seq. 2) 1.10E+05 2.20E−05 2.00E−10 DVD1273 IL-1B(seq. 1) 6.90E+05 1.90E−04 2.70E−10 AB269 IL-1B (seq. 1) 6.50E+054.60E−05 7.10E−11 AB274 IL-17 (seq. 2) 5.50E+04 2.00E−05 3.60E−10DVD1274 IL-1B (seq. 2) 1.30E+06 4.00E−05 3.10E−11 DVD1274 IL-17 (seq. 2)— — — DVD1275 IL-17 (seq. 2) 1.40E+05 2.10E−05 1.50E−10 DVD1275 IL-1B(seq. 2) 7.60E+05 1.10E−04 1.50E−10 AB270 IL-1B (seq. 3) 6.50E+065.80E−04 8.90E−11 AB274 IL-17 (seq. 2) 5.50E+04 2.00E−05 3.60E−10DVD1276 IL-1B (seq. 3) 5.60E+06 4.50E−04 8.20E−11 DVD1276 IL-17 (seq. 2)— — — DVD1277 IL-17 (seq. 2) 1.30E+05 2.20E−05 1.60E−10 DVD1277 IL-1B(seq. 3) 2.30E+05 4.90E−04 2.10E−09 AB271 IL-1B (seq. 4) 5.10E+065.50E−04 1.10E−10 AB274 IL-17 (seq. 2) 5.50E+04 2.00E−05 3.60E−10DVD1278 IL-1B (seq. 4) 6.90E+06 4.70E−04 6.90E−11 DVD1278 IL-17 (seq. 2)— — — DVD1279 IL-17 (seq. 2) 1.90E+05 2.30E−05 1.20E−10 DVD1279 IL-1B(seq. 4) 3.20E+05 4.50E−04 1.40E−09 AB272 IL-1B (seq. 5) 3.90E+065.30E−04 1.40E−10 AB274 IL-17 (seq. 2) 5.50E+04 2.00E−05 3.60E−10DVD1280 IL-1B (seq. 5) 7.90E+06 6.30E−04 8.00E−11 DVD1280 IL-17 (seq. 2)— — — DVD1281 IL-17 (seq. 2) 2.00E+05 2.00E−05 1.00E−10 DVD1281 IL-1B(seq. 5) 2.80E+05 5.80E−04 2.00E−09 AB268 IL-1B (seq. 1) 9.80E+054.20E−05 4.30E−11 AB275 IL-17 (seq. 3) 2.80E+03 2.40E−05 8.80E−09DVD1282 IL-1B (seq. 1) 1.70E+06 7.20E−05 4.30E−11 DVD1282 IL-17 (seq. 3)— — — DVD1283 IL-17 (seq. 3) 1.30E+05 5.80E−05 4.60E−10 DVD1283 IL-1B(seq. 1) 2.50E+06 2.60E−04 1.00E−10 AB269 IL-1B (seq. 1) 6.50E+054.60E−05 7.10E−11 AB275 IL-17 (seq. 3) 2.80E+03 2.40E−05 8.80E−09DVD1284 IL-1B (seq. 2) 1.10E+06 1.90E−05 1.70E−11 DVD1284 IL-17 (seq. 3)— — — DVD1285 IL-17 (seq. 3) 1.50E+05 5.80E−05 3.90E−10 DVD1285 IL-1B(seq. 2) 8.20E+05 2.00E−04 2.40E−10 AB270 IL-1B (seq. 3) 6.50E+065.80E−04 8.90E−11 AB275 IL-17 (seq. 3) 2.80E+03 2.40E−05 8.80E−09DVD1286 IL-1B (seq. 3) 7.20E+06 5.00E−04 7.00E−11 DVD1286 IL-17 (seq. 3)— — — DVD1287 IL-17 (seq. 3) 1.60E+05 4.70E−05 3.00E−10 DVD1287 IL-1B(seq. 3) 3.10E+05 3.70E−04 1.20E−09 AB271 IL-1B (seq. 4) 5.10E+065.50E−04 1.10E−10 AB275 IL-17 (seq. 3) 2.80E+03 2.40E−05 8.80E−09DVD1288 IL-1B (seq. 4) 6.10E+06 4.60E−04 7.60E−11 DVD1288 IL-17 (seq. 3)— — — DVD1289 IL-17 (seq. 3) 1.40E+05 5.60E−05 4.00E−10 DVD1289 IL-1B(seq. 4) 3.70E+05 4.80E−04 1.30E−09 AB272 IL-1B (seq. 5) 3.90E+065.30E−04 1.40E−10 AB275 IL-17 (seq. 3) 2.80E+03 2.40E−05 8.80E−09DVD1290 IL-1B (seq. 5) 7.50E+06 6.50E−04 8.60E−11 DVD1290 IL-17 (seq. 3)— — — DVD1291 IL-17 (seq. 3) 1.20E+04 6.00E−07 4.80E−11 DVD1291 IL-1B(seq. 5) 2.10E+05 5.80E−04 2.80E−09 AB268 IL-1B (seq. 1) 1.20E+064.10E−05 3.40E−11 AB273 IL-17 (seq. 1) 2.80E+06 1.20E−05 4.10E−12DVD1590 IL-17 (seq. 1) 3.80E+06 7.00E−06 1.80E−12 DVD1590 IL-1B (seq. 1)2.50E+05 4.60E−05 1.90E−10 AB269 IL-1B (seq. 2) 7.80E+05 4.10E−055.30E−11 AB273 IL-17 (seq. 1) 2.80E+06 1.20E−05 4.10E−12 DVD1591 IL-1B(seq. 2) 9.60E+05 3.10E−05 3.20E−11 DVD1591 IL-17 (seq. 1) 3.10E+05  <1e−06 1.00E−12 DVD1592 IL-17 (seq. 1) 3.20E+06 2.00E−05 6.40E−12DVD1592 IL-1B (seq. 2) 6.90E+05 4.90E−06 7.20E−12 AB270 IL-1B (seq. 1)6.70E+06 5.50E−04 8.20E−11 AB273 IL-17 (seq. 1) 2.80E+06 1.20E−054.10E−12 DVD1593 IL-1B (seq. 1) 7.40E+06 4.70E−04 6.40E−11 DVD1593 IL-17(seq. 1) 3.40E+05 9.20E−06 2.70E−11 DVD1594 IL-17 (seq. 1) 4.20E+062.30E−05 5.60E−12 DVD1594 IL-1B (seq. 1) 7.10E+05 4.30E−04 6.00E−10AB271 IL-1B (seq. 4) 6.00E+06 5.70E−04 9.60E−11 AB273 IL-17 (seq. 1)2.80E+06 1.20E−05 4.10E−12 DVD1595 IL-1B (seq. 4) 7.40E+06 4.10E−045.50E−11 DVD1595 IL-17 (seq. 1) 1.40E+06 6.00E−06 4.30E−12 DVD1596 IL-17(seq. 1) 4.10E+06 1.30E−05 3.30E−12 DVD1596 IL-1B (seq. 4) 7.00E+053.60E−04 5.10E−10 AB272 IL-1B (seq. 5) 5.30E+06 6.60E−04 1.20E−10 AB273IL-17 (seq. 1) 2.80E+06 1.20E−05 4.10E−12 DVD1597 IL-1B (seq. 5)8.40E+06 6.30E−04 7.50E−11 DVD1597 IL-17 (seq. 1) 3.50E+05 4.10E−061.20E−11 DVD1598 IL-17 (seq. 1) 3.50E+06 1.80E−05 5.10E−12 DVD1598 IL-1B(seq. 5) 6.30E+05 7.40E−04 1.20E−09 AB268 IL-1B (seq. 1) 1.20E+064.10E−05 3.40E−11 AB274 IL-17 (seq. 2) 2.70E+06 2.10E−05 7.60E−12DVD1599 IL-1B (seq. 1) 2.00E+06 4.10E−05 2.10E−11 DVD1599 IL-17 (seq. 2)1.20E+05   <1e−06 7.40E−14 DVD1600 IL-17 (seq. 2) 2.80E+06   <1e−063.80E−12 DVD1600 IL-1B (seq. 1) 1.70E+05 9.40E−05 5.50E−10 AB269 IL-1B(seq. 1) 7.80E+05 4.10E−05 5.30E−11 AB274 IL-17 (seq. 2) 2.70E+062.10E−05 7.60E−12 DVD1601 IL-1B (seq. 2) 1.20E+06 2.00E−05 1.60E−11DVD1601 IL-17 (seq. 2) 1.20E+05   <1e−06 1.20E−13 DVD1602 IL-17 (seq. 2)2.70E+06 1.40E−05 5.10E−12 DVD1602 IL-1B (seq. 2) 1.30E+05 2.30E−051.80E−10 AB270 IL-1B (seq. 3) 6.70E+06 5.50E−04 8.20E−11 AB274 IL-17(seq. 2) 2.70E+06 2.10E−05 7.60E−12 DVD1603 IL-1B (seq. 3) 6.90E+064.80E−04 6.90E−11 DVD1603 IL-17 (seq. 2) 3.10E+05   <1e−06 2.70E−13DVD1604 IL-17 (seq. 2) 3.80E+06 9.70E−06 2.60E−12 DVD1604 IL-1B (seq. 3)1.30E+06 3.70E−04 2.90E−10 AB271 IL-1B (seq. 4) 6.00E+06 5.70E−049.60E−11 AB274 IL-17 (seq. 2) 2.70E+06 2.10E−05 7.60E−12 DVD1605 IL-1B(seq. 4) 8.60E+06 5.00E−04 5.90E−11 DVD1605 IL-17 (seq. 2) 4.10E+05  <1e−06 6.80E−14 DVD1606 IL-17 (seq. 2) 4.40E+06 3.00E−06 6.70E−13DVD1606 IL-1B (seq. 4) 1.40E+06 4.40E−04 3.20E−10 AB272 IL-1B (seq. 5)5.30E+06 6.60E−04 1.20E−10 AB274 IL-17 (seq. 2) 2.70E+06 2.10E−057.60E−12 DVD1608 IL-17 (seq. 2) 4.80E+06 1.20E−05 2.60E−12 DVD1608 IL-1B(seq. 5) 1.50E+06 5.60E−04 3.70E−10 AB268 IL-1B (seq. 1) 1.20E+064.10E−05 3.40E−11 AB275 IL-17 (seq. 3) 4.20E+06 8.10E−05 1.90E−11DVD1609 IL-1B (seq. 1) 2.10E+06 4.60E−05 2.20E−11 DVD1609 IL-17 (seq. 3)8.90E+04   <1e−06 8.40E−13 DVD1610 IL-17 (seq. 3) 3.50E+06 5.70E−051.70E−11 DVD1610 IL-1B (seq. 1) 2.90E+05 7.30E−05 2.50E−10 AB269 IL-1B(seq. 1) 7.80E+05 4.10E−05 5.30E−11 AB275 IL-17 (seq. 3) 4.20E+068.10E−05 1.90E−11 DVD1611 IL-1B (seq. 2) 3.10E+05 1.30E−04 4.20E−10DVD1611 IL-17 (seq. 3) 4.10E+06 6.00E−05 1.50E−11 DVD1612 IL-17 (seq. 3)3.20E+06 5.10E−05 1.60E−11 DVD1612 IL-1B (seq. 2) 1.60E+05 2.50E−051.50E−10 AB270 IL-1B (seq. 3) 6.70E+06 5.50E−04 8.20E−11 AB275 IL-17(seq. 3) 4.20E+06 8.10E−05 1.90E−11 DVD1613 IL-1B (seq. 3) 7.80E+064.60E−04 5.90E−11 DVD1613 IL-17 (seq. 3) 3.60E+05   <1e−06 1.50E−13DVD1614 IL-17 (seq. 3) 3.50E+06 4.80E−05 1.40E−11 DVD1614 IL-1B (seq. 3)1.70E+06 3.00E−04 1.80E−10 AB271 IL-1B (seq. 4) 6.00E+06 5.70E−049.60E−11 AB275 IL-17 (seq. 3) 4.20E+06 8.10E−05 1.90E−11 DVD1615 IL-1B(seq. 4) 9.90E+06 5.50E−04 5.50E−11 DVD1615 IL-17 (seq. 3) 3.90E+056.00E−05 1.50E−10 DVD1616 IL-17 (seq. 3) 3.30E+06 4.90E−05 1.50E−11DVD1616 IL-1B (seq. 4) 1.60E+06 3.60E−04 2.20E−10 AB272 IL-1B (seq. 5)5.30E+06 6.60E−04 1.20E−10 AB275 IL-17 (seq. 3) 4.20E+06 8.10E−051.90E−11 DVD1618 IL-17 (seq. 3) 3.20E+06 6.30E−05 1.90E−11 DVD1618 IL-1B(seq. 5) 2.40E+06 6.20E−04 2.60E−10 AB268 IL-1B (seq. 1) 8.90E+052.10E−04 2.40E−10 AB273 IL-17 (seq. 1) 2.70E+06 1.30E−05 4.60E−12DVD1620 IL-17 (seq. 1) 3.80E+06 7.10E−06 1.90E−12 DVD1620 IL-1B (seq. 1)3.30E+05 9.40E−05 2.90E−10 AB269 IL-1B (seq. 2) 5.40E+05 1.10E−042.00E−10 AB273 IL-17 (seq. 1) 2.70E+06 1.30E−05 4.60E−12 DVD1622 IL-17(seq. 1) 3.70E+06 1.70E−06 4.60E−13 DVD1622 IL-1B (seq. 2) 1.50E+062.30E−04 1.60E−10 AB270 IL-1B (seq. 1) 6.60E+06 5.30E−04 8.00E−11 AB273IL-17 (seq. 1) 2.70E+06 1.30E−05 4.60E−12 DVD1623 IL-1B (seq. 1)6.60E+06 4.90E−04 7.50E−11 DVD1623 IL-17 (seq. 1) 2.30E+05   <1e−063.40E−14 DVD1624 IL-17 (seq. 1) 3.70E+06 4.10E−05 1.10E−11 DVD1624 IL-1B(seq. 1) 5.50E+05 4.60E−04 8.40E−10 AB271 IL-1B (seq. 4) 4.60E+065.10E−04 1.10E−10 AB273 IL-17 (seq. 1) 2.70E+06 1.30E−05 4.60E−12DVD1625 IL-1B (seq. 4) 8.60E+06 5.40E−04 6.30E−11 DVD1625 IL-17 (seq. 1)6.30E+05 3.20E−06 5.10E−12 DVD1626 IL-17 (seq. 1) 4.80E+06 1.60E−053.40E−12 DVD1626 IL-1B (seq. 4) 4.70E+05 4.70E−04 1.00E−09 AB272 IL-1B(seq. 5) 4.00E+06 5.60E−04 1.40E−10 AB273 IL-17 (seq. 1) 2.70E+061.30E−05 4.60E−12 DVD1627 IL-1B (seq. 5) 6.80E+06 5.90E−04 8.60E−11DVD1627 IL-17 (seq. 1) 2.00E+05 1.70E−06 8.40E−12 DVD1628 IL-17 (seq. 1)4.00E+06 2.20E−05 5.50E−12 DVD1628 IL-1B (seq. 5) 4.90E+05 4.90E−041.00E−09 AB268 IL-1B (seq. 1) 8.90E+05 2.10E−04 2.40E−10 AB274 IL-17(seq. 2) 2.70E+06 1.80E−05 6.80E−12 DVD1629 IL-1B (seq. 1) 1.90E+067.30E−05 3.90E−11 DVD1629 IL-17 (seq. 2) 1.40E+06   <1e−06 1.10E−13DVD1630 IL-17 (seq. 2) 3.40E+06 1.60E−05 4.50E−12 DVD1630 IL-1B (seq. 1)1.70E+05 7.60E−05 4.50E−10 AB269 IL-1B (seq. 1) 5.40E+05 1.10E−042.00E−10 AB274 IL-17 (seq. 2) 2.70E+06 1.80E−05 6.80E−12 DVD1631 IL-1B(seq. 2) 1.30E+06 2.20E−05 1.70E−11 DVD1631 IL-17 (seq. 2) 2.50E+05  <1e−06 1.40E−13 DVD1632 IL-17 (seq. 2) 3.20E+06 1.60E−05 5.00E−12DVD1632 IL-1B (seq. 2) 1.10E+05 4.70E−05 4.20E−10 AB270 IL-1B (seq. 3)6.60E+06 5.30E−04 8.00E−11 AB274 IL-17 (seq. 2) 2.70E+06 1.80E−056.80E−12 DVD1633 IL-1B (seq. 3) 9.00E+06 5.70E−04 6.30E−11 DVD1633 IL-17(seq. 2) 1.60E+05   <1e−06 3.70E−14 DVD1634 IL-17 (seq. 2) 3.70E+061.90E−05 5.20E−12 DVD1634 IL-1B (seq. 3) 8.70E+05 5.50E−04 6.30E−10AB271 IL-1B (seq. 4) 4.60E+06 5.10E−04 1.10E−10 AB274 IL-17 (seq. 2)2.70E+06 1.80E−05 6.80E−12 DVD1635 IL-1B (seq. 4) 7.60E+06 4.50E−046.00E−11 DVD1635 IL-17 (seq. 2) 3.60E+05 4.90E−05 1.40E−10 DVD1636 IL-17(seq. 2) 4.10E+06 1.90E−05 4.60E−12 DVD1636 IL-1B (seq. 4) 1.00E+066.30E−04 6.00E−10 AB272 IL-1B (seq. 5) 4.00E+06 5.60E−04 1.40E−10 AB274IL-17 (seq. 2) 2.70E+06 1.80E−05 6.80E−12 DVD1637 IL-1B (seq. 5)7.90E+06 5.90E−04 7.50E−11 DVD1637 IL-17 (seq. 2) 2.30E+05   <1e−062.50E−12 DVD1638 IL-17 (seq. 2) 3.90E+06 2.70E−05 6.80E−12 DVD1638 IL-1B(seq. 5) 1.30E+06 8.50E−04 6.30E−10 AB268 IL-1B (seq. 1) 8.90E+052.10E−04 2.40E−10 AB275 IL-17 (seq. 3) 4.70E+06 8.50E−05 1.80E−11DVD1639 IL-1B (seq. 1) 1.20E+06 5.60E−05 4.50E−11 DVD1639 IL-17 (seq. 3)3.70E+05 1.00E−06 2.80E−12 DVD1640 IL-17 (seq. 3) 3.80E+06 6.50E−051.70E−11 DVD1640 IL-1B (seq. 1) 1.30E+05 1.20E−05 9.00E−11 AB269 IL-1B(seq. 1) 5.40E+05 1.10E−04 2.00E−10 AB275 IL-17 (seq. 3) 4.70E+068.50E−05 1.80E−11 DVD1641 IL-1B (seq. 2) 1.00E+06 1.90E−05 1.80E−11DVD1641 IL-17 (seq. 3) 8.40E+04 2.20E−05 2.70E−10 DVD1642 IL-17 (seq. 3)3.90E+06 4.10E−05 1.10E−11 DVD1642 IL-1B (seq. 2) 9.60E+05   <1e−06  <1E−12 AB270 IL-1B (seq. 3) 6.60E+06 5.30E−04 8.00E−11 AB275 IL-17(seq. 3) 4.70E+06 8.50E−05 1.80E−11 DVD1643 IL-1B (seq. 3) 6.50E+064.80E−04 7.40E−11 DVD1643 IL-17 (seq. 3) 1.80E+05 9.40E−05 5.20E−10AB271 IL-1B (seq. 4) 4.60E+06 5.10E−04 1.10E−10 AB275 IL-17 (seq. 3)4.70E+06 8.50E−05 1.80E−11 DVD1645 IL-1B (seq. 4) 7.00E+06 5.60E−048.00E−11 DVD1645 IL-17 (seq. 3) 1.20E+05 8.10E−05 6.50E−10 DVD1646 IL-17(seq. 3) 3.90E+06 4.70E−05 1.20E−11 DVD1646 IL-1B (seq. 4) 1.00E+066.30E−04 6.20E−10 AB272 IL-1B (seq. 5) 4.00E+06 5.60E−04 1.40E−10 AB275IL-17 (seq. 3) 4.70E+06 8.50E−05 1.80E−11 DVD1647 IL-1B (seq. 5)7.10E+06 5.90E−04 8.30E−11 DVD1647 IL-17 (seq. 3) 1.70E+05 9.00E−055.30E−10 DVD1648 IL-17 (seq. 3) 3.10E+06 6.20E−05 2.00E−11 DVD1648 IL-1B(seq. 5) 1.30E+06 7.50E−04 5.60E−10

Binding of all DVD-Ig constructs characterized by Biacore technology wasmaintained and comparable to that of parent antibodies. All N-terminalvariable domains bound with a similar high affinity as the parentantibody.

Example 1.1.2 Assays Used to Determine the Functional Activity of ParentAntibodies and DVD-Ig Example 1.1.2.A Cytokine Bioassay

The ability of an anti-cytokine or an anti-growth factor parent antibodyor DVD-Ig containing anti-cytokine or anti-growth factor sequences toinhibit or neutralize a target cytokine or growth factor bioactivity isanalyzed by determining the inhibitory potential of the antibody orDVD-Ig. For example, the ability of an anti-IL-4 antibody to inhibitIL-4 mediated IgE production may be used. For example, human naive Bcells are isolated from peripheral blood, respectively, buffy coats byFicoll-paque density centrifugation, followed by magnetic separationwith MACS beads (Miltenyi Biotec, Bergisch Gladbach, Germany) specificfor human slgD FITC labeled goat F(ab)2 antibodies followed by anti-FITCMACS beads. Magnetically sorted naive B cells are adjusted to 3×10⁵cells per ml in XV15 and plated out in 100 μl per well of 96-well platesin a 6×6 array in the center of the plate, surrounded by PBS filledwells during the 10 days of culture at 37° C. in the presence of 5% CO₂.One plate each is prepared per antibody to be tested, consisting of 3wells each of un-induced and induced controls and quintuplicate repeatsof antibody titrations starting at 7 μg/ml and running in 3-folddilution down to 29 ng/ml final concentrations added in 50 μl four timesconcentrated pre-dilution. To induce IgE production, rhIL-4 at 20 ng/mlplus anti-CD40 monoclonal antibody (Novartis, Basel, Switzerland) at 0.5μg/ml final concentrations in 50 μl each are added to each well, and IgEconcentrations are determined at the end of the culture period by astandard sandwich ELISA method.

Example 1.1.2.B Cytokine Release Assay

The ability of a parent antibody or DVD-Ig to cause cytokine release isanalyzed. Peripheral blood is withdrawn from three healthy donors byvenipuncture into heparized vacutainer tubes. Whole blood is diluted 1:5with RPMI-1640 medium and placed in 24-well tissue culture plates at 0.5mL per well. The anti-cytokine antibodies (e.g., anti-IL-4) are dilutedinto RPMI-1640 and placed in the plates at 0.5 mL/well to give finalconcentrations of 200, 100, 50, 10, and 1 μg/mL. The final dilution ofwhole blood in the culture plates is 1:10. LPS and PHA are added toseparate wells at 2 μg/mL and 5 μg/mL final concentration as a positivecontrol for cytokine release. Polyclonal human IgG is used as negativecontrol antibody. The experiment is performed in duplicate. Plates areincubated at 37° C. at 5% CO₂. Twenty-four hours later the contents ofthe wells are transferred into test tubes and spun for 5 minutes at 1200rpm. Cell-free supernatants are collected and frozen for cytokineassays. Cells left over on the plates and in the tubes are lysed with0.5 mL of lysis solution, and placed at −20° C. and thawed. 0.5 mL ofmedium is added (to bring the volume to the same level as the cell-freesupernatant samples) and the cell preparations are collected and frozenfor cytokine assays. Cell-free supernatants and cell lysates are assayedfor cytokine levels by ELISA, for example, for levels of IL-8, IL-6,IL-1β, IL-1 RA, or TNF-α.

Example 1.1.2.C Cytokine Cross-Reactivity Study

The ability of an anti-cytokine parent antibody or DVD-Ig directed to acytokine(s) of interest to cross react with other cytokines is analyzed.Parent antibodies or DVD-Ig are immobilized on a Biacore biosensormatrix. An anti-human Fc mAb is covalently linked via free amine groupsto the dextran matrix by first activating carboxyl groups on the matrixwith 100 mM N-hydroxysuccinimide (NHS) and 400 mMN-Ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC).Approximately 50 μL of each antibody or DVD-Ig preparation at aconcentration of 25 μg/mL, diluted in sodium acetate, pH 4.5, isinjected across the activated biosensor and free amines on the proteinare bound directly to the activated carboxyl groups. Typically, 5000Resonance Units (RU's) are immobilized. Unreacted matrix EDC-esters aredeactivated by an injection of 1 M ethanolamine. A second flow cell isprepared as a reference standard by immobilizing human IgG1/K using thestandard amine coupling kit. SPR measurements are performed using the CMbiosensor chip. All antigens to be analyzed on the biosensor surface arediluted in HBS-EP running buffer containing 0.01% P20.

To examine the cytokine binding specificity, excess cytokine of interest(100 nM, e.g., soluble recombinant human) is injected across theanti-cytokine parent antibody or DVD-Ig immobilized biosensor surface (5minute contact time). Before injection of the cytokine of interest andimmediately afterward, HBS-EP buffer alone flows through each flow cell.The net difference in the signals between the baseline and the pointcorresponding to approximately 30 seconds after completion of cytokineinjection are taken to represent the final binding value. Again, theresponse is measured in Resonance Units. Biosensor matrices areregenerated using 10 mM HCl before injection of the next sample where abinding event is observed, otherwise running buffer is injected over thematrices. Human cytokines (e.g., IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5,IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17,IL-18, IL-19, IL-20, IL-22, IL-23, IL-27, TNF-α, TNF-β, and IFN-γ, forexample) are also simultaneously injected over the immobilized mouseIgG1/K reference surface to record any nonspecific binding background.By preparing a reference and reaction surface, Biacore can automaticallysubtract the reference surface data from the reaction surface data inorder to eliminate the majority of the refractive index change andinjection noise. Thus, it is possible to ascertain the true bindingresponse attributed to an anti-cytokine antibody or DVD-Ig bindingreaction.

When a cytokine of interest is injected across immobilized anti-cytokineantibody, significant binding is observed. 10 mM HCl regenerationcompletely removes all non-covalently associated proteins. Examinationof the sensorgram shows that immobilized anti-cytokine antibody orDVD-Ig binding to soluble cytokine is strong and robust. Afterconfirming the expected result with the cytokine of interest, the panelof remaining recombinant human cytokines is tested, for each antibody orDVD-Ig separately. The amount of anti-cytokine antibody or DVD-Ig boundor unbound cytokine for each injection cycle is recorded. The resultsfrom three independent experiments are used to determine the specificityprofile of each antibody or DVD-Ig. Antibodies or DVD-Ig with theexpected binding to the cytokine of interest and no binding to any othercytokine are selected.

Example 1.1.2.D Tissue Cross Reactivity

Tissue cross reactivity studies are done in three stages, with the firststage including cryosections of 32 tissues, second stage including up to38 tissues, and the 3^(rd) stage including additional tissues from 3unrelated adults as described below. Studies are done typically at twodose levels.

Stage 1:

Cryosections (about 5 μm) of human tissues (32 tissues (typically:Adrenal Gland, Gastrointestinal Tract, Prostate, Bladder, Heart,Skeletal Muscle, Blood Cells, Kidney, Skin, Bone Marrow, Liver, SpinalCord, Breast, Lung, Spleen, Cerebellum, Lymph Node, Testes, CerebralCortex, Ovary, Thymus, Colon, Pancreas, Thyroid, Endothelium,Parathyroid, Ureter, Eye, Pituitary, Uterus, Fallopian Tube andPlacenta) from one human donor obtained at autopsy or biopsy) are fixedand dried on object glass. The peroxidase staining of tissue sections isperformed, using the avidin-biotin system.

Stage 2:

Cryosections (about 5 μm) of human tissues 38 tissues (includingadrenal, blood, blood vessel, bone marrow, cerebellum, cerebrum, cervix,esophagus, eye, heart, kidney, large intestine, liver, lung, lymph node,breast mammary gland, ovary, oviduct, pancreas, parathyroid, peripheralnerve, pituitary, placenta, prostate, salivary gland, skin, smallintestine, spinal cord, spleen, stomach, striated muscle, testis,thymus, thyroid, tonsil, ureter, urinary bladder, and uterus) from 3unrelated adults obtained at autopsy or biopsy) are fixed and dried onobject glass. The peroxidase staining of tissue sections is performed,using the avidin-biotin system.

Stage 3:

Cryosections (about 5 μm) of cynomolgus monkey tissues (38 tissues(including adrenal, blood, blood vessel, bone marrow, cerebellum,cerebrum, cervix, esophagus, eye, heart, kidney, large intestine, liver,lung, lymph node, breast mammary gland, ovary, oviduct, pancreas,parathyroid, peripheral nerve, pituitary, placenta, prostate, salivarygland, skin, small intestine, spinal cord, spleen, stomach, striatedmuscle, testis, thymus, thyroid, tonsil, ureter, urinary bladder, anduterus) from 3 unrelated adult monkeys obtained at autopsy or biopsy)are fixed and dried on object glass. The peroxidase staining of tissuesections is performed, using the avidin-biotin system.

The antibody or DVD-Ig is incubated with the secondary biotinylatedanti-human IgG and developed into immune complex. The immune complex atthe final concentrations of 2 and 10 μg/mL of antibody or DVD-Ig isadded onto tissue sections on object glass and then the tissue sectionsare reacted for 30 minutes with a avidin-biotin-peroxidase kit.Subsequently, DAB (3,3′-diaminobenzidine), a substrate for theperoxidase reaction, is applied for 4 minutes for tissue staining.Antigen-Sepharose beads are used as positive control tissue sections.Target antigen and human serum blocking studies serve as additionalcontrols. The immune complex at the final concentrations of 2 and 10μg/mL of antibody or DVD-Ig is pre-incubated with target antigen (finalconcentration of 100 μg/ml) or human serum (final concentration 10%) for30 minutes, and then added onto the tissue sections on object glass andthen the tissue sections are reacted for 30 minutes with aavidin-biotin-peroxidase kit. Subsequently, DAB (3,3′-diaminobenzidine),a substrate for the peroxidase reaction, is applied for 4 minutes fortissue staining.

Any specific staining is judged to be either an expected (e.g.,consistent with antigen expression) or unexpected reactivity based uponknown expression of the target antigen in question. Any staining judgedspecific is scored for intensity and frequency. The tissue stainingbetween stage 2 (human tissue) and stage 3 (cynomolgus monkey tissue) iseither judged to be similar or different.

Example 1.1.2.E Tumoricidal Effect of A Parent or DVD-Ig Antibody InVitro

Parent antibodies or DVD-Ig that bind to target antigens on tumor cellsmay be analyzed for tumoricidal activity. Briefly, parent antibodies orDVD-Ig are diluted in D-PBS-BSA (Dulbecco's phosphate buffered salinewith 0.1% BSA) and added to human tumor cells at final concentrations of0.01 μg/mL to 100 μg/mL in 200 μL. The plates are incubated at 37° C. ina humidified, 5% CO₂ atmosphere for 3 days. The number of live cells ineach well is quantified using MTS reagents according to themanufacturer's instructions (Promega, Madison, Wis.) to determine thepercent of tumor growth inhibition. Wells without antibody treatment areused as controls of 0% inhibition whereas wells without cells areconsidered to show 100% inhibition.

For assessment of apoptosis, caspase-3 activation is determined by thefollowing protocol: antibody-treated cells in 96 well plates are lysedin 120 μl of 1× lysis buffer (1.67 mM Hepes, pH 7.4, 7 mM KCl, 0.83 mMMgCl₂, 0.11 mM EDTA, 0.11 mM EGTA, 0.57% CHAPS, 1 mM DTT, 1× proteaseinhibitor cocktail tablet; EDTA-free; Roche Pharmaceuticals, Nutley,N.J.) at room temperature with shaking for 20 minutes. After cell lysis,80 μl of a caspase-3 reaction buffer (48 mM Hepes, pH 7.5, 252 mMsucrose, 0.1% CHAPS, 4 mM DTT, and 20 μM Ac-DEVD-AMC substrate; BiomolResearch Labs, Inc., Plymouth Meeting, Pa.) is added and the plates areincubated for 2 hours at 37° C. The plates are read on a 1420 VICTORMultilabel Counter (Perkin Elmer Life Sciences, Downers Grove, Ill.)using the following settings: excitation=360/40, emission=460/40. Anincrease of fluorescence units from antibody-treated cells relative tothe isotype antibody control-treated cells is seen, which is indicativeof apoptosis.

Example 1.1.2.F Inhibition of Receptor Activation by Antibody or DVD-IgConstructs In Vitro

Parent antibodies or DVD-Ig that bind to cell receptors or their ligandsmay be tested for inhibition of receptor activation. Parent antibodiesor DVD-Ig diluted in D-PBS-BSA (Dulbecco's phosphate buffered salinewith 0.1% BSA) are added to human carcinoma cells at finalconcentrations of 0.01 μg/mL to 100 μg/mL (180 μL). The plates areincubated at 37° C. in a humidified, 5% CO₂ atmosphere for 1 hour.Growth factors (e.g., EGF) at a final concentration of 1-100 ng/mL (20μL) are added to the cells for 5-15 minutes to stimulate receptor (e.g.,EGFR) autophosphorylation. Wells without antibody treatment are used ascontrols of 0% inhibition whereas wells without growth factorstimulation are considered to show 100% inhibition. Cell lysates aremade by incubation with cell extraction buffer (10 mM Tris, pH 7.4, 100mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM sodium orthovanadate, 1%Triton X-100, 10% Glycerol, 0.1% SDS, and protease inhibitor cocktail).For example, phospho-EGFR in these cell lysates is determined using thep-EGFR ELISA kit from R&D Systems (#DYC1095, Minneapolis, Minn.)according to the manufacturer's instructions.

Example 1.1.2.G Efficacy of an Anti-Tumor Cell Antigen Antibody orDVD-Ig by Itself or in Combination with Chemotherapy on the Growth ofHuman Carcinoma Xenografts (Subcutaneous Flank, Orthotopic, orSpontaneous Metastases)

Human cancer cells are grown in vitro to 99% viability, 85% confluencein tissue culture flasks. SCID mice (Charles Rivers Labs) at 19-25 gramsare ear tagged and shaved. Mice are then inoculated subcutaneously intothe right flank with 0.2 ml of 2×10⁶ human tumor cells (1:1 matrigel) onstudy day 0. Administration (IP, Q3D/week) of vehicle (PBS), antibody orDVD-Ig, and/or chemotherapy is initiated after mice are size matchedinto separate ages of mice with mean tumor volumes of approximately 150to 200 mm³. The tumors are measured by a pair of calipers twice a weekstarting on approximately day 10 post inoculation and the tumor volumescalculated according to the formula V=L×W2/2 (V: volume, mm3; L: length,mm; W: width, mm). Reduction in tumor volume is seen in animals treatedwith the antibody or DVD-Ig alone or in combination with chemotherapyrelative to tumors in animals that received only vehicle or an isotypecontrol mAb.

Example 1.1.2.H Binding of Monoclonal Antibodies to the Surface of HumanTumor Cell Lines as Assessed by Flow Cytometry

Stable cell lines overexpressing a cell-surface antigen of interest orhuman tumor cell lines are harvested from tissue culture flasks andresuspended in phosphate buffered saline (PBS) containing 5% fetalbovine serum (PBS/FBS). Prior to staining, human tumor cells areincubated on ice with (100 μl) human IgG at 5 μg/ml in PBS/FCS. 1−5×10⁵cells are incubated with antibody or DVD-Ig (2 μg/mL) in PBS/FBS for30-60 minutes on ice. Cells are washed twice and 100 μl of F(ab′)2 goatanti human IgG, Fcγ-phycoerythrin (1:200 dilution in PBS) (JacksonImmunoResearch, West Grove, Pa., Cat. #109-116-170) is added. After 30minutes incubation on ice, cells are washed twice and resuspended inPBS/FBS. Fluorescence is measured using a Becton Dickinson FACSCalibur(Becton Dickinson, San Jose, Calif.).

Example 1.1.2.1 Binding of Monoclonal Antibodies to the Surface ofActivated NK Cells as Assessed by Flow Cytometry

Activated NK cells were plated at 0.5×10⁵ cells/well on a 96 well roundbottom plate. Antibodies and DVD-Igs were diluted to 10 μg/ml in FACSbuffer (1% FBS in PBS pH 7.4). The supernatant was removed from thecells and 30 μL of diluted antibodies or DVD-Igs was added to the wells.Cells were incubated with the antibodies at 4° C. for 30 minutes.Following incubation, the cells were washed three times with 150 μL FACSbuffer. The cells were resuspended in 50 μL FACS buffer with 1:125diluted R-PE conjugated anti-human IgG F(Ab′)₂ (Jackson ImmunoResearch,West Grove, Pa., Cat. #109-116-170), anti-CD56-APC (eBioscience, SanDiego, Calif., Cat. #17-0569), or anti-CD3-488 (eBioscience, San Diego,Calif., Cat. #53-0037) and incubated at 4° C. for 30 minutes. Cells werewashed three times, and finally resuspended in 100 pt FACS buffer.Samples were run on a FACSCalibur machine (Becton Dickinson, San Jose,Calif.). FACSCalibur settings for FL1, FL2, and FL4 were adjusted suchthat a non-antibody-treated control sample had a GMFI of 3. Experimentalsamples were run subsequently. FlowJo software (Treestar, Inc, Ashland,Oreg.) was used to analyze the data and determine R-PE GMFI on CD56positive, live cells as designated by a forward and side scatter gate.

Example 1.1.2.J Binding of Monoclonal Antibodies to the Surface of HumanTumor Cell Lines as Assessed by Flow Cytometry Using FACSCanto

Stable cell lines overexpressing a cell-surface antigen of interest orhuman tumor cell lines were harvested from tissue culture flasks andresuspended in phosphate buffered saline (PBS) containing 5% fetalbovine serum (PBS/FBS). Prior to staining, human tumor cells wereincubated on ice with (100 μl) human IgG at 5 μg/ml in PBS/FCS. 1−5×10⁵cells were incubated with antibody or DVD-Ig (2 μg/mL) in PBS/FBS for30-60 minutes on ice. Cells were washed twice and 100 μl of F(ab′)2 goatanti human IgG, Fcγ-Dylight488 (1:200 dilution in PBS) (JacksonImmunoResearch, West Grove, Pa., Cat. #109-486-098) was added. After 30minutes incubation on ice, cells were washed twice and resuspended inPBS/FBS. Fluorescence was measured using a Becton Dickinson FACSCantomachine (Becton Dickinson, San Jose, Calif.).

Example 1.1.2.K IL-1α/β Bioassay and Neutralization Assay

MRC5 cells were plated at 1.5−2×10⁴ cells per well in a 100 μL volumeand incubated overnight at 37° C., 5% CO₂. A 20 μg/mL working stock ofantibody (4× concentrated) was prepared in complete MEM medium. An eightpoint serial dilution was performed (5 μg/mL-0.0003 μg/mL) in completeMEM in Marsh dilution plates. Sixty-five μL/well of each antibodydilution was added in quadruplicate to a 96 well v-bottom (Costar#3894)plate and 65 μL of a 200 pg/mL solution of IL-1α or IL-1β or 65 μL of amixed solution containing a 50 pg/mL solution of both IL-1α and IL-1βwas also added. Control wells received 65 μL 200 pg/ml of IL-1α or IL-1βor 50 pg/mL mixed IL-1α/β (4× concentrated) plus 65 μL MEM media andmedia control wells received 130 μL of media. Following a 1 hourincubation, 100 μL of the Ab/Ag mixture was added to the MRC5 cells. Allwell volumes were equal to 200 μL. All plate reagents were then 1×concentrated. After a 16-20 hour incubation, the well contents (150 μL)were transferred into a 96-well round bottom plate (Costar#3799) andplaced in a −20° C. freezer. The supernatants were tested for hIL-8levels by using a human IL-8 ELISA kit (R&D Systems, Minneapolis, Minn.)or hIL-8 chemiluminescence kit (MDS). Neutralization potency wasdetermined by calculating percent inhibition relative to the IL-1α,IL-β, or the IL-1α/β alone control value. Results are shown in Table 5.

TABLE 5 IL-1βNeutralization Assay With IL-1β Parent Antibody and DVD-IgConstructs N-Terminal C-Terminal N-Terminal VD Parent Variable VariableIL-1β C-Terminal VD IL-1β Antibody or Domain Domain NeutralizationNeutralization DVD-Ig ID (VD) (VD) Assay EC50 nM Assay EC50 nM AB268IL-1B (seq. 1) 0.0098 AB269 IL-1B (seq. 2) 0.0019 AB270 IL-1B (seq. 3)0.2448 AB271 IL-1B (seq. 4) 0.3080 AB272 IL-1B (seq. 5) 0.2982 DVD1262IL-1B (seq. 1) IL-17 (seq. 1) 0.0164 — DVD1263 IL-17 (seq. 1) IL-1B(seq. 1) — 19.9650 DVD1264 IL-1B (seq. 2) IL-17 (seq. 1) 0.1205 —DVD1265 IL-17 (seq. 1) IL-1B (seq. 2) — 0.9248 DVD1266 IL-1B (seq. 3)IL-17 (seq. 1) 0.3274 — DVD1267 IL-17 (seq. 1) IL-1B (seq. 3) — >40DVD1268 IL-1B (seq. 4) IL-17 (seq. 1) 0.1459 — DVD1269 IL-17 (seq. 1)IL-1B (seq. 4) — >45 DVD1270 IL-1B (seq. 5) IL-17 (seq. 1) 0.2652 —DVD1271 IL-17 (seq. 1) IL-1B (seq. 5) — >30 DVD1272 IL-1B (seq. 1) IL-17(seq. 2) 0.0139 — DVD1273 IL-17 (seq. 2) IL-1B (seq. 1) — 18.4350DVD1274 IL-1B (seq. 2) IL-17 (seq. 2) 0.0068 — DVD1275 IL-17 (seq. 2)IL-1B (seq. 2) — 1.9160 DVD1276 IL-1B (seq. 3) IL-17 (seq. 2) 0.1683 —DVD1277 IL-17 (seq. 2) IL-1B (seq. 3) — >20 DVD1278 IL-1B (seq. 4) IL-17(seq. 2) 0.1454 — DVD1279 IL-17 (seq. 2) IL-1B (seq. 4) — >200 DVD1280IL-1B (seq. 5) IL-17 (seq. 2) 0.1488 — DVD1281 IL-17 (seq. 2) IL-1B(seq. 5) — >150 DVD1282 IL-1B (seq. 1) IL-17 (seq. 3) 0.0091 — DVD1283IL-17 (seq. 3) IL-1B (seq. 1) — 7.6090 DVD1284 IL-1B (seq. 2) IL-17(seq. 3) 0.0065 — DVD1285 IL-17 (seq. 3) IL-1B (seq. 2) — 1.2680 DVD1286IL-1B (seq. 3) IL-17 (seq. 3) 0.1647 — DVD1287 IL-17 (seq. 3) IL-1B(seq. 3) — >50 DVD1288 IL-1B (seq. 4) IL-17 (seq. 3) 0.2124 — DVD1289IL-17 (seq. 3) IL-1B (seq. 4) — 18.8000 DVD1290 IL-1B (seq. 5) IL-17(seq. 3) 0.2523 — DVD1291 IL-17 (seq. 3) IL-1B (seq. 5) — >100 DVD1589IL-1B (seq. 1) IL-17 (seq. 1) 0.0068 — DVD1590 IL-17 (seq. 1) IL-1B(seq. 1) — 1.5970 DVD1591 IL-1B (seq. 2) IL-17 (seq. 1) 0.0023 — DVD1592IL-17 (seq. 1) IL-1B (seq. 2) — 0.1093 DVD1593 IL-1B (seq. 3) IL-17(seq. 1) 0.1840 — DVD1594 IL-17 (seq. 1) IL-1B (seq. 3) — 9.0950 DVD1595IL-1B (seq. 4) IL-17 (seq. 1) 0.2041 — DVD1596 IL-17 (seq. 1) IL-1B(seq. 4) — 3.4390 DVD1597 IL-1B (seq. 5) IL-17 (seq. 1) 0.3259 — DVD1598IL-17 (seq. 1) IL-1B (seq. 5) — 11.9100 DVD1599 IL-1B (seq. 1) IL-17(seq. 2) 0.0048 — DVD1600 IL-17 (seq. 2) IL-1B (seq. 1) — 0.7940 DVD1601IL-1B (seq. 2) IL-17 (seq. 2) 0.0036 — DVD1602 IL-17 (seq. 2) IL-1B(seq. 2) — 0.1330 DVD1603 IL-1B (seq. 3) IL-17 (seq. 2) 0.0803 — DVD1604IL-17 (seq. 2) IL-1B (seq. 3) — 2.0270 DVD1605 IL-1B (seq. 4) IL-17(seq. 2) 0.2417 — DVD1606 IL-17 (seq. 2) IL-1B (seq. 4) — 1.6260 DVD1607IL-1B (seq. 5) IL-17 (seq. 2) 0.4554 — DVD1608 IL-17 (seq. 2) IL-1B(seq. 5) — 4.2460 DVD1609 IL-1B (seq. 1) IL-17 (seq. 3) 0.0038 — DVD1610IL-17 (seq. 3) IL-1B (seq. 1) — 1.0000 DVD1611 IL-1B (seq. 2) IL-17(seq. 3) 0.0041 — DVD1612 IL-17 (seq. 3) IL-1B (seq. 2) — 0.1532 DVD1613IL-1B (seq. 3) IL-17 (seq. 3) 0.2464 — DVD1614 IL-17 (seq. 3) IL-1B(seq. 3) — 0.8015 DVD1615 IL-1B (seq. 4) IL-17 (seq. 3) 0.1907 — DVD1616IL-17 (seq. 3) IL-1B (seq. 4) — 1.1220 DVD1617 IL-1B (seq. 5) IL-17(seq. 3) 0.2471 — DVD1618 IL-17 (seq. 3) IL-1B (seq. 5) — 2.7500 DVD1619IL-1B (seq. 1) IL-17 (seq. 1) 0.1385 — DVD1620 IL-17 (seq. 1) IL-1B(seq. 1) — 17.43 DVD1621 IL-1B (seq. 2) IL-17 (seq. 1)  0.01139 —DVD1622 IL-17 (seq. 1) IL-1B (seq. 2) — 3.915 DVD1623 IL-1B (seq. 3)IL-17 (seq. 1) 0.1595 — DVD1624 IL-17 (seq. 1) IL-1B (seq. 3) — >20DVD1625 IL-1B (seq. 4) IL-17 (seq. 1) 0.5217 — DVD1626 IL-17 (seq. 1)IL-1B (seq. 4) — 17.44 DVD1627 IL-1B (seq. 5) IL-17 (seq. 1) 0.6208 —DVD1628 IL-17 (seq. 1) IL-1B (seq. 5) — 5.85 DVD1629 IL-1B (seq. 1)IL-17 (seq. 2)  0.01264 — DVD1630 IL-17 (seq. 2) IL-1B (seq. 1) — 9.383DVD1631 IL-1B (seq. 2) IL-17 (seq. 2)  0.00417 — DVD1632 IL-17 (seq. 2)IL-1B (seq. 2) — 0.438 DVD1633 IL-1B (seq. 3) IL-17 (seq. 2) 0.3712 —DVD1634 IL-17 (seq. 2) IL-1B (seq. 3) — >12 DVD1635 IL-1B (seq. 4) IL-17(seq. 2) 0.2402 — DVD1636 IL-17 (seq. 2) IL-1B (seq. 4) — 27.12 DVD1637IL-1B (seq. 5) IL-17 (seq. 2) 0.5522 — DVD1638 IL-17 (seq. 2) IL-1B(seq. 5) — >20 DVD1639 IL-1B (seq. 1) IL-17 (seq. 3)  0.01131 — DVD1640IL-17 (seq. 3) IL-1B (seq. 1) — 2.849 DVD1641 IL-1B (seq. 2) IL-17 (seq.3)  0.07861 — DVD1642 IL-17 (seq. 3) IL-1B (seq. 2) — 0.6281 DVD1643IL-1B (seq. 3) IL-17 (seq. 3) 0.465  — DVD1644 IL-17 (seq. 3) IL-1B(seq. 3) — 1.085 DVD1645 IL-1B (seq. 4) IL-17 (seq. 3) 0.4169 — DVD1646IL-17 (seq. 3) IL-1B (seq. 4) — 20.65 DVD1647 IL-1B (seq. 5) IL-17 (seq.3) 0.1519 — DVD1648 IL-17 (seq. 3) IL-1B (seq. 5) — 16.16

All DVD-Igs containing VDs from AB268, AB269, AB270, AB271, or AB272 ineither the N-terminal or C-terminal position showed neutralization inthe MRC5 IL-1Iα/β neutralization assay.

Example 1.1.2.L IL-17 Bioassay and Neutralization Assay

The human HS27 cell line (ATCC #CRL-1634) secretes IL-6 in response toIL-17. The IL-17-induced IL-6 secretion is inhibited by neutralizinganti-IL-17 antibodies (See, e.g., J. Immunol. 155:5483-5486, 1995 orCytokine 9:794-800, 1997).

HS27 cells were maintained in assay medium (DMEM high glucose medium(Gibco #11965) with 10% fetal bovine serum (Gibco#26140), 4 mML-glutamine, 1 mM sodium pyruvate, penicillin G (100 U/500 ml) andstreptomycin (100 μg/500 ml)). Cells were grown in T150 flasks untilthey were about 80-90% confluent on the day of the assay. Human IL-17(R&D Systems, #317-IL/CF) was reconstituted in sterile PBS without Ca²⁺and Mg²⁺ stored frozen, freshly thawed for use and diluted to 40 ng/ml(4×) in assay medium. Serial dilutions of antibodies were made in aseparate plate (4× concentrations), mixed with equal volume of 40 ng/ml(4×) of hu IL-17 and incubated at 37° C. for 1 hour. HS27 cells(typically about 20,000 cells in 50 μl assay medium) were added to eachwell of a 96-well flat-bottom tissue culture plate (Costar #3599),followed by the addition of 50 μl of the pre-incubated antibody plusIL-17 mixture. The final concentration of IL-17 is 10 ng/ml. Cells wereincubated for about 24 hours at 37° C. The media supernatants were thencollected. The level of IL-17 neutralization was measured by determiningthe amount of IL-6 in the supernatant using a commercial Meso ScaleDiscovery kit according to manufacturers instruction. IC50 values wereobtained using logarithm of antibody vs. IL-6 amount variable slope fit(Table 6).

TABLE 6 IL-17 Neutralization Assay With IL-17 Parent Antibody and DVD-IgConstructs Parent N-terminal C-terminal N-terminal VD Antibody VariableVariable IL-17 C-terminal VD IL-17 or DVD- Domain DomainNeutralizationAssay NeutralizationAssayEC50 Ig ID (VD) (VD) EC50 nM nMAB273 IL-17 (seq. 1) 0.0161 AB274 IL-17 (seq. 2) 0.0020 AB275 IL-17(seq. 3) 0.0032 DVD1262 IL-1B (seq. 1) IL-17 (seq. 1) — 0.0162 DVD1263IL-17 (seq. 1) IL-1B (seq. 1) 0.0052 — DVD1264 IL-1B (seq. 2) IL-17(seq. 1) — 0.0084 DVD1265 IL-17 (seq. 1) IL-1B (seq. 2) 0.0028 — DVD1266IL-1B (seq. 3) IL-17 (seq. 1) — 0.0150 DVD1267 IL-17 (seq. 1) IL-1B(seq. 3) 0.0109 — DVD1268 IL-1B (seq. 4) IL-17 (seq. 1) — 0.0034 DVD1269IL-17 (seq. 1) IL-1B (seq. 4) 0.0082 — DVD1270 IL-1B (seq. 5) IL-17(seq. 1) — 0.0407 DVD1271 IL-17 (seq. 1) IL-1B (seq. 5) 0.0109 — DVD1272IL-1B (seq. 1) IL-17 (seq. 2) — 0.3463 DVD1273 IL-17 (seq. 2) IL-1B(seq. 1) 0.0013 — DVD1274 IL-1B (seq. 2) IL-17 (seq. 2) 1.081  DVD1275IL-17 (seq. 2) IL-1B (seq. 2) 0.0006 — DVD1276 IL-1B (seq. 3) IL-17(seq. 2) — 1.207  DVD1277 IL-17 (seq. 2) IL-1B (seq. 3) 0.0092 — DVD1278IL-1B (seq. 4) IL-17 (seq. 2) — 0.3456 DVD1279 IL-17 (seq. 2) IL-1B(seq. 4) 0.0052 — DVD1280 IL-1B (seq. 5) IL-17 (seq. 2) — 0.2564 DVD1281IL-17 (seq. 2) IL-1B (seq. 5) 0.0027 — DVD1282 IL-1B (seq. 1) IL-17(seq. 3) — >20     DVD1283 IL-17 (seq. 3) IL-1B (seq. 1) 0.0238 —DVD1284 IL-1B (seq. 2) IL-17 (seq. 3) — >20     DVD1285 IL-17 (seq. 3)IL-1B (seq. 2) 0.0021 — DVD1286 IL-1B (seq. 3) IL-17 (seq. 3) — 0.2587DVD1287 IL-17 (seq. 3) IL-1B (seq. 3) 0.0035 — DVD1288 IL-1B (seq. 4)IL-17 (seq. 3) — 0.1113 DVD1289 IL-17 (seq. 3) IL-1B (seq. 4) 0.0960 —DVD1290 IL-1B (seq. 5) IL-17 (seq. 3) — 0.0181 DVD1291 IL-17 (seq. 3)IL-1B (seq. 5) 0.0062 — DVD1589 IL-1B (seq. 1) IL-17 (seq. 1) — 0.0011DVD1590 IL-17 (seq. 1) IL-1B (seq. 1) 0.0016 — DVD1591 IL-1B (seq. 2)IL-17 (seq. 1) — 0.0393 DVD1592 IL-17 (seq. 1) IL-1B (seq. 2) 0.0117 —DVD1593 IL-1B (seq. 3) IL-17 (seq. 1) — 0.0010 DVD1594 IL-17 (seq. 1)IL-1B (seq. 3) 0.0025 — DVD1595 IL-1B (seq. 4) IL-17 (seq. 1) — 0.0019DVD1596 IL-17 (seq. 1) IL-1B (seq. 4) 0.0007 — DVD1597 IL-1B (seq. 5)IL-17 (seq. 1) — 0.0008 DVD1598 IL-17 (seq. 1) IL-1B (seq. 5) 0.0053 —DVD1599 IL-1B (seq. 1) IL-17 (seq. 2) — 0.0504 DVD1600 IL-17 (seq. 2)IL-1B (seq. 1) 0.0055 — DVD1601 IL-1B (seq. 2) IL-17 (seq. 2) — 0.0264DVD1602 IL-17 (seq. 2) IL-1B (seq. 2) 0.0033 — DVD1603 IL-1B (seq. 3)IL-17 (seq. 2) — 0.0407 DVD1604 IL-17 (seq. 2) IL-1B (seq. 3) 0.0031 —DVD1605 IL-1B (seq. 4) IL-17 (seq. 2) — 0.0082 DVD1606 IL-17 (seq. 2)IL-1B (seq. 4) 0.0188 — DVD1607 IL-1B (seq. 5) IL-17 (seq. 2) — 0.0031DVD1608 IL-17 (seq. 2) IL-1B (seq. 5) 0.0082 — DVD1609 IL-1B (seq. 1)IL-17 (seq. 3) — 0.1728 DVD1610 IL-17 (seq. 3) IL-1B (seq. 1) 0.0046 —DVD1611 IL-1B (seq. 2) IL-17 (seq. 3) — 0.3001 DVD1612 IL-17 (seq. 3)IL-1B (seq. 2) 0.0238 — DVD1613 IL-1B (seq. 3) IL-17 (seq. 3) — 0.1013DVD1614 IL-17 (seq. 3) IL-1B (seq. 3) 0.0142 — DVD1615 IL-1B (seq. 4)IL-17 (seq. 3) — 0.0610 DVD1616 IL-17 (seq. 3) IL-1B (seq. 4) 0.0062 —DVD1617 IL-1B (seq. 5) IL-17 (seq. 3) — 0.0424 DVD1618 IL-17 (seq. 3)IL-1B (seq. 5) 0.0045 — DVD1619 IL-1B (seq. 1) IL-17 (seq. 1) — 0.0345DVD1620 IL-17 (seq. 1) IL-1B (seq. 1) 0.0067 — DVD1621 IL-1B (seq. 2)IL-17 (seq. 1) — 0.0397 DVD1622 IL-17 (seq. 1) IL-1B (seq. 2) 0.0083 —DVD1623 IL-1B (seq. 3) IL-17 (seq. 1) — 0.0238 DVD1624 IL-17 (seq. 1)IL-1B (seq. 3) 0.0042 — DVD1625 IL-1B (seq. 4) IL-17 (seq. 1) — 0.0076DVD1626 IL-17 (seq. 1) IL-1B (seq. 4) 0.0064 — DVD1627 IL-1B (seq. 5)IL-17 (seq. 1) — 0.0586 DVD1628 IL-17 (seq. 1) IL-1B (seq. 5) 0.0163 —DVD1629 IL-1B (seq. 1) IL-17 (seq. 2) — 0.3595 DVD1630 IL-17 (seq. 2)IL-1B (seq. 1) 0.0041 — DVD1631 IL-1B (seq. 2) IL-17 (seq. 2) — 0.4604DVD1632 IL-17 (seq. 2) IL-1B (seq. 2) 0.0065 — DVD1633 IL-1B (seq. 3)IL-17 (seq. 2) — 0.1463 DVD1634 IL-17 (seq. 2) IL-1B (seq. 3) 0.0241 —DVD1635 IL-1B (seq. 4) IL-17 (seq. 2) — 0.1273 DVD1636 IL-17 (seq. 2)IL-1B (seq. 4) 0.0075 — DVD1637 IL-1B (seq. 5) IL-17 (seq. 2) — 0.0271DVD1638 IL-17 (seq. 2) IL-1B (seq. 5) 0.0069 — DVD1639 IL-1B (seq. 1)IL-17 (seq. 3) — 2.613  DVD1640 IL-17 (seq. 3) IL-1B (seq. 1) 0.0061 —DVD1641 IL-1B (seq. 2) IL-17 (seq. 3) — 1.874  DVD1642 IL-17 (seq. 3)IL-1B (seq. 2) 0.0043 — DVD1643 IL-1B (seq. 3) IL-17 (seq. 3) — 0.1206DVD1644 IL-17 (seq. 3) IL-1B (seq. 3) 0.0122 — DVD1645 IL-1B (seq. 4)IL-17 (seq. 3) — 0.1497 DVD1646 IL-17 (seq. 3) IL-1B (seq. 4) 0.0082 —DVD1647 IL-1B (seq. 5) IL-17 (seq. 3) — 0.3398 DVD1648 IL-17 (seq. 3)IL-1B (seq. 5) 0.0089 —

All DVD-Igs containing VDs from AB273, AB274, or AB275 in either theN-terminal or C-terminal position showed neutralization in the IL-17neutralization assay.

Example 1.2 Generation of Parent Monoclonal Antibodies to a HumanAntigen of Interest

Parent mouse mAbs able to bind to and neutralize a human antigen ofinterest and a variant thereof are obtained as follows:

Example 1.2.A Immunization of Mice with a Human Antigen of Interest

Twenty micrograms of recombinant purified human antigen (e.g., IGF1,2)mixed with complete Freund's adjuvant or Immunoeasy adjuvant (Qiagen,Valencia, Calif.) is injected subcutaneously into five 6-8 week-oldBalb/C, five C57B/6 mice, and five AJ mice on Day 1. On days 24, 38, and49, twenty micrograms of recombinant purified human antigen variantmixed with incomplete Freund's adjuvant or Immunoeasy adjuvant isinjected subcutaneously into the same mice. On day 84 or day 112 or day144, mice are injected intravenously with 1 μg recombinant purifiedhuman antigen of interest.

Example 1.2.B Generation of a Hybridoma

Splenocytes obtained from the immunized mice described in Example 1.2.Aare fused with SP2/O-Ag-14 cells at a ratio of 5:1 according to theestablished method described in Kohler, G. and Milstein (1975) Nature,256:495 to generate hybridomas. Fusion products are plated in selectionmedia containing azaserine and hypoxanthine in 96-well plates at adensity of 2.5×10⁶ spleen cells per well. Seven to ten days post fusion,macroscopic hybridoma colonies are observed. Supernatant from each wellcontaining hybridoma colonies is tested by ELISA for the presence ofantibody to the antigen of interest (as described in Example 1.1.1).Supernatants displaying antigen-specific activity are then tested foractivity (as described in the assays of Example 1.1.2), for example, theability to neutralize the antigen of interest in a bioassay such as thatdescribed in Example 1.1.2.).

Example 1.2.C Identification and Characterization of Parent MonoclonalAntibodies to a Human Target Antigen of Interest Example 1.2.C.1Analyzing Parent Monoclonal Antibody Neutralizing Activity

Hybridoma supernatants are assayed for the presence of parent antibodiesthat bind an antigen of interest, generated according to Examples 1.2.Aand 1.2.B, and a variant of the antigen of interest (“antigen variant”).Supernatants with antibodies positive in both assays are then tested fortheir antigen neutralization potency, for example, in the cytokinebioassay of Example 1.1.2. The hybridomas producing antibodies with IC₅₀values in the bioassay less than 1,000 μM, in an embodiment, less than100 pM are scaled up and cloned by limiting dilution. Hybridoma cellsare expanded into media containing 10% low IgG fetal bovine serum(Hyclone #SH30151, Logan, Utah). On average, 250 mL of each hybridomasupernatant (derived from a clonal population) is harvested,concentrated and purified by protein A affinity chromatography, asdescribed in Harlow, E. and Lane, D. 1988 “Antibodies: A LaboratoryManual”. The ability of purified mAbs to inhibit the activity of itstarget antigen is determined, for example, using the cytokine bioassayas described in Example 1.1.2.

Example 1.2.C.2 Analyzing Parent Monoclonal Antibody Cross-Reactivity toCynomolgus Target Antigen of Interest

To determine whether the selected mAbs described herein recognizecynomolgus antigen of interest, BIACORE analysis is conducted asdescribed herein (Example 1.1.1.B) using recombinant cynomolgus targetantigen. In addition, neutralization potencies of mAbs againstrecombinant cynomolgus antigen of interest may also be measured in thecytokine bioassay (Example 1.1.2.A). MAbs with good cynocross-reactivity (in an embodiment, within 5-fold of reactivity forhuman antigen) are selected for future characterization.

Example 1.2.D Determination of the Amino Acid Sequence of the VariableRegion for Each Murine Anti-Human Monoclonal Antibody

Isolation of the cDNAs, expression and characterization of therecombinant anti-human mouse mAbs is conducted as follows. For eachamino acid sequence determination, approximately 1×10⁶ hybridoma cellsare isolated by centrifugation and processed to isolate total RNA withTrizol (Gibco BRL/Invitrogen, Carlsbad, Calif.) following manufacturer'sinstructions. Total RNA is subjected to first strand DNA synthesis usingthe SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad,Calif.) per the manufacturer's instructions. Oligo(dT) is used to primefirst-strand synthesis to select for poly(A)+ RNA. The first-strand cDNAproduct is then amplified by PCR with primers designed for amplificationof murine immunoglobulin variable regions (Ig-Primer Sets, Novagen,Madison, Wis.). PCR products are resolved on an agarose gel, excised,purified, and then subcloned with the TOPO Cloning kit into pCR2.1-TOPOvector (Invitrogen, Carlsbad, Calif.) and transformed into TOP10chemically competent E. coli (Invitrogen, Carlsbad, Calif.). Colony PCRis performed on the transformants to identify clones containing insert.Plasmid DNA is isolated from clones containing insert using a QIAprepMiniprep kit (Qiagen, Valencia, Calif.). Inserts in the plasmids aresequenced on both strands to determine the variable heavy or variablelight chain DNA sequences using M13 forward and M13 reverse primers(Fermentas Life Sciences, Hanover Md.). Variable heavy and variablelight chain sequences of the mAbs are identified. In an embodiment, theselection criteria for a panel of lead mAbs for next step development(humanization) includes the following:

-   -   The antibody does not contain any N-linked glycosylation sites        (NXS), except from the standard one in CH2    -   The antibody does not contain any extra cysteines in addition to        the normal cysteines in every antibody    -   The antibody sequence is aligned with the closest human germline        sequences for VH and VL and any unusual amino acids should be        checked for occurrence in other natural human antibodies    -   N-terminal Glutamine (Q) is changed to Glutamic acid (E) if it        does not affect the activity of the antibody. This will reduce        heterogeneity due to cyclization of Q    -   Efficient signal sequence cleavage is confirmed by Mass        Spectrophotometry. This can be done with COS cell or 293 cell        material    -   The protein sequence is checked for the risk of deamidation of        Asn that could result in loss of activity    -   The antibody has a low level of aggregation    -   The antibody has solubility >5-10 mg/ml (in research phase); >25        mg/ml    -   The antibody has a normal size (5-6 nm) by Dynamic Light        Scattering (DLS)    -   The antibody has a low charge heterogeneity    -   The antibody lacks cytokine release (see Example 1.1.2.B)    -   The antibody has specificity for the intended cytokine (see        Example 1.1.2.C)    -   The antibody lacks unexpected tissue cross reactivity (see        Example 1.1.2.D)    -   The antibody has similarity between human and cynomolgus tissue        cross reactivity (see Example 1.1.2.D)

Example 1.2.2 Recombinant Humanized Parent Antibodies Example 1.2.2.1Construction and Expression of Recombinant Chimeric Anti Human ParentAntibodies

The DNA encoding the heavy chain constant region of murine anti-humanparent mAbs is replaced by a cDNA fragment encoding the human IgG1constant region containing 2 hinge-region amino acid mutations byhomologous recombination in bacteria. These mutations are a leucine toalanine change at position 234 (EU numbering) and a leucine to alaninechange at position 235 (Lund et al. (1991) J. Immunol.: 147:2657). Thelight chain constant region of each of these antibodies is replaced by ahuman kappa constant region. Full-length chimeric antibodies aretransiently expressed in COS cells by co-transfection of chimeric heavyand light chain cDNAs ligated into the pBOS expression plasmid(Mizushima and Nagata (1990) Nucl. Acids Res. 18: 5322). Cellsupernatants containing recombinant chimeric antibody are purified byProtein A Sepharose chromatography and bound antibody is eluted byaddition of acid buffer. Antibodies are neutralized and dialyzed intoPBS.

The heavy chain cDNA encoding a chimeric mAb is co-transfected with itschimeric light chain cDNA (both ligated in the pBOS vector) into COScells. Cell supernatant containing recombinant chimeric antibody ispurified by Protein A Sepharose chromatography and bound antibody iseluted by addition of acid buffer. Antibodies are neutralized anddialyzed into PBS.

The purified chimeric anti-human parent mAbs are then tested for theirability to bind (by Biacore) and for functional activity, e.g., toinhibit the cytokine induced production of IgE as described in Examples1.1.1 and 1.1.2. Chimeric mAbs that maintain the activity of the parenthybridoma mAbs are selected for future development.

Example 1.2.2.2 Construction and Expression of Humanized Anti HumanParent Antibodies Example 1.2.2.2.A Selection of Human AntibodyFrameworks

Each murine variable heavy and variable light chain gene sequence wasseparately aligned against 44 human immunoglobulin germline variableheavy chain or 46 germline variable light chain sequences (derived fromNCBI Ig Blast website athttp://www.ncbi.nlm.nih.gov/igblast/retrieveig.html.) using Vector NTIsoftware.

Humanization was based on amino acid sequence homology, CDR clusteranalysis, frequency of use among expressed human antibodies, andavailable information on the crystal structures of human antibodies.Taking into account possible effects on antibody binding, VH-VL pairing,and other factors, murine residues were mutated to human residues wheremurine and human framework residues were different, with a fewexceptions. Additional humanization strategies were designed based on ananalysis of human germline antibody sequences, or a subgroup thereof,that possessed a high degree of homology, i.e., sequence similarity, tothe actual amino acid sequence of the murine antibody variable regions.

Homology modeling was used to identify residues unique to the murineantibody sequences that were predicted to be critical to the structureof the antibody combining site, the CDRs. Homology modeling is acomputational method whereby approximate three dimensional coordinatesare generated for a protein. The source of initial coordinates andguidance for their further refinement is a second protein, the referenceprotein, for which the three dimensional coordinates are known and thesequence of which is related to the sequence of the first protein. Therelationship among the sequences of the two proteins is used to generatea correspondence between the reference protein and the protein for whichcoordinates are desired, the target protein. The primary sequences ofthe reference and target proteins are aligned with coordinates ofidentical portions of the two proteins transferred directly from thereference protein to the target protein. Coordinates for mismatchedportions of the two proteins, e.g., from residue mutations, insertions,or deletions, are constructed from generic structural templates andenergy refined to insure consistency with the already transferred modelcoordinates. This computational protein structure may be further refinedor employed directly in modeling studies. The quality of the modelstructure is determined by the accuracy of the contention that thereference and target proteins are related and the precision with whichthe sequence alignment is constructed.

For the murine mAbs, a combination of BLAST searching and visualinspection was used to identify suitable reference structures. Sequenceidentity of 25% between the reference and target amino acid sequenceswas considered the minimum necessary to attempt a homology modelingexercise. Sequence alignments were constructed manually and modelcoordinates were generated with the program Jackal (see Petrey, D. etal. (2003) Proteins 53 (Suppl. 6): 430-435).

The primary sequences of the murine and human framework regions of theselected antibodies shared significant identity. Residue positions thatdiffer were candidates for inclusion of the murine residue in thehumanized sequence in order to retain the observed binding potency ofthe murine antibody. A list of framework residues that differ betweenthe human and murine sequences was constructed manually. Table 7 showsthe framework sequences chosen for this study.

TABLE 7 Sequence Of Human IgG Heavy Chain Constant Domain And LightChain Constant Domain SEQ Sequence ID 1234567890123456789012345678901234Protein NO 5678901 Wild type 46 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP hIgG1EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV constantVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS region CDKTHTCPPCPAPE 

 GGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Mutant 47 ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPhIgG1 EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV constantVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS regionCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMI SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Ig kappa 48 TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRconstant EAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS regionSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC Ig Lambda 49QPKAAPSVTLFPPSSEELQANKATLVCLISDFYP constantGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAAS regionSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPT ECS

The likelihood that a given framework residue would impact the bindingproperties of the antibody depends on its proximity to the CDR residues.Therefore, using the model structures, the residues that differ betweenthe murine and human sequences are ranked according to their distancefrom any atom in the CDRs. Those residues that fell within 4.5 Å of anyCDR atom are identified as most important and are recommended to becandidates for retention of the murine residue in the humanized antibody(i.e., back mutation).

In silico constructed humanized antibodies are constructed usingoligonucleotides. For each variable region cDNA, 6 oligonucleotides of60-80 nucleotides each are designed to overlap each other by 20nucleotides at the 5′ and/or 3′ end of each oligonucleotide. In anannealing reaction, all 6 oligonulceotides are combined, boiled, andannealed in the presence of dNTPs. DNA polymerase I, Large (Klenow)fragment (New England Biolabs #M0210, Beverley, Mass.) is added tofill-in the approximately 40 bp gaps between the overlappingoligonucleotides. PCR is performed to amplify the entire variable regiongene using two outermost primers containing overhanging sequencescomplementary to the multiple cloning site in a modified pBOS vector(Mizushima, S. and Nagata, S. (1990) Nucleic Acids Res. 18: 17). The PCRproducts derived from each cDNA assembly are separated on an agarose geland the band corresponding to the predicted variable region cDNA size isexcised and purified. The variable heavy region is inserted in-frameonto a cDNA fragment encoding the human IgG1 constant region containing2 hinge-region amino acid mutations by homologous recombination inbacteria. These mutations are a leucine to alanine change at position234 (EU numbering) and a leucine to alanine change at position 235 (Lundet al. (1991) J. Immunol. 147:2657). The variable light chain region isinserted in-frame with the human kappa constant region by homologousrecombination. Bacterial colonies are isolated and plasmid DNAextracted. cDNA inserts are sequenced in their entirety. Correcthumanized heavy and light chains corresponding to each antibody areco-transfected into COS cells to transiently produce full-lengthhumanized anti-human antibodies. Cell supernatants containingrecombinant chimeric antibody are purified by Protein A Sepharosechromatography and bound antibody is eluted by addition of acid buffer.Antibodies are neutralized and dialyzed into PBS.

Example 1.2.2.3 Characterization of Humanized Antibodies

The ability of purified humanized antibodies to inhibit a functionalactivity is determined, e.g., using the cytokine bioassay as describedin Examples 1.1.2.A. The binding affinities of the humanized antibodiesto recombinant human antigen are determined using surface plasmonresonance (Biacore®) measurement as described in Example 1.1.1.B. TheIC₅₀ values from the bioassays and the affinity of the humanizedantibodies are ranked. The humanized mAbs that fully maintain theactivity of the parent hybridoma mAbs are selected as candidates forfuture development. The top 2-3 most favorable humanized mAbs arefurther characterized.

Example 1.2.2.3.A Pharmacokinetic Analysis of Humanized Antibodies

Pharmacokinetic studies are carried out in Sprague-Dawley rats andcynomolgus monkeys. Male and female rats and cynomolgus monkeys aredosed intravenously or subcutaneously with a single dose of 4 mg/kg mAband samples are analyzed using antigen capture ELISA, andpharmacokinetic parameters are determined by noncompartmental analysis.Briefly, ELISA plates are coated with goat anti-biotin antibody (5mg/ml, 4° C., overnight), blocked with Superblock (Pierce), andincubated with biotinylated human antigen at 50 ng/ml in 10% SuperblockTTBS at room temperature for 2 hours. Serum samples are serially diluted(0.5% serum, 10% Superblock in TTBS) and incubated on the plate for 30minutes at room temperature. Detection is carried out with HRP-labeledgoat anti human antibody and concentrations are determined with the helpof standard curves using the four parameter logistic fit. Values for thepharmacokinetic parameters are determined by non-compartmental modelusing WinNonlin software (Pharsight Corporation, Mountain View, Calif.).Humanized mAbs with good pharmacokinetics profile (T½ is 8-13 days orbetter, with low clearance and excellent bioavailability 50-100%) areselected.

Example 1.2.2.3.B Physicochemical and In Vitro Stability Analysis ofHumanized Monoclonal Antibodies Size Exclusion Chromatography

Antibodies were diluted to 2.5 mg/mL with water and 20 mL was analyzedon a Shimadzu HPLC system using a TSK gel G3000 SWXL column (TosohBioscience, cat#k5539-05k). Samples were eluted from the column with 211mM sodium sulfate, 92 mM sodium phosphate, pH 7.0, at a flow rate of 0.3mL/minutes. The HPLC system operating conditions were the following:

Mobile phase: 211 mM Na₂SO₄, 92 mM Na₂HPO₄*7H₂O, pH 7.0

Gradient: Isocratic

Flow rate: 0.3 mL/minute

Detector wavelength: 280 nm

Autosampler cooler temp: 4° C.

Column oven temperature: Ambient

Run time: 50 minutes

TABLE 8 Purity of Parent Antibodies and DVD-Ig Constructs as Determinedby Size Exclusion Chromatography (SEC) Parent N-Terminal C-TerminalAntibody Variable Variable Domain or DVD-Ig ID Domain (VD) (VD) %Monomer (purity) AB268 IL-1B (seq. 1) 99 AB269 IL-1B (seq. 2) 99 AB270IL-1B (seq. 3) 90.6 AB271 IL-1B (seq. 4) 95.5 AB272 IL-1B (seq. 5) 93.1AB273 IL-17 (seq. 1) 100 AB274 IL-17 (seq. 2) 70.7 AB275 IL-17 (seq. 3)94.5 DVD1262 IL-1B (seq. 1) IL-17 (seq. 1) 98.7 DVD1263 IL-17 (seq. 1)IL-1B (seq. 1) 100 DVD1264 IL-1B (seq. 2) IL-17 (seq. 1) 99 DVD1265IL-17 (seq. 1) IL-1B (seq. 2) 98.9 DVD1266 IL-1B (seq. 3) IL-17 (seq. 1)85.7 DVD1267 IL-17 (seq. 1) IL-1B (seq. 3) 100 DVD1268 IL-1B (seq. 4)IL-17 (seq. 1) 88.2 DVD1269 IL-17 (seq. 1) IL-1B (seq. 4) 98 DVD1270IL-1B (seq. 5) IL-17 (seq. 1) 93.3 DVD1271 IL-17 (seq. 1) IL-1B (seq. 5)99.2 DVD1272 IL-1B (seq. 1) IL-17 (seq. 2) 98.9 DVD1273 IL-17 (seq. 2)IL-1B (seq. 1) 62.1 DVD1274 IL-1B (seq. 2) IL-17 (seq. 2) 99.7 DVD1275IL-17 (seq. 2) IL-1B (seq. 2) 63.6 DVD1276 IL-1B (seq. 3) IL-17 (seq. 2)91 DVD1277 IL-17 (seq. 2) IL-1B (seq. 3) 77.2 DVD1278 IL-1B (seq. 4)IL-17 (seq. 2) 95.9 DVD1279 IL-17 (seq. 2) IL-1B (seq. 4) 62.9 DVD1280IL-1B (seq. 5) IL-17 (seq. 2) 92 DVD1281 IL-17 (seq. 2) IL-1B (seq. 5)66.5 DVD1282 IL-1B (seq. 1) IL-17 (seq. 3) 97.1 DVD1283 IL-17 (seq. 3)IL-1B (seq. 1) 100 DVD1284 IL-1B (seq. 2) IL-17 (seq. 3) 98.7 DVD1285IL-17 (seq. 3) IL-1B (seq. 2) 92.4 DVD1286 IL-1B (seq. 3) IL-17 (seq. 3)100 DVD1287 IL-17 (seq. 3) IL-1B (seq. 3) 100 DVD1288 IL-1B (seq. 4)IL-17 (seq. 3) 94.9 DVD1289 IL-17 (seq. 3) IL-1B (seq. 4) 95.9 DVD1290IL-1B (seq. 5) IL-17 (seq. 3) 100 DVD1291 IL-17 (seq. 3) IL-1B (seq. 5)100 DVD1589 IL-1B (seq. 1) IL-17 (seq. 1) 98.4 DVD1590 IL-17 (seq. 1)IL-1B (seq. 1) 98.9 DVD1591 IL-1B (seq. 2) IL-17 (seq. 1) 100 DVD1592IL-17 (seq. 1) IL-1B (seq. 2) 100 DVD1593 IL-1B (seq. 3) IL-17 (seq. 1)95.4 DVD1594 IL-17 (seq. 1) IL-1B (seq. 3) 98.5 DVD1595 IL-1B (seq. 4)IL-17 (seq. 1) 93 DVD1596 IL-17 (seq. 1) IL-1B (seq. 4) 97.7 DVD1597IL-1B (seq. 5) IL-17 (seq. 1) 95.7 DVD1598 IL-17 (seq. 1) IL-1B (seq. 5)100 DVD1599 IL-1B (seq. 1) IL-17 (seq. 2) 99.1 DVD1600 IL-17 (seq. 2)IL-1B (seq. 1) 60.7 DVD1601 IL-1B (seq. 2) IL-17 (seq. 2) 99.3 DVD1602IL-17 (seq. 2) IL-1B (seq. 2) 58 DVD1603 IL-1B (seq. 3) IL-17 (seq. 2)93.7 DVD1604 IL-17 (seq. 2) IL-1B (seq. 3) 64.8 DVD1605 IL-1B (seq. 4)IL-17 (seq. 2) 97.8 DVD1606 IL-17 (seq. 2) IL-1B (seq. 4) 62.2 DVD1607IL-1B (seq. 5) IL-17 (seq. 2) 95.9 DVD1608 IL-17 (seq. 2) IL-1B (seq. 5)64.5 DVD1609 IL-1B (seq. 1) IL-17 (seq. 3) 95.5 DVD1610 IL-17 (seq. 3)IL-1B (seq. 1) 98.6 DVD1611 IL-1B (seq. 2) IL-17 (seq. 3) 98 DVD1612IL-17 (seq. 3) IL-1B (seq. 2) 98.1 DVD1613 IL-1B (seq. 3) IL-17 (seq. 3)85.5 DVD1614 IL-17 (seq. 3) IL-1B (seq. 3) 98.1 DVD1615 IL-1B (seq. 4)IL-17 (seq. 3) 93.3 DVD1616 IL-17 (seq. 3) IL-1B (seq. 4) 97.9 DVD1617IL-1B (seq. 5) IL-17 (seq. 3) 89.5 DVD1618 IL-17 (seq. 3) IL-1B (seq. 5)100 DVD1619 IL-1B (seq. 1) IL-17 (seq. 1) 98.6 DVD1620 IL-17 (seq. 1)IL-1B (seq. 1) 100 DVD1621 IL-1B (seq. 2) IL-17 (seq. 1) 99.3 DVD1622IL-17 (seq. 1) IL-1B (seq. 2) 100 DVD1623 IL-1B (seq. 3) IL-17 (seq. 1)90.8 DVD1624 IL-17 (seq. 1) IL-1B (seq. 3) 100 DVD1625 IL-1B (seq. 4)IL-17 (seq. 1) 93.9 DVD1626 IL-17 (seq. 1) IL-1B (seq. 4) 96.7 DVD1627IL-1B (seq. 5) IL-17 (seq. 1) 95.4 DVD1628 IL-17 (seq. 1) IL-1B (seq. 5)97.9 DVD1629 IL-1B (seq. 1) IL-17 (seq. 2) 100 DVD1630 IL-17 (seq. 2)IL-1B (seq. 1) 65.3 DVD1631 IL-1B (seq. 2) IL-17 (seq. 2) 100 DVD1632IL-17 (seq. 2) IL-1B (seq. 2) 61.6 DVD1633 IL-1B (seq. 3) IL-17 (seq. 2)93.4 DVD1634 IL-17 (seq. 2) IL-1B (seq. 3) 76.7 DVD1635 IL-1B (seq. 4)IL-17 (seq. 2) 98.6 DVD1636 IL-17 (seq. 2) IL-1B (seq. 4) 75.7 DVD1637IL-1B (seq. 5) IL-17 (seq. 2) 98.6 DVD1638 IL-17 (seq. 2) IL-1B (seq. 5)69.3 DVD1639 IL-1B (seq. 1) IL-17 (seq. 3) 100 DVD1640 IL-17 (seq. 3)IL-1B (seq. 1) 100 DVD1641 IL-1B (seq. 2) IL-17 (seq. 3) 100 DVD1642IL-17 (seq. 3) IL-1B (seq. 2) 100 DVD1643 IL-1B (seq. 3) IL-17 (seq. 3)93.3 DVD1644 IL-17 (seq. 3) IL-1B (seq. 3) 100 DVD1645 IL-1B (seq. 4)IL-17 (seq. 3) 100 DVD1646 IL-17 (seq. 3) IL-1B (seq. 4) 100 DVD1647IL-1B (seq. 5) IL-17 (seq. 3) 98.1 DVD1648 IL-17 (seq. 3) IL-1B (seq. 5)100DVD-Igs showed an excellent SEC profile with most DVD-Igs showing >90%monomer. This DVD-ig profile is similar to that observed for parentantibodies.

SDS-PAGE

Antibodies are analyzed by sodium dodecyl sulfate-polyacrylamide gelelectrophoresis (SDS-PAGE) under both reducing and non-reducingconditions. Adalimumab lot AFP04C is used as a control. For reducingconditions, the samples are mixed 1:1 with 2× tris glycine SDS-PAGEsample buffer (Invitrogen, cat#LC2676, lot#1323208) with 100 mM DTT, andheated at 60° C. for 30 minutes. For non-reducing conditions, thesamples are mixed 1:1 with sample buffer and heated at 100° C. for 5minutes. The reduced samples (10 mg per lane) are loaded on a 12%pre-cast tris-glycine gel (Invitrogen, cat#EC6005box, lot#6111021), andthe non-reduced samples (10 mg per lane) are loaded on an 8%-16%pre-cast tris-glycine gel (Invitrogen, cat#EC6045box, lot#6111021).SeeBlue Plus 2 (Invitrogen, cat#LC5925, lot#1351542) is used as amolecular weight marker. The gels are run in a XCell SureLock mini cellgel box (Invitrogen, cat#EI0001) and the proteins are separated by firstapplying a voltage of 75 to stack the samples in the gel, followed by aconstant voltage of 125 until the dye front reached the bottom of thegel. The running buffer used is 1× tris glycine SDS buffer, preparedfrom a 10× tris glycine SDS buffer (ABC, MPS-79-080106)). The gels arestained overnight with colloidal blue stain (Invitrogen cat#46-7015,46-7016) and destained with Milli-Q water until the background is clear.The stained gels are then scanned using an Epson Expression scanner(model 1680, S/N DASX003641).

Sedimentation Velocity Analysis

Antibodies are loaded into the sample chamber of each of three standardtwo-sector carbon epon centerpieces. These centerpieces have a 1.2 cmoptical path length and are built with sapphire windows. PBS is used fora reference buffer and each chamber contained 140 μL. All samples areexamined simultaneously using a 4-hole (AN-60Ti) rotor in a BeckmanProteomeLab XL-I analytical ultracentrifuge (serial #PL106C01).

Run conditions are programmed and centrifuge control is performed usingProteomeLab (v5.6). The samples and rotor are allowed to thermallyequilibrate for one hour prior to analysis (20.0±0.1° C.). Confirmationof proper cell loading is performed at 3000 rpm and a single scan isrecorded for each cell. The sedimentation velocity conditions are thefollowing:

Sample Cell Volume: 420 mL

Reference Cell Volume: 420 mL

Temperature: 20° C.

Rotor Speed: 35,000 rpm

Time: 8:00 hours

UV Wavelength: 280 nm

Radial Step Size: 0.003 cm

Data Collection One data point per step without signal averaging.

Total Number of Scans: 100

LC-MS Molecular Weight Measurement of Intact Antibodies

Molecular weights of intact antibodies are analyzed by LC-MS. Eachantibody is diluted to approximately 1 mg/mL with water. An 1100 HPLC(Agilent) system with a protein microtrap (Michrom Bioresources, Inc,cat#004/25109/03) is used to desalt and introduce 5 mg of the sampleinto an API Qstar pulsar i mass spectrometer (Applied Biosystems). Ashort gradient is used to elute the samples. The gradient is run withmobile phase A (0.08% FA, 0.02% TFA in HPLC water) and mobile phase B(0.08% FA and 0.02% TFA in acetonitrile) at a flow rate of 50 mL/minute.The mass spectrometer is operated at 4.5 kvolts spray voltage with ascan range from 2000 to 3500 mass to charge ratio.

LC-MS Molecular Weight Measurement of Antibody Light and Heavy Chains

Molecular weight measurement of antibody light chain (LC), heavy chain(HC) and deglycosylated HC are analyzed by LC-MS. Antibody is diluted to1 mg/mL with water and the sample is reduced to LC and HC with a finalconcentration of 10 mM DTT for 30 minutes at 37° C. To deglycosylate theantibody, 100 mg of the antibody is incubated with 2 mL of PNGase F, 5mL of 10% N-octylglucoside in a total volume of 100 mL overnight at 37°C. After deglycosylation the sample is reduced with a finalconcentration of 10 mM DTT for 30 minutes at 37° C. An Agilent 1100 HPLCsystem with a C4 column (Vydac, cat#214TP5115, S/N 060206537204069) isused to desalt and introduce the sample (5 mg) into an API Qstar pulsari mass spectrometer (Applied Biosystems). A short gradient is used toelute the sample. The gradient is run with mobile phase A (0.08% FA,0.02% TFA in HPLC water) and mobile phase B (0.08% FA and 0.02% TFA inacetonitrile) at a flow rate of 50 mL/minute. The mass spectrometer isoperated at 4.5 kvolts spray voltage with a scan range from 800 to 3500mass to charge ratio.

Peptide Mapping

Antibody is denatured for 15 minutes at room temperature with a finalconcentration of 6 M guanidine hydrochloride in 75 mM ammoniumbicarbonate. The denatured samples are reduced with a finalconcentration of 10 mM DTT at 37° C. for 60 minutes, followed byalkylation with 50 mM iodoacetic acid (IAA) in the dark at 37° C. for 30minutes. Following alkylation, the sample is dialyzed overnight againstfour liters of 10 mM ammonium bicarbonate at 4° C. The dialyzed sampleis diluted to 1 mg/mL with 10 mM ammonium bicarbonate, pH 7.8 and 100 mgof antibody is either digested with trypsin (Promega, cat#V5111) orLys-C (Roche, cat#11 047 825 001) at a 1:20 (w/w) trypsin/Lys-C:antibodyratio at 37° C. for 4 hrs. Digests are quenched with 1 mL of 1 N HCl.For peptide mapping with mass spectrometer detection, 40 mL of thedigests are separated by reverse phase high performance liquidchromatography (RPHPLC) on a C18 column (Vydac, cat#218TP51, S/N NE960610.3.5) with an Agilent 1100 HPLC system. The peptide separation is runwith a gradient using mobile phase A (0.02% TFA and 0.08% FA in HPLCgrade water) and mobile phase B (0.02% TFA and 0.08% FA in acetonitrile)at a flow rate of 50 mL/minutes. The API QSTAR Pulsar i mass spectromeris operated in positive mode at 4.5 kvolts spray voltage and a scanrange from 800 to 2500 mass to charge ratio.

Disulfide Bond Mapping

To denature the antibody, 100 mL of the antibody is mixed with 300 mL of8 M guanidine HCl in 100 mM ammonium bicarbonate. The pH is checked toensure that it is between 7 and 8 and the samples are denatured for 15minutes at room temperature in a final concentration of 6 M guanidineHCl. A portion of the denatured sample (100 mL) is diluted to 600 mLwith Milli-Q water to give a final guanidine-HCl concentration of 1M.The sample (220 mg) is digested with either trypsin (Promega, cat#V5111, lot#22265901) or Lys-C (Roche, cat#11047825001, lot#12808000) ata 1:50 trypsin or 1:50 Lys-C: antibody (w/w) ratios (4.4 mg enzyme: 220mg sample) at 37° C. for approximately 16 hours. An additional 5 mg oftrypsin or Lys-C is added to the samples and digestion is allowed toproceed for an additional 2 hours at 37° C. Digestions are stopped byadding 1 mL of TFA to each sample. Digested samples are separated byRPHPLC using a C18 column (Vydac, cat#218TP51 S/N NE020630-4-1A) on anAgilent HPLC system. The separation is run with the same gradient usedfor peptide mapping using mobile phase A (0.02% TFA and 0.08% FA in HPLCgrade water) and mobile phase B (0.02% TFA and 0.08% FA in acetonitrile)at a flow rate of 50 mL/minute. The HPLC operating conditions are thesame as those used for peptide mapping. The API QSTAR Pulsar i massspectromer is operated in positive mode at 4.5 kvolts spray voltage anda scan range from 800 to 2500 mass-to-charge ratio. Disulfide bonds areassigned by matching the observed MWs of peptides with the predicted MWsof tryptic or Lys-C peptides linked by disulfide bonds.

Free Sulfhydryl Determination

The method used to quantify free cysteines in an antibody is based onthe reaction of Ellman's reagent, 5,5¢-dithio-bis(2-nitrobenzoic acid)(DTNB), with sulfhydryl groups (SH) which gives rise to a characteristicchromophoric product, 5-thio-(2-nitrobenzoic acid) (TNB). The reactionis illustrated in the formula:

DTNB+RSH®RS−TNB+TNB−+H+

The absorbance of the TNB- is measured at 412 nm using a Cary 50spectrophotometer. An absorbance curve is plotted using dilutions of 2mercaptoethanol (b-ME) as the free SH standard and the concentrations ofthe free sulfhydryl groups in the protein are determined from absorbanceat 412 nm of the sample.

The b-ME standard stock is prepared by a serial dilution of 14.2 M b-MEwith HPLC grade water to a final concentration of 0.142 mM. Thenstandards in triplicate for each concentration are prepared. Antibody isconcentrated to 10 mg/mL using an amicon ultra 10,000 MWCO centrifugalfilter (Millipore, cat#UFC801096, lot#L3KN5251) and the buffer ischanged to the formulation buffer used for adalimumab (5.57 mM sodiumphosphate monobasic, 8.69 mM sodium phosphate dibasic, 106.69 mM NaCl,1.07 mM sodium citrate, 6.45 mM citric acid, 66.68 mM mannitol, pH 5.2,0.1% (w/v) Tween). The samples are mixed on a shaker at room temperaturefor 20 minutes. Then 180 mL of 100 mM Tris buffer, pH 8.1 is added toeach sample and standard followed by the addition of 300 mL of 2 mM DTNBin 10 mM phosphate buffer, pH 8.1. After thorough mixing, the samplesand standards are measured for absorption at 412 nm on a Cary 50spectrophotometer. The standard curve is obtained by plotting the amountof free SH and OD₄₁₂ nm of the b-ME standards. Free SH content ofsamples are calculated based on this curve after subtraction of theblank.

Weak Cation Exchange Chromatography

Antibody is diluted to 1 mg/mL with 10 mM sodium phosphate, pH 6.0.Charge heterogeneity is analyzed using a Shimadzu HPLC system with aWCX-10 ProPac analytical column (Dionex, cat#054993, S/N 02722). Thesamples are loaded on the column in 80% mobile phase A (10 mM sodiumphosphate, pH 6.0) and 20% mobile phase B (10 mM sodium phosphate, 500mM NaCl, pH 6.0) and eluted at a flow rate of 1.0 mL/minute.

Oligosaccharide Profiling

Oligosaccharides released after PNGase F treatment of antibody arederivatized with 2-aminobenzamide (2-AB) labeling reagent. Thefluorescent-labeled oligosaccharides are separated by normal phase highperformance liquid chromatography (NPHPLC) and the different forms ofoligosaccharides are characterized based on retention time comparisonwith known standards.

The antibody is first digested with PNGaseF to cleave N-linkedoligosaccharides from the Fc portion of the heavy chain. The antibody(200 mg) is placed in a 500 mL Eppendorf tube along with 2 mL PNGase Fand 3 mL of 10% N-octylglucoside. Phosphate buffered saline is added tobring the final volume to 60 mL. The sample is incubated overnight at37° C. in an Eppendorf thermomixer set at 700 RPM. Adalimumab lot AFP04Cis also digested with PNGase F as a control.

After PNGase F treatment, the samples are incubated at 95° C. for 5minutes in an Eppendorf thermomixer set at 750 RPM to precipitate outthe proteins, then the samples are placed in an Eppendorf centrifuge for2 minutes at 10,000 RPM to spin down the precipitated proteins. Thesupernatant containing the oligosaccharides are transferred to a 500 mLEppendorf tube and dried in a speed-vac at 65° C.

The oligosaccharides are labeled with 2AB using a 2AB labeling kitpurchased from Prozyme (cat#GKK-404, lot#132026). The labeling reagentis prepared according to the manufacturer's instructions. Acetic acid(150 mL, provided in kit) is added to the DMSO vial (provided in kit)and mixed by pipeting the solution up and down several times. The aceticacid/DMSO mixture (100 mL) is transferred to a vial of 2-AB dye (justprior to use) and mixed until the dye is fully dissolved. The dyesolution is then added to a vial of reductant (provided in kit) andmixed well (labeling reagent). The labeling reagent (5 mL) is added toeach dried oligosaccharide sample vial, and mixed thoroughly. Thereaction vials are placed in an Eppendorf thermomixer set at 65° C. and700-800 RPM for 2 hours of reaction.

After the labeling reaction, the excess fluorescent dye is removed usingGlycoClean S Cartridges from Prozyme (cat#GKI-4726). Prior to adding thesamples, the cartridges are washed with 1 mL of milli-Q water followedwith 5 washes of 1 mL 30% acetic acid solution. Just prior to adding thesamples, 1 mL of acetonitrile (Burdick and Jackson, cat#AH015-4) isadded to the cartridges.

After all of the acetonitrile passed through the cartridge, the sampleis spotted onto the center of the freshly washed disc and allowed toadsorb onto the disc for 10 minutes. The disc is washed with 1 mL ofacetonitrile followed by five washes of 1 mL of 96% acetonitrile. Thecartridges are placed over a 1.5 mL Eppendorf tube and the 2-AB labeledoligosaccharides are eluted with 3 washes (400 mL each wash) of milli Qwater.

The oligosaccharides are separated using a Glycosep N HPLC(cat#GKI-4728) column connected to a Shimadzu HPLC system. The ShimadzuHPLC system consisted of a system controller, degasser, binary pumps,autosampler with a sample cooler, and a fluorescent detector.

Stability at Elevated Temperatures

The buffer of antibody is either 5.57 mM sodium phosphate monobasic,8.69 mM sodium phosphate dibasic, 106.69 mM NaCl, 1.07 mM sodiumcitrate, 6.45 mM citric acid, 66.68 mM mannitol, 0.1% (w/v) Tween, pH5.2; or 10 mM histidine, 10 mM methionine, 4% mannitol, pH 5.9 usingAmicon ultra centrifugal filters. The final concentration of theantibodies is adjusted to 2 mg/mL with the appropriate buffers. Theantibody solutions are then filter sterilized and 0.25 mL aliquots areprepared under sterile conditions. The aliquots are left at either −80°C., 5° C., 25° C., or 40° C. for 1, 2 or 3 weeks. At the end of theincubation period, the samples are analyzed by size exclusionchromatography and SDS-PAGE.

The stability samples are analyzed by SDS-PAGE under both reducing andnon-reducing conditions. The procedure used is the same as describedherein. The gels are stained overnight with colloidal blue stain(Invitrogen cat#46-7015, 46-7016) and destained with Milli-Q water untilthe background is clear. The stained gels are then scanned using anEpson Expression scanner (model 1680, S/N DASX003641). To obtain moresensitivity, the same gels are silver stained using silver staining kit(Owl Scientific) and the recommended procedures given by themanufacturer is used.

Dynamic Scanning Fluorimetry

The DVD's were dialysed in 10 mM citrate 10 mM phosphate buffer, pH 6.0to get a final concentration of 1 mg/ml. Triplicates were run for eachDVD. For each sample, 27 μl of the DVD was added in a well of a 96 wellplate and mixed with 3 μl of 4× diluted SYPRO Orange dye (Invitrogen).The dye is supplied in DMSO at a concentration of 5000× and was dilutedto the working concentration of 4× in water. The plate was centrifugedfor 30 sec to ensure that both the dye and the protein settle to thebottom of the wells and complete mixing was ensured by gentle aspirationby a pipette tip. The plate was then sealed with an adhesive film.

A real time PCR (Applied Biosciences, 7500 Series) was used formeasuring the change in fluorescence intensities with temperature. Theplate was heated from 25° C. to 95° C. at a temperature ramp rate ofapproximately 0.5° C./min and emission fluorescence was collected usingTAMRA filter. The data was exported to Microsoft Excel and plotted astemperature vs fluorescence for each DVD. Onset of melting was noted asthe temperature where the thermogram rises above the baselinefluorescence. SYPRO Orange is a hydrophobic dye and preferentially bindsto the exposed hydrophobic residues in an unfolded protein molecule.Hence the onset of unfolding temperature, as measured by an increase influorescence is an indication of the thermal stability of the DVD. Theunfolding temperature for the DVD-Igs can be found in Table 9.

TABLE 9 Thermal Stability of Parent Antibodies and CDR-grafted DVD-IgConstructs as Determined by Dynamic Scanning Fluorimetry ParentN-terminal Antibody or Variable C-terminal Variable Onset of meltingDVD-Ig ID Domain (VD) Domain (VD) (rank) (deg C.) DVD1262 IL-1B (seq. 1)IL-17 (seq. 1) 57 DVD1264 IL-1B (seq. 2) IL-17 (seq. 1) 58 DVD1265 IL-17(seq. 1) IL-1B (seq. 2) 50 DVD1266 IL-1B (seq. 3) IL-17 (seq. 1) 59DVD1268 IL-1B (seq. 4) IL-17 (seq. 1) 55 DVD1270 IL-1B (seq. 5) IL-17(seq. 1) 58 DVD1272 IL-1B (seq. 1) IL-17 (seq. 2) 64 DVD1278 IL-1B (seq.4) IL-17 (seq. 2) 59 DVD1280 IL-1B (seq. 5) IL-17 (seq. 2) 59 DVD1286IL-1B (seq. 3) IL-17 (seq. 3) 60 DVD1288 IL-1B (seq. 4) IL-17 (seq. 3)57 DVD1290 IL-1B (seq. 5) IL-17 (seq. 3) 59 DVD1593 IL-1B (seq. 3) IL-17(seq. 1) 42 DVD1595 IL-1B (seq. 4) IL-17 (seq. 1) 44 DVD1597 IL-1B (seq.5) IL-17 (seq. 1) 57 DVD1599 IL-1B (seq. 1) IL-17 (seq. 2) 59 DVD1600IL-17 (seq. 2) IL-1B (seq. 1) 52 DVD1601 IL-1B (seq. 2) IL-17 (seq. 2)60 DVD1602 IL-17 (seq. 2) IL-1B (seq. 2) 52 DVD1609 IL-1B (seq. 1) IL-17(seq. 3) 58 DVD1611 IL-1B (seq. 2) IL-17 (seq. 3) 58 DVD1612 IL-17 (seq.3) IL-1B (seq. 2) 47 DVD1613 IL-1B (seq. 3) IL-17 (seq. 3) 56 DVD1614IL-17 (seq. 3) IL-1B (seq. 3) 44 DVD1615 IL-1B (seq. 4) IL-17 (seq. 3)52 DVD1617 IL-1B (seq. 5) IL-17 (seq. 3) 57 DVD1623 IL-1B (seq. 3) IL-17(seq. 1) 51 DVD1625 IL-1B (seq. 4) IL-17 (seq. 1) 55 DVD1627 IL-1B (seq.5) IL-17 (seq. 1) 53 DVD1629 IL-1B (seq. 1) IL-17 (seq. 2) 61 DVD1631IL-1B (seq. 2) IL-17 (seq. 2) 60 DVD1632 IL-17 (seq. 2) IL-1B (seq. 2)53 DVD1635 IL-1B (seq. 4) IL-17 (seq. 2) 56 DVD1637 IL-1B (seq. 5) IL-17(seq. 2) 56 DVD1639 IL-1B (seq. 1) IL-17 (seq. 3) 61 DVD1642 IL-17 (seq.3) IL-1B (seq. 2) 50 DVD1645 IL-1B (seq. 4) IL-17 (seq. 3) 58 DVD1647IL-1B (seq. 5) IL-17 (seq. 3) 58

Most DVD-Igs showed an unfolding temperature >50. This DVD-Ig profile issimilar to that observed for parent antibodies.

Solubility Determination

DVD candidates were dialyzed in 15 mM His, pH 6.0. This was followed byconcentrating them up to 50 μl in centricons with a 30K cutoff.Solubility was visually confirmed by absence of precipitation afterstorage at 4° C. and quantitatively determined by UV absorbancemeasurement at 280 nm.

TABLE 10 Solubility of DVD-Ig Constructs as Determined by UV AbsorbanceParent Antibody or N-terminal C-terminal Solubility (rank) DVD-IgVariable Variable 15 mM His, pH 6 ID Domain (VD) Domain (VD) Appearancemg/ml DVD1262 IL-1B (seq. 1) IL-17 (seq. 1) clear >28 DVD1264 IL-1B(seq. 2) IL-17 (seq. 1) ppt 21 DVD1265 IL-17 (seq. 1) IL-1B (seq. 2)opalascent 7 DVD1266 IL-1B (seq. 3) IL-17 (seq. 1) phase separation 17DVD1268 IL-1B (seq. 4) IL-17 (seq. 1) opalascent 5 DVD1270 IL-1B (seq.5) IL-17 (seq. 1) opalascent DVD1272 IL-1B (seq. 1) IL-17 (seq. 2)clear >127 DVD1278 IL-1B (seq. 4) IL-17 (seq. 2) phase separation 14DVD1280 IL-1B (seq. 5) IL-17 (seq. 2) clear >133 DVD1286 IL-1B (seq. 3)IL-17 (seq. 3) clear >99 DVD1288 IL-1B (seq. 4) IL-17 (seq. 3)clear >130 DVD1290 IL-1B (seq. 5) IL-17 (seq. 3) clear >80 DVD1593 IL-1B(seq. 3) IL-17 (seq. 1) ppt DVD1595 IL-1B (seq. 4) IL-17 (seq. 1) ppt 15DVD1597 IL-1B (seq. 5) IL-17 (seq. 1) ppt DVD1599 IL-1B (seq. 1) IL-17(seq. 2) clear >99 DVD1600 IL-17 (seq. 2) IL-1B (seq. 1) opalascentDVD1601 IL-1B (seq. 2) IL-17 (seq. 2) clear >129 DVD1602 IL-17 (seq. 2)IL-1B (seq. 2) opalascent 5 DVD1609 IL-1B (seq. 1) IL-17 (seq. 3)clear >59 DVD1611 IL-1B (seq. 2) IL-17 (seq. 3) clear >79 DVD1612 IL-17(seq. 3) IL-1B (seq. 2) clear >35 DVD1613 IL-1B (seq. 3) IL-17 (seq. 3)clear >67 DVD1614 IL-17 (seq. 3) IL-1B (seq. 3) ppt 10 DVD1615 IL-1B(seq. 4) IL-17 (seq. 3) phase separation 19 DVD1617 IL-1B (seq. 5) IL-17(seq. 3) clear >123 DVD1623 IL-1B (seq. 3) IL-17 (seq. 1) phaseseparation 22 DVD1625 IL-1B (seq. 4) IL-17 (seq. 1) opalascent 25DVD1627 IL-1B (seq. 5) IL-17 (seq. 1) phase separation DVD1629 IL-1B(seq. 1) IL-17 (seq. 2) clear >101 DVD1631 IL-1B (seq. 2) IL-17 (seq. 2)clear >104 DVD1632 IL-17 (seq. 2) IL-1B (seq. 2) clear >79 DVD1635 IL-1B(seq. 4) IL-17 (seq. 2) ppt DVD1637 IL-1B (seq. 5) IL-17 (seq. 2)clear >34 DVD1639 IL-1B (seq. 1) IL-17 (seq. 3) clear >49 DVD1642 IL-17(seq. 3) IL-1B (seq. 2) clear >70 DVD1645 IL-1B (seq. 4) IL-17 (seq. 3)phase separation 20 DVD1647 IL-1B (seq. 5) IL-17 (seq. 3) clear >50

Most DVD-Igs showed clear appearance and could be concentrated togreater than 25 mg/ml. This DVD-Ig profile is similar to that observedfor parent antibodies.

Example 1.2.2.3.C Efficacy of a Humanized Monoclonal Antibody by Itselfor in Combination with Chemotherapy on the Growth of Human CarcinomaXenografts

Human cancer cells are grown in vitro to 99% viability, 85% confluencein tissue culture flasks. SCID female or male mice (Charles Rivers Labs)at 19-25 grams, are ear tagged and shaved. Mice are then inoculatedsubcutaneously into the right flank with 0.2 ml of 2×10⁶ human tumorcells (1:1 matrigel) on study day 0. Administration (IP, Q3D/week) ofvehicle (PBS), humanized antibody, and/or chemotherapy is initiatedafter mice are size matched into separate cages of mice with mean tumorvolumes of approximately 150 to 200 mm³. The tumors are measured by apair of calipers twice a week starting on approximately day 10 postinoculation and the tumor volumes calculated according to the formulaV=L×W²/2 (V: volume, mm³; L: length, mm; W: width, m). Reduction intumor volume is seen in animals treated with mAb alone or in combinationwith chemotherapy relative to tumors in animals that received onlyvehicle or an isotype control mAb.

Example 1.2.2.3.D FACS Based Redirected Cytotoxicity (rCTL) Assay

Human CD3+ T cells qre isolated from previously frozen isolatedperipheral blood mononuclear cells (PBMC) by a negative selectionenrichment column (R&D Systems, Minneapolis, Minn.; Cat. #HTCC-525). Tcells are stimulated for 4 days in flasks (vent cap, Corning, Acton,Mass.) coated with 10 μg/mL anti-CD3 (OKT-3, eBioscience, Inc., SanDiego, Calif.) and 2 μg/mL anti-CD28 (CD28.2, eBioscience, Inc., SanDiego, Calif.) in D-PBS (Invitrogen, Carlsbad, Calif.) and cultured in30 U/mL IL-2 (Roche) in complete RPMI 1640 media (Invitrogen, Carlsbad,Calif.) with L-glutamine, 55 mM β-ME, Pen/Strep, 10% FBS). T cells arethen rested overnight in 30 U/mL IL-2 before using in assay. DoHH2 orRaji target cells are labeled with PKH26 (Sigma-Aldrich, St. Louis, Mo.)according to manufacturer's instructions. RPMI 1640 media (no phenol,Invitrogen, Carlsbad, Calif.) containing L-glutamine and 10% FBS(Hyclone, Logan, Utah) is used throughout the rCTL assay. (See Dreier etal. (2002) Int J Cancer 100:690).

Effector T cells (E) and targets (T) are plated at a final cellconcentration of 10⁵ and 10⁴ cells/well in 96-well plates (Costar #3799,Acton, Mass.), respectively to give an E:T ratio of 10:1. DVD-Igmolecules are diluted to obtain concentration-dependent titrationcurves. After an overnight incubation cells are pelleted and washed withD-PBS once before resuspending in FACS buffer containing 0.1% BSA(Invitrogen, Carlsbad, Calif.), 0.1% sodium azide and 0.5 μg/mLpropidium iodide (BD) in D-PBS. FACS data is collected on a FACS CantoII machine (Becton Dickinson, San Jose, Calif.) and analyzed in Flowjo(Treestar). The percent live targets in the DVD-Ig treated samplesdivided by the percent total targets (control, no treatment) iscalculated to determine percent specific lysis. IC50s are calculated inPrism (Graphpad).

Example 1.2.2.3.E Antibody-Dependent Cell Mediated Cytotoxicity (ADCC)Method

Target (DoHH2, A431, and U87MGde2-7) cells were harvested and washedwith 10 mL RPMI no phenol red medium (Invitrogen, Carlsbad, Calif., Cat.#11835) and incubated in calcein-AM (eBioscience, San Diego, Calif.,Cat. #65-0853) at a concentration of 4×10⁶ cells/mL for 30 minutes.Target cells were washed 3 times with 10 mL RPMI no phenol red 10% FBS(Thermo Scientific HyClone, Logan, Utah, Cat. #SH30070.03) and aliquotedat 180,000 cells/well in a 96-well round bottom plate. Antibodies andDVD-Igs were diluted in RPMI no phenol red 10% FBS to 10 μg/mL. Thesupernatant is removed from the target cells, and 30 μL/well of thediluted antibodies and DVD-Igs were added. Cells were incubated on icefor 1 hour and then washed 3 times with 150 μL/well RPMI no phenol red10% FBS. Cells were transferred to a 2 mL assay block and resuspended ata concentration of 1.33×10⁵ cells/mL. Unactivated human NK cells(Astarte Biologics, Redmond, Wash., Cat. #1027) or activated human NKcells (In-house blood donor program PBMCs activated 2 weeks using kit,Myltenyi Biotech, Auburn, Calif., Cat. #130-094-483) were thawed, washedwith 10 mL RPMI no phenol red 10% FBS twice, and resuspended at 1.2×10⁶cells/mL. NK cells and target cells were then aliquoted at a ratio of9:1 onto 96-well V bottom plate by transferring 75 μL of NK cells and 75μL of target cells to the same well. Media is added instead of NK cellsfor wells that were used to determine spontaneous calcein-AM release. 2%triton (Sigma-Aldrich, St. Louis, Mo., Cat. #93443) is added instead ofNK cells to wells that were used to determine total lysis. Allconditions were plated in triplicate.

Cells were incubated for 2-2.5 hours at 37° C. and then spun down at1300 rpm for 5 minutes. 100 μL/well of supernatant is transferred toblack cliniplates. Plates were read on a 2103 EnVision Multilabel Reader(Perkin Elmer, Waltham, Mass.)

Example 1.2.2.3.F FcR Binding Method

Cells (FcRn: FcRnGPI-CHO, FcγRI: THP-1, FcγRIIa: K562, FcγRIIb:CHO-FcγRII-b-1) were plated at 1×10⁵ cells/well on a 96 well roundbottom plate. Antibodies and DVD-Igs were diluted 100 μg/ml in FACSbuffer (1% FBS in PBS pH6.4 for FcRn samples, pH7.4 for the rest). Thesupernatant was removed from the cells and 30 μL of diluted antibodiesand DVD-Igs was added to well. Cells were incubated with the antibodiesat 4° C. for 2 hours. Following incubation, the cells were washed threetimes with 150 μL FACS buffer (pH 6.4 for FcRn samples, pH 7.4 for therest). The cells were resuspended in 50 μL FACS buffer (pH 6.4 for FcRnsamples, pH 7.4 for the rest) with 1:125 diluted R-PE conjugatedanti-human IgG F(Ab′)₂ (Jackson ImmunoResearch, West Grove, Pa., Cat.#109-116-170) and incubated at 4° C. for 40 minutes. Cells were washedthree times, and finally resuspended in 100 μL FACS buffer (pH 6.4 forFcRn samples, pH 7.4 for the rest). Samples were run on a FACSCaliburmachine (Becton Dickinson, San Jose, Calif.). FACSCalibur settings forFL2 were adjusted such that a non-antibody-treated control sample had aGMFI of 3. Experimental samples were run subsequently. FlowJo software(Treestar, Inc, Ashland, Oreg.) was used to analyze the data anddetermine R-PE GMFI on live cells as designated by a forward and sidescatter gate.

Example 1.4 Generation of a DVD-Ig

DVD-Ig molecules that bind two antigens are constructed using two parentmonoclonal antibodies, one against human antigen A, and the otheragainst human antigen B, selected as described herein.

Example 1.4.1 Generation of a DVD-Ig Having Two Linker Lengths

A constant region containing μ1 Fc with mutations at 234, and 235 toeliminate ADCC/CDC effector functions was used. Four different anti-A/BDVD-Ig constructs were generated: 2 with short linker (SL) and 2 withlong linker (LL), each in two different domain orientations:V_(A)-V_(B)-C and V_(B)-V_(A)-C (see Table 11). The linker sequences,derived from the N-terminal sequence of human Cl/Ck or CH1 domain, wereas follows:

For DVDAB constructs:

light chain (if anti-A has λ): (SEQ ID NO: 15) Short linker: QPKAAP;(SEQ ID NO: 16) Long linker: QPKAAPSVTLFPP light chain (if anti-A hasκ): (SEQ ID NO: 13) Short linker: TVAAP; (SEQ ID NO: 14) Long linker:TVAAPSVFIFPP heavy chain (γ1): (SEQ ID NO: 21) Short linker: ASTKGP;(SEQ ID NO: 22) Long linker: ASTKGPSVFPLAP

For DVDBA constructs:

light chain (if anti-B has λ): (SEQ ID NO: 15) Short linker: QPKAAP;(SEQ ID NO: 16) Long linker: QPKAAPSVTLFPP light chain (if anti-B hask): (SEQ ID NO: 13) Short linker: TVAAP; (SEQ ID NO: 14) Long linker:TVAAPSVFIFPP heavy chain (γ1): (SEQ ID NO: 21) Short linker: ASTKGP;(SEQ ID NO: 22) Long linker: ASTKGPSVFPLAP

Heavy and light chain constructs were subcloned into the pBOS expressionvector, and expressed in COS cells, followed by purification by ProteinA chromatography. The purified materials were subjected to SDS-PAGE andSEC analysis.

Table 11 describes the heavy chain and light chain constructs used toexpress each anti-A/B DVD-Ig protein.

TABLE 11 Anti-A/B DVD-Ig Constructs DVD-Ig protein Heavy chain constructLight chain construct DVDABSL DVDABHC-SL DVDABLC-SL DVDABLL DVDABHC-LLDVDABLC-LL DVDBASL DVDBAHC-SL DVDBALC-SL DVDBALL DVDBAHC-LL DVDBALC-LL

Example 1.4.2 Molecular Cloning of DNA Constructs for DVDABSL andDVDABLL

To generate heavy chain constructs DVDABHC-LL and DVDABHC-SL, VH domainof A antibody is PCR amplified using specific primers (3′ primerscontain short/long linker sequence for SL/LL constructs, respectively);meanwhile VH domain of B antibody is amplified using specific primers(5′ primers contains short/long linker sequence for SL/LL constructs,respectively). Both PCR reactions are performed according to standardPCR techniques and procedures. The two PCR products are gel-purified,and used together as overlapping template for the subsequent overlappingPCR reaction. The overlapping PCR products are subcloned into Srf I andSal I double digested pBOS-hCγ1,z non-a mammalian expression vector(Abbott) by using standard homologous recombination approach.

To generate light chain constructs DVDABLC-LL and DVDABLC-SL, VL domainof A antibody is PCR amplified using specific primers (3′ primerscontain short/long linker sequence for SL/LL constructs, respectively);meanwhile VL domain of B antibody is amplified using specific primers(5′ primers contains short/long linker sequence for SL/LL constructs,respectively). Both PCR reactions are performed according to standardPCR techniques and procedures. The two PCR products are gel-purified,and used together as overlapping template for the subsequent overlappingPCR reaction using standard PCR conditions. The overlapping PCR productsare subcloned into Srf I and Not I double digested pBOS-hCk mammalianexpression vector (Abbott) by using standard homologous recombinationapproach. Similar approach has been used to generate DVDBASL and DVDBALLas described below:

Example 1.4.3 Molecular Cloning of DNA Constructs for DVDBASL andDVDBALL

To generate heavy chain constructs DVDBAHC-LL and DVDBAHC-SL, VH domainof antibody B is PCR amplified using specific primers (3′ primerscontain short/long linker sequence for SL/LL constructs, respectively);meanwhile VH domain of antibody A is amplified using specific primers(5′ primers contains short/long linker sequence for SL/LL constructs,respectively). Both PCR reactions are performed according to standardPCR techniques and procedures. The two PCR products are gel-purified,and used together as overlapping template for the subsequent overlappingPCR reaction using standard PCR conditions. The overlapping PCR productsare subcloned into Sri I and Sal I double digested pBOS-hCγ1,z non-amammalian expression vector (Abbott) by using standard homologousrecombination approach.

To generate light chain constructs DVDBALC-LL and DVDBALC-SL, VL domainof antibody B is PCR amplified using specific primers (3′ primerscontain short/long linker sequence for SL/LL constructs, respectively);meanwhile VL domain of antibody A is amplified using specific primers(5′ primers contains short/long linker sequence for SL/LL constructs,respectively). Both PCR reactions are performed according to standardPCR techniques and procedures. The two PCR products are gel-purified,and used together as overlapping template for the subsequent overlappingPCR reaction using standard PCR conditions. The overlapping PCR productsare subcloned into Srf I and Not I double digested pBOS-hCk mammalianexpression vector (Abbott) by using standard homologous recombinationapproach.

Example 1.4.4 Construction and Expression of Additional DVD-Ig Example1.4.4.1 Preparation of DVD-Ig Vector Constructs

Parent antibody amino acid sequences for specific antibodies, whichrecognize specific antigens or epitopes thereof, for incorporation intoa DVD-Ig can be obtained by preparation of hybridomas as described aboveor can be obtained by sequencing known antibody proteins or nucleicacids. In addition, known sequences can be obtained from the literature.The sequences can be used to synthesize nucleic acids using standard DNAsynthesis or amplification technologies and assembling the desiredantibody fragments into expression vectors, using standard recombinantDNA technology, for expression in cells.

For example, nucleic acid codons were determined from amino acidssequences and oligonucleotide DNA is synthesized by Blue HeronBiotechnology, Inc. (www.blueheronbio.com) Bothell, Wash. USA. Theoligonucleotides were assembled into 300-2,000 base pair double-strandedDNA fragments, cloned into a plasmid vector and sequence-verified.Cloned fragments were assembled using an enzymatic process to yield thecomplete gene and subcloned into an expression vector. (See U.S. Pat.Nos. 7,306,914; 7,297,541; 7,279,159; 7,150,969; 20080115243;20080102475; 20080081379; 20080075690; 20080063780; 20080050506;20080038777; 20080022422; 20070289033; 20070287170; 20070254338;20070243194; 20070225227; 20070207171; 20070150976; 20070135620;20070128190; 20070104722; 20070092484; 20070037196; 20070028321;20060172404; 20060162026; 20060153791; 20030215458; 20030157643).

A group of pHybE vectors (U.S. Patent Application Ser. No. 61/021,282)were used for parental antibody and DVD-Ig cloning. V1, derived frompJP183; pHybE-hCg1,z,non-a V2, was used for cloning of antibody and DVDheavy chains with a wildtype constant region. V2, derived from pJP191;pHybE-hCk V2, was used for cloning of antibody and DVD light chains witha kappa constant region. V3, derived from pJP192; pHybE-hCl V2, was usedfor cloning of antibody and DVDs light chains with a lambda constantregion. V4, built with a lambda signal peptide and a kappa constantregion, was used for cloning of DVD light chains with a lambda-kappahybrid V domain. V5, built with a kappa signal peptide and a lambdaconstant region, was used for cloning of DVD light chains with akappa-lambda hybrid V domain. V7, derived from pJP183;pHybE-hCg1,z,non-a V2, was used for cloning of antibody and DVD heavychains with a (234,235 AA) mutant constant region.

Referring to Table 12, a number of vectors were used in the cloning ofthe parent antibodies and DVD-Ig VH and VL chains.

TABLE 12 Vectors Used to Clone Parent Antibodies and DVD-Igs ID Heavychain vector Light chain vector AB268 V1 V2 AB269 V1 V2 AB270 V1 V2AB271 V1 V2 AB272 V1 V2 AB273 V1 V2 AB274 V1 V2 AB275 V1 V2 DVD1262 V1V2 DVD1263 V1 V2 DVD1264 V1 V2 DVD1265 V1 V2 DVD1266 V1 V2 DVD1267 V1 V2DVD1268 V1 V2 DVD1269 V1 V2 DVD1270 V1 V2 DVD1271 V1 V2 DVD1272 V1 V2DVD1273 V1 V2 DVD1274 V1 V2 DVD1275 V1 V2 DVD1276 V1 V2 DVD1277 V1 V2DVD1278 V1 V2 DVD1279 V1 V2 DVD1280 V1 V2 DVD1281 V1 V2 DVD1282 V1 V2DVD1283 V1 V2 DVD1284 V1 V2 DVD1285 V1 V2 DVD1286 V1 V2 DVD1287 V1 V2DVD1288 V1 V2 DVD1289 V1 V2 DVD1290 V1 V2 DVD1291 V1 V2 DVD1589 V1 V2DVD1590 V1 V2 DVD1591 V1 V2 DVD1592 V1 V2 DVD1593 V1 V2 DVD1594 V1 V2DVD1595 V1 V2 DVD1596 V1 V2 DVD1597 V1 V2 DVD1598 V1 V2 DVD1599 V1 V2DVD1600 V1 V2 DVD1601 V1 V2 DVD1602 V1 V2 DVD1603 V1 V2 DVD1604 V1 V2DVD1605 V1 V2 DVD1606 V1 V2 DVD1607 V1 V2 DVD1608 V1 V2 DVD1609 V1 V2DVD1610 V1 V2 DVD1611 V1 V2 DVD1612 V1 V2 DVD1613 V1 V2 DVD1614 V1 V2DVD1615 V1 V2 DVD1616 V1 V2 DVD1617 V1 V2 DVD1618 V1 V2 DVD1619 V1 V2DVD1620 V1 V2 DVD1621 V1 V2 DVD1622 V1 V2 DVD1623 V1 V2 DVD1624 V1 V2DVD1625 V1 V2 DVD1626 V1 V2 DVD1627 V1 V2 DVD1628 V1 V2 DVD1629 V1 V2DVD1630 V1 V2 DVD1631 V1 V2 DVD1632 V1 V2 DVD1633 V1 V2 DVD1634 V1 V2DVD1635 V1 V2 DVD1636 V1 V2 DVD1637 V1 V2 DVD1638 V1 V2 DVD1639 V1 V2DVD1640 V1 V2 DVD1641 V1 V2 DVD1642 V1 V2 DVD1643 V1 V2 DVD1644 V1 V2DVD1645 V1 V2 DVD1646 V1 V2 DVD1647 V1 V2 DVD1648 V1 V2

Example 1.4.4.2 Transfection and Expression in 293 Cells

The DVD-Ig vector constructs were transfected into 293 cells forproduction of DVD-Ig protein. The 293 transient transfection procedureused was a modification of the methods published in Durocher et al.(2002) Nucleic Acids Res. 30(2):E9 and Pham et al. (2005) Biotech.Bioengineering 90(3):332-44. Reagents that were used in the transfectionincluded:

-   -   HEK 293-6E cells (human embryonic kidney cell line stably        expressing EBNA1; obtained from National Research Council        Canada) cultured in disposable Erlenmeyer flasks in a humidified        incubator set at 130 rpm, 37° C. and 5% CO₂.    -   Culture medium: FreeStyle 293 Expression Medium (Invitrogen        12338-018) plus 25 μg/mL Geneticin (G418) (Invitrogen 10131-027)        and 0.1% Pluronic F-68 (Invitrogen 24040-032).    -   Transfection medium: FreeStyle 293 Expression Medium plus 10 mM        HEPES (Invitrogen 15630-080).    -   Polyethylenimine (PEI) stock: 1 mg/mL sterile stock solution, pH        7.0, prepared with linear 25 kDa PEI (Polysciences) and stored        at less than −15° C.    -   Tryptone Feed Medium: 5% w/v sterile stock of Tryptone N1        (Organotechnie, 19554) in FreeStyle 293 Expression Medium.        Cell preparation for transfection: Approximately 2-4 hours prior        to transfection, HEK 293-6E cells were harvested by        centrifugation and resuspended in culture medium at a cell        density of approximately 1 million viable cells per mL. For each        transfection, 40 mL of the cell suspension was transferred into        a disposable 250-mL Erlenmeyer flask and incubated for 2-4        hours.

Transfection: The transfection medium and PEI stock were prewarmed toroom temperature (RT). For each transfection, 25 μg of plasmid DNA and50 μg of polyethylenimine (PEI) were combined in 5 mL of transfectionmedium and incubated for 15-20 minutes at RT to allow the DNA:PEIcomplexes to form. For the BR3-Ig transfections, 25 μg of BR3-Ig plasmidwas used per transfection. Each 5-mL DNA:PEI complex mixture was addedto a 40-mL culture prepared previously and returned to the humidifiedincubator set at 130 rpm, 37° C. and 5% CO₂. After 20-28 hours, 5 mL ofTryptone Feed Medium was added to each transfection and the cultureswere continued for six days.

The expression profile for the DVD-Igs is shown in Table 13.

TABLE 13 Transient HEK293 Expression Yields of NKG2D ContainingAntibodies and DVD-Igs N-terminal C-terminal Variable VariableExpression DVD ID Domain (VD) Domain (VD) Yield (mg/L) AB268 IL-1B(seq. 1) 32 AB269 IL-1B (seq. 2) 27.2 AB270 IL-1B (seq. 3) 52 AB271IL-1B (seq. 4) 34.2 AB272 IL-1B (seq. 5) 66.6 AB273 IL-17 (seq. 1) 16.6AB274 IL-17 (seq. 2) 44.6 AB275 IL-17 (seq. 3) 44.2 DVD1262 IL-1B(seq. 1) IL-17 (seq. 1) 29.6 DVD1263 IL-17 (seq. 1) IL-1B (seq. 1) 19DVD1264 IL-1B (seq. 2) IL-17 (seq. 1) 18.18 DVD1265 IL-17 (seq. 1) IL-1B(seq. 2) 16.86 DVD1266 IL-1B (seq. 3) IL-17 (seq. 1) 43 DVD1267 IL-17(seq. 1) IL-1B (seq. 3) 37.8 DVD1268 IL-1B (seq. 4) IL-17 (seq. 1) 28.18DVD1269 IL-17 (seq. 1) IL-1B (seq. 4) 32.74 DVD1270 IL-1B (seq. 5) IL-17(seq. 1) 43.8 DVD1271 IL-17 (seq. 1) IL-1B (seq. 5) 36.6 DVD1272 IL-1B(seq. 1) IL-17 (seq. 2) 45.8 DVD1273 IL-17 (seq. 2) IL-1B (seq. 1) 31.4DVD1274 IL-1B (seq. 2) IL-17 (seq. 2) 55.36 DVD1275 IL-17 (seq. 2) IL-1B(seq. 2) 34.52 DVD1276 IL-1B (seq. 3) IL-17 (seq. 2) 85.3 DVD1277 IL-17(seq. 2) IL-1B (seq. 3) 73 DVD1278 IL-1B (seq. 4) IL-17 (seq. 2) 69.38DVD1279 IL-17 (seq. 2) IL-1B (seq. 4) 57.62 DVD1280 IL-1B (seq. 5) IL-17(seq. 2) 88.6 DVD1281 IL-17 (seq. 2) IL-1B (seq. 5) 65 DVD1282 IL-1B(seq. 1) IL-17 (seq. 3) 53.2 DVD1283 IL-17 (seq. 3) IL-1B (seq. 1) 65.8DVD1284 IL-1B (seq. 2) IL-17 (seq. 3) 32.2 DVD1285 IL-17 (seq. 3) IL-1B(seq. 2) 30.2 DVD1286 IL-1B (seq. 3) IL-17 (seq. 3) 96.2 DVD1287 IL-17(seq. 3) IL-1B (seq. 3) 83.6 DVD1288 IL-1B (seq. 4) IL-17 (seq. 3) 78.4DVD1289 IL-17 (seq. 3) IL-1B (seq. 4) 5.36 DVD1290 IL-1B (seq. 5) IL-17(seq. 3) 28.6 DVD1291 IL-17 (seq. 3) IL-1B (seq. 5) 49.6 DVD1589 IL-1B(seq. 1) IL-17 (seq. 1) 22.4 DVD1590 IL-17 (seq. 1) IL-1B (seq. 1) 3.86DVD1591 IL-1B (seq. 2) IL-17 (seq. 1) 7.52 DVD1592 IL-17 (seq. 1) IL-1B(seq. 2) 0.54 DVD1593 IL-1B (seq. 3) IL-17 (seq. 1) 9.82 DVD1594 IL-17(seq. 1) IL-1B (seq. 3) 35.38 DVD1595 IL-1B (seq. 4) IL-17 (seq. 1)37.28 DVD1596 IL-17 (seq. 1) IL-1B (seq. 4) 35.8 DVD1597 IL-1B (seq. 5)IL-17 (seq. 1) 22.4 DVD1598 IL-17 (seq. 1) IL-1B (seq. 5) 29.22 DVD1599IL-1B (seq. 1) IL-17 (seq. 2) 41.3 DVD1600 IL-17 (seq. 2) IL-1B (seq. 1)10.58 DVD1601 IL-1B (seq. 2) IL-17 (seq. 2) 31.76 DVD1602 IL-17 (seq. 2)IL-1B (seq. 2) 10.7 DVD1603 IL-1B (seq. 3) IL-17 (seq. 2) 2.66 DVD1604IL-17 (seq. 2) IL-1B (seq. 3) 6.54 DVD1605 IL-1B (seq. 4) IL-17 (seq. 2)3.5 DVD1606 IL-17 (seq. 2) IL-1B (seq. 4) 1.28 DVD1607 IL-1B (seq. 5)IL-17 (seq. 2) 0.34 DVD1608 IL-17 (seq. 2) IL-1B (seq. 5) 0.82 DVD1609IL-1B (seq. 1) IL-17 (seq. 3) 44.74 DVD1610 IL-17 (seq. 3) IL-1B(seq. 1) 21.5 DVD1611 IL-1B (seq. 2) IL-17 (seq. 3) 35.98 DVD1612 IL-17(seq. 3) IL-1B (seq. 2) 13.98 DVD1613 IL-1B (seq. 3) IL-17 (seq. 3)28.38 DVD1614 IL-17 (seq. 3) IL-1B (seq. 3) 25.78 DVD1615 IL-1B (seq. 4)IL-17 (seq. 3) 74.94 DVD1616 IL-17 (seq. 3) IL-1B (seq. 4) 51.34 DVD1617IL-1B (seq. 5) IL-17 (seq. 3) 85.5 DVD1618 IL-17 (seq. 3) IL-1B (seq. 5)45.92 DVD1619 IL-1B (seq. 1) IL-17 (seq. 1) 39.88 DVD1620 IL-17 (seq. 1)IL-1B (seq. 1) 23.2 DVD1621 IL-1B (seq. 2) IL-17 (seq. 1) 38.22 DVD1622IL-17 (seq. 1) IL-1B (seq. 2) 15.54 DVD1623 IL-1B (seq. 3) IL-17(seq. 1) 35.88 DVD1624 IL-17 (seq. 1) IL-1B (seq. 3) 37.38 DVD1625 IL-1B(seq. 4) IL-17 (seq. 1) 60.96 DVD1626 IL-17 (seq. 1) IL-1B (seq. 4)66.38 DVD1627 IL-1B (seq. 5) IL-17 (seq. 1) 72.02 DVD1628 IL-17 (seq. 1)IL-1B (seq. 5) 52.2 DVD1629 IL-1B (seq. 1) IL-17 (seq. 2) 70.36 DVD1630IL-17 (seq. 2) IL-1B (seq. 1) 58.84 DVD1631 IL-1B (seq. 2) IL-17 (seq.2) 68.04 DVD1632 IL-17 (seq. 2) IL-1B (seq. 2) 55.08 DVD1633 IL-1B (seq.3) IL-17 (seq. 2) 1 DVD1634 IL-17 (seq. 2) IL-1B (seq. 3) 0.9 DVD1635IL-1B (seq. 4) IL-17 (seq. 2) 16.58 DVD1636 IL-17 (seq. 2) IL-1B (seq.4) 6.52 DVD1637 IL-1B (seq. 5) IL-17 (seq. 2) 11.14 DVD1638 IL-17 (seq.2) IL-1B (seq. 5) 2.24 DVD1639 IL-1B (seq. 1) IL-17 (seq. 3) 9.2 DVD1640IL-17 (seq. 3) IL-1B (seq. 1) 4.84 DVD1641 IL-1B (seq. 2) IL-17 (seq. 3)12.8 DVD1642 IL-17 (seq. 3) IL-1B (seq. 2) 26.48 DVD1643 IL-1B (seq. 3)IL-17 (seq. 3) 2.94 DVD1644 IL-17 (seq. 3) IL-1B (seq. 3) 32.68 DVD1645IL-1B (seq. 4) IL-17 (seq. 3) 51.1 DVD1646 IL-17 (seq. 3) IL-1B (seq. 4)32.68 DVD1647 IL-1B (seq. 5) IL-17 (seq. 3) 14.13 DVD1648 IL-17 (seq. 3)IL-1B (seq. 5) 5.12

All DVDs expressed well in 293 cells. DVDs could be easily purified overa protein A column. In most cases >5 mg/L purified DVD-Ig could beobtained easily from supernatants of 293 cells.

Example 1.4.5 Characterization and Lead Selection of A/B DVD-Igs

The binding affinities of anti-A/B DVD-Igs are analyzed on Biacoreagainst both protein A and protein B. The tetravalent property of theDVD-Ig is examined by multiple binding studies on Biacore. Meanwhile,the neutralization potency of the DVD-Igs for protein A and protein Bare assessed by bioassays, respectively, as described herein. The DVD-Igmolecules that best retain the affinity and potency of the originalparent mAbs are selected for in-depth physicochemical and bio-analytical(rat PK) characterizations as described herein for each mAb. Based onthe collection of analyses, the final lead DVD-Ig is advanced into CHOstable cell line development, and the CHO-derived material is employedin stability, pharmacokinetic and efficacy studies in cynomolgus monkey,and preformulation activities.

Example 2 Generation and Characterization of Dual Variable DomainImmunoglobulins (DVD-Ig)

Dual variable domain immunoglobulins (DVD-Ig) using parent antibodieswith known amino acid sequences were generated by synthesizingpolynucleotide fragments encoding DVD-Ig variable heavy and DVD-Igvariable light chain sequences and cloning the fragments into a pHybC-D2vector according to Example 1.4.4.1. The DVD-Ig constructs were clonedinto and expressed in 293 cells as described in Example 1, 4.4.2. TheDVD-Ig protein was purified according to standard methods. Functionalcharacteristics were determined according to the methods described inExample 1.1.1 and 1.1.2 as indicated. DVD-Ig VH and VL chains for theDVD-Igs are provided below.

Example 2.1 Generation of IL-1β (Seq. 1) and IL-17 (seq. 1) DVD-Igs withLinker Set 1

TABLE 14 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 12345678901234567890123456789 NO Name Name Name012345 50 DVD1262H AB268VH AB273VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGT YYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVT VSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQGLEWMG VNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYCTRYSKWDSFDG MDYWGQGTTVTVSS 51 DVD1262L AB268VL AB273VLDIQMTQSPSSLSASVGDRVTITCRASGNI HNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYY CQHFWSIPYTFGQGTKLQITRTVAAPDIQMTQSPSSLSASVGDRVTITCRASSGIISY IDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQ VGSYPETFGQGTKLEIKR 52 DVD1263H AB273VHAB268VH EVQLVQSGAEVKKPGSSVKVSCKASGYTF TDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLR SEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPEVQLVESGGGVVQPGRSL RLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSK NTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS 53 DVD1263L AB273VL AB268VL DIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLASGV PSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKRTVAAPDIQ MTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSR FSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR

Example 2.2 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 1) DVD-Igs withLinker Set 1

TABLE 15 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 12345678901234567890123456789 NO Name Name Name012345 54 DVD1264H AB269VH AB273VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGT YYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVT VSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQGLEWMG VNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYCTRYSKWDSFDG MDYWGQGTTVTVSS 55 DVD1264L AB269VL AB273VLDIQMTQSPSSLSASVGDRVTITCRASGNI HNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIATYY CQHFWSIPYTFGQGTKLQITRTVAAPDIQMTQSPSSLSASVGDRVTITCRASSGIISY IDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQ VGSYPETFGQGTKLEIKR 56 DVD1265H AB273VHAB269VH EVQLVQSGAEVKKPGSSVKVSCKASGYTF TDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLR SEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPEVQLVESGGGVVQPGRSL RLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSK NTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVTVSS 57 DVD1265L AB273VL AB269VL DIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLASGV PSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKRTVAAPDIQ MTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSR FSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR

Example 2.3 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 1) DVD-Igs withLinker Set 1

TABLE 16 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 58 DVD1266H AB270VH AB273VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGG GDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYG MDYWGQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEI HWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRS EDTAVYYCTRYSKWDSFDGMDYWGQGT TVTVSS 59DVD1266L AB270VL AB273VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTL RPGVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKR TVAAPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIY ATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTK LEIKR 60 DVD1267H AB273VH AB270VHEVQLVQSGAEVKKPGSSVKVSCKASGY TFTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYM ELSSLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPEVQLQESG PGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSP LKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGT LVTVSS 61 DVD1267L AB273VL AB270VLDIQMTQSPSSLSASVGDRVTITCRASS GIISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPE DFATYYCRQVGSYPETFGQGTKLEIKRTVAAPDTQVTQSPSSLSASVGDRVTIT CITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLQPEDFATYYCLQSDNLPLTFGQGTK LEIKR

Example 2.4 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 1) DVD-Igs withLinker Set 1

TABLE 17 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 12345678901234567890123456789 NO Name Name Name012345 62 DVD1268H AB271VH AB273VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTY YNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGT LVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQGLE WMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYCTRYSKWDS FDGMDYWGQGTTVTVSS 63 DVD1268L AB271VLAB273VL DTVVTQSPAFLSVTPGEKVTITCITSTDI DVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLEAEDAATYY CLQSDNLPLTFGQGTKLEIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASSGIISY IDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQ VGSYPETFGQGTKLEIKR 64 DVD1269H AB273VHAB271VH EVQLVQSGAEVKKPGSSVKVSCKASGYTF TDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLR SEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPEVQLQESGPGLVKPSETL SLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLKSRLTISKDNSKS QVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 65 DVD1269L AB273VL AB271VLDIQMTQSPSSLSASVGDRVTITCRASSGI ISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYY CRQVGSYPETFGQGTKLEIKRTVAAPDTVVTQSPAFLSVTPGEKVTITCITSTDIDVD MNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQ SDNLPLTFGQGTKLEIKR

Example 2.5 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 1) DVD-Igs withLinker Set 1

TABLE 18 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 66 DVD1270H AB272VH AB273VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQA PGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYC TRYSKWDSFDGMDYWGQGTTVTVSS 67 DVD1270LAB272VL AB273VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLA SGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKR 68 DVD1271H AB273VH AB272VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPEVQLVESGGGLVQ PGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDTYYNSPLKSRLTI SKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 69 DVD1271L AB273VL AB272VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPETTVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.6 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 2) DVD-Igs withLinker Set 1

TABLE 19 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 70 DVD1272H AB268VH AB274VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQ GLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARD PNEFWNGYYSTHDFDSWGQGTTVTVSS 71 DVD1272LAB268VL AB274VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 72 DVD1273H AB274VH AB268VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSV KGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS 73 DVD1273L AB274VL AB268VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASG NIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDI ATYYCQHFWSIPYTFGQGTKLQITR

Example 2.7 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 2) DVD-Igs withLinker Set 1

TABLE 20 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 74 DVD1274H AB269VH AB274VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQ GLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARD PNEFWNGYYSTHDFDSWGQGTTVTVSS 75 DVD1274LAB269VL AB274VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 76 DVD1275H AB274VH AB269VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSV KGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVTVSS 77 DVD1275L AB274VL AB269VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASG NIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDI ATYYCQHFWSIPYTFGQGTKLQITR

Example 2.8 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 2) DVD-Igs withLinker Set 1

TABLE 21 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 78 DVD1276H AB270VH AB274VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQA PGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC ARDPNEFWNGYYSTHDFDSWGQGTTVTV SS 79 DVD1276LAB270VL AB274VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 80 DVD1277H AB274VH AB270VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQLQESG PGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 81 DVD1277L AB274VL AB270VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPDTQVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.9 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 2) DVD-Igs withLinker Set 1

TABLE 22 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 82 DVD1278H AB271VH AB274VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQA PGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC ARDPNEFWNGYYSTHDFDSWGQGTTVTV SS 83 DVD1278LAB271VL AB274VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 84 DVD1279H AB274VH AB271VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQLQESG PGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 85 DVD1279L AB274VL AB271VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPDTVVTQSPAFLSVTPGEKVTITCITST DIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLEAEDA ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.10 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 2) DVD-Igswith Linker Set 1

TABLE 23 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 86 DVD1280H AB272VH AB274VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQA PGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC ARDPNEFWNGYYSTHDFDSWGQGTTVTV SS 87 DVD1280LAB272VL AB274VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 88 DVD1281H AB274VH AB272VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 89 DVD1281L AB274VL AB272VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPETTVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.11 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 3) DVD-Igswith Linker Set 1

TABLE 24 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 90 DVD1282H AB268VH AB275VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQAPGQ GLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARE PNDFWNGYYDTHDFDSWGQGTTVTVSS 91 DVD1282LAB268VL AB275VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 92 DVD1283H AB275VH AB268VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSV KGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS 93 DVD1283L AB275VL AB268VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASG NIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDI ATYYCQHFWSIPYTFGQGTKLQITR

Example 2.12 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 3) DVD-Igswith Linker Set 1

TABLE 25 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 94 DVD1284H AB269VH AB275VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQAPGQ GLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARE PNDFWNGYYDTHDFDSWGQGTTVTVSS 95 DVD1284LAB269VL AB275VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 96 DVD1285H AB275VH AB269VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSV KGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVTVSS 97 DVD1285L AB275VL AB269VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASG NIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDI ATYYCQHFWSIPYTFGQGTKLQITR

Example 2.13 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 3) DVD-Igswith Linker Set 1

TABLE 26 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 98 DVD1286H AB270VH AB275VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQA PGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC AREPNDFWNGYYDTHDFDSWGQGTTVTV SS 99 DVD1286LAB270VL AB275VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 100 DVD1287H AB275VH AB270VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLQESG PGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 101 DVD1287L AB275VL AB270VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPDTQVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.14 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 3) DVD-Igswith Linker Set 1

TABLE 27 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 102 DVD1288H AB271VH AB275VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQA PGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC AREPNDFWNGYYDTHDFDSWGQGTTVTV SS 103DVD1288L AB271VL AB275VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 104 DVD1289H AB275VH AB271VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLQESG PGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 105 DVD1289L AB275VL AB271VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPDTVVTQSPAFLSVTPGEKVTITCITST DIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLEAEDA ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.15 Generation of IL-1β (Seq. 5) and IL-17 (seq. 3) DVD-IgsWith Linker Set 1

TABLE 28 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 106 DVD1290H AB272VH AB275VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQA PGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC AREPNDFWNGYYDTHDFDSWGQGTTVTV SS 107DVD1290L AB272VL AB275VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 108 DVD1291H AB275VH AB272VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 109 DVD1291L AB275VL AB272VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPETTVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.16 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 1) DVD-Igswith Linker Set 2

TABLE 29 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 110 DVD1589H AB268VH AB273VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQ GLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYCTRY SKWDSFDGMDYWGQGTTVTVSS 111 DVD1589L AB268VLAB273VL DIQMTQSPSSLSASVGDRVTITCRASGN IHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIA TYYCQHFWSIPYTFGQGTKLQITRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTIS SLQPEDFATYYCRQVGSYPETFGQGTKL EIKR 112DVD1590H AB273VH AB268VH EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQGLEWMGVNDPESG GTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYCTRYSKWDSFDGMDYWG QGTTVTVSSASTKGPEVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAP GKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCA RGGVTKGYFDVWGQGTPVTVSS 113 DVD1590L AB273VLAB268VL DIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTKL QITR

Example 2.17 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 1) DVD-Igswith Linker Set 2

TABLE 30 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 114 DVD1591H AB269VH AB273VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQ GLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYCTRY SKWDSFDGMDYWGQGTTVTVSS 115 DVD1591L AB269VLAB273VL DIQMTQSPSSLSASVGDRVTITCRASGN IHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDIA TYYCQHFWSIPYTFGQGTKLQITRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTIS SLQPEDFATYYCRQVGSYPETFGQGTKL EIKR 116DVD1592H AB273VH AB269VH EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQGLEWMGVNDPESG GTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYCTRYSKWDSFDGMDYWG QGTTVTVSSASTKGPEVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAP GKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCA RGGVYKGYFDVWGQGTPVTVSS 117 DVD1592L AB273VLAB269VL DIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTKL QITR

Example 2.18 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 1) DVD-Igswith Linker Set 2

TABLE 31 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 118 DVD1593H AB270VH AB273VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQA PGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYC TRYSKWDSFDGMDYWGQGTTVTVSS 119 DVD1593LAB270VL AB273VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLI YATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKL EIKR 120 DVD1594H AB273VH AB270VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPEVQLQESGPGLVK PSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLKSRLTI SKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 121 DVD1594L AB273VL AB270VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPDTQVTQSPSSLSASVGDRVT ITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLQPEDFATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.19 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 1) DVD-Igswith Linker Set 2

TABLE 32 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 122 DVD1595H AB271VH AB273VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQA PGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYC TRYSKWDSFDGMDYWGQGTTVTVSS 123 DVD1595LAB271VL AB273VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLI YATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKL EIKR 124 DVD1596H AB273VH AB271VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPEVQLQESGPGLVK PSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLKSRLTI SKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 125 DVD1596L AB273VL AB271VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPDTVVTQSPAFLSVTPGEKVT ITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLEAEDAATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.20 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 1) DVD-Igswith Linker Set 2

TABLE 33 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 126 DVD1597H AB272VH AB273VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQA PGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTAVYYC TRYSKWDSFDGMDYWGQGTTVTVSS 127 DVD1597LAB272VL AB273VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLI YATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKL EIKR 128 DVD1598H AB273VH AB272VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPEVQLVESGGGLVQ PGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDTYYNSPLKSRLTI SKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 129 DVD1598L AB273VL AB272VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPETTVTQSPSSLSASVGDRVT ITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLQPEDFATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.21 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 2) DVD-Igswith Linker Set 2

TABLE 34 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 130 DVD1599H AB268VH AB274VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHG GAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDV WGQGTPVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWV RQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDT AVYYCARDPNEFWNGYYSTHDFDSWGQ GTTVTVSS 131DVD1599L AB268VL AB274VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTL ADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR TVAAPSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQ PPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPY TFGPGTKVDIKR 132 DVD1600H AB274VH AB268VHEVQLVQSGAEVKKPGSSVKVSCKASGG SFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYM ELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQ LVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAG TYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQ GTPVTVSS 133 DVD1600L AB274VL AB268VLEIVLTQSPDFQSVTPKEKVTITCRASQ DIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAE DAGTYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPDIQMTQSPSSLSASV GDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGT DYTFTISSLQPEDIATYYCQHFWSIPY TFGQGTKLQITR

Example 2.22 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 2) DVD-Igswith Linker Set 2

TABLE 35 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 134 DVD1601H AB269VH AB274VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQ GLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARD PNEFWNGYYSTHDFDSWGQGTTVTVSS 135 DVD1601LAB269VL AB274VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLI KYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKV DIKR 136 DVD1602H AB274VH AB269VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSV KGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVTVSS 137 DVD1602L AB274VL AB269VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTKL QITR

Example 2.23 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 2) DVD-Igswith Linker Set 2

TABLE 36 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 138 DVD1603H AB270VH AB274VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGG GDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYG MDYWGQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGI GWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTS DDTAVYYCARDPNEFWNGYYSTHDFDS WGQGTTVTVSS 139DVD1603L AB270VL AB274VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTL RPGVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKR TVAAPSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQ PPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPY TFGPGTKVDIKR 140 DVD1604H AB274VH AB270VHEVQLVQSGAEVKKPGSSVKVSCKASGG SFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYM ELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQ LQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDY WGQGTLVTVSS 141 DVD1604L AB274VL AB270VLEIVLTQSPDFQSVTPKEKVTITCRASQ DIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAE DAGTYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPDTQVTQSPSSLSASV GDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGT DFTFTISSLQPEDFATYYCLQSDNLPL TFGQGTKLEIKR

Example 2.24 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 2) DVD-Igswith Linker Set 2

TABLE 37 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 142 DVD1605H AB271VH AB274VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQA PGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC ARDPNEFWNGYYSTHDFDSWGQGTTVTV SS 143DVD1605L AB271VL AB274VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLI KYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKV DIKR 144 DVD1606H AB274VH AB271VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQLQESG PGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 145 DVD1606L AB274VL AB271VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPDTVVTQSPAFLSVTPGEKVT ITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLEAEDAATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.25 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 2) DVD-Igswith Linker Set 2

TABLE 38 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 146 DVD1607H AB272VH AB274VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQA PGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC ARDPNEFWNGYYSTHDFDSWGQGTTVTV SS 147DVD1607L AB272VL AB274VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLI KYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKV DIKR 148 DVD1608H AB274VH AB272VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 149 DVD1608L AB274VL AB272VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPETTVTQSPSSLSASVGDRVT ITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLQPEDFATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.26 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 3) DVD-Igswith Linker Set 2

TABLE 39 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 150 DVD1609H AB268VH AB275VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQAPGQ GLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARE PNDFWNGYYDTHDFDSWGQGTTVTVSS 151 DVD1609LAB268VL AB275VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLI KYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKV DIKR 152 DVD1610H AB275VH AB268VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSV KGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSS 153 DVD1610L AB275VL AB268VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTKL QITR

Example 2.27 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 3) DVD-Igswith Linker Set 2

TABLE 40 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 154 DVD1611H AB269VH AB275VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQG TPVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQAPGQ GLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARE PNDFWNGYYDTHDFDSWGQGTTVTVSS 155 DVD1611LAB269VL AB275VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLI KYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKV DIKR 156 DVD1612H AB275VH AB269VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLVESG GGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSV KGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVTVSS 157 DVD1612L AB275VL AB269VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTKL QITR

Example 2.28 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 3) DVD-Igswith Linker Set 2

TABLE 41 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 158 DVD1613H AB270VH AB275VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQA PGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC AREPNDFWNGYYDTHDFDSWGQGTTVTV SS 159DVD1613L AB270VL AB275VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKFGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKFDQSPKLLI KYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKV DIKR 160 DVD1614H AB275VH AB270VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLQESG PGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 161 DVD1614L AB275VL AB270VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPDTQVTQSPSSLSASVGDRVT ITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLQPEDFATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.29 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 3) DVD-Igswith Linker Set 2

TABLE 42 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 162 DVD1615H AB271VH AB275VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISWVRQA PGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYC AREPNDFWNGYYDTHDFDSWGQGTTVTV SS 163DVD1615L AB271VL AB275VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKFDQPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSFKLLI KYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKV DIKR 164 DVD1616H AB275VH AB271VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPEVQLQESG PGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDTYYNSPLK SRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTV SS 165 DVD1616L AB275VL AB271VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPDTVVTQSPAFLSVTPGEKVT ITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLEAEDAATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.30 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 3) DVD-Igswith Linker Set 2

TABLE 43 Outer Inner DVD Variable Variable Variable Sequence SEQ IDDomain Domain Domain 12345678901234567890123 NO Name Name Name456789012345 166 DVD1617H AB272VH AB275VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLE WLGLIWGGGDTYYNSPLKSRLTI SKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQG TLVTVSSASTKGPEVQLVQSGAE VKKPGESVKISCKASGGSFRSYGISWVRQAPGQGLEWMGGITHFFG ITDYAQKFQGRVTITADESTTTA YMELSGLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSS 167 DVD1617L AB272VL AB275VLETTVTQSPSSLSASVGDRVTITC ITSTDIDVDMNWYQQKPGKPPKL LISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSD NLPLTFGQGTKLEIKRTVAAPSV FIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPD QSPKLLIKYASHSISGVPSRFSG SGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 168 DVD1618H AB275VH AB272VHEVQLVQSGAEVKKPGESVKISCK ASGGSFRSYGISWVRQAPGQGLE WMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTA VYYCAREPNDFWNGYYDTHDFDS WGQGTTVTVSSASTKGPEVQLVESGGGLVQPGGSLRLSCAVSGFTL SDYGVSWIRQAPGKGLEWLGLIW GGGDTYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQ RTLWGYDLYGMDYWGQGTLVTVSS 169 DVD1618L AB275VLAB272VL EIVLTQSPDFQSVTPKEKVTITC RASQNIGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGT DFTLTINGLEAEDAATYYCHQSD TLPHTFGQGTKVDIKRTVAAPSVFIFPPETTVTQSPSSLSASVGDR VTITCITSTDIDVDMNWYQQKPG KPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDFATYY CLQSDNLPLTFGQGTKLEIKR

Example 2.31 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 1) DVD-Igswith Linker Set 3

TABLE 44 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 170 DVD1619H AB268VH AB273VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQG TPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHW VRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTA VYYCTRYSKWDSFDGMDYWGQGTTVTVS S 171 DVD1619LAB268VL AB273VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLA SGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKR 172 DVD1620H AB273VH AB268VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVFPLAPEVQLVE SGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPD SVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVS S 173 DVD1620L AB273VL AB268VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASG NIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDI ATYYCQHFWSIPYTFGQGTKLQITR

Example 2.32 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 1) DVD-Igswith Linker Set 3

TABLE 45 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 174 DVD1621H AB269VH AB273VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQG TPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHW VRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTA VYYCTRYSKWDSFDGMDYWGQGTTVTVS S 175 DVD1621LAB269VL AB273VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLA SGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKR 176 DVD1622H AB273VH AB269VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVFPLAPEVQLVE SGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPD SVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVTVS S 177 DVD1622L AB273VL AB269VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASG NIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDI ATYYCQHFWSIPYTFGQGTKLQITR

Example 2.33 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 1) DVD-Igswith Linker Set 3

TABLE 46 Outer Inner DVD Variable Variable Variable Sequence SEQ DomainDomain Domain 12345678901234567890123 ID NO Name Name Name 456789012345178 DVD1623H AB270VH AB273VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLE WLGLIWGGGDTYYNSPLKSRLTI SKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQG TLVTVSSASTKGPSVFPLAPEVQ LVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQGLEWMG VNDPESGGTFYNQKFDGRVTLTA DESTSTAYMELSSLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVT VSS 179 DVD1623L AB270VL AB273VLDTQVTQSPSSLSASVGDRVTITC ITSTDIDVDMNWYQQKPGKPPKL LISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSD NLPLTFGQGTKLEIKRTVAAPDI QMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLI YATFDLASGVPSRFSGSGSGTDY TLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKR 180 DVD1624H AB273VH AB270VH EVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHWVRQAPGQGLE WMGVNDPESGGTFYNQKFDGRVT LTADESTSTAYMELSSLRSEDTAVYYCTRYSKWDSFDGMDYWGQGT TVTVSSASTKGPSVFPLAPEVQL QESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGL IWGGGDTYYNSPLKSRLTISKDN SKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQGTLVT VSS 181 DVD1624L AB273VL AB270VLDIQMTQSPSSLSASVGDRVTITC RASSGIISYIDWFQQKPGKAPKR LIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVG SYPETFGQGTKLEIKRTVAAPDT QVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLI SQGNTLRPGVPSRFSSSGSGTDF TFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.34 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 1) DVD-Igswith Linker Set 3

TABLE 47 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 182 DVD1625H AB271VH AB273VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGG GDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYG MDYWGQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGY TFTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYM ELSSLRSEDTAVYYCTRYSKWDSFDGM DYWGQGTTVTVSS183 DVD1625L AB271VL AB273VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTL RPGVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKR TVAAPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIY ATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTK LEIKR 184 DVD1626H AB273VH AB271VHEVQLVQSGAEVKKPGSSVKVSCKASGY TFTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYM ELSSLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVFPLAPE VQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGG DTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGM DYWGQGTLVTVSS 185 DVD1626L AB273VL AB271VLDIQMTQSPSSLSASVGDRVTITCRASS GIISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPE DFATYYCRQVGSYPETFGQGTKLEIKRTVAAPDTVVTQSPAFLSVTPGEKVTIT CITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLEAEDAATYYCLQSDNLPLTFGQGTK LEIKR

Example 2.35 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 1) DVD-Igswith Linker Set 3

TABLE 48 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 186 DVD1627H AB272VH AB273VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYE IHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSE DTAVYYCTRYSKWDSFDGMDYWGQGTTV TVSS 187DVD1627L AB272VL AB273VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLA SGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKR 188 DVD1628H AB273VH AB272VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVFPLAPEVQLVE SGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDTYYNSP LKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLV TVSS 189 DVD1628L AB273VL AB272VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPETTVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.36 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 2) DVD-Igswith Linker Set 3

TABLE 49 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 190 DVD1629H AB268VH AB274VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQG TPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGW VRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTA VYYCARDPNEFWNGYYSTHDFDSWGQGT TVTVSS 191DVD1629L AB268VL AB274VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 192 DVD1630H AB274VH AB268VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAG TYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGT PVTVSS 193 DVD1630L AB274VL AB268VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASG NIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDI ATYYCQHFWSIPYTFGQGTKLQITR

Example 2.37 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 2) DVD-Igswith Linker Set 3

TABLE 50 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 194 DVD1631H AB269VH AB274VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHG GAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDV WGQGTPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGGSFG GYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTH DFDSWGQGTTVTVSS195 DVD1631L AB269VL AB274VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTL ADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR TVAAPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIK YASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTK VDIKR 196 DVD1632H AB274VH AB269VHEVQLVQSGAEVKKPGSSVKVSCKASGG SFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYM ELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPSVF PLAPEVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAY ISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKG YFDVWGQGTPVTVSS 197 DVD1632L AB274VL AB269VLEIVLTQSPDFQSVTPKEKVTITCRASQ DIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAE DAGTYYCHQTDSLPYTFGPGTKVDIKRTVAAPDIQMTQSPSSLSASVGDRVTIT CRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTK LQITR

Example 2.38 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 2) DVD-Igswith Linker Set 3

TABLE 51 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 198 DVD1633H AB270VH AB274VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYG IGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCARDPNEFWNGYYSTHDFDSWG QGTTVTVSS 199DVD1633L AB270VL AB274VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 200 DVD1634H AB274VH AB270VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 201 DVD1634L AB274VL AB270VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPDTQVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.39 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 2) DVD-Igswith Linker Set 3

TABLE 52 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 202 DVD1635H AB271VH AB274VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYG IGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCARDPNEFWNGYYSTHDFDSWG QGTTVTVSS 203DVD1635L AB271VL AB274VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 204 DVD1636H AB274VH AB271VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 205 DVD1636L AB274VL AB271VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPDTVVTQSPAFLSVTPGEKVTITCITST DIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLEAEDA ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.40 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 2) DVD-Igswith Linker Set 3

TABLE 53 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 206 DVD1637H AB272VH AB274VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYG IGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCARDPNEFWNGYYSTHDFDSWG QGTTVTVSS 207DVD1637L AB272VL AB274VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHST SGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 208 DVD1638H AB274VH AB272VHEVQLVQSGAEVKKPGSSVKVSCKASGGS FGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 209 DVD1638L AB274VL AB272VLEIVLTQSPDFQSVTPKEKVTITCRASQD IGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAG TYYCHQTDSLPYTFGPGTKVDIKRTVAAPETTVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.41 Generation of IL-1β (Seq. 1) and IL-17 (seq. 3) DVD-IgsWith Linker Set 3

TABLE 54 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 210 DVD1639H AB268VH AB275VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQG TPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISW VRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTA VYYCAREPNDFWNGYYDTHDFDSWGQGT TVTVSS 211DVD1639L AB268VL AB275VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 212 DVD1640H AB275VH AB268VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAG TYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGT PVTVSS 213 DVD1640L AB275VL AB268VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPDIQMTQSPSSLSASVGDRVTITCRASG NIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSLQPEDI ATYYCQHFWSIPYTFGQGTKLQITR

Example 2.42 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 3) DVD-Igswith Linker Set 3

TABLE 55 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 214 DVD1641H AB269VH AB275VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHG GAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDV WGQGTPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFR SYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTH DFDSWGQGTTVTVSS215 DVD1641L AB269VL AB275VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTL ADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR TVAAPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIK YASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTK VDIKR 216 DVD1642H AB275VH AB269VHEVQLVQSGAEVKKPGESVKISCKASGG SFRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYM ELSGLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVF PLAPEVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAY ISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKG YFDVWGQGTPVTVSS 217 DVD1642L AB275VL AB269VLEIVLTQSPDFQSVTPKEKVTITCRASQ NIGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAE DAATYYCHQSDTLPHTFGQGTKVDIKRTVAAPDIQMTQSPSSLSASVGDRVTIT CRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTK LQITR

Example 2.43 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 3) DVD-Igswith Linker Set 3

TABLE 56 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 218 DVD1643H AB270VH AB275VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYG ISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCAREPNDFWNGYYDTHDFDSWG QGTTVTVSS 219DVD1643L AB270VL AB275VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 220 DVD1644H AB275VH AB270VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 221 DVD1644L AB275VL AB270VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPDTQVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.44 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 3) DVD-Igswith Linker Set 3

TABLE 57 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 222 DVD1645H AB271VH AB275VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYG ISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCAREPNDFWNGYYDTHDFDSWG QGTTVTVSS 223DVD1645L AB271VL AB275VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 224 DVD1646H AB275VH AB271VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 225 DVD1646L AB275VL AB271VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPDTVVTQSPAFLSVTPGEKVTITCITST DIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLEAEDA ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.45 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 3) DVD-Igswith Linker Set 3

TABLE 58 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 226 DVD1647H AB272VH AB275VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYG ISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCAREPNDFWNGYYDTHDFDSWG QGTTVTVSS 227DVD1647L AB272VL AB275VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSI SGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 228 DVD1648H AB275VH AB272VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 229 DVD1648L AB275VL AB272VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPETTVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDF ATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.46 Generation of IL-1β (Seq. 1) and IL-17 (seq. 1) DVD-IgsWith Linker Set 4

TABLE 59 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 230 DVD1649H AB268VH AB273VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQG TPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHW VRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTA VYYCTRYSKWDSFDGMDYWGQGTTVTVS S 231 DVD1649LAB268VL AB273VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PSVFIFPPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLI YATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKL EIKR 232 DVD1650H AB273VH AB268VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVFPLAPEVQLVE SGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPD SVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVS S 233 DVD1650L AB273VL AB268VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTKL QITR

Example 2.47 Generation of IL-1β (Seq. 2) and IL-17 (seq. 1) DVD-IgsWith Linker Set 4

TABLE 60 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 234 DVD1651H AB269VH AB273VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQG TPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYEIHW VRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSEDTA VYYCTRYSKWDSFDGMDYWGQGTTVTVS S 235 DVD1651LAB269VL AB273VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PSVFIFPPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLI YATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKL EIKR 236 DVD1652H AB273VH AB269VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVFPLAPEVQLVE SGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPD SVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGTPVTVS S 237 DVD1652L AB273VL AB269VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTKL QITR

Example 2.48 Generation of IL-1β (Seq. 3) and IL-17 (seq. 1) DVD-IgsWith Linker Set 4

TABLE 61 Outer Inner DVD Variable Variable Variable Sequence SEQ IDDomain Domain Domain 12345678901234567890123456 NO Name Name Name789012345 238 DVD1653H AB270VH AB273VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIW GGGDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGY DLYGMDYWGQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVS CKASGYTFTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTAD ESTSTAYMELSSLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSS 239 DVD1653L AB270VL AB273VLDTQVTQSPSSLSASVGDRVTITCITS TDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSL QPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAAPSVFIFPPDIQMTQSPSS LSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLIYATFDLASGVPSRF SGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKLEIKR 240 DVD1654H AB273VH AB270VHEVQLVQSGAEVKKPGSSVKVSCKASG YTFTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTST AYMELSSLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVF PLAPEVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWL GLIWGGGDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRT LWGYDLYGMDYWGQGTLVTVSS 241 DVD1654L AB273VLAB270VL DIQMTQSPSSLSASVGDRVTITCRAS SGIISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSL QPEDFATYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPDTQVTQSPSS LSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRF SSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.49 Generation of IL-1β (Seq. 4) and IL-17 (seq. 1) DVD-IgsWith Linker Set 4

TABLE 62 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 242 DVD1655H AB271VH AB273VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGG GDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYG MDYWGQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGY TFTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYM ELSSLRSEDTAVYYCTRYSKWDSFDGM DYWGQGTTVTVSS243 DVD1655L AB271VL AB273VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTL RPGVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKR TVAAPSVFIFPPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGK APKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPE TFGQGTKLEIKR 244 DVD1656H AB273VH AB271VHEVQLVQSGAEVKKPGSSVKVSCKASGY TFTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYM ELSSLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVFPLAPE VQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGG DTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGM DYWGQGTLVTVSS 245 DVD1656L AB273VL AB271VLDIQMTQSPSSLSASVGDRVTITCRASS GIISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPE DFATYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPDTVVTQSPAFLSVTP GEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGT DFTFTISSLEAEDAATYYCLQSDNLPL TFGQGTKLEIKR

Example 2.50 Generation of IL-1β (Seq. 5) and IL-17 (seq. 1) DVD-IgsWith Linker Set 4

TABLE 63 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 246 DVD1657H AB272VH AB273VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYE IHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELSSLRSE DTAVYYCTRYSKWDSFDGMDYWGQGTTV TVSS 247DVD1657L AB272VL AB273VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPDIQMTQSPSSLSASVGDRVTITCRASSGIISYIDWFQQKPGKAPKRLI YATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCRQVGSYPETFGQGTKL EIKR 248 DVD1658H AB273VH AB272VHEVQLVQSGAEVKKPGSSVKVSCKASGYT FTDYEIHWVRQAPGQGLEWMGVNDPESGGTFYNQKFDGRVTLTADESTSTAYMELS SLRSEDTAVYYCTRYSKWDSFDGMDYWGQGTTVTVSSASTKGPSVFPLAPEVQLVE SGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDTYYNSP LKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLV TVSS 249 DVD1658L AB273VL AB272VLDIQMTQSPSSLSASVGDRVTITCRASSG IISYIDWFQQKPGKAPKRLIYATFDLASGVPSRFSGSGSGTDYTLTISSLQPEDFA TYYCRQVGSYPETFGQGTKLEIKRTVAAPSVFIFPPETTVTQSPSSLSASVGDRVT ITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLQPEDFATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.51 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 2) DVD-Igswith Linker Set 4

TABLE 64 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 250 DVD1659H AB268VH AB274VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHG GAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDV WGQGTPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGGSFG GYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTH DFDSWGQGTTVTVSS251 DVD1659L AB268VL AB274VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTL ADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR TVAAPSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQ PPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPY TFGPGTKVDIKR 252 DVD1660H AB274VH AB268VHEVQLVQSGAEVKKPGSSVKVSCKASGG SFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYM ELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPSVF PLAPEVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAY ISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKG YFDVWGQGTPVTVSS 253 DVD1660L AB274VL AB268VLEIVLTQSPDFQSVTPKEKVTITCRASQ DIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAE DAGTYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPDIQMTQSPSSLSASV GDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGT DYTFTISSLQPEDIATYYCQHFWSIPY TFGQGTKLQITR

Example 2.52 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 2) DVD-Igswith Linker Set 4

TABLE 65 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 254 DVD1661H AB269VH AB274VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHG GAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDV WGQGTPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGGSFG GYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCARDPNEFWNGYYSTH DFDSWGQGTTVTVSS255 DVD1661L AB269VL AB274VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTL ADGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR TVAAPSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPDQ PPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPY TFGPGTKVDIKR 256 DVD1662H AB274VH AB269VHEVQLVQSGAEVKKPGSSVKVSCKASGG SFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYM ELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTKGPSVF PLAPEVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAY ISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKG YFDVWGQGTPVTVSS 257 DVD1662L AB274VL AB269VLEIVLTQSPDFQSVTPKEKVTITCRASQ DIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAE DAGTYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPDIQMTQSPSSLSASV GDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGT DYTFTISSLQPEDIATYYCQHFWSIPY TFGQGTKLQITR

Example 2.53 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 2) DVD-Igswith Linker Set 4

TABLE 66 Outer Inner DVD Variable Variable Variable Sequence SEQ IDDomain Domain Domain 12345678901234567890123 NO Name Name Name456789012345 258 DVD1663H AB270VH AB274VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLE WLGLIWGGGDTYYNSPLKSRLTI SKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWGQG TLVTVSSASTKGPSVFPLAPEVQ LVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQGLEWMG GITPFFGFADYAQKFQGRVTITA DESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQ GTTVTVSS 259 DVD1663L AB270VL AB274VLDTQVTQSPSSLSASVGDRVTITC ITSTDIDVDMNWYQQKPGKPPKL LISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSD NLPLTFGQGTKLEIKRTVAAPSV FIFPPEIVLTQSPDFQSVTPKEKVTITCRASQDIGSELHWYQQKPD QPPKLLIKYASHSTSGVPSRFSG SGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 260 DVD1664H AB274VH AB270VHEVQLVQSGAEVKKPGSSVKVSCK ASGGSFGGYGIGWVRQAPGQGLE WMGGITPFFGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTA VYYCARDPNEFWNGYYSTHDFDS WGQGTTVTVSSASTKGPSVFPLAPEVQLQESGPGLVKPSETLSLTC TVSGFSLSDYGVSWIRQPPGKGL EWLGLIWGGGDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTA VYYCAKQRTLWGYDLYGMDYWGQ GTLVTVSS 261 DVD1664LAB274VL AB270VL EIVLTQSPDFQSVTPKEKVTITC RASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGT DFTLTINGLEAEDAGTYYCHQTD SLPYTFGPGTKVDIKRTVAAPSVFIFPPDTQVTQSPSSLSASVGDR VTITCITSTDIDVDMNWYQQKPG KPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPEDFATYY CLQSDNLPLTFGQGTKLEIKR

Example 2.54 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 2) DVD-Igswith Linker Set 4

TABLE 67 Outer Inner DVD Variable Variable Variable Sequence SEQ IDDomain Domain Domain 12345678901234567890123456 NO Name Name Name789012345 262 DVD1665H AB271VH AB274VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIW GGGDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGY DLYGMDYWGQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVS CKASGGSFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITAD ESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVS S 263 DVD1665L AB271VL AB274VLDTVVTQSPAFLSVTPGEKVTITCITS TDIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSL EAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAAPSVFIFPPEIVLTQSPDF QSVTPKEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRF SGSGSGTDFTLTINGLEAEDAGTYYCHQTDSLPYTFGPGTKVDIKR 264 DVD1666H AB274VH AB271VHEVQLVQSGAEVKKPGSSVKVSCKASG GSFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTT AYMELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSSASTK GPSVFPLAPEVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGK GLEWLGLIWGGGDTYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYC AKQRTLWGYDLYGMDYWGQGTLVTVS S 265 DVD1666LAB274VL AB271VL EIVLTQSPDFQSVTPKEKVTITCRAS QDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGL EAEDAGTYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPDTVVTQSPAF LSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRF SSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKR

Example 2.55 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 2) DVD-Igswith Linker Set 4

TABLE 68 Outer Inner SEQ DVD Variable Variable Variable Sequence IDDomain Domain Domain 123456789012345678901234567 NO Name Name Name89012345 266 DVD1667H AB272VH AB274VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGG GDTYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYG MDYWGQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGSSVKVSCKASGG SFGGYGIGWVRQAPGQGLEWMGGITPFFGFADYAQKFQGRVTITADESTTTAYM ELSGLTSDDTAVYYCARDPNEFWNGYYSTHDFDSWGQGTTVTVSS 267 DVD1667L AB272VL AB274VLETTVTQSPSSLSASVGDRVTITCITST DIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTISSLQPE DFATYYCLQSDNLPLTFGQGTKLEIKRTVAAPSVFIFPPEIVLTQSPDFQSVTP KEKVTITCRASQDIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGT DFTLTINGLEAEDAGTYYCHQTDSLPY TFGPGTKVDIKR 268DVD1668H AB274VH AB272VH EVQLVQSGAEVKKPGSSVKVSCKASGGSFGGYGIGWVRQAPGQGLEWMGGITPF FGFADYAQKFQGRVTITADESTTTAYMELSGLTSDDTAVYYCARDPNEFWNGYY STHDFDSWGQGTTVTVSSASTKGPSVFPLAPEVQLVESGGGLVQPGGSLRLSCA VSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDTYYNSPLKSRLTISKDNSKST VYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWGQGTLVTVSS 269 DVD1668L AB274VL AB272VLEIVLTQSPDFQSVTPKEKVTITCRASQ DIGSELHWYQQKPDQPPKLLIKYASHSTSGVPSRFSGSGSGTDFTLTINGLEAE DAGTYYCHQTDSLPYTFGPGTKVDIKRTVAAPSVFIFPPETTVTQSPSSLSASV GDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGT DFTFTISSLQPEDFATYYCLQSDNLPL TFGQGTKLEIKR

Example 2.56 Generation of IL-1β (Seq. 1) and IL-17 (Seq. 3) DVD-Igswith Linker Set 4

TABLE 69 Outer Inner DVD Variable Variable Variable Sequence SEQ IDDomain Domain Domain 12345678901234567890123456 NO Name Name Name789012345 270 DVD1669H AB268VH AB275VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYIS HGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKG YFDVWGQGTPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKA SGGSFRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADEST TTAYMELSGLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSS 271 DVD1669L AB268VL AB275VLDIQMTQSPSSLSASVGDRVTITCRAS GNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTISSL QPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAAPSVFIFPPEIVLTQSPDF QSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLIKYASHSISGVPSRF SGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKVDIKR 272 DVD1670H AB275VH AB268VHEVQLVQSGAEVKKPGESVKISCKASG GSFRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTT AYMELSGLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTK GPSVFPLAPEVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGK GLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYF CARGGVTKGYFDVWGQGTPVTVSS 273 DVD1670L AB275VLAB268VL EIVLTQSPDFQSVTPKEKVTITCRAS QNIGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGL EAEDAATYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPDIQMTQSPSS LSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRF SGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITR

Example 2.57 Generation of IL-1β (Seq. 2) and IL-17 (Seq. 3) DVD-Igswith Linker Set 4

TABLE 70 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 274 DVD1671H AB269VH AB275VH EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGA GTYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQG TPVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYGISW VRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSDDTA VYYCAREPNDFWNGYYDTHDFDSWGQGT TVTVSS 275DVD1671L AB269VL AB275VL DIQMTQSPSSLSASVGDRVTITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLAD GVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQHFWSIPYTFGQGTKLQITRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLI KYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKV DIKR 276 DVD1672H AB275VH AB269VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAG TYYPDSVKGRFTISRDNSKNTLFLQMDSLRAEDTAVYYCARGGVYKGYFDVWGQGT PVTVSS 277 DVD1672L AB275VL AB269VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPDIQMTQSPSSLSASVGDRVT ITCRASGNIHNYLTWYQQTPGKAPKLLIYNAKTLADGVPSRFSGSGSGTDYTFTIS SLQPEDIATYYCQHFWSIPYTFGQGTKL QITR

Example 2.58 Generation of IL-1β (Seq. 3) and IL-17 (Seq. 3) DVD-Igswith Linker Set 4

TABLE 71 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 278 DVD1673H AB270VH AB275VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYG ISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCAREPNDFWNGYYDTHDFDSWG QGTTVTVSS 279DVD1673L AB270VL AB275VL DTQVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLI KYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKV DIKR 280 DVD1674H AB275VH AB270VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 281 DVD1674L AB275VL AB270VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPDTQVTQSPSSLSASVGDRVT ITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLQPEDFATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.59 Generation of IL-1β (Seq. 4) and IL-17 (Seq. 3) DVD-Igswith Linker Set 4

TABLE 72 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 282 DVD1675H AB271VH AB275VH EVQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYG ISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCAREPNDFWNGYYDTHDFDSWG QGTTVTVSS 283DVD1675L AB271VL AB275VL DTVVTQSPAFLSVTPGEKVTITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLEAEDAATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLI KYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKV DIKR 284 DVD1676H AB275VH AB271VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLQESGPGLVKPSETLSLTCTVSGFSLSDYGVSWIRQPPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSQVSLKLSSVTAADTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 285 DVD1676L AB275VL AB271VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPDTVVTQSPAFLSVTPGEKVT ITCITSTDIDVDMNWYQQKPDQPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLEAEDAATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.60 Generation of IL-1β (Seq. 5) and IL-17 (Seq. 3) DVD-Igswith Linker Set 4

TABLE 73 DVD Outer Inner Variable Variable Variable Sequence SEQ IDDomain Domain Domain 1234567890123456789012345678 NO Name Name Name9012345 286 DVD1677H AB272VH AB275VH EVQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGD TYYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYW GQGTLVTVSSASTKGPSVFPLAPEVQLVQSGAEVKKPGESVKISCKASGGSFRSYG ISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELSGLTSD DTAVYYCAREPNDFWNGYYDTHDFDSWG QGTTVTVSS 287DVD1677L AB272VL AB275VL ETTVTQSPSSLSASVGDRVTITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRP GVPSRFSSSGSGTDFTFTISSLQPEDFATYYCLQSDNLPLTFGQGTKLEIKRTVAA PSVFIFPPEIVLTQSPDFQSVTPKEKVTITCRASQNIGSELHWYQQKPDQSPKLLI KYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAATYYCHQSDTLPHTFGQGTKV DIKR 288 DVD1678H AB275VH AB272VHEVQLVQSGAEVKKPGESVKISCKASGGS FRSYGISWVRQAPGQGLEWMGGITHFFGITDYAQKFQGRVTITADESTTTAYMELS GLTSDDTAVYYCAREPNDFWNGYYDTHDFDSWGQGTTVTVSSASTKGPSVFPLAPE VQLVESGGGLVQPGGSLRLSCAVSGFTLSDYGVSWIRQAPGKGLEWLGLIWGGGDT YYNSPLKSRLTISKDNSKSTVYLQMNSLRAEDTAVYYCAKQRTLWGYDLYGMDYWG QGTLVTVSS 289 DVD1678L AB275VL AB272VLEIVLTQSPDFQSVTPKEKVTITCRASQN IGSELHWYQQKPDQSPKLLIKYASHSISGVPSRFSGSGSGTDFTLTINGLEAEDAA TYYCHQSDTLPHTFGQGTKVDIKRTVAAPSVFIFPPETTVTQSPSSLSASVGDRVT ITCITSTDIDVDMNWYQQKPGKPPKLLISQGNTLRPGVPSRFSSSGSGTDFTFTIS SLQPEDFATYYCLQSDNLPLTFGQGTKL EIKR

Example 2.61 Cloning Vector Sequences Used to Clone Parent Antibody andDVD-Ig Sequences

TABLE 74 Nucleotide sequences Vector SEQ ID1234567890123456789012345678901234567890123456 name NO 78901 V1 290GCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGCGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGCGGCCGCTCGAGGCCGGCAAGGCCGGATCCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCCGGACGAACTAAACCTGACTACGACATCTCTGCCCCTTCTTCGCGGGGCAGTGCATGTAATCCCTTCAGTTGGTTGGTACAACTTGCCAACTGGGCCCTGTTCCACATGTGACACGGGGGGGGACCAAACACAAAGGGGTTCTCTGACTGTAGTTGACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTCATCCTGGAGCAGACTTTGCAGTCTGTGGACTGCAACACAACATTGCCTTTATGTGTAACTCTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCCCAGGGGCCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGTTTATAAGGCCCCCTTGTTAACCCTAAACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATCCAGACTAACCCTAATTCAATAGCATATGTTACCCAACGGGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCTAAGGAACAGCGATATCTCCCACCCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAGGATTCCACGAGGGTAGTGAACCATTTTAGTCACAAGGGCAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACTCTCCTGAATCTTCGCCTGCTTCTTCATTCTCCTTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAGGTGCTCGAAAACAAGGTTTCAGGTGACGCCCCCAGAATAAAATTTGGACGGGGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCCTCACAAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCTGAATATCTTTAACAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGCAATATGATACTGGGGTTATTAAGATGTGTCCCAGGCAGGGACCAAGACAGGTGAACCATGTTGTTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCCGACAGCAGCGGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTAAACGGGGCTCCACGCCAATGGGGCCCATAAACAAAGACAAGTGGCCACTCTTTTTTTTGAAATTGTGGAGTGGGGGCACGCGTCAGCCCCCACACGCCGCCCTGCGGTTTTGGACTGTAAAATAAGGGTGTAATAACTTGGCTGATTGTAACCCCGCTAACCACTGCGGTCAAACCACTTGCCCACAAAACCACTAATGGCACCCCGGGGAATACCTGCATAAGTAGGTGGGCGGGCCAAGATAGGGGCGCGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAGCGCCAAGCACAGGGTTGTTGGTCCTCATATTCACGAGGTCGCTGAGAGCACGGTGGGCTAATGTTGCCATGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAGCTAGAGGTCGAGTCCCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGGAATTCTCTAGAGATCCCTCGACCTCGAGATCCATTGTGCCCGGGCGCCACCATGGAGTTTGGGCTGAGCTGGCTTTTTCTTGTCGCGATTTTAAAAGGT GTCCAGTGC V2 291ACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTGAGCGGCCGCTCGAGGCCGGCAAGGCCGGATCCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCCGGACGAACTAAACCTGACTACGACATCTCTGCCCCTTCTTCGCGGGGCAGTGCATGTAATCCCTTCAGTTGGTTGGTACAACTTGCCAACTGGGCCCTGTTCCACATGTGACACGGGGGGGGACCAAACACAAAGGGGTTCTCTGACTGTAGTTGACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTCATCCTGGAGCAGACTTTGCAGTCTGTGGACTGCAACACAACATTGCCTTTATGTGTAACTCTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCCCAGGGGCCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGTTTATAAGGCCCCCTTGTTAACCCTAAACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATCCAGACTAACCCTAATTCAATAGCATATGTTACCCAACGGGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCTAAGGAACAGCGATATCTCCCACCCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAGGATTCCACGAGGGTAGTGAACCATTTTAGTCACAAGGGCAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACTCTCCTGAATCTTCGCCTGCTTCTTCATTCTCCTTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAGGTGCTCGAAAACAAGGTTTCAGGTGACGCCCCCAGAATAAAATTTGGACGGGGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCCTCACAAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCTGAATATCTTTAACAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGCAATATGATACTGGGGTTATTAAGATGTGTCCCAGGCAGGGACCAAGACAGGTGAACCATGTTGTTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCCGACAGCAGCGGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTAAACGGGGCTCCACGCCAATGGGGCCCATAAACAAAGACAAGTGGCCACTCTTTTTTTTGAAATTGTGGAGTGGGGGCACGCGTCAGCCCCCACACGCCGCCCTGCGGTTTTGGACTGTAAAATAAGGGTGTAATAACTTGGCTGATTGTAACCCCGCTAACCACTGCGGTCAAACCACTTGCCCACAAAACCACTAATGGCACCCCGGGGAATACCTGCATAAGTAGGTGGGCGGGCCAAGATAGGGGCGCGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAGCGCCAAGCACAGGGTTGTTGGTCCTCATATTCACGAGGTCGCTGAGAGCACGGTGGGCTAATGTTGCCATGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAGCTAGAGGTCGAGTCCCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGGAATTCTCTAGAGATCCCTCGACCTCGAGATCCATTGTGCCCGGGCGCACCATGGACATGCGCGTGCCCGCCCAGCTGCTGGGCCTGCTGCTGCTGTGGTTCCCCGGCTCGCGATGC V3 292CAACCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCATGAGCGGCCGCTCGAGGCCGGCAAGGCCGGATCCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCCGGACGAACTAAACCTGACTACGACATCTCTGCCCCTTCTTCGCGGGGCAGTGCATGTAATCCCTTCAGTTGGTTGGTACAACTTGCCAACTGGGCCCTGTTCCACATGTGACACGGGGGGGGACCAAACACAAAGGGGTTCTCTGACTGTAGTTGACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTCATCCTGGAGCAGACTTTGCAGTCTGTGGACTGCAACACAACATTGCCTTTATGTGTAACTCTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCCCAGGGGCCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGTTTATAAGGCCCCCTTGTTAACCCTAAACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATCCAGACTAACCCTAATTCAATAGCATATGTTACCCAACGGGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCTAAGGAACAGCGATATCTCCCACCCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAGGATTCCACGAGGGTAGTGAACCATTTTAGTCACAAGGGCAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACTCTCCTGAATCTTCGCCTGCTTCTTCATTCTCCTTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAGGTGCTCGAAAACAAGGTTTCAGGTGACGCCCCCAGAATAAAATTTGGACGGGGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCCTCACAAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCTGAATATCTTTAACAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGCAATATGATACTGGGGTTATTAAGATGTGTCCCAGGCAGGGACCAAGACAGGTGAACCATGTTGTTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCCGACAGCAGCGGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTAAACGGGGCTCCACGCCAATGGGGCCCATAAACAAAGACAAGTGGCCACTCTTTTTTTTGAAATTGTGGAGTGGGGGCACGCGTCAGCCCCCACACGCCGCCCTGCGGTTTTGGACTGTAAAATAAGGGTGTAATAACTTGGCTGATTGTAACCCCGCTAACCACTGCGGTCAAACCACTTGCCCACAAAACCACTAATGGCACCCCGGGGAATACCTGCATAAGTAGGTGGGCGGGCCAAGATAGGGGCGCGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAGCGCCAAGCACAGGGTTGTTGGTCCTCATATTCACGAGGTCGCTGAGAGCACGGTGGGCTAATGTTGCCATGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAGCTAGAGGTCGAGTCCCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGGAATTCTCTAGAGATCCCTCGACCTCGAGATCCATTGTGCCCGGGCGCCACCATGACTTGGACCCCACTCCTCTTCCTCACCCTCCTCCTCCACTGCACAGGAAGCTTATCG V4 293ACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTGAGCGGCCGCTCGAGGCCGGCAAGGCCGGATCCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCCGGACGAACTAAACCTGACTACGACATCTCTGCCCCTTCTTCGCGGGGCAGTGCATGTAATCCCTTCAGTTGGTTGGTACAACTTGCCAACTGGGCCCTGTTCCACATGTGACACGGGGGGGGACCAAACACAAAGGGGTTCTCTGACTGTAGTTGACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTCATCCTGGAGCAGACTTTGCAGTCTGTGGACTGCAACACAACATTGCCTTTATGTGTAACTCTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCCCAGGGGCCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGTTTATAAGGCCCCCTTGTTAACCCTAAACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATCCAGACTAACCCTAATTCAATAGCATATGTTACCCAACGGGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCTAAGGAACAGCGATATCTCCCACCCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAGGATTCCACGAGGGTAGTGAACCATTTTAGTCACAAGGGCAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACTCTCCTGAATCTTCGCCTGCTTCTTCATTCTCCTTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAGGTGCTCGAAAACAAGGTTTCAGGTGACGCCCCCAGAATAAAATTTGGACGGGGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCCTCACAAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCTGAATATCTTTAACAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGCAATATGATACTGGGGTTATTAAGATGTGTCCCAGGCAGGGACCAAGACAGGTGAACCATGTTGTTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCCGACAGCAGCGGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTAAACGGGGCTCCACGCCAATGGGGCCCATAAACAAAGACAAGTGGCCACTCTTTTTTTTGAAATTGTGGAGTGGGGGCACGCGTCAGCCCCCACACGCCGCCCTGCGGTTTTGGACTGTAAAATAAGGGTGTAATAACTTGGCTGATTGTAACCCCGCTAACCACTGCGGTCAAACCACTTGCCCACAAAACCACTAATGGCACCCCGGGGAATACCTGCATAAGTAGGTGGGCGGGCCAAGATAGGGGCGCGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAGCGCCAAGCACAGGGTTGTTGGTCCTCATATTCACGAGGTCGCTGAGAGCACGGTGGGCTAATGTTGCCATGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAGCTAGAGGTCGAGTCCCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGGAATTCTCTAGAGATCCCTCGACCTCGAGATCCATTGTGCCCGGGCGCACCATGACTTGGACCCCACTCCTCTTCCTCACCCTCCTCCTCCACTGCACAGGAAGCTTATCG V5 294CAACCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCATGAGCGGCCGCTCGAGGCCGGCAAGGCCGGATCCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCCGGACGAACTAAACCTGACTACGACATCTCTGCCCCTTCTTCGCGGGGCAGTGCATGTAATCCCTTCAGTTGGTTGGTACAACTTGCCAACTGGGCCCTGTTCCACATGTGACACGGGGGGGGACCAAACACAAAGGGGTTCTCTGACTGTAGTTGACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTCATCCTGGAGCAGACTTTGCAGTCTGTGGACTGCAACACAACATTGCCTTTATGTGTAACTCTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCCCAGGGGCCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGTTTATAAGGCCCCCTTGTTAACCCTAAACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATCCAGACTAACCCTAATTCAATAGCATATGTTACCCAACGGGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCTAAGGAACAGCGATATCTCCCACCCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAGGATTCCACGAGGGTAGTGAACCATTTTAGTCACAAGGGCAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACTCTCCTGAATCTTCGCCTGCTTCTTCATTCTCCTTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAGGTGCTCGAAAACAAGGTTTCAGGTGACGCCCCCAGAATAAAATTTGGACGGGGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCCTCACAAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCTGAATATCTTTAACAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGCAATATGATACTGGGGTTATTAAGATGTGTCCCAGGCAGGGACCAAGACAGGTGAACCATGTTGTTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCCGACAGCAGCGGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTAAACGGGGCTCCACGCCAATGGGGCCCATAAACAAAGACAAGTGGCCACTCTTTTTTTTGAAATTGTGGAGTGGGGGCACGCGTCAGCCCCCACACGCCGCCCTGCGGTTTTGGACTGTAAAATAAGGGTGTAATAACTTGGCTGATTGTAACCCCGCTAACCACTGCGGTCAAACCACTTGCCCACAAAACCACTAATGGCACCCCGGGGAATACCTGCATAAGTAGGTGGGCGGGCCAAGATAGGGGCGCGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAGCGCCAAGCACAGGGTTGTTGGTCCTCATATTCACGAGGTCGCTGAGAGCACGGTGGGCTAATGTTGCCATGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAGCTAGAGGTCGAGTCCCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGGAATTCTCTAGAGATCCCTCGACCTCGAGATCCATTGTGCCCGGGCGCCACCATGGACATGCGCGTGCCCGCCCAGCTGCTGGGCCTGCTGCTGCTGTGGTTCCCCGGCTCGCGATGC V7 295GCGTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAAGCCGCGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGCGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGCGGCCGCTCGAGGCCGGCAAGGCCGGATCCCCCGACCTCGACCTCTGGCTAATAAAGGAAATTTATTTTCATTGCAATAGTGTGTTGGAATTTTTTGTGTCTCTCACTCGGAAGGACATATGGGAGGGCAAATCATTTGGTCGAGATCCCTCGGAGATCTCTAGCTAGAGGATCGATCCCCGCCCCGGACGAACTAAACCTGACTACGACATCTCTGCCCCTTCTTCGCGGGGCAGTGCATGTAATCCCTTCAGTTGGTTGGTACAACTTGCCAACTGGGCCCTGTTCCACATGTGACACGGGGGGGGACCAAACACAAAGGGGTTCTCTGACTGTAGTTGACATCCTTATAAATGGATGTGCACATTTGCCAACACTGAGTGGCTTTCATCCTGGAGCAGACTTTGCAGTCTGTGGACTGCAACACAACATTGCCTTTATGTGTAACTCTTGGCTGAAGCTCTTACACCAATGCTGGGGGACATGTACCTCCCAGGGGCCCAGGAAGACTACGGGAGGCTACACCAACGTCAATCAGAGGGGCCTGTGTAGCTACCGATAAGCGGACCCTCAAGAGGGCATTAGCAATAGTGTTTATAAGGCCCCCTTGTTAACCCTAAACGGGTAGCATATGCTTCCCGGGTAGTAGTATATACTATCCAGACTAACCCTAATTCAATAGCATATGTTACCCAACGGGAAGCATATGCTATCGAATTAGGGTTAGTAAAAGGGTCCTAAGGAACAGCGATATCTCCCACCCCATGAGCTGTCACGGTTTTATTTACATGGGGTCAGGATTCCACGAGGGTAGTGAACCATTTTAGTCACAAGGGCAGTGGCTGAAGATCAAGGAGCGGGCAGTGAACTCTCCTGAATCTTCGCCTGCTTCTTCATTCTCCTTCGTTTAGCTAATAGAATAACTGCTGAGTTGTGAACAGTAAGGTGTATGTGAGGTGCTCGAAAACAAGGTTTCAGGTGACGCCCCCAGAATAAAATTTGGACGGGGGGTTCAGTGGTGGCATTGTGCTATGACACCAATATAACCCTCACAAACCCCTTGGGCAATAAATACTAGTGTAGGAATGAAACATTCTGAATATCTTTAACAATAGAAATCCATGGGGTGGGGACAAGCCGTAAAGACTGGATGTCCATCTCACACGAATTTATGGCTATGGGCAACACATAATCCTAGTGCAATATGATACTGGGGTTATTAAGATGTGTCCCAGGCAGGGACCAAGACAGGTGAACCATGTTGTTACACTCTATTTGTAACAAGGGGAAAGAGAGTGGACGCCGACAGCAGCGGACTCCACTGGTTGTCTCTAACACCCCCGAAAATTAAACGGGGCTCCACGCCAATGGGGCCCATAAACAAAGACAAGTGGCCACTCTTTTTTTTGAAATTGTGGAGTGGGGGCACGCGTCAGCCCCCACACGCCGCCCTGCGGTTTTGGACTGTAAAATAAGGGTGTAATAACTTGGCTGATTGTAACCCCGCTAACCACTGCGGTCAAACCACTTGCCCACAAAACCACTAATGGCACCCCGGGGAATACCTGCATAAGTAGGTGGGCGGGCCAAGATAGGGGCGCGATTGCTGCGATCTGGAGGACAAATTACACACACTTGCGCCTGAGCGCCAAGCACAGGGTTGTTGGTCCTCATATTCACGAGGTCGCTGAGAGCACGGTGGGCTAATGTTGCCATGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTAATAGAGATTAGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATATACTACCCAAATATCTGGATAGCATATGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATTTATATCTGGGTAGCATAGGCTATCCTAATCTATATCTGGGTAGCATATGCTATCCTAATCTATATCTGGGTAGTATATGCTATCCTAATCTGTATCCGGGTAGCATATGCTATCCTCATGATAAGCTGTCAAACATGAGAATTTTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAGCTAGAGGTCGAGTCCCTCCCCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTTGCAAAGATGGATAAAGTTTTAAACAGAGAGGAATCTTTGCAGCTAATGGACCTTCTAGGTCTTGAAAGGAGTGGGAATTGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCCTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGAGGAATTCTCTAGAGATCCCTCGACCTCGAGATCCATTGTGCCCGGGCGCCACCATGGAGTTTGGGCTGAGCTGGCTTTTTCTTGTCGCGATTTTAAAAGGT GTCCAGTGC

The present disclosure incorporates by reference in their entiretytechniques well known in the field of molecular biology and drugdelivery. These techniques include, but are not limited to, techniquesdescribed in the following publications:

-   Ausubel et al. (eds.), Current Protocols in Molecular Biology, John    Wiley & Sons, NY (1993);-   Ausubel et al. (eds.), Short Protocols In Molecular Biology, John    Wiley & Sons, NY (4^(th) edition, 1999) (ISBN 0-471-32938-X);-   Giege, R. and Ducruix, A. Barrett, Crystallization of Nucleic Acids    and Proteins, a Practical Approach, 2nd ea., pp. 20 1-16, Oxford    University Press, New York, N.Y., (1999);-   Goodson, in Medical Applications of Controlled Release, vol. 2, pp.    115-138 (1984);-   Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas    563-681 (Elsevier, N.Y., 1981;-   Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor    Laboratory Press, 2nd ed. 1988);-   Kabat et al., Sequences of Proteins of Immunological Interest    (National Institutes of Health, Bethesda, Md. (1987) and (1991);-   Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological    Interest, Fifth Edition, U.S. Department of Health and Human    Services, NIH Publication No. 91-3242;-   Kontermann and Dubel eds., Antibody Engineering (2001)    Springer-Verlag. New York. 790 pp. (ISBN 3-540-41354-5);-   Kriegler, Gene Transfer and Expression, A Laboratory Manual,    Stockton Press, NY (1990);-   Langer and Wise (eds.), Medical Applications of Controlled Release,    CRC Press, Boca Raton, Fla. (1974);-   Lu and Weiner eds., Cloning and Expression Vectors for Gene Function    Analysis (2001) BioTechniques Press. Westborough, Mass. 298 pp.    (ISBN 1-881299-21-X);-   Old, R. W. & S. B. Primrose, Principles of Gene Manipulation: An    Introduction To Genetic Engineering (3d Ed. 1985) Blackwell    Scientific Publications, Boston. Studies in Microbiology; V.2:409    pp. (ISBN 0-632-01318-4);-   Robinson, J. R. (ed.), Sustained and Controlled Release Drug    Delivery Systems, Marcel Dekker, Inc., NY (1978);-   Ruan, Q., Skinner, J. P. and Tetin, S. Y. Using non-fluorescent FRET    acceptors in protein binding studies. Analyt. Biochemistry (2009),    393, 196-204;-   Sambrook, J. et al. eds., Molecular Cloning: A Laboratory Manual (2d    Ed. 1989) Cold Spring Harbor Laboratory Press, NY. Vols. 1-3. (ISBN    0-87969-309-6);-   Smolen and Ball (eds.), Controlled Drug Bioavailability, Drug    Product Design and Performance, John Wiley & Sons, NY (1984);-   Winnacker, E. L. From Genes To Clones: Introduction To Gene    Technology (1987) VCH Publishers, NY (translated by Horst    lbelgaufts). 634 pp. (ISBN 0-89573-614-4).

INCORPORATION BY REFERENCE

The contents of all cited references (including literature references,patents, patent applications, databases and websites) that maybe citedthroughout this application are hereby expressly incorporated byreference in their entirety for any purpose, as are the references citedtherein. The practice of the present disclosure will employ, unlessotherwise indicated, conventional techniques of immunology, molecularbiology and cell biology, which are well known in the art.

EQUIVALENTS

The disclosure may be embodied in other specific forms without departingfrom the spirit or essential characteristics thereof. The foregoingembodiments are therefore to be considered in all respects illustrativerather than limiting. Scope is thus indicated by the appended claimsrather than by the foregoing description, and all changes that comewithin the meaning and range of equivalency of the claims are thereforeintended to be embraced herein.

1-90. (canceled)
 91. A method for treating a subject for a disease or adisorder, comprising administering to the subject a binding proteincomprising first and second polypeptide chains, each independentlycomprising VD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first variabledomain; VD2 is a second variable domain; C is a constant domain; X1 is alinker; X2 is an Fc region; n is 0 or 1; wherein the VD1 domains on thefirst and second polypeptide chains form a first functional targetbinding site and the VD2 domains on the first and second polypeptidechains form a second functional target binding site, wherein the bindingprotein is capable of binding IL-17 and TNFα, and wherein the variabledomains that form a functional target binding site for IL-17 compriseCDRs 1-3 from SEQ ID NO: 40 and CDRs 1-3 from SEQ ID NO:
 41. 92. Themethod of claim 91, wherein the disease or the disorder is selected froma group consisting of rheumatoid arthritis, osteoarthritis, juvenilechronic arthritis, septic arthritis, Lyme arthritis, psoriaticarthritis, reactive arthritis, spondyloarthropathy, systemic lupuserythematosus, Crohn's disease, ulcerative colitis, inflammatory boweldisease, insulin dependent diabetes mellitus, thyroiditis, asthma,allergic diseases, psoriasis, dermatitis scleroderma, graft versus hostdisease, organ transplant rejection, acute or chronic immune diseaseassociated with organ transplantation, sarcoidosis, atherosclerosis,disseminated intravascular coagulation, Kawasaki's disease, Grave'sdisease, nephrotic syndrome, chronic fatigue syndrome, Wegener'sgranulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis ofthe kidneys, chronic active hepatitis, uveitis, septic shock, toxicshock syndrome, sepsis syndrome, cachexia, infectious diseases,parasitic diseases, acquired immunodeficiency syndrome, acute transversemyelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease,stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heartfailure, myocardial infarction, Addison's disease, sporadic,polyglandular deficiency type I and polyglandular deficiency type II,Schmidt's syndrome, adult (acute) respiratory distress syndrome,alopecia, alopecia areata, seronegative arthropathy, arthropathy,Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy,enteropathic synovitis, chlamydia, yersinia and salmonella associatedarthropathy, spondyloarthropathy, atheromatous disease/arteriosclerosis,atopic allergy, autoimmune bullous disease, pemphigus vulgaris,pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmunehaemolytic anaemia, Coombs positive haemolytic anaemia, acquiredpernicious anaemia, juvenile pernicious anaemia, myalgicencephalitis/Royal Free Disease, chronic mucocutaneous candidiasis,giant cell arteritis, primary sclerosing hepatitis, cryptogenicautoimmune hepatitis, acquired immunodeficiency disease syndrome,acquired immunodeficiency related diseases, hepatitis B, hepatitis C,common varied immunodeficiency (common variable hypogammaglobulinaemia),dilated cardiomyopathy, female infertility, ovarian failure, prematureovarian failure, fibrotic lung disease, cryptogenic fibrosingalveolitis, post-inflammatory interstitial lung disease, interstitialpneumonitis, connective tissue disease associated interstitial lungdisease, mixed connective tissue disease associated lung disease,systemic sclerosis associated interstitial lung disease, rheumatoidarthritis associated interstitial lung disease, systemic lupuserythematosus associated lung disease, dermatomyositis/polymyositisassociated lung disease, Sjögren's disease associated lung disease,ankylosing spondylitis associated lung disease, vasculitic diffuse lungdisease, haemosiderosis associated lung disease, drug-inducedinterstitial lung disease, fibrosis, radiation fibrosis, bronchiolitisobliterans, chronic eosinophilic pneumonia, lymphocytic infiltrativelung disease, postinfectious interstitial lung disease, gouty arthritis,autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmuneor lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibodyhepatitis), autoimmune mediated hypoglycaemia, type B insulin resistancewith acanthosis nigricans, hypoparathyroidism, acute immune diseaseassociated with organ transplantation, chronic immune disease associatedwith organ transplantation, osteoarthrosis, primary sclerosingcholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia,autoimmune neutropaenia, renal disease NOS, glomerulonephritides,microscopic vasulitis of the kidneys, lyme disease, discoid lupuserythematosus, male infertility idiopathic or NOS, sperm autoimmunity,multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonaryhypertension secondary to connective tissue disease, Goodpasture'ssyndrome, pulmonary manifestation of polyarteritis nodosa, acuterheumatic fever, rheumatoid spondylitis, Still's disease, systemicsclerosis, Sjörgren's syndrome, Takayasu's disease/arteritis, autoimmunethrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroiddisease, hyperthyroidism, goitrous autoimmune hypothyroidism(Hashimoto's disease), atrophic autoimmune hypothyroidism, primarymyxoedema, phacogenic uveitis, primary vasculitis, vitiligo acute liverdisease, chronic liver diseases, alcoholic cirrhosis, alcohol-inducedliver injury, cholestasis, idiosyncratic liver disease, Drug-Inducedhepatitis, Non-alcoholic Steatohepatitis, allergy and asthma, group Bstreptococci (GBS) infection, mental disorders, depression,schizophrenia, Th2 Type and Th1 Type mediated diseases, acute pain,chronic pain, cancer, lung cancer, breast cancer, stomach cancer,bladder cancer, colon cancer, pancreatic cancer, ovarian cancer,prostate cancer, rectal cancer, hematopoietic malignancies, leukemia,lymphoma, abetalipoprotemia, acrocyanosis, acute and chronic parasiticor infectious processes, acute leukemia, acute lymphoblastic leukemia(ALL), acute myeloid leukemia (AML), acute or chronic bacterialinfection, acute pancreatitis, acute renal failure, adenocarcinomas,aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis,allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis,allograft rejection, alpha-l-antitrypsin deficiency, amyotrophic lateralsclerosis, anemia, angina pectoris, anterior horn cell degeneration,anti cd3 therapy, antiphospholipid syndrome, anti-receptorhypersensitivity reactions, aortic and peripheral aneuryisms, aorticdissection, arterial hypertension, arteriosclerosis, arteriovenousfistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrialflutter, atrioventricular block, B cell lymphoma, bone graft rejection,bone marrow transplant (BMT) rejection, bundle branch block, Burkitt'slymphoma, burns, cardiac arrhythmias, cardiac stun syndrome, cardiactumors, cardiomyopathy, cardiopulmonary bypass inflammation response,cartilage transplant rejection, cerebellar cortical degenerations,cerebellar disorders, chaotic or multifocal atrial tachycardia,chemotherapy associated disorders, chronic myelocytic leukemia (CML),chronic alcoholism, chronic inflammatory pathologies, chroniclymphocytic leukemia (CLL), chronic obstructive pulmonary disease(COPD), chronic salicylate intoxication, colorectal carcinoma,congestive heart failure, conjunctivitis, contact dermatitis, corpulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culturenegative sepsis, cystic fibrosis, cytokine therapy associated disorders,Dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever,dermatitis, dermatologic conditions, diabetes, diabetes mellitus,diabetic ateriosclerotic disease, diffuse Lewy body disease, dilatedcongestive cardiomyopathy, disorders of the basal ganglia, Down'ssyndrome in middle age, drug-induced movement disorders induced by drugswhich block CNS dopamine receptors, drug sensitivity, eczema,encephalomyelitis, endocarditis, endocrinopathy, epiglottitis,epstein-barr virus infection, erythromelalgia, extrapyramidal andcerebellar disorders, familial hematophagocytic lymphohistiocytosis,fetal thymus implant rejection, Friedreich's ataxia, functionalperipheral arterial disorders, fungal sepsis, gas gangrene, gastriculcer, glomerular nephritis, graft rejection of any organ or tissue,gram negative sepsis, gram positive sepsis, granulomas due tointracellular organisms, hairy cell leukemia, Hallervorden-Spatzdisease, Hashimoto's thyroiditis, hay fever, heart transplant rejection,hemachromatosis, hemodialysis, hemolytic uremic syndrome/thrombolyticthrombocytopenic purpura, hemorrhage, hepatitis A, His bundlearrythmias, HIV infection/HIV neuropathy, Hodgkin's disease,hyperkinetic movement disorders, hypersensitivity reactions,hypersensitivity pneumonitis, hypertension, hypokinetic movementdisorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathicAddison's disease, idiopathic pulmonary fibrosis, antibody mediatedcytotoxicity, asthenia, infantile spinal muscular atrophy, inflammationof the aorta, influenza A, ionizing radiation exposure,iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury,ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal muscularatrophy, Kaposi's sarcoma, kidney transplant rejection, legionella,leishmaniasis, leprosy, lesions of the corticospinal system, lipedema,liver transplant rejection, lymphedema, malaria, malignant lymphoma,malignant histiocytosis, malignant melanoma, meningitis,meningococcemia, metabolic/idiopathic, migraine headache, mitochondrialmulti.system disorder, mixed connective tissue disease, monoclonalgammopathy, multiple myeloma, multiple systems degenerations, MencelDejerine-Thomas Shi-Drager degeneration, Machado-Joseph degeneration,myasthenia gravis, mycobacterium avium intracellulare, mycobacteriumtuberculosis, myelodyplastic syndrome, myocardial infarction, myocardialischemic disorders, nasopharyngeal carcinoma, neonatal chronic lungdisease, nephritis, nephrosis, neurodegenerative diseases, neurogenicmuscular atrophies, neutropenic fever, non-hodgkins lymphoma, occlusionof the abdominal aorta and its branches, occlusive arterial disorders,okt3 therapy, orchitis/epidydimitis, orchitis/vasectomy reversalprocedures, organomegaly, osteoporosis, pancreas transplant rejection,pancreatic carcinoma, paraneoplastic syndrome/hypercalcemia ofmalignancy, parathyroid transplant rejection, pelvic inflammatorydisease, perennial rhinitis, pericardial disease, peripheralarteriosclerotic disease, peripheral vascular disorders, peritonitis,pernicious anemia, pneumocystis carinii pneumonia, pneumonia, POEMSsyndrome, polyneuropathy, organomegaly, endocrinopathy, monoclonalgammopathy, skin changes syndrome, post perfusion syndrome, post pumpsyndrome, post-MI cardiotomy syndrome, preeclampsia, progressivesupranuclear palsy, primary pulmonary hypertension, radiation therapy,Raynaud's phenomenon and disease, Raynoud's disease, Refsum's disease,regular narrow QRS tachycardia, renovascular hypertension, reperfusioninjury, restrictive cardiomyopathy, sarcomas, scleroderma, senilechorea, senile dementia of Lewy body type, seronegative arthropathies,shock, sickle cell anemia, skin allograft rejection, skin changessyndrome, small bowel transplant rejection, solid tumors, specificarrythmias, spinal ataxia, spinocerebellar degenerations, streptococcalmyositis, structural lesions of the cerebellum, subacute sclerosingpanencephalitis, Syncope, syphilis of the cardiovascular system,systemic anaphalaxis, systemic inflammatory response syndrome, systemiconset juvenile rheumatoid arthritis, T-cell or FAB ALL, telangiectasia,thromboangitis obliterans, thrombocytopenia, toxicity, transplants,trauma/hemorrhage, type III hypersensitivity reactions, type IVhypersensitivity, unstable angina, uremia, urosepsis, urticaria,valvular heart diseases, varicose veins, vasculitis, venous diseases,venous thrombosis, ventricular fibrillation, viral and fungalinfections, viral encephalitis/aseptic meningitis, viral-associatedhemaphagocytic syndrome, Wernicke-Korsakoff syndrome, Wilson's disease,xenograft rejection of any organ or tissue, acute coronary syndromes,acute idiopathic polyneuritis, acute inflammatory demyelinatingpolyradiculoneuropathy, acute ischemia, adult Still's disease, alopeciaareata, anaphylaxis, anti-phospholipid antibody syndrome, aplasticanemia, arteriosclerosis, atopic eczema, atopic dermatitis, autoimmunedermatitis, autoimmune disorder associated with streptococcus infection,autoimmune enteropathy, autoimmune hearing loss, autoimmunelymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmunepremature ovarian failure, blepharitis, bronchiectasis, bullouspemphigoid, cardiovascular disease, catastrophic antiphospholipidsyndrome, celiac disease, cervical spondylosis, chronic ischemia,cicatricial pemphigoid, clinically isolated syndrome (cis) with risk formultiple sclerosis, conjunctivitis, childhood onset psychiatricdisorder, chronic obstructive pulmonary disease (COPD), dacryocystitis,dermatomyositis, diabetic retinopathy, diabetes mellitus, diskherniation, disk prolapse, drug induced immune hemolytic anemia,endocarditis, endometriosis, endophthalmitis, episcleritis, erythemamultiforme, erythema multiforme major, gestational pemphigoid,Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathicParkinson's disease, idiopathic interstitial pneumonia, IgE-mediatedallergy, immune hemolytic anemia, inclusion body myositis, infectiousocular inflammatory disease, inflammatory demyelinating disease,inflammatory heart disease, inflammatory kidney disease, IPF/UIP,iritis, keratitis, keratoconjunctivitis sicca, Kussmaul disease orKussmaul-Meier disease, Landry's paralysis, Langerhan's cellhistiocytosis, livedo reticularis, macular degeneration, microscopicpolyangiitis, morbus bechterev, motor neuron disorders, mucous membranepemphigoid, multiple organ failure, myasthenia gravis, myelodysplasticsyndrome, myocarditis, nerve root disorders, neuropathy, non-A non-Bhepatitis, optic neuritis, osteolysis, pauciarticular JRA, peripheralartery occlusive disease (PAOD), peripheral vascular disease (PVD),peripheral artery, disease (PAD), phlebitis, polyarteritis nodosa,periarteritis nodosa, polychondritis, polymyalgia rheumatica, poliosis,polyarticular JRA, polyendocrine deficiency syndrome, polymyositis,polymyalgia rheumatica (PMR), post-pump syndrome, primary Parkinsonism,prostatitis, pure red cell aplasia, primary adrenal insufficiency,recurrent neuromyelitis optica, restenosis, rheumatic heart disease,sapho (synovitis, acne, pustulosis, hyperostosis, and osteitis),scleroderma, secondary amyloidosis, shock lung, scleritis, sciatica,secondary adrenal insufficiency, silicone associated connective tissuedisease, sneddon-wilkinson dermatosis, spondilitis ankylosans,Stevens-Johnson syndrome (SJS), systemic inflammatory response syndrome,temporal arteritis, toxoplasmic retinitis, toxic epidermal necrolysis,transverse myelitis, TRAPS (tumor necrosis factor receptor, type 1allergic reaction, type II diabetes, urticaria, usual interstitialpneumonia (UIP), vasculitis, vernal conjunctivitis, viral retinitis,Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular degeneration,wound healing, Yersinia, and salmonella associated arthropathy.
 93. Themethod of claim 91, wherein the disease or the disorder is aninflammatory disorder, an autoimmune disorder, a neurological disorder,or a neurodegenerative disorder.
 94. The method of claim 93, wherein thedisease or the disorder is selected from the group consisting ofrheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, septicarthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis,spondyloarthropathy, gouty arthritis, osteoarthrosis, spondilitisankylosans, systemic lupus erythematosus, Crohn's disease, ulcerativecolitis, inflammatory bowel disease, diabetes mellitus, thyroiditis,asthma, psoriasis, dermatitis, sarcoidosis, Kawasaki's disease,Wegener's granulomatosis, Henoch-Schoenlein purpurea, vasculitis,hepatitis, uveitis, temporal arteritis, toxoplasmic retinitis, toxicepidermal necrolysis, transverse myelitis, Vogt-Koyanagi-Harada syndrome(VKH syndrome), eczema, autoimmune lymphoproliferative syndrome (ALPS),autoimmune myocarditis, autoimmune premature ovarian failure,blepharitis, celiac disease, Guillain-Barré syndrome (GBS), Hughessyndrome, SAPHO (synovitis, acne, pustulosis, hyperostosis, andosteitis), scleroderma, scleritis, Sneddon-Wilkinson dermatosis,Schmidt's syndrome, Reiter's disease, enteropathic synovitis, autoimmunebullous disease, giant cell arteritis, hepatitis, Goodpasture'ssyndrome, Still's disease, Sjörgren's syndrome, Takayasu's disease,Huntington's disease, Parkinson's disease, Alzheimer's disease, stroke,multiple sclerosis, spinal cord injury, traumatic brain injury, andamyotrophic lateral sclerosis.
 95. The method of claim 91, wherein thebinding protein is administered parenterally, subcutaneously,intramuscularly, intravenously, intrarticularly, intrabronchially,intraabdominally, intracapsularly, intracartilaginously,intracavitarily, intracelially, intracerebellarly,intracerebroventricularly, intracolically, intracervically,intragastrically, intrahepatically, intramyocardially, intraosteally,intrapelvically, intrapericardially, intraperitoneally, intrapleurally,intraprostatically, intrapulmonarily, intrarectally, intrarenally,intraretinally, intraspinally, intrasynovially, intrathoracicallyintrauterine, intravesically, bolusly, vaginally, rectally, buccally,sublingually, intranasally, or transdermally.
 96. The method of claim91, wherein the variable domains that form a functional target bindingsite for IL-17 comprise SEQ ID NO: 40 and SEQ ID NO:
 41. 97. The methodof claim 91, wherein (a) X1 comprises any one of SEQ ID NOs: 1-29; (b)the binding protein is a crystallized binding protein; (c) the Fc regionis a variant sequence Fc region; (d) the Fc region is from an IgG1,IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD; and/or (e) the binding proteincomprises two first polypeptide chains and two second polypeptide chainsand four functional target binding sites.
 98. A pharmaceuticalcomposition comprising a binding protein, wherein the binding proteincomprises first and second polypeptide chains, each independentlycomprising VD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first variabledomain; VD2 is a second variable domain; C is a constant domain; X1 is alinker; X2 is an Fc region; n is 0 or 1; wherein the VD1 domains on thefirst and second polypeptide chains form a first functional targetbinding site and the VD2 domains on the first and second polypeptidechains form a second functional target binding site, wherein the bindingprotein is capable of binding IL-17 and TNFα, and wherein the variabledomains that form a functional target binding site for IL-17 compriseCDRs 1-3 from SEQ ID NO: 40 and CDRs 1-3 from SEQ ID NO:
 41. 99. Thepharmaceutical composition of claim 98, wherein the variable domainsthat form a functional target binding site for IL-17 comprise SEQ ID NO:40 and SEQ ID NO:
 41. 100. The pharmaceutical composition of claim 98,wherein (a) X1 comprises any one of SEQ ID NOs: 1-29; (b) the bindingprotein is a crystallized binding protein; (c) the Fc region is avariant sequence Fc region; (d) the Fc region is from an IgG1, IgG2,IgG3, IgG4, IgA, IgM, IgE, or IgD; and/or (e) the binding proteincomprises two first polypeptide chains and two second polypeptide chainsand four functional target binding sites.
 101. The pharmaceuticalcomposition of claim 98, further comprising a pharmaceuticallyacceptable carrier.
 102. The pharmaceutical composition of claim 101,further comprising at least one additional therapeutic agent.
 103. Thepharmaceutical composition of claim 102, wherein the therapeutic agentis selected from a group consisting of an imaging agent, a cytotoxicagent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulationmolecule blocker, an adhesion molecule blocker, an anti-cytokineantibody or functional fragment thereof, methotrexate, cyclosporine,rapamycin, FK506, a detectable label or reporter, a TNF antagonist, anantirheumatic, a muscle relaxant, a narcotic, a non-steroidanti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative,a local anesthetic, a neuromuscular blocker, an antimicrobial, anantipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin,an immunization, an immunoglobulin, an immunosuppressive, a growthhormone, a hormone replacement drug, a radiopharmaceutical, anantidepressant, an antipsychotic, a stimulant, an asthma medication, abeta agonist, an inhaled steroid, an epinephrine or analog, a cytokine,and a cytokine antagonist.
 104. An isolated nucleic acid encoding abinding protein amino acid sequence, wherein the binding proteincomprises first and second polypeptide chains, each independentlycomprising VD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first variabledomain; VD2 is a second variable domain; C is a constant domain; X1 is alinker; X2 is an Fc region; n is 0 or 1; wherein the VD1 domains on thefirst and second polypeptide chains form a first functional targetbinding site and the VD2 domains on the first and second polypeptidechains form a second functional target binding site, wherein the bindingprotein is capable of binding IL-17 and TNFα, and wherein the variabledomains that form a functional target binding site for IL-17 compriseCDRs 1-3 from SEQ ID NO: 40 and CDRs 1-3 from SEQ ID NO:
 41. 105. Avector comprising the isolated nucleic acid of claim
 104. 106. Thevector of claim 105, wherein the vector is selected from the groupconsisting of PcDNA™, pTT, pTT3, pEFBOS, pBV, pJV, PcDNA3.1™ TOPO™, pEF6TOPO™, and pBJ.
 107. A host cell comprising the vector of claim 105.108. The host cell of claim 107, wherein the host cell is selected fromthe group consisting of a prokaryotic cell, an E. Coli cell, aeukaryotic cell, an animal cell, a plant cell, a fungal cell, amammalian cell, an avian cell, an insect cell, a CHO cell, a COS cell, ayeast cell, a Saccharomyces cerevisiae cell, and an Sf9 cell.
 109. Amethod of producing a binding protein, comprising culturing the hostcell of claim 107 under conditions sufficient to produce the bindingprotein.
 110. The nucleic acid of claim 104, wherein the variabledomains that form a functional target binding site for IL-17 compriseSEQ ID NO: 40 and SEQ ID NO:
 41. 111. The nucleic acid of claim 104,wherein (a) X1 comprises any one of SEQ ID NOs: 1-29; (b) the Fc regionis a variant sequence Fc region; (c) the Fc region is from an IgG1,IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD; and/or (d) the binding proteincomprises two first polypeptide chains and two second polypeptide chainsand four functional target binding sites.
 112. A method of determiningthe presence, amount, or concentration of IL-17 and/or TNFα in a testsample by an immunoassay, wherein the immunoassay comprises contactingthe test sample with at least one binding protein and at least onedetectable label, and wherein the at least one binding protein comprisesfirst and second polypeptide chains, each independently comprisingVD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first variable domain; VD2 is asecond variable domain; C is a constant domain; X1 is a linker; X2 is anFc region; n is 0 or 1; wherein the VD1 domains on the first and secondpolypeptide chains form a first functional target binding site and theVD2 domains on the first and second polypeptide chains form a secondfunctional target binding site, wherein the binding protein is capableof binding IL-17 and TNFα, and wherein the variable domains that form afunctional target binding site for IL-17 comprise CDRs 1-3 from SEQ IDNO: 40 and CDRs 1-3 from SEQ ID NO:
 41. 113. The method of claim 112further comprising: (a) contacting the test sample with at least onebinding protein, wherein the binding protein binds to an epitope on thetarget or fragment thereof so as to form a first complex; (b) contactingthe complex with at least one detectable label, wherein the detectablelabel binds to the binding protein or an epitope on the target orfragment thereof that is not bound by the binding protein to form asecond complex; and (c) detecting the presence of the target or fragmentthereof in the test sample based on the signal generated by thedetectable label in the second complex, wherein the presence of thetarget or fragment thereof is directly correlated with the signalgenerated by the detectable label.
 114. The method of claim 112 furthercomprising: (a) contacting the test sample with at least one bindingprotein, wherein the binding protein binds to an epitope on the targetor fragment thereof so as to form a first complex; (b) contacting thecomplex with at least one detectable label, wherein the detectable labelcompetes with the target or fragment thereof for binding to the bindingprotein so as to form a second complex; and (c) detecting the presenceof the target or fragment thereof in the test sample based on the signalgenerated by the detectable label in the second complex, wherein thepresence of the target or fragment thereof is indirectly correlated withthe signal generated by the detectable label.
 115. The method of claim112, wherein the variable domains that form a functional target bindingsite for IL-17 comprise SEQ ID NO: 40 and SEQ ID NO:
 41. 116. The methodof claim 112, wherein (a) X1 comprises any one of SEQ ID NOs: 1-29; (b)the binding protein is a crystallized binding protein; (c) the Fc regionis a variant sequence Fc region; (d) the Fc region is from an IgG1,IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD; and/or (e) the binding proteincomprises two first polypeptide chains and two second polypeptide chainsand four functional target binding sites.
 117. A kit for assaying a testsample for the presence, amount, or concentration of IL-17 and/or TNFα,the kit comprising (a) instructions for assaying the test sample forIL-17 and/or TNFα and (b) at least one binding protein comprising firstand second polypeptide chains, each independently comprisingVD1-(X1)n-VD2-C—(X2)n, wherein VD1 is a first variable domain; VD2 is asecond variable domain; C is a constant domain; X1 is a linker; X2 is anFc region; n is 0 or 1; wherein the VD1 domains on the first and secondpolypeptide chains form a first functional target binding site and theVD2 domains on the first and second polypeptide chains form a secondfunctional target binding site, wherein the binding protein is capableof binding IL-17 and TNFα, and wherein the variable domains that form afunctional target binding site for IL-17 comprise CDRs 1-3 from SEQ IDNO: 40 and CDRs 1-3 from SEQ ID NO:
 41. 118. The kit of claim 117,wherein the variable domains that form a functional target binding sitefor IL-17 comprise SEQ ID NO: 40 and SEQ ID NO:
 41. 119. The kit ofclaim 117, wherein (a) X1 comprises any one of SEQ ID NOs: 1-29; (b) thebinding protein is a crystallized binding protein; (c) the Fc region isa variant sequence Fc region; (d) the Fc region is from an IgG1, IgG2,IgG3, IgG4, IgA, IgM, IgE, or IgD; and/or (e) the binding proteincomprises two first polypeptide chains and two second polypeptide chainsand four functional target binding sites.